{"fb317870f3ed36f9a5c3e87d76e0f6e4d821bfa0": [["IntroductionInhibition of enzymes may occur either reversibly or irreversibly.", [["enzymes", "PROTEIN", 26, 33], ["IntroductionInhibition of enzymes", "TEST", 0, 33], ["irreversibly", "OBSERVATION_MODIFIER", 65, 77]]], ["In the case of irreversible inhibition, a covalent reaction between a nucleophilic amino acid (in most cases, an activated Cys, Ser or Thr side chain), either of the active or an allosteric site, reacts with an electrophilic functional group of the inhibitor, the so-called \"warhead\".", [["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["Cys", "CHEMICAL", 123, 126], ["Ser", "CHEMICAL", 128, 131], ["Thr", "CHEMICAL", 135, 138], ["amino acid", "SIMPLE_CHEMICAL", 83, 93], ["Ser", "AMINO_ACID", 128, 131], ["irreversible inhibition", "PROBLEM", 15, 38], ["a covalent reaction", "PROBLEM", 40, 59], ["a nucleophilic amino acid", "TREATMENT", 68, 93], ["an activated Cys", "PROBLEM", 110, 126], ["Ser or Thr side chain", "TREATMENT", 128, 149], ["an allosteric site", "PROBLEM", 176, 194], ["irreversible inhibition", "OBSERVATION", 15, 38], ["active", "OBSERVATION_MODIFIER", 166, 172], ["allosteric site", "OBSERVATION", 179, 194]]], ["Besides this reactive building block, enzyme inhibitors also contain a recognition unit fitting into the substrate binding pockets.", [["substrate binding pockets", "PROTEIN", 105, 130], ["this reactive building block", "PROBLEM", 8, 36], ["enzyme inhibitors", "TREATMENT", 38, 55], ["the substrate binding pockets", "PROBLEM", 101, 130], ["reactive", "OBSERVATION_MODIFIER", 13, 21], ["binding pockets", "OBSERVATION", 115, 130]]], ["In the case of protease inhibitors these are mainly peptidic or peptidomimetic sequences.", [["protease inhibitors", "TREATMENT", 15, 34], ["mainly peptidic or peptidomimetic sequences", "PROBLEM", 45, 88]]], ["However, not all covalent reactions of enzyme and inhibitor lead to irreversible inhibition, and this has received increasing attention in drug development in the last years to design covalent, but reversible inhibitors due to several advantages over non-covalent inhibitors such as longer target residence times or higher potency and ligand efficiency (for reviews on this topic see [1] [2] [3] [4] [5] [6] [7] [8] ).IntroductionIn contrast to classical electrophilic building blocks like Michael-acceptor systems [9] [10] [11] [12] [13] [14] [15] [16] [17] , nitriles [18] [19] [20] [21] , aldehydes, ketones [22] [23] [24] , three-membered heterocycles [25] [26] [27] [28] or a iodoacetic acid moiety [29, 30] , (hetero)aromatic electrophiles, which can react via nucleophilic addition (yielding \u03c0or \u03c3-complexes) or substitution reactions (S N Ar) have only rarely been employed [31] [32] [33] [34] [35] .", [["nitriles [18] [19] [20] [21] , aldehydes", "CHEMICAL", 561, 601], ["ketones", "CHEMICAL", 603, 610], ["iodoacetic acid", "CHEMICAL", 681, 696], ["[29, 30]", "CHEMICAL", 704, 712], ["S N Ar", "CHEMICAL", 843, 849], ["nitriles", "CHEMICAL", 561, 569], ["aldehydes", "CHEMICAL", 592, 601], ["ketones", "CHEMICAL", 603, 610], ["heterocycles", "CHEMICAL", 643, 655], ["iodoacetic acid", "CHEMICAL", 681, 696], ["S N Ar", "CHEMICAL", 843, 849], ["[1] [2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 384, 415], ["Michael-acceptor systems [9] [10] [11] [12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 490, 558], ["nitriles [18] [19] [20] [21] , aldehydes", "SIMPLE_CHEMICAL", 561, 601], ["ketones [22] [23] [24] , three-membered heterocycles [25] [26] [27] [28]", "SIMPLE_CHEMICAL", 603, 675], ["iodoacetic acid moiety [29, 30] , (hetero)aromatic electrophiles", "SIMPLE_CHEMICAL", 681, 745], ["\u03c0or \u03c3-complexes", "SIMPLE_CHEMICAL", 799, 814], ["S N Ar", "SIMPLE_CHEMICAL", 843, 849], ["[31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 882, 906], ["enzyme and inhibitor", "TREATMENT", 39, 59], ["irreversible inhibition", "PROBLEM", 68, 91], ["reversible inhibitors", "TREATMENT", 198, 219], ["non-covalent inhibitors", "TREATMENT", 251, 274], ["IntroductionIn contrast to classical electrophilic building blocks", "TREATMENT", 418, 484], ["Michael-acceptor systems", "TREATMENT", 490, 514], ["nitriles", "TEST", 561, 569], ["aldehydes", "TEST", 592, 601], ["ketones", "TEST", 603, 610], ["a iodoacetic acid moiety", "TEST", 679, 703], ["substitution reactions", "PROBLEM", 819, 841]]], ["Such aromatic moieties have also seldom been investigated as non-covalently binding parts of the recognition units of enzyme inhibitors [36, 37] .IntroductionWe therefore aimed to explore the potential of such groups as new building blocks for cysteine proteases of the papain family, specifically the human cathepsins B and L, and the Trypanosoma protease rhodesain.", [["cysteine", "CHEMICAL", 244, 252], ["papain", "GENE_OR_GENE_PRODUCT", 270, 276], ["human", "ORGANISM", 302, 307], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 308, 320], ["L", "GENE_OR_GENE_PRODUCT", 325, 326], ["Trypanosoma protease rhodesain", "ORGANISM", 336, 366], ["cysteine proteases", "PROTEIN", 244, 262], ["papain family", "PROTEIN", 270, 283], ["human cathepsins B", "PROTEIN", 302, 320], ["L", "PROTEIN", 325, 326], ["Trypanosoma protease rhodesain", "PROTEIN", 336, 366], ["human", "SPECIES", 302, 307], ["human", "SPECIES", 302, 307], ["Trypanosoma protease", "SPECIES", 336, 356], ["Such aromatic moieties", "PROBLEM", 0, 22], ["enzyme inhibitors", "TEST", 118, 135], ["cysteine proteases", "TREATMENT", 244, 262], ["the papain family", "TREATMENT", 266, 283], ["the human cathepsins B and L", "TREATMENT", 298, 326], ["the Trypanosoma protease rhodesain", "TREATMENT", 332, 366], ["aromatic moieties", "OBSERVATION", 5, 22], ["Trypanosoma protease", "OBSERVATION", 336, 356]]], ["The human enzymes of this family play crucial roles in tumor diseases [38, 39] .", [["tumor", "ANATOMY", 55, 60], ["tumor", "DISEASE", 55, 60], ["human", "ORGANISM", 4, 9], ["tumor", "CANCER", 55, 60], ["human enzymes", "PROTEIN", 4, 17], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human enzymes", "TEST", 0, 17], ["tumor diseases", "PROBLEM", 55, 69], ["tumor", "OBSERVATION", 55, 60]]], ["The cathepsin L-like protease rhodesain from Trypanosoma brucei rhodesiense, the parasite causing human African trypanosomiasis (HAT), is essential for the parasite's survival, since it is involved in several pathological processes in the host.", [["Trypanosoma brucei rhodesiense", "DISEASE", 45, 75], ["human African trypanosomiasis", "DISEASE", 98, 127], ["HAT", "DISEASE", 129, 132], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 4, 15], ["Trypanosoma brucei rhodesiense", "ORGANISM", 45, 75], ["human African trypanosomiasis", "ORGANISM", 98, 127], ["HAT", "CANCER", 129, 132], ["cathepsin L-like protease rhodesain", "PROTEIN", 4, 39], ["Trypanosoma brucei", "SPECIES", 45, 63], ["rhodesiense", "SPECIES", 64, 75], ["human", "SPECIES", 98, 103], ["Trypanosoma brucei rhodesiense", "SPECIES", 45, 75], ["human", "SPECIES", 98, 103], ["The cathepsin L", "TREATMENT", 0, 15], ["protease rhodesain", "TREATMENT", 21, 39], ["Trypanosoma brucei rhodesiense", "PROBLEM", 45, 75], ["the parasite", "PROBLEM", 77, 89], ["human African trypanosomiasis", "PROBLEM", 98, 127], ["the parasite's survival", "PROBLEM", 152, 175], ["Trypanosoma brucei rhodesiense", "OBSERVATION", 45, 75]]], ["These include, e.g., the crossing of the parasite through the blood-brain barrier as well as the turnover of variant surface glycoproteins (VSGs), and degradation of host immunoglobulins [40, 41] .IntroductionIn the current proof-of-principle study, we tested the overall potency of (hetero)aromatics as building blocks for peptidic protease inhibitors.", [["blood", "ANATOMY", 62, 67], ["brain", "ANATOMY", 68, 73], ["surface", "ANATOMY", 117, 124], ["(hetero)aromatics", "CHEMICAL", 283, 300], ["blood", "MULTI-TISSUE_STRUCTURE", 62, 67], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 68, 81], ["variant surface glycoproteins", "GENE_OR_GENE_PRODUCT", 109, 138], ["VSGs", "GENE_OR_GENE_PRODUCT", 140, 144], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 171, 186], ["(hetero)aromatics", "SIMPLE_CHEMICAL", 283, 300], ["variant surface glycoproteins", "PROTEIN", 109, 138], ["VSGs", "PROTEIN", 140, 144], ["host immunoglobulins", "PROTEIN", 166, 186], ["the blood-brain barrier", "TREATMENT", 58, 81], ["host immunoglobulins", "TEST", 166, 186], ["principle study", "TEST", 233, 248], ["(hetero)aromatics", "TREATMENT", 283, 300], ["peptidic protease inhibitors", "TREATMENT", 324, 352], ["parasite", "OBSERVATION", 41, 49], ["brain", "ANATOMY", 68, 73]]], ["Since we were interested in the inhibition properties of the (hetero)aromatic moiety, we used the same recognition unit, the dipeptide sequence H 2 N-l-Phe-l-Leu-OBn, and attached various (hetero)aromatic electrophiles to its N-terminus.", [["-l-Phe-l-Leu-OBn", "CHEMICAL", 149, 165], ["dipeptide", "CHEMICAL", 125, 134], ["H 2 N-l-Phe-l-Leu-OBn", "CHEMICAL", 144, 165], ["N", "CHEMICAL", 226, 227], ["-l-Phe-l-Leu-OBn", "SIMPLE_CHEMICAL", 149, 165], ["N-terminus", "PROTEIN", 226, 236], ["the (hetero)aromatic moiety", "TREATMENT", 57, 84], ["the dipeptide sequence H", "TEST", 121, 145], ["attached various (hetero)aromatic electrophiles", "TREATMENT", 171, 218]]], ["This dipeptide was chosen for two reasons: (1) It was previously shown to be an appropriate recognition unit for cathepsin L-like cysteine proteases supposed to bind into the substrate-binding pockets in an anti-substrate orientation [14, 15, 42] ; (2) In contrast to amino acids with functionalized side chains, no additional protection/deprotection steps are necessary during synthesis.IntroductionFor one inhibitor, we observed that the benzyl ester of the recognition unit was hydrolyzed by the target proteases.", [["amino acids", "CHEMICAL", 268, 279], ["benzyl ester", "CHEMICAL", 440, 452], ["dipeptide", "CHEMICAL", 5, 14], ["cysteine", "CHEMICAL", 130, 138], ["amino acids", "CHEMICAL", 268, 279], ["benzyl ester", "CHEMICAL", 440, 452], ["cathepsin", "GENE_OR_GENE_PRODUCT", 113, 122], ["amino acids", "AMINO_ACID", 268, 279], ["benzyl ester", "SIMPLE_CHEMICAL", 440, 452], ["cathepsin L", "PROTEIN", 113, 124], ["cysteine proteases", "PROTEIN", 130, 148], ["substrate-binding pockets", "PROTEIN", 175, 200], ["target proteases", "PROTEIN", 499, 515], ["This dipeptide", "TREATMENT", 0, 14], ["cathepsin L-like cysteine proteases", "TREATMENT", 113, 148], ["amino acids with functionalized side chains", "TREATMENT", 268, 311], ["additional protection/deprotection steps", "TREATMENT", 316, 356], ["one inhibitor", "TREATMENT", 404, 417]]], ["Intriguingly, the resulting free acid (with HN-l-Phe-l-Leu-OH moiety) represents a nanomolar inhibitor against rhodesain.IntroductionThe inhibition potencies of the new inhibitors were tested on the human cathepsins B and L (cath.", [["HN-l-Phe-l-Leu-OH", "CHEMICAL", 44, 61], ["rhodesain", "CHEMICAL", 111, 120], ["HN-l-Phe-l-Leu-OH", "CHEMICAL", 44, 61], ["free acid", "SIMPLE_CHEMICAL", 28, 37], ["HN-l-Phe-l-Leu-OH moiety", "SIMPLE_CHEMICAL", 44, 68], ["rhodesain", "SIMPLE_CHEMICAL", 111, 120], ["human", "ORGANISM", 199, 204], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 205, 217], ["human cathepsins B and L (cath", "PROTEIN", 199, 229], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["free acid", "TEST", 28, 37], ["HN", "TEST", 44, 46], ["Leu-OH moiety", "TREATMENT", 55, 68], ["a nanomolar inhibitor", "TREATMENT", 81, 102], ["rhodesain", "PROBLEM", 111, 120], ["the new inhibitors", "TREATMENT", 161, 179], ["the human cathepsins B and L (cath", "TREATMENT", 195, 229]]], ["B, cath.", [["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["cath", "TEST", 3, 7], ["cath", "OBSERVATION", 3, 7]]], ["L), the cathepsin L-like protease rhodesain (rhod.) from T. b. rhodesiense, and, in order to check their selectivity and to exclude promiscuous inhibition, on the Staphylococcus aureus cysteine protease and transpeptidase sortase A with a \"reversely protonated\" catalytic cysteine residue [43] , as well as on the serine protease of the Dengue virus (DENV PR), which shares the P1 specificity for Arg with cathepsins.IntroductionThe formation of a complex between inhibitor and the target protease rhodesain was indicated by mass spectrometry and NMR spectroscopy.", [["rhodesain", "CHEMICAL", 34, 43], ["Dengue", "DISEASE", 337, 343], ["cysteine", "CHEMICAL", 185, 193], ["cysteine", "CHEMICAL", 272, 280], ["serine", "CHEMICAL", 314, 320], ["Arg", "CHEMICAL", 397, 400], ["cathepsin L-like protease rhodesain", "GENE_OR_GENE_PRODUCT", 8, 43], ["T. b. rhodesiense", "ORGANISM", 57, 74], ["Staphylococcus aureus", "ORGANISM", 163, 184], ["transpeptidase sortase A", "GENE_OR_GENE_PRODUCT", 207, 231], ["Dengue virus", "ORGANISM", 337, 349], ["DENV PR", "ORGANISM", 351, 358], ["Arg", "AMINO_ACID", 397, 400], ["cathepsins", "GENE_OR_GENE_PRODUCT", 406, 416], ["cathepsin L", "PROTEIN", 8, 19], ["protease rhodesain", "PROTEIN", 25, 43], ["rhod", "PROTEIN", 45, 49], ["Staphylococcus aureus cysteine protease", "PROTEIN", 163, 202], ["transpeptidase sortase A", "PROTEIN", 207, 231], ["serine protease", "PROTEIN", 314, 329], ["PR", "PROTEIN", 356, 358], ["cathepsins", "PROTEIN", 406, 416], ["T. b. rhodesiense", "SPECIES", 57, 74], ["Staphylococcus aureus", "SPECIES", 163, 184], ["Dengue virus", "SPECIES", 337, 349], ["T. b. rhodesiense", "SPECIES", 57, 74], ["Staphylococcus aureus", "SPECIES", 163, 184], ["Dengue virus", "SPECIES", 337, 349], ["DENV", "SPECIES", 351, 355], ["the cathepsin L", "TREATMENT", 4, 19], ["promiscuous inhibition", "PROBLEM", 132, 154], ["the Staphylococcus aureus cysteine protease", "TREATMENT", 159, 202], ["transpeptidase sortase", "TEST", 207, 229], ["a \"reversely protonated\" catalytic cysteine residue", "TREATMENT", 237, 288], ["the serine protease", "TREATMENT", 310, 329], ["the Dengue virus", "PROBLEM", 333, 349], ["cathepsins", "TREATMENT", 406, 416], ["a complex between inhibitor", "TREATMENT", 446, 473], ["the target protease rhodesain", "TREATMENT", 478, 507], ["mass spectrometry", "TEST", 525, 542], ["NMR spectroscopy", "TEST", 547, 563]]], ["Possible binding modes of selected inhibitors were analyzed by docking, followed by subsequent molecular dynamics (MD) simulations.", [["selected inhibitors", "TREATMENT", 26, 45]]], ["Additionally, we performed quantum mechanical (QM) computations for model systems and quantum mechanics / molecular mechanics (QM/MM) simulations, which include the enzyme environment.", [["quantum mechanical (QM) computations", "TREATMENT", 27, 63], ["model systems", "TREATMENT", 68, 81], ["quantum mechanics / molecular mechanics (QM/MM) simulations", "TREATMENT", 86, 145]]], ["The potential inhibitors were synthesized either by SNAr reaction on a (hetero)aromatic unit carrying two potential leaving groups (compounds 2, 3, and 7) or by reaction with an electrophilic group attached to the ring system (e.g., acid chloride, isocyanate and compounds 1, 4, 5, and 6, Scheme 2).", [["SNAr", "CHEMICAL", 52, 56], ["compounds 2, 3, and 7", "CHEMICAL", 132, 153], ["acid chloride", "CHEMICAL", 233, 246], ["isocyanate", "CHEMICAL", 248, 258], ["chloride", "CHEMICAL", 238, 246], ["isocyanate", "CHEMICAL", 248, 258], ["SNAr", "SIMPLE_CHEMICAL", 52, 56], ["acid chloride", "SIMPLE_CHEMICAL", 233, 246], ["isocyanate", "SIMPLE_CHEMICAL", 248, 258], ["The potential inhibitors", "TREATMENT", 0, 24], ["SNAr reaction", "PROBLEM", 52, 65], ["acid chloride", "TREATMENT", 233, 246]]], ["Syntheses of potential protease inhibitors of the general structure R-NH-L-Phe-L-Leu-OBn with (hetero)aromatic units (R).", [["R-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 68, 88], ["R-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 68, 88], ["R-NH-L-Phe-L-Leu-OBn", "SIMPLE_CHEMICAL", 68, 88], ["(hetero)aromatic units", "SIMPLE_CHEMICAL", 94, 116], ["potential protease inhibitors", "TREATMENT", 13, 42], ["Leu", "TEST", 81, 84]]], ["The potential inhibitors were synthesized either by S N Ar reaction on a (hetero)aromatic unit carrying two potential leaving groups (compounds 2, 3, and 7) or by reaction with an electrophilic group attached to the ring system (e.g., acid chloride, isocyanate and compounds 1, 4, 5, and 6, Scheme 2).IntroductionMolecules 2020, 25, x FOR PEER REVIEW 3 of 23SynthesesThe synthesis of the new inhibitors started from commercially available L-leucine benzyl ester p-toluenesulfonate and Boc-protected L-phenylalanine, which were coupled by carbodiimide chemistry.", [["S N Ar", "CHEMICAL", 52, 58], ["compounds 2, 3, and 7", "CHEMICAL", 134, 155], ["acid chloride", "CHEMICAL", 235, 248], ["isocyanate", "CHEMICAL", 250, 260], ["L-leucine benzyl ester", "CHEMICAL", 439, 461], ["Boc-protected L-phenylalanine", "CHEMICAL", 485, 514], ["carbodiimide", "CHEMICAL", 538, 550], ["S N", "CHEMICAL", 52, 55], ["chloride", "CHEMICAL", 240, 248], ["isocyanate", "CHEMICAL", 250, 260], ["L-leucine benzyl ester p-toluenesulfonate", "CHEMICAL", 439, 480], ["Boc-protected L-phenylalanine", "CHEMICAL", 485, 514], ["carbodiimide", "CHEMICAL", 538, 550], ["S N Ar", "SIMPLE_CHEMICAL", 52, 58], ["acid chloride", "SIMPLE_CHEMICAL", 235, 248], ["isocyanate", "SIMPLE_CHEMICAL", 250, 260], ["L-leucine benzyl ester p-toluenesulfonate", "SIMPLE_CHEMICAL", 439, 480], ["Boc-protected L-phenylalanine", "SIMPLE_CHEMICAL", 485, 514], ["carbodiimide", "SIMPLE_CHEMICAL", 538, 550], ["The potential inhibitors", "TREATMENT", 0, 24], ["acid chloride", "TREATMENT", 235, 248], ["the new inhibitors", "TREATMENT", 384, 402], ["L-leucine benzyl ester p-toluenesulfonate", "TREATMENT", 439, 480], ["Boc-protected L-phenylalanine", "TREATMENT", 485, 514]]], ["The dipeptide product was easily purified by recrystallization (Scheme 1).", [["dipeptide", "CHEMICAL", 4, 13], ["The dipeptide product", "TREATMENT", 0, 21]]], ["Deprotection with either hydrochloric acid in dioxane (4 M) or trifluoro-acetic acid (TFA) in dichloromethane (DCM)(40%) afforded the ammonium salt, which was directly used in the subsequent steps.", [["hydrochloric acid", "CHEMICAL", 25, 42], ["dioxane", "CHEMICAL", 46, 53], ["4 M", "CHEMICAL", 55, 58], ["trifluoro-acetic acid", "CHEMICAL", 63, 84], ["TFA", "CHEMICAL", 86, 89], ["dichloromethane", "CHEMICAL", 94, 109], ["DCM", "CHEMICAL", 111, 114], ["ammonium salt", "CHEMICAL", 134, 147], ["hydrochloric acid", "CHEMICAL", 25, 42], ["dioxane", "CHEMICAL", 46, 53], ["trifluoro-acetic acid", "CHEMICAL", 63, 84], ["TFA", "CHEMICAL", 86, 89], ["dichloromethane", "CHEMICAL", 94, 109], ["DCM", "CHEMICAL", 111, 114], ["ammonium", "CHEMICAL", 134, 142], ["hydrochloric acid", "SIMPLE_CHEMICAL", 25, 42], ["dioxane", "SIMPLE_CHEMICAL", 46, 53], ["trifluoro-acetic acid", "SIMPLE_CHEMICAL", 63, 84], ["TFA", "SIMPLE_CHEMICAL", 86, 89], ["dichloromethane", "SIMPLE_CHEMICAL", 94, 109], ["DCM", "SIMPLE_CHEMICAL", 111, 114], ["ammonium salt", "SIMPLE_CHEMICAL", 134, 147], ["Deprotection", "TREATMENT", 0, 12], ["hydrochloric acid in dioxane", "TREATMENT", 25, 53], ["trifluoro-acetic acid (TFA) in dichloromethane (DCM)", "TREATMENT", 63, 115], ["the ammonium salt", "TREATMENT", 130, 147]]], ["The potential inhibitors were synthesized either by SNAr reaction on a (hetero)aromatic unit carrying two potential leaving groups (compounds 2, 3, and 7) or by reaction with an electrophilic group attached to the ring system (e.g., acid chloride, isocyanate and compounds 1, 4, 5, and 6, Scheme 2).", [["SNAr", "CHEMICAL", 52, 56], ["compounds 2, 3, and 7", "CHEMICAL", 132, 153], ["acid chloride", "CHEMICAL", 233, 246], ["isocyanate", "CHEMICAL", 248, 258], ["chloride", "CHEMICAL", 238, 246], ["isocyanate", "CHEMICAL", 248, 258], ["SNAr", "SIMPLE_CHEMICAL", 52, 56], ["acid chloride", "SIMPLE_CHEMICAL", 233, 246], ["isocyanate", "SIMPLE_CHEMICAL", 248, 258], ["The potential inhibitors", "TREATMENT", 0, 24], ["SNAr reaction", "PROBLEM", 52, 65], ["acid chloride", "TREATMENT", 233, 246]]], ["Syntheses of potential protease inhibitors of the general structure R-NH-L-Phe-L-Leu-OBn with (hetero)aromatic units (R).", [["R-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 68, 88], ["R-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 68, 88], ["R-NH-L-Phe-L-Leu-OBn", "SIMPLE_CHEMICAL", 68, 88], ["(hetero)aromatic units", "SIMPLE_CHEMICAL", 94, 116], ["potential protease inhibitors", "TREATMENT", 13, 42], ["Leu", "TEST", 81, 84]]], ["To further investigate whether the hydrolysis product of compound 7 is the active compound as indicated by MS, NMR and hydrolysis studies (see Sections 2.3-2.5), the corresponding free acid 8 was also synthesized (Scheme 3).", [["the hydrolysis product of compound", "PROBLEM", 31, 65], ["the active compound", "PROBLEM", 71, 90], ["NMR", "TEST", 111, 114], ["hydrolysis studies", "TEST", 119, 137], ["Sections", "TEST", 143, 151], ["the corresponding free acid", "TEST", 162, 189]]], ["First attempts to cleave the benzyl ester of compound 7 with PPL (porcine pancreatic lipase) were unsuccessful.", [["pancreatic", "ANATOMY", 74, 84], ["benzyl ester", "CHEMICAL", 29, 41], ["PPL", "CHEMICAL", 61, 64], ["benzyl ester", "CHEMICAL", 29, 41], ["benzyl ester", "SIMPLE_CHEMICAL", 29, 41], ["compound 7", "SIMPLE_CHEMICAL", 45, 55], ["PPL", "SIMPLE_CHEMICAL", 61, 64], ["porcine", "ORGANISM", 66, 73], ["pancreatic", "ORGAN", 74, 84], ["lipase", "GENE_OR_GENE_PRODUCT", 85, 91], ["PPL", "PROTEIN", 61, 64], ["porcine pancreatic lipase", "PROTEIN", 66, 91], ["porcine", "SPECIES", 66, 73], ["PPL (porcine pancreatic lipase", "TREATMENT", 61, 91], ["pancreatic", "ANATOMY", 74, 84]]], ["The compound was synthesized starting from the fully protected dipeptide Boc-NH-l-Phe-l-Leu-OBn.", [["Boc-NH-l-Phe-l-", "CHEMICAL", 73, 88], ["Boc-NH-l-Phe-l-Leu-OBn", "CHEMICAL", 73, 95], ["dipeptide Boc-NH-l-Phe-l-Leu-OBn", "SIMPLE_CHEMICAL", 63, 95]]], ["In a first step, the benzyl ester was removed by hydrogenolysis.", [["benzyl ester", "CHEMICAL", 21, 33], ["benzyl ester", "CHEMICAL", 21, 33], ["benzyl ester", "SIMPLE_CHEMICAL", 21, 33], ["the benzyl ester", "TREATMENT", 17, 33]]], ["A short filtration over celite yielded a crude material that was subjected to acidolytic removal of the Boc-protecting group with trifluoroacetic acid (TFA).", [["trifluoroacetic acid", "CHEMICAL", 130, 150], ["TFA", "CHEMICAL", 152, 155], ["trifluoroacetic acid", "CHEMICAL", 130, 150], ["TFA", "CHEMICAL", 152, 155], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 130, 150], ["TFA", "SIMPLE_CHEMICAL", 152, 155], ["A short filtration over celite", "TREATMENT", 0, 30], ["a crude material", "PROBLEM", 39, 55], ["acidolytic removal", "TREATMENT", 78, 96], ["trifluoroacetic acid (TFA", "TREATMENT", 130, 155], ["short", "OBSERVATION_MODIFIER", 2, 7]]], ["The solvent was removed to perform the reaction with the warhead (1,2-difluoro-4,5-dinitrobenzene) in ethanol in the presence of triethylamine.", [["1,2-difluoro-4,5-dinitrobenzene", "CHEMICAL", 66, 97], ["ethanol", "CHEMICAL", 102, 109], ["triethylamine", "CHEMICAL", 129, 142], ["(1,2-difluoro-4,5-dinitrobenzene", "CHEMICAL", 65, 97], ["ethanol", "CHEMICAL", 102, 109], ["triethylamine", "CHEMICAL", 129, 142], ["1,2-difluoro-4,5-dinitrobenzene", "SIMPLE_CHEMICAL", 66, 97], ["ethanol", "SIMPLE_CHEMICAL", 102, 109], ["triethylamine", "SIMPLE_CHEMICAL", 129, 142], ["The solvent", "TREATMENT", 0, 11], ["the reaction", "PROBLEM", 35, 47], ["the warhead", "TREATMENT", 53, 64], ["difluoro", "TREATMENT", 70, 78], ["dinitrobenzene", "TREATMENT", 83, 97], ["ethanol", "TREATMENT", 102, 109], ["triethylamine", "TREATMENT", 129, 142]]], ["After 21 h at 80 \u2022 C, the desired acid 8 was obtained after purification by preparative high-performance liquid chromatography (HPLC).", [["the desired acid", "TEST", 22, 38]]], ["To further investigate whether the hydrolysis product of compound 7 is the active compound as indicated by MS, NMR and hydrolysis studies (see 2.3, 2.4 and 2.5), the corresponding free acid 8 was also synthesized (Scheme 3).", [["the hydrolysis product of compound", "PROBLEM", 31, 65], ["the active compound", "PROBLEM", 71, 90], ["MS", "TEST", 107, 109], ["NMR", "TEST", 111, 114], ["hydrolysis studies", "TEST", 119, 137], ["the corresponding free acid", "TEST", 162, 189]]], ["First attempts to cleave the benzyl ester of compound 7 with PPL (porcine pancreatic lipase) were unsuccessful.", [["pancreatic", "ANATOMY", 74, 84], ["benzyl ester", "CHEMICAL", 29, 41], ["PPL", "CHEMICAL", 61, 64], ["benzyl ester", "CHEMICAL", 29, 41], ["benzyl ester", "SIMPLE_CHEMICAL", 29, 41], ["compound 7", "SIMPLE_CHEMICAL", 45, 55], ["PPL", "SIMPLE_CHEMICAL", 61, 64], ["porcine", "ORGANISM", 66, 73], ["pancreatic", "ORGAN", 74, 84], ["lipase", "GENE_OR_GENE_PRODUCT", 85, 91], ["PPL", "PROTEIN", 61, 64], ["porcine pancreatic lipase", "PROTEIN", 66, 91], ["porcine", "SPECIES", 66, 73], ["PPL (porcine pancreatic lipase", "TREATMENT", 61, 91], ["pancreatic", "ANATOMY", 74, 84]]], ["The compound was synthesized starting from the fully protected dipeptide Boc-NH-L-Phe-L-Leu-OBn.", [["Boc-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 73, 95], ["Boc-NH-L-Phe-L-Leu-OBn", "CHEMICAL", 73, 95], ["dipeptide Boc-NH-L-Phe-L-Leu-OBn", "SIMPLE_CHEMICAL", 63, 95]]], ["In a first step, the benzyl ester was removed by hydrogenolysis.", [["benzyl ester", "CHEMICAL", 21, 33], ["benzyl ester", "CHEMICAL", 21, 33], ["benzyl ester", "SIMPLE_CHEMICAL", 21, 33], ["the benzyl ester", "TREATMENT", 17, 33]]], ["A short filtration over celite yielded a crude material that was subjected to acidolytic removal of the Boc-protecting group with trifluoroacetic acid (TFA).", [["trifluoroacetic acid", "CHEMICAL", 130, 150], ["TFA", "CHEMICAL", 152, 155], ["trifluoroacetic acid", "CHEMICAL", 130, 150], ["TFA", "CHEMICAL", 152, 155], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 130, 150], ["TFA", "SIMPLE_CHEMICAL", 152, 155], ["A short filtration over celite", "TREATMENT", 0, 30], ["a crude material", "PROBLEM", 39, 55], ["acidolytic removal", "TREATMENT", 78, 96], ["trifluoroacetic acid (TFA", "TREATMENT", 130, 155], ["short", "OBSERVATION_MODIFIER", 2, 7]]], ["The solvent was removed to perform the reaction with the warhead (1,2-difluoro-4,5-dinitrobenzene) in ethanol in the presence of triethylamine.", [["1,2-difluoro-4,5-dinitrobenzene", "CHEMICAL", 66, 97], ["ethanol", "CHEMICAL", 102, 109], ["triethylamine", "CHEMICAL", 129, 142], ["(1,2-difluoro-4,5-dinitrobenzene", "CHEMICAL", 65, 97], ["ethanol", "CHEMICAL", 102, 109], ["triethylamine", "CHEMICAL", 129, 142], ["1,2-difluoro-4,5-dinitrobenzene", "SIMPLE_CHEMICAL", 66, 97], ["ethanol", "SIMPLE_CHEMICAL", 102, 109], ["triethylamine", "SIMPLE_CHEMICAL", 129, 142], ["The solvent", "TREATMENT", 0, 11], ["the reaction", "PROBLEM", 35, 47], ["the warhead", "TREATMENT", 53, 64], ["difluoro", "TREATMENT", 70, 78], ["dinitrobenzene", "TREATMENT", 83, 97], ["ethanol", "TREATMENT", 102, 109], ["triethylamine", "TREATMENT", 129, 142]]], ["After 21 h at 80 \u00b0C, the desired acid 8 was obtained after purification by preparative high-performance liquid chromatography (HPLC).Enzyme AssaysInhibition of cathepsins and rhodesain was tested with the fluorogenic substrate Cbz-Phe-Arg-AMC as described previously [19] .", [["rhodesain", "CHEMICAL", 175, 184], ["Cbz-Phe-Arg", "CHEMICAL", 227, 238], ["rhodesain", "CHEMICAL", 175, 184], ["Cbz-Phe-Arg-AMC", "CHEMICAL", 227, 242], ["cathepsins", "GENE_OR_GENE_PRODUCT", 160, 170], ["rhodesain", "SIMPLE_CHEMICAL", 175, 184], ["Cbz-Phe-Arg-AMC", "SIMPLE_CHEMICAL", 227, 242], ["cathepsins", "PROTEIN", 160, 170], ["the desired acid", "TEST", 21, 37], ["Enzyme", "TEST", 133, 139], ["cathepsins", "TREATMENT", 160, 170], ["rhodesain", "TEST", 175, 184], ["the fluorogenic substrate Cbz", "TEST", 201, 230], ["Phe", "TEST", 231, 234], ["AMC", "PROBLEM", 239, 242]]], ["First, a screening at 20 \u00b5M inhibitor concentration was performed.", [["a screening", "TEST", 7, 18]]], ["For compounds showing >60% inhibition at this concentration, the IC50 values were determined.", [["compounds", "TEST", 4, 13], ["the IC50 values", "TEST", 61, 76]]], ["For the most active compounds, namely 4 and 7, the IC50 values were determined at different substrate concentrations in order to check for competitive or non-competitive inhibition [44, 45] .", [["the IC50 values", "TEST", 47, 62], ["most active", "OBSERVATION_MODIFIER", 8, 19], ["compounds", "OBSERVATION", 20, 29]]], ["IC50 values were found to increase linearly with increasing substrate concentrations in both cases, indicating competitive inhibition (see exemplarily Figure 1 for compound 7) .", [["IC50 values", "TEST", 0, 11], ["increasing substrate concentrations", "PROBLEM", 49, 84], ["competitive inhibition", "PROBLEM", 111, 133], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["linearly", "OBSERVATION_MODIFIER", 35, 43], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["substrate concentrations", "OBSERVATION", 60, 84], ["competitive inhibition", "OBSERVATION", 111, 133]]], ["The respective Ki values (Table 1) were determined from plots of the IC50 values against substrate concentration according to the Cheng-Prusoff relationship [46] .Enzyme AssaysInhibition of cathepsins and rhodesain was tested with the fluorogenic substrate Cbz-Phe-Arg-AMC as described previously [19] .", [["rhodesain", "CHEMICAL", 205, 214], ["Cbz-Phe-Arg", "CHEMICAL", 257, 268], ["rhodesain", "CHEMICAL", 205, 214], ["Cbz-Phe-Arg-AMC", "CHEMICAL", 257, 272], ["cathepsins", "GENE_OR_GENE_PRODUCT", 190, 200], ["rhodesain", "SIMPLE_CHEMICAL", 205, 214], ["Cbz-Phe-Arg-AMC", "SIMPLE_CHEMICAL", 257, 272], ["cathepsins", "PROTEIN", 190, 200], ["The respective Ki values", "TEST", 0, 24], ["the IC50 values", "TEST", 65, 80], ["Enzyme", "TEST", 163, 169], ["cathepsins", "TREATMENT", 190, 200], ["rhodesain", "TEST", 205, 214], ["the fluorogenic substrate Cbz", "TEST", 231, 260], ["Phe", "TEST", 261, 264], ["AMC", "PROBLEM", 269, 272]]], ["First, a screening at 20 \u00b5M inhibitor concentration was performed.", [["a screening", "TEST", 7, 18]]], ["For compounds showing >60% inhibition at this concentration, the IC 50 values were determined.", [["compounds", "TEST", 4, 13]]], ["IC 50 values were found to increase linearly with increasing substrate concentrations in both cases, indicating competitive inhibition (see exemplarily Figure 1 for compound 7).", [["increasing substrate concentrations", "PROBLEM", 50, 85], ["competitive inhibition", "PROBLEM", 112, 134], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["linearly", "OBSERVATION_MODIFIER", 36, 44], ["increasing", "OBSERVATION_MODIFIER", 50, 60], ["substrate concentrations", "OBSERVATION", 61, 85]]], ["The respective K i values (Table 1) were determined from plots of the IC 50 values against substrate concentration according to the Cheng-Prusoff relationship [46] .", [["The respective K i values", "TEST", 0, 25]]], ["The progress curves for inhibition of cathepsins and rhodesain by the compounds were found to be linear in all cases, i.e., no time-dependent inhibition was observed, pointing to fast reversible inhibition.Enzyme AssaysThe highest inhibition of cathepsin L was found with the benzoic acid amide 4 (Ki = 0.66 \u00b5M) The progress curves for inhibition of cathepsins and rhodesain by the compounds were found to be linear in all cases, i.e., no time-dependent inhibition was observed, pointing to fast reversible inhibition.Enzyme AssaysThe highest inhibition of cathepsin L was found with the benzoic acid amide 4 (K i = 0.66 \u00b5M) and the amine 7 (K i = 1.6 \u00b5M).", [["rhodesain", "CHEMICAL", 53, 62], ["benzoic acid", "CHEMICAL", 276, 288], ["rhodesain", "CHEMICAL", 365, 374], ["benzoic acid", "CHEMICAL", 588, 600], ["K", "CHEMICAL", 610, 611], ["amine", "CHEMICAL", 633, 638], ["K", "CHEMICAL", 642, 643], ["rhodesain", "CHEMICAL", 53, 62], ["benzoic acid amide", "CHEMICAL", 276, 294], ["rhodesain", "CHEMICAL", 365, 374], ["benzoic acid amide", "CHEMICAL", 588, 606], ["amine", "CHEMICAL", 633, 638], ["cathepsins", "GENE_OR_GENE_PRODUCT", 38, 48], ["rhodesain", "SIMPLE_CHEMICAL", 53, 62], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 245, 256], ["benzoic acid amide 4", "SIMPLE_CHEMICAL", 276, 296], ["cathepsins", "GENE_OR_GENE_PRODUCT", 350, 360], ["rhodesain", "SIMPLE_CHEMICAL", 365, 374], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 557, 568], ["benzoic acid", "SIMPLE_CHEMICAL", 588, 600], ["cathepsins", "PROTEIN", 38, 48], ["cathepsin L", "PROTEIN", 245, 256], ["cathepsins", "PROTEIN", 350, 360], ["cathepsin L", "PROTEIN", 557, 568], ["inhibition of cathepsins", "TREATMENT", 24, 48], ["rhodesain", "TREATMENT", 53, 62], ["fast reversible inhibition", "PROBLEM", 179, 205], ["Enzyme Assays", "TEST", 206, 219], ["cathepsin L", "TREATMENT", 245, 256], ["the benzoic acid amide", "TREATMENT", 272, 294], ["Ki", "TEST", 298, 300], ["inhibition of cathepsins", "TREATMENT", 336, 360], ["rhodesain", "TREATMENT", 365, 374], ["fast reversible inhibition", "PROBLEM", 491, 517], ["Enzyme Assays", "TEST", 518, 531], ["cathepsin L", "TREATMENT", 557, 568], ["the benzoic acid amide", "TEST", 584, 606], ["K i", "TEST", 610, 613], ["the amine", "TEST", 629, 638], ["K i", "TEST", 642, 645], ["linear", "OBSERVATION_MODIFIER", 97, 103], ["reversible inhibition", "OBSERVATION", 184, 205], ["linear", "OBSERVATION_MODIFIER", 409, 415], ["reversible inhibition", "OBSERVATION", 496, 517]]], ["The latter also turned out to be the best inhibitor of cathepsin B and the Dengue virus (DENV) protease [47, 48] , however with lower inhibitory potency (Cath.", [["Dengue", "DISEASE", 75, 81], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 55, 66], ["Dengue virus", "ORGANISM", 75, 87], ["DENV", "ORGANISM", 89, 93], ["cathepsin B", "PROTEIN", 55, 66], ["Dengue virus (DENV) protease", "PROTEIN", 75, 103], ["Dengue virus", "SPECIES", 75, 87], ["Dengue virus", "SPECIES", 75, 87], ["DENV", "SPECIES", 89, 93], ["cathepsin B", "TREATMENT", 55, 66], ["the Dengue virus", "PROBLEM", 71, 87], ["Cath", "TEST", 154, 158]]], ["B: K i = 4.4 \u00b5M; DENV PR: 31% at 20 \u00b5M).", [["DENV PR", "PROTEIN", 17, 24], ["K i", "TEST", 3, 6], ["DENV PR", "TEST", 17, 24]]], ["These two compounds were also tested for inhibition of the cathepsin L-like parasitic protease rhodesain.", [["cathepsin L", "GENE_OR_GENE_PRODUCT", 59, 70], ["cathepsin L-like parasitic protease rhodesain", "PROTEIN", 59, 104], ["the cathepsin L", "TREATMENT", 55, 70], ["parasitic protease rhodesain", "PROBLEM", 76, 104]]], ["While only a weak inhibitory potency (45% inhibition at 20 \u00b5M) was detected for compound 7, the amide 4 displayed a K i value of 0.29 \u00b5M.Enzyme AssaysThe benzyl ester 7 was found to be hydrolyzed, yielding the free acid 8 (see Sections 2.3-2.5).", [["K", "CHEMICAL", 116, 117], ["benzyl ester", "CHEMICAL", 154, 166], ["amide", "CHEMICAL", 96, 101], ["benzyl ester", "CHEMICAL", 154, 166], ["amide 4", "SIMPLE_CHEMICAL", 96, 103], ["benzyl ester 7", "SIMPLE_CHEMICAL", 154, 168], ["a weak inhibitory potency", "PROBLEM", 11, 36], ["a K i value", "TEST", 114, 125], ["Enzyme Assays", "TEST", 137, 150], ["the free acid", "TEST", 206, 219], ["Sections", "TEST", 227, 235]]], ["Thus, the enzyme assays were also performed with the acid 8.", [["the enzyme assays", "TEST", 6, 23], ["the acid", "TEST", 49, 57]]], ["K i values of 3.0 \u00b1 0.9 \u00b5M for cathepsin L (n = 10), 1.50 \u00b1 0.29 \u00b5M for cathepsin B (n = 6) and, most interestingly, 4.0 \u00b1 1.3 nM (n = 14) for rhodesain, were determined ( Figure 2 ).", [["K", "CHEMICAL", 0, 1], ["rhodesain", "CHEMICAL", 143, 152], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 31, 42], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 72, 83], ["rhodesain", "SIMPLE_CHEMICAL", 143, 152], ["cathepsin L", "PROTEIN", 31, 42], ["cathepsin B", "PROTEIN", 72, 83], ["K i values", "TEST", 0, 10], ["cathepsin L (n", "TEST", 31, 45], ["cathepsin B (n", "TEST", 72, 86], ["nM", "TEST", 127, 129], ["rhodesain", "PROBLEM", 143, 152]]], ["This indicates that acid 8 and ester 7 are similarly active on cathepsins L and B, whereas in the case of rhodesain, an enormous increase in inhibition potency was observed comparing the benzyl ester 7 and the respective free acid 8.", [["acid 8 and ester", "CHEMICAL", 20, 36], ["rhodesain", "CHEMICAL", 106, 115], ["benzyl ester", "CHEMICAL", 187, 199], ["ester", "CHEMICAL", 31, 36], ["rhodesain", "CHEMICAL", 106, 115], ["benzyl ester", "CHEMICAL", 187, 199], ["ester 7", "SIMPLE_CHEMICAL", 31, 38], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 63, 75], ["B", "GENE_OR_GENE_PRODUCT", 80, 81], ["rhodesain", "SIMPLE_CHEMICAL", 106, 115], ["benzyl ester 7", "SIMPLE_CHEMICAL", 187, 201], ["cathepsins L and B", "PROTEIN", 63, 81], ["acid", "TEST", 20, 24], ["an enormous increase in inhibition potency", "PROBLEM", 117, 159], ["the benzyl ester", "TEST", 183, 199], ["the respective free acid", "TEST", 206, 230], ["active", "OBSERVATION_MODIFIER", 53, 59], ["enormous", "OBSERVATION_MODIFIER", 120, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["inhibition potency", "OBSERVATION", 141, 159]]], ["The progress curves for inhibition of cathepsins and rhodesain by the compounds were found to be linear in all cases, i.e., no time-dependent inhibition was observed, pointing to fast reversible inhibition.Enzyme AssaysThe highest inhibition of cathepsin L was found with the benzoic acid amide 4 (Ki = 0.66 \u00b5M) and the amine 7 (Ki = 1.6 \u00b5M).", [["rhodesain", "CHEMICAL", 53, 62], ["benzoic acid amide", "CHEMICAL", 276, 294], ["amine", "CHEMICAL", 320, 325], ["rhodesain", "CHEMICAL", 53, 62], ["benzoic acid amide", "CHEMICAL", 276, 294], ["amine", "CHEMICAL", 320, 325], ["cathepsins", "GENE_OR_GENE_PRODUCT", 38, 48], ["rhodesain", "SIMPLE_CHEMICAL", 53, 62], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 245, 256], ["benzoic acid amide 4", "SIMPLE_CHEMICAL", 276, 296], ["cathepsins", "PROTEIN", 38, 48], ["cathepsin L", "PROTEIN", 245, 256], ["inhibition of cathepsins", "TREATMENT", 24, 48], ["rhodesain", "TREATMENT", 53, 62], ["fast reversible inhibition", "PROBLEM", 179, 205], ["Enzyme Assays", "TEST", 206, 219], ["cathepsin L", "TREATMENT", 245, 256], ["the benzoic acid amide", "TEST", 272, 294], ["Ki", "TEST", 298, 300], ["the amine", "TEST", 316, 325], ["Ki", "TEST", 329, 331], ["linear", "OBSERVATION_MODIFIER", 97, 103], ["reversible inhibition", "OBSERVATION", 184, 205]]], ["The latter also turned out to be the best inhibitor of cathepsin B and the Dengue virus (DENV) protease [47, 48] , however with lower inhibitory potency (Cath.", [["Dengue", "DISEASE", 75, 81], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 55, 66], ["Dengue virus", "ORGANISM", 75, 87], ["DENV", "ORGANISM", 89, 93], ["cathepsin B", "PROTEIN", 55, 66], ["Dengue virus (DENV) protease", "PROTEIN", 75, 103], ["Dengue virus", "SPECIES", 75, 87], ["Dengue virus", "SPECIES", 75, 87], ["DENV", "SPECIES", 89, 93], ["cathepsin B", "TREATMENT", 55, 66], ["the Dengue virus", "PROBLEM", 71, 87], ["Cath", "TEST", 154, 158]]], ["B: Ki = 4.4 \u00b5M; DENV PR: 31% at 20 \u00b5M).", [["PR", "PROTEIN", 21, 23], ["DENV PR", "TEST", 16, 23]]], ["These two compounds were also tested for inhibition of the cathepsin L-like parasitic protease rhodesain.", [["cathepsin L", "GENE_OR_GENE_PRODUCT", 59, 70], ["cathepsin L-like parasitic protease rhodesain", "PROTEIN", 59, 104], ["the cathepsin L", "TREATMENT", 55, 70], ["parasitic protease rhodesain", "PROBLEM", 76, 104]]], ["While only a weak inhibitory potency (45% inhibition at 20 \u00b5M) was detected for compound 7, the amide 4 displayed a Ki value of 0.29 \u00b5M.Enzyme AssaysThe benzyl ester 7 was found to be hydrolyzed, yielding the free acid 8 (see 2.3, 2.4 and 2.5).", [["benzyl ester", "CHEMICAL", 153, 165], ["amide", "CHEMICAL", 96, 101], ["benzyl ester", "CHEMICAL", 153, 165], ["amide 4", "SIMPLE_CHEMICAL", 96, 103], ["benzyl ester 7", "SIMPLE_CHEMICAL", 153, 167], ["a weak inhibitory potency", "PROBLEM", 11, 36], ["a Ki value", "TEST", 114, 124], ["Enzyme Assays", "TEST", 136, 149], ["the free acid", "TEST", 205, 218]]], ["Thus, the enzyme assays were also performed with the acid 8.", [["the enzyme assays", "TEST", 6, 23], ["the acid", "TEST", 49, 57]]], ["Ki values of 3.0 \u00b1 0.9 \u00b5M for cathepsin L (n = 10), 1.50 \u00b1 0.29 \u00b5M for cathepsin B (n = 6) and, most interestingly, 4.0 \u00b1 1.3 nM (n = 14) for rhodesain, were determined ( Figure 2 ).", [["rhodesain", "CHEMICAL", 142, 151], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 30, 41], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 71, 82], ["rhodesain", "SIMPLE_CHEMICAL", 142, 151], ["cathepsin L", "PROTEIN", 30, 41], ["cathepsin B", "PROTEIN", 71, 82], ["Ki values", "TEST", 0, 9], ["cathepsin L (n", "TEST", 30, 44], ["cathepsin B (n", "TEST", 71, 85], ["nM", "TEST", 126, 128], ["rhodesain", "PROBLEM", 142, 151]]], ["This indicates that acid 8 and ester 7 are similarly active on cathepsins L and B, whereas in the case of rhodesain, an enormous increase in inhibition potency was observed comparing the benzyl ester 7 and the respective free acid 8.Enzyme AssaysTo investigate the inhibitory effects against a cysteine protease with a protonated thiol instead of an imidazolium/thiolate dyad, compounds 4, 7 and 8 were tested for inhibition of the S. aureus sortase A. None of the inhibitors showed significant inhibition at a final inhibitor concentration of 20 \u00b5M (compound 4: 11%; compound 7: 16%; compound 8: 0%), indicating selectivity for cysteine proteases from the CA-clan (cathepsins and rhodesain) over the CL-clan sortase A [49] .", [["acid 8 and ester", "CHEMICAL", 20, 36], ["rhodesain", "CHEMICAL", 106, 115], ["benzyl ester", "CHEMICAL", 187, 199], ["cysteine", "CHEMICAL", 294, 302], ["thiol", "CHEMICAL", 330, 335], ["imidazolium", "CHEMICAL", 350, 361], ["cysteine", "CHEMICAL", 629, 637], ["ester", "CHEMICAL", 31, 36], ["rhodesain", "CHEMICAL", 106, 115], ["benzyl ester", "CHEMICAL", 187, 199], ["cysteine", "CHEMICAL", 294, 302], ["thiol", "CHEMICAL", 330, 335], ["imidazolium", "CHEMICAL", 350, 361], ["thiolate", "CHEMICAL", 362, 370], ["cysteine", "CHEMICAL", 629, 637], ["ester 7", "SIMPLE_CHEMICAL", 31, 38], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 63, 75], ["B", "GENE_OR_GENE_PRODUCT", 80, 81], ["rhodesain", "SIMPLE_CHEMICAL", 106, 115], ["benzyl ester 7", "SIMPLE_CHEMICAL", 187, 201], ["thiol", "SIMPLE_CHEMICAL", 330, 335], ["imidazolium/thiolate dyad", "SIMPLE_CHEMICAL", 350, 375], ["S. aureus", "ORGANISM", 432, 441], ["CA-clan", "GENE_OR_GENE_PRODUCT", 657, 664], ["cathepsins", "GENE_OR_GENE_PRODUCT", 666, 676], ["rhodesain", "SIMPLE_CHEMICAL", 681, 690], ["cathepsins L and B", "PROTEIN", 63, 81], ["cysteine protease", "PROTEIN", 294, 311], ["cysteine proteases", "PROTEIN", 629, 647], ["CA-clan", "PROTEIN", 657, 664], ["cathepsins", "PROTEIN", 666, 676], ["rhodesain", "PROTEIN", 681, 690], ["S. aureus", "SPECIES", 432, 441], ["S. aureus", "SPECIES", 432, 441], ["acid", "TEST", 20, 24], ["an enormous increase in inhibition potency", "PROBLEM", 117, 159], ["the benzyl ester", "TEST", 183, 199], ["the respective free acid", "TEST", 206, 230], ["Enzyme Assays", "TEST", 233, 246], ["a cysteine protease", "TREATMENT", 292, 311], ["a protonated thiol", "TREATMENT", 317, 335], ["an imidazolium/thiolate dyad", "TREATMENT", 347, 375], ["the S. aureus sortase A.", "PROBLEM", 428, 452], ["the inhibitors", "TEST", 461, 475], ["significant inhibition", "PROBLEM", 483, 505], ["compound", "TEST", 585, 593], ["cysteine proteases", "PROBLEM", 629, 647], ["the CA-clan (cathepsins and rhodesain)", "TREATMENT", 653, 691], ["active", "OBSERVATION_MODIFIER", 53, 59], ["enormous", "OBSERVATION_MODIFIER", 120, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["inhibition potency", "OBSERVATION", 141, 159]]], ["To investigate the inhibitory effects against a cysteine protease with a protonated thiol instead of an imidazolium/thiolate dyad, compounds 4, 7 and 8 were tested for inhibition of the S. aureus sortase A. None of the inhibitors showed significant inhibition at a final inhibitor concentration of 20 \u00b5M (compound 4: 11%; compound 7: 16%; compound 8: 0%), indicating selectivity for cysteine proteases from the CA-clan (cathepsins and rhodesain) over the CL-clan sortase A [49] .Enzyme AssaysThe progress curves for inhibition of cathepsins L and B and rhodesain by compound 8 did not clearly show time-dependent behavior.", [["cysteine", "CHEMICAL", 48, 56], ["thiol", "CHEMICAL", 84, 89], ["imidazolium", "CHEMICAL", 104, 115], ["cysteine", "CHEMICAL", 383, 391], ["cysteine", "CHEMICAL", 48, 56], ["thiol", "CHEMICAL", 84, 89], ["imidazolium", "CHEMICAL", 104, 115], ["thiolate", "CHEMICAL", 116, 124], ["cysteine", "CHEMICAL", 383, 391], ["rhodesain", "CHEMICAL", 553, 562], ["thiol", "SIMPLE_CHEMICAL", 84, 89], ["imidazolium/thiolate dyad", "SIMPLE_CHEMICAL", 104, 129], ["S. aureus", "ORGANISM", 186, 195], ["CA-clan", "GENE_OR_GENE_PRODUCT", 411, 418], ["cathepsins", "GENE_OR_GENE_PRODUCT", 420, 430], ["rhodesain", "SIMPLE_CHEMICAL", 435, 444], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 530, 542], ["B", "GENE_OR_GENE_PRODUCT", 547, 548], ["rhodesain", "SIMPLE_CHEMICAL", 553, 562], ["cysteine protease", "PROTEIN", 48, 65], ["cysteine proteases", "PROTEIN", 383, 401], ["CA-clan", "PROTEIN", 411, 418], ["cathepsins", "PROTEIN", 420, 430], ["rhodesain", "PROTEIN", 435, 444], ["cathepsins L and B", "PROTEIN", 530, 548], ["S. aureus", "SPECIES", 186, 195], ["S. aureus", "SPECIES", 186, 195], ["a cysteine protease", "TREATMENT", 46, 65], ["a protonated thiol", "TREATMENT", 71, 89], ["an imidazolium/thiolate dyad", "TREATMENT", 101, 129], ["the S. aureus sortase A.", "PROBLEM", 182, 206], ["the inhibitors", "TEST", 215, 229], ["significant inhibition", "PROBLEM", 237, 259], ["compound", "TEST", 339, 347], ["cysteine proteases", "PROBLEM", 383, 401], ["the CA-clan (cathepsins and rhodesain)", "TREATMENT", 407, 445], ["Enzyme Assays", "TEST", 479, 492], ["cathepsins L and B and rhodesain", "TREATMENT", 530, 562]]], ["Since the inhibition mechanism (reversible vs. irreversible) can unequivocally not be deduced from the progress curves, we also used other methods to ascertain the (ir)reversibility of the inhibition: (A) The IC 50 values for inhibition of rhodesain were determined in dependence of incubation time of enzyme and inhibitor prior to substrate addition (10 min vs. 45 min).", [["rhodesain", "CHEMICAL", 240, 249], ["rhodesain", "CHEMICAL", 240, 249], ["rhodesain", "SIMPLE_CHEMICAL", 240, 249], ["the inhibition mechanism", "PROBLEM", 6, 30], ["other methods", "TREATMENT", 133, 146], ["inhibition of rhodesain", "TREATMENT", 226, 249], ["enzyme and inhibitor", "TREATMENT", 302, 322]]], ["No differences were observed indicating reversible inhibition; (B) Furthermore, dilution assays were performed with rhodesain.", [["rhodesain", "CHEMICAL", 116, 125], ["rhodesain", "SIMPLE_CHEMICAL", 116, 125], ["reversible inhibition", "PROBLEM", 40, 61], ["Furthermore, dilution assays", "TEST", 67, 95], ["rhodesain", "PROBLEM", 116, 125], ["reversible inhibition", "OBSERVATION", 40, 61]]], ["To this end, the enzyme was completely inhibited by an inhibitor concentration 100 fold higher than the IC 50 value.", [["the enzyme", "TEST", 13, 23], ["an inhibitor concentration", "TEST", 52, 78]]], ["After dilution of the enzyme-inhibitor mixture with a buffer by a factor of 100, slow and time-dependent reactivation of the enzyme was observed, finally proving the reversibility of inhibition (see Supplementary Material).19 F NMR SpectroscopyThe interaction of the fluorinated inhibitors 7 and 8 with rhodesain was probed via 19 F NMR spectroscopy ( Figure 3 ).", [["rhodesain", "CHEMICAL", 303, 312], ["19 F", "CHEMICAL", 223, 227], ["rhodesain", "CHEMICAL", 303, 312], ["rhodesain", "SIMPLE_CHEMICAL", 303, 312], ["enzyme", "PROTEIN", 22, 28], ["enzyme", "PROTEIN", 125, 131], ["the enzyme-inhibitor mixture", "TREATMENT", 18, 46], ["a buffer", "TREATMENT", 52, 60], ["a factor", "TEST", 64, 72], ["the enzyme", "TEST", 121, 131], ["NMR Spectroscopy", "TEST", 228, 244], ["the fluorinated inhibitors", "TREATMENT", 263, 289], ["NMR spectroscopy", "TEST", 333, 349]]], ["Compound 7 displayed some solubility issues apparent from the observed turbidity of the sample and the reduced signal-to-noise ratio in the spectrum (Figure 3a ).", [["some solubility issues", "PROBLEM", 21, 43], ["the sample", "TEST", 84, 94], ["the reduced signal", "PROBLEM", 99, 117], ["some solubility", "OBSERVATION_MODIFIER", 21, 36]]], ["To probe the rhodesain-mediated turnover of 7 into 8, we recorded time-resolved 19 F NMR spectra of 7 (800 \u00b5M) in the presence of 4 \u00b5M rhodesain ( Figure 3b ).", [["rhodesain", "CHEMICAL", 13, 22], ["rhodesain", "CHEMICAL", 135, 144], ["rhodesain", "SIMPLE_CHEMICAL", 13, 22], ["NMR spectra", "TEST", 85, 96]]], ["During the measurement, the solution became clear and a dramatic difference in the chemical shift occurred to values identical to those observed for compound 8.", [["the measurement", "TEST", 7, 22], ["a dramatic difference", "PROBLEM", 54, 75], ["the chemical shift", "PROBLEM", 79, 97], ["clear", "OBSERVATION", 44, 49], ["dramatic", "OBSERVATION_MODIFIER", 56, 64], ["difference", "OBSERVATION_MODIFIER", 65, 75], ["chemical shift", "OBSERVATION", 83, 97]]], ["The reaction was subsequently analyzed by MS (see Section 2.4), which confirmed the formation of the free acid 8.19 F NMR SpectroscopyMolecules 2020, 25, x FOR PEER REVIEW 6 of 2319 F NMR SpectroscopyThe progress curves for inhibition of cathepsins L and B and rhodesain by compound 8 did not clearly show time-dependent behavior.", [["8.19 F", "CHEMICAL", 111, 117], ["2319 F", "CHEMICAL", 177, 183], ["rhodesain", "CHEMICAL", 261, 270], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 238, 250], ["B", "GENE_OR_GENE_PRODUCT", 255, 256], ["rhodesain", "SIMPLE_CHEMICAL", 261, 270], ["cathepsins L and B", "PROTEIN", 238, 256], ["The reaction", "PROBLEM", 0, 12], ["the free acid", "TEST", 97, 110], ["NMR Spectroscopy", "TEST", 184, 200], ["cathepsins L and B and rhodesain", "TREATMENT", 238, 270]]], ["Since the inhibition mechanism (reversible vs. irreversible) can unequivocally not be deduced from the progress curves, we also used other methods to ascertain the (ir)reversibility of the inhibition: A) The IC50 values for inhibition of rhodesain were determined in dependence of incubation time of enzyme and inhibitor prior to substrate addition (10 min vs. 45 min).", [["rhodesain", "CHEMICAL", 238, 247], ["rhodesain", "CHEMICAL", 238, 247], ["rhodesain", "SIMPLE_CHEMICAL", 238, 247], ["the inhibition mechanism", "PROBLEM", 6, 30], ["other methods", "TREATMENT", 133, 146], ["The IC50 values", "TEST", 204, 219], ["inhibition of rhodesain", "TREATMENT", 224, 247], ["enzyme", "TREATMENT", 300, 306], ["inhibitor", "TREATMENT", 311, 320]]], ["No differences were observed indicating reversible inhibition; B) Furthermore, dilution assays were performed with rhodesain.", [["rhodesain", "CHEMICAL", 115, 124], ["rhodesain", "SIMPLE_CHEMICAL", 115, 124], ["reversible inhibition", "PROBLEM", 40, 61], ["Furthermore, dilution assays", "TEST", 66, 94], ["rhodesain", "PROBLEM", 115, 124]]], ["To this end, the enzyme was completely inhibited by an inhibitor concentration 100 fold higher than the IC50 value.", [["the enzyme", "TEST", 13, 23], ["an inhibitor concentration", "TEST", 52, 78], ["the IC50 value", "TEST", 100, 114]]], ["After dilution of the enzyme-inhibitor mixture with a buffer by a factor of 100, slow and time-dependent reactivation of the enzyme was observed, finally proving the reversibility of inhibition (see Supplementary Material).19 F NMR SpectroscopyThe interaction of the fluorinated inhibitors 7 and 8 with rhodesain was probed via 19 F NMR spectroscopy ( Figure 3 ).", [["rhodesain", "CHEMICAL", 303, 312], ["19 F", "CHEMICAL", 223, 227], ["rhodesain", "CHEMICAL", 303, 312], ["rhodesain", "SIMPLE_CHEMICAL", 303, 312], ["enzyme", "PROTEIN", 22, 28], ["enzyme", "PROTEIN", 125, 131], ["the enzyme-inhibitor mixture", "TREATMENT", 18, 46], ["a buffer", "TREATMENT", 52, 60], ["a factor", "TEST", 64, 72], ["the enzyme", "TEST", 121, 131], ["NMR Spectroscopy", "TEST", 228, 244], ["the fluorinated inhibitors", "TREATMENT", 263, 289], ["NMR spectroscopy", "TEST", 333, 349]]], ["Compound 7 displayed some solubility issues apparent from the observed turbidity of the sample and the reduced signal-to-noise ratio in the spectrum (Figure 3a ).", [["some solubility issues", "PROBLEM", 21, 43], ["the sample", "TEST", 84, 94], ["the reduced signal", "PROBLEM", 99, 117], ["some solubility", "OBSERVATION_MODIFIER", 21, 36]]], ["To probe the rhodesain-mediated turnover of 7 into 8, we recorded time-resolved 19 F NMR spectra of 7 (800 \u00b5M) in the presence of 4 \u00b5M rhodesain (Figure 3b ).", [["rhodesain", "CHEMICAL", 13, 22], ["rhodesain", "CHEMICAL", 135, 144], ["rhodesain", "SIMPLE_CHEMICAL", 13, 22], ["NMR spectra", "TEST", 85, 96]]], ["During the measurement, the solution became clear and a dramatic difference in the chemical shift occurred to values identical to those observed for compound 8.", [["the measurement", "TEST", 7, 22], ["a dramatic difference", "PROBLEM", 54, 75], ["the chemical shift", "PROBLEM", 79, 97], ["clear", "OBSERVATION", 44, 49], ["dramatic", "OBSERVATION_MODIFIER", 56, 64], ["difference", "OBSERVATION_MODIFIER", 65, 75], ["chemical shift", "OBSERVATION", 83, 97]]], ["The reaction was subsequently analyzed by MS (see 2.4), which confirmed the formation of the free acid 8.19 F NMR SpectroscopyTo observe the chemical shift of the rhodesain-bound reaction product, a higher concentration of rhodesain (150 or 450 \u00b5M) was incubated with 8.", [["rhodesain", "CHEMICAL", 163, 172], ["rhodesain", "CHEMICAL", 223, 232], ["8.19 F", "CHEMICAL", 103, 109], ["rhodesain", "CHEMICAL", 163, 172], ["rhodesain", "CHEMICAL", 223, 232], ["rhodesain", "SIMPLE_CHEMICAL", 163, 172], ["rhodesain", "SIMPLE_CHEMICAL", 223, 232], ["the free acid", "TEST", 89, 102], ["NMR Spectroscopy", "TEST", 110, 126]]], ["Indeed, a new, broad peak (Figure 3c, asterisk) was observed, which probably results from an enzyme-inhibitor adduct (see 2.6 and 2.7).", [["enzyme", "PROTEIN", 93, 99], ["a new, broad peak (Figure 3c", "PROBLEM", 8, 36], ["an enzyme-inhibitor adduct", "TEST", 90, 116], ["new", "OBSERVATION_MODIFIER", 10, 13], ["broad", "OBSERVATION_MODIFIER", 15, 20], ["peak", "OBSERVATION_MODIFIER", 21, 25]]], ["19 F NMR shows rhodesain-dependent turnover of 7 into 8.", [["rhodesain", "SIMPLE_CHEMICAL", 15, 24], ["NMR", "TEST", 5, 8], ["rhodesain-dependent turnover", "PROBLEM", 15, 43], ["dependent", "OBSERVATION_MODIFIER", 25, 34]]], ["As a control, a separate spectrum of the expected amount of compound 8 that should have formed from 7 in the NMR-based enzymatic assay is recorded (blue trace).", [["the NMR", "TEST", 105, 112], ["enzymatic assay", "TEST", 119, 134], ["amount", "OBSERVATION_MODIFIER", 50, 56]]], ["Due to the poor solubility of compound 7 (compare (a)), no peak was observed within the 128 scans run for each time-trace.", [["trace", "OBSERVATION", 116, 121]]], ["Upon addition of rhodesain, the turbid sample gradually turned clear and the resonance for compound 8 appeared.", [["rhodesain", "CHEMICAL", 17, 26], ["rhodesain", "CHEMICAL", 17, 26], ["rhodesain", "SIMPLE_CHEMICAL", 17, 26], ["rhodesain", "TREATMENT", 17, 26], ["the turbid sample", "TEST", 28, 45], ["the resonance", "TEST", 73, 86], ["turbid", "OBSERVATION_MODIFIER", 32, 38]]], ["Therefore, the spectral region has been confined to that displaying the chemical shift for compound 8. (c) Acid 8 forms a stable complex (asterisk) with rhodesain.", [["(c) Acid", "CHEMICAL", 103, 111], ["c) Acid 8", "SIMPLE_CHEMICAL", 104, 113], ["rhodesain", "SIMPLE_CHEMICAL", 153, 162], ["Acid", "TEST", 107, 111], ["rhodesain", "PROBLEM", 153, 162], ["stable", "OBSERVATION_MODIFIER", 122, 128]]], ["The peak intensity depends on the amount of protein.", [["peak", "OBSERVATION_MODIFIER", 4, 8], ["intensity", "OBSERVATION_MODIFIER", 9, 18]]], ["For reference, the spectrum of free compound 8 (blue) is included (as shown in (a)).Mass SpectrometryTo further characterize the interaction between rhodesain and the different inhibitors, we performed a liquid chromatography-mass spectrometric (LC-MS coupled to nano-ESI-Q-TOF) analysis of rhodesain that had been incubated with compounds 4 or 7.", [["rhodesain", "CHEMICAL", 149, 158], ["rhodesain", "CHEMICAL", 291, 300], ["rhodesain", "CHEMICAL", 149, 158], ["rhodesain", "SIMPLE_CHEMICAL", 149, 158], ["rhodesain", "SIMPLE_CHEMICAL", 291, 300], ["Mass Spectrometry", "PROBLEM", 84, 101], ["rhodesain", "TREATMENT", 149, 158], ["the different inhibitors", "TREATMENT", 163, 187], ["a liquid chromatography", "TEST", 202, 225], ["mass spectrometric", "PROBLEM", 226, 244], ["LC", "TEST", 246, 248], ["MS", "PROBLEM", 249, 251], ["nano", "TEST", 263, 267], ["ESI", "TEST", 268, 271], ["rhodesain", "PROBLEM", 291, 300], ["Spectrometry", "OBSERVATION", 89, 101]]], ["Samples were analyzed in positive ion mode on a quadrupole time-of-flight mass spectrometer (Synapt G2-S HDMS, Waters Corporation) using electrospray ionization (ESI).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a quadrupole time", "TEST", 46, 63]]], ["Rhodesain without inhibitor served as a control.", [["Rhodesain", "CHEMICAL", 0, 9], ["Rhodesain", "SIMPLE_CHEMICAL", 0, 9], ["inhibitor", "TREATMENT", 18, 27]]], ["Both compounds reacted with rhodesain ( Figure 4 ).", [["rhodesain", "CHEMICAL", 28, 37], ["rhodesain", "CHEMICAL", 28, 37], ["rhodesain", "SIMPLE_CHEMICAL", 28, 37]]], ["Interestingly, we found that rhodesain catalyzes the hydrolysis of the benzyl esters of the dipeptide recognition units to the corresponding acids, 19 F NMR shows rhodesain-dependent turnover of 7 into 8.", [["rhodesain", "CHEMICAL", 29, 38], ["benzyl esters", "CHEMICAL", 71, 84], ["rhodesain", "CHEMICAL", 163, 172], ["benzyl esters", "CHEMICAL", 71, 84], ["dipeptide", "CHEMICAL", 92, 101], ["rhodesain", "SIMPLE_CHEMICAL", 29, 38], ["benzyl esters", "SIMPLE_CHEMICAL", 71, 84], ["rhodesain", "SIMPLE_CHEMICAL", 163, 172], ["the corresponding acids", "TEST", 123, 146], ["NMR", "TEST", 153, 156], ["rhodesain", "TEST", 163, 172]]], ["As a control, a separate spectrum of the expected amount of compound 8 that should have formed from 7 in the NMR-based enzymatic assay is recorded (blue trace).", [["the NMR", "TEST", 105, 112], ["enzymatic assay", "TEST", 119, 134], ["amount", "OBSERVATION_MODIFIER", 50, 56]]], ["Due to the poor solubility of compound 7 (compare (a)), no peak was observed within the 128 scans run for each time-trace.", [["trace", "OBSERVATION", 116, 121]]], ["Upon addition of rhodesain, the turbid sample gradually turned clear and the resonance for compound 8 appeared.", [["rhodesain", "CHEMICAL", 17, 26], ["rhodesain", "CHEMICAL", 17, 26], ["rhodesain", "SIMPLE_CHEMICAL", 17, 26], ["rhodesain", "TREATMENT", 17, 26], ["the turbid sample", "TEST", 28, 45], ["the resonance", "TEST", 73, 86], ["turbid", "OBSERVATION_MODIFIER", 32, 38]]], ["Therefore, the spectral region has been confined to that displaying the chemical shift for compound 8. (c) Acid 8 forms a stable complex (asterisk) with rhodesain.", [["(c) Acid", "CHEMICAL", 103, 111], ["c) Acid 8", "SIMPLE_CHEMICAL", 104, 113], ["rhodesain", "SIMPLE_CHEMICAL", 153, 162], ["Acid", "TEST", 107, 111], ["rhodesain", "PROBLEM", 153, 162], ["stable", "OBSERVATION_MODIFIER", 122, 128]]], ["The peak intensity depends on the amount of protein.", [["peak", "OBSERVATION_MODIFIER", 4, 8], ["intensity", "OBSERVATION_MODIFIER", 9, 18]]], ["For reference, the spectrum of free compound 8 (blue) is included (as shown in (a)).Mass SpectrometryTo observe the chemical shift of the rhodesain-bound reaction product, a higher concentration of rhodesain (150 or 450 \u00b5M) was incubated with 8.", [["rhodesain", "CHEMICAL", 138, 147], ["rhodesain", "CHEMICAL", 198, 207], ["rhodesain", "CHEMICAL", 138, 147], ["rhodesain", "CHEMICAL", 198, 207], ["rhodesain", "SIMPLE_CHEMICAL", 138, 147], ["rhodesain", "SIMPLE_CHEMICAL", 198, 207], ["Mass Spectrometry", "PROBLEM", 84, 101], ["Spectrometry", "OBSERVATION", 89, 101]]], ["Indeed, a new, broad peak (Figure 3c , asterisk) was observed, which probably results from an enzyme-inhibitor adduct (see Sections 2.6 and 2.7).Mass SpectrometryTo further characterize the interaction between rhodesain and the different inhibitors, we performed a liquid chromatography-mass spectrometric (LC-MS coupled to nano-ESI-Q-TOF) analysis of rhodesain that had been incubated with compounds 4 or 7.", [["rhodesain", "CHEMICAL", 210, 219], ["rhodesain", "CHEMICAL", 352, 361], ["rhodesain", "CHEMICAL", 210, 219], ["rhodesain", "SIMPLE_CHEMICAL", 210, 219], ["rhodesain", "SIMPLE_CHEMICAL", 352, 361], ["enzyme", "PROTEIN", 94, 100], ["a new, broad peak (Figure", "PROBLEM", 8, 33], ["an enzyme-inhibitor adduct", "TEST", 91, 117], ["Sections", "TEST", 123, 131], ["Mass Spectrometry", "PROBLEM", 145, 162], ["rhodesain", "TREATMENT", 210, 219], ["the different inhibitors", "TREATMENT", 224, 248], ["a liquid chromatography", "TEST", 263, 286], ["mass spectrometric", "PROBLEM", 287, 305], ["LC", "TEST", 307, 309], ["MS", "PROBLEM", 310, 312], ["nano", "TEST", 324, 328], ["ESI", "TEST", 329, 332], ["rhodesain", "PROBLEM", 352, 361], ["new", "OBSERVATION_MODIFIER", 10, 13], ["broad", "OBSERVATION_MODIFIER", 15, 20], ["peak", "OBSERVATION_MODIFIER", 21, 25], ["Spectrometry", "OBSERVATION", 150, 162]]], ["Samples were analyzed in positive ion mode on a quadrupole time-of-flight mass spectrometer (Synapt G2-S HDMS, Waters Corporation) using electrospray ionization (ESI).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a quadrupole time", "TEST", 46, 63]]], ["Rhodesain without inhibitor served as a control.", [["Rhodesain", "CHEMICAL", 0, 9], ["Rhodesain", "SIMPLE_CHEMICAL", 0, 9], ["inhibitor", "TREATMENT", 18, 27]]], ["Interestingly, we found that rhodesain catalyzes the hydrolysis of the benzyl esters of the dipeptide recognition units to the corresponding acids, indicated by a mass shift of 90 Da corresponding to the loss of the terminal benzyl group ( Figure 4) .", [["rhodesain", "CHEMICAL", 29, 38], ["benzyl esters", "CHEMICAL", 71, 84], ["benzyl", "CHEMICAL", 225, 231], ["benzyl esters", "CHEMICAL", 71, 84], ["dipeptide", "CHEMICAL", 92, 101], ["benzyl", "CHEMICAL", 225, 231], ["rhodesain", "SIMPLE_CHEMICAL", 29, 38], ["benzyl esters", "SIMPLE_CHEMICAL", 71, 84], ["benzyl", "SIMPLE_CHEMICAL", 225, 231], ["a mass shift", "PROBLEM", 161, 173], ["mass", "OBSERVATION", 163, 167]]], ["Notably, only reaction products of the hydrolyzed compounds with rhodesain were detectable by LC-MS analysis.", [["rhodesain", "CHEMICAL", 65, 74], ["rhodesain", "CHEMICAL", 65, 74], ["rhodesain", "SIMPLE_CHEMICAL", 65, 74], ["the hydrolyzed compounds", "PROBLEM", 35, 59], ["MS analysis", "TEST", 97, 108]]], ["Since the NMR experiments also showed conversion of ester 7 into the acid 8 catalyzed by rhodesain, the LC-MS analyses were repeated with the acid 8.", [["ester 7", "CHEMICAL", 52, 59], ["rhodesain", "CHEMICAL", 89, 98], ["ester", "CHEMICAL", 52, 57], ["rhodesain", "CHEMICAL", 89, 98], ["ester 7", "SIMPLE_CHEMICAL", 52, 59], ["rhodesain", "SIMPLE_CHEMICAL", 89, 98], ["the NMR experiments", "TEST", 6, 25], ["the LC-MS analyses", "TEST", 100, 118], ["the acid", "TEST", 138, 146]]], ["These experiments revealed the formation of an adduct with rhodesain for both acid 8 and ester 7 showing exactly the same pattern ( Figure 4 ).", [["rhodesain", "CHEMICAL", 59, 68], ["ester", "CHEMICAL", 89, 94], ["rhodesain", "CHEMICAL", 59, 68], ["ester", "CHEMICAL", 89, 94], ["rhodesain", "SIMPLE_CHEMICAL", 59, 68], ["ester 7", "SIMPLE_CHEMICAL", 89, 96], ["These experiments", "TEST", 0, 17], ["both acid", "TEST", 73, 82], ["adduct", "OBSERVATION", 47, 53]]], ["These data are in line with the previous NMR spectroscopic observation that the benzyl ester of the dipeptide recognition unit is first hydrolyzed by rhodesain, which subsequently forms a very stable complex with the hydrolysis product.", [["benzyl ester", "CHEMICAL", 80, 92], ["rhodesain", "CHEMICAL", 150, 159], ["benzyl ester", "CHEMICAL", 80, 92], ["dipeptide", "CHEMICAL", 100, 109], ["rhodesain", "CHEMICAL", 150, 159], ["benzyl ester", "SIMPLE_CHEMICAL", 80, 92], ["rhodesain", "SIMPLE_CHEMICAL", 150, 159], ["the hydrolysis product", "TREATMENT", 213, 235], ["very", "OBSERVATION_MODIFIER", 188, 192], ["stable", "OBSERVATION_MODIFIER", 193, 199], ["hydrolysis product", "OBSERVATION", 217, 235]]], ["This may also hold true for inhibitor 4.", [["inhibitor", "TREATMENT", 28, 37]]], ["Since the complex formation is reversible-as shown by the enzyme assays discussed above-and the mass spectra show the mass of the adduct of enzyme and acid 8 and not the mass of an adduct resulting from nucleophilic substitution of either the fluoride or a nitro group, the S N Ar reaction cannot be completed.", [["fluoride", "CHEMICAL", 243, 251], ["nitro", "CHEMICAL", 257, 262], ["fluoride", "CHEMICAL", 243, 251], ["nitro", "CHEMICAL", 257, 262], ["S N", "CHEMICAL", 274, 277], ["fluoride", "SIMPLE_CHEMICAL", 243, 251], ["S N Ar", "SIMPLE_CHEMICAL", 274, 280], ["enzyme", "PROTEIN", 140, 146], ["the enzyme assays", "TEST", 54, 71], ["the mass spectra", "TEST", 92, 108], ["the mass", "PROBLEM", 114, 122], ["acid", "TEST", 151, 155], ["the mass", "PROBLEM", 166, 174], ["an adduct", "PROBLEM", 178, 187], ["nucleophilic substitution", "TREATMENT", 203, 228], ["the fluoride", "TREATMENT", 239, 251], ["a nitro group", "TREATMENT", 255, 268], ["the S N Ar reaction", "PROBLEM", 270, 289], ["reversible", "OBSERVATION_MODIFIER", 31, 41], ["mass", "OBSERVATION", 118, 122], ["mass", "OBSERVATION", 170, 174], ["adduct", "OBSERVATION", 181, 187], ["nucleophilic substitution", "OBSERVATION", 203, 228]]], ["Hence, the data are only consistent with a \u03c0or a Meisenheimer (\u03c3-) complex.Mass SpectrometryMolecules 2020, 25, x FOR PEER REVIEW 7 of 23 indicated by a mass shift of 90 Da corresponding to the loss of the terminal benzyl group (Figure 4) .", [["benzyl", "CHEMICAL", 215, 221], ["benzyl", "CHEMICAL", 215, 221], ["benzyl", "SIMPLE_CHEMICAL", 215, 221], ["Meisenheimer (\u03c3-) complex", "PROTEIN", 49, 74], ["the data", "TEST", 7, 15], ["Mass SpectrometryMolecules", "TEST", 75, 101], ["PEER REVIEW", "TEST", 118, 129], ["a mass shift", "PROBLEM", 151, 163], ["consistent with", "UNCERTAINTY", 25, 40], ["mass", "OBSERVATION", 153, 157]]], ["Notably, only reaction products of the hydrolyzed compounds with rhodesain were detectable by LC-MS analysis.", [["rhodesain", "CHEMICAL", 65, 74], ["rhodesain", "CHEMICAL", 65, 74], ["rhodesain", "SIMPLE_CHEMICAL", 65, 74], ["the hydrolyzed compounds", "PROBLEM", 35, 59], ["MS analysis", "TEST", 97, 108]]], ["Since the NMR experiments also showed conversion of ester 7 into the acid 8 catalyzed by rhodesain, the LC-MS analyses were repeated with the acid 8.", [["ester 7", "CHEMICAL", 52, 59], ["rhodesain", "CHEMICAL", 89, 98], ["ester", "CHEMICAL", 52, 57], ["rhodesain", "CHEMICAL", 89, 98], ["ester 7", "SIMPLE_CHEMICAL", 52, 59], ["rhodesain", "SIMPLE_CHEMICAL", 89, 98], ["the NMR experiments", "TEST", 6, 25], ["the LC-MS analyses", "TEST", 100, 118], ["the acid", "TEST", 138, 146]]], ["These experiments revealed the formation of an adduct with rhodesain for both acid 8 and ester 7 showing exactly the same pattern ( Figure 4 ).", [["rhodesain", "CHEMICAL", 59, 68], ["ester", "CHEMICAL", 89, 94], ["rhodesain", "CHEMICAL", 59, 68], ["ester", "CHEMICAL", 89, 94], ["rhodesain", "SIMPLE_CHEMICAL", 59, 68], ["ester 7", "SIMPLE_CHEMICAL", 89, 96], ["These experiments", "TEST", 0, 17], ["both acid", "TEST", 73, 82], ["adduct", "OBSERVATION", 47, 53]]], ["These data are in line with the previous NMR spectroscopic observation that the benzyl ester of the dipeptide recognition unit is first hydrolyzed by rhodesain, which subsequently forms a very stable complex with the hydrolysis product.", [["benzyl ester", "CHEMICAL", 80, 92], ["rhodesain", "CHEMICAL", 150, 159], ["benzyl ester", "CHEMICAL", 80, 92], ["dipeptide", "CHEMICAL", 100, 109], ["rhodesain", "CHEMICAL", 150, 159], ["benzyl ester", "SIMPLE_CHEMICAL", 80, 92], ["rhodesain", "SIMPLE_CHEMICAL", 150, 159], ["the hydrolysis product", "TREATMENT", 213, 235], ["very", "OBSERVATION_MODIFIER", 188, 192], ["stable", "OBSERVATION_MODIFIER", 193, 199], ["hydrolysis product", "OBSERVATION", 217, 235]]], ["This may also hold true for inhibitor 4.", [["inhibitor", "TREATMENT", 28, 37]]], ["Since the complex formation is reversible-as shown by the enzyme assays discussed above-and the mass spectra show the mass of the adduct of enzyme and acid 8 and not the mass of an adduct resulting from nucleophilic substitution of either the fluoride or a nitro group, the SNAr reaction cannot be completed.", [["fluoride", "CHEMICAL", 243, 251], ["nitro", "CHEMICAL", 257, 262], ["fluoride", "CHEMICAL", 243, 251], ["nitro", "CHEMICAL", 257, 262], ["fluoride", "SIMPLE_CHEMICAL", 243, 251], ["SNAr", "SIMPLE_CHEMICAL", 274, 278], ["enzyme", "PROTEIN", 140, 146], ["the enzyme assays", "TEST", 54, 71], ["the mass spectra", "TEST", 92, 108], ["the mass", "PROBLEM", 114, 122], ["the adduct of enzyme", "TEST", 126, 146], ["acid", "TEST", 151, 155], ["the mass", "PROBLEM", 166, 174], ["an adduct", "PROBLEM", 178, 187], ["nucleophilic substitution", "TREATMENT", 203, 228], ["the fluoride", "TREATMENT", 239, 251], ["a nitro group", "TREATMENT", 255, 268], ["the SNAr reaction", "PROBLEM", 270, 287], ["reversible", "OBSERVATION_MODIFIER", 31, 41], ["mass", "OBSERVATION", 118, 122], ["mass", "OBSERVATION", 170, 174], ["adduct", "OBSERVATION", 181, 187], ["nucleophilic substitution", "OBSERVATION", 203, 228]]], ["Hence, the data are only consistent with a \u03c0-or a Meisenheimer (\u03c3-) complex.Hydrolysis of Ester 7 by RhodesainIn order to verify that the ester cleavage of compound 7 indeed occurs by enzymatic hydrolysis catalyzed by the target protease rhodesain, the compound was incubated with: a) catalytically active rhodesain; b) reaction buffer; or c) rhodesain inactivated by the vinyl sulfone K11777 [50] .", [["Ester 7", "CHEMICAL", 90, 97], ["ester", "CHEMICAL", 138, 143], ["rhodesain", "CHEMICAL", 238, 247], ["rhodesain", "CHEMICAL", 343, 352], ["vinyl sulfone", "CHEMICAL", 372, 385], ["Ester 7", "CHEMICAL", 90, 97], ["ester", "CHEMICAL", 138, 143], ["rhodesain", "CHEMICAL", 306, 315], ["vinyl sulfone K11777", "CHEMICAL", 372, 392], ["Ester 7", "SIMPLE_CHEMICAL", 90, 97], ["RhodesainIn", "SIMPLE_CHEMICAL", 101, 112], ["ester", "SIMPLE_CHEMICAL", 138, 143], ["compound 7", "SIMPLE_CHEMICAL", 156, 166], ["rhodesain", "SIMPLE_CHEMICAL", 238, 247], ["c) rhodesain", "SIMPLE_CHEMICAL", 340, 352], ["vinyl sulfone", "SIMPLE_CHEMICAL", 372, 385], ["Meisenheimer (\u03c3-) complex", "PROTEIN", 50, 75], ["the data", "TEST", 7, 15], ["Hydrolysis of Ester", "TREATMENT", 76, 95], ["the ester cleavage of compound", "TREATMENT", 134, 164], ["enzymatic hydrolysis catalyzed", "TREATMENT", 184, 214]]], ["The reaction mixtures were subsequently analyzed by LC-MS.", [["The reaction mixtures", "TREATMENT", 0, 21]]], ["Unconverted ester 7 and acid 8 were eluted at t(8) = 0.9 min and t (7)Hydrolysis of Ester 7 by RhodesainIn order to verify that the ester cleavage of compound 7 indeed occurs by enzymatic hydrolysis catalyzed by the target protease rhodesain, the compound was incubated with: (a) catalytically active rhodesain; (b) reaction buffer; or (c) rhodesain inactivated by the vinyl sulfone K11777 [50] .", [["ester 7 and acid 8", "CHEMICAL", 12, 30], ["Ester", "CHEMICAL", 84, 89], ["ester", "CHEMICAL", 132, 137], ["rhodesain", "CHEMICAL", 232, 241], ["rhodesain", "CHEMICAL", 301, 310], ["rhodesain", "CHEMICAL", 340, 349], ["vinyl sulfone", "CHEMICAL", 369, 382], ["ester", "CHEMICAL", 12, 17], ["Ester 7", "CHEMICAL", 84, 91], ["ester", "CHEMICAL", 132, 137], ["rhodesain", "CHEMICAL", 301, 310], ["vinyl sulfone K11777", "CHEMICAL", 369, 389], ["Unconverted ester 7", "SIMPLE_CHEMICAL", 0, 19], ["acid 8", "SIMPLE_CHEMICAL", 24, 30], ["Ester 7", "SIMPLE_CHEMICAL", 84, 91], ["ester", "SIMPLE_CHEMICAL", 132, 137], ["compound 7", "SIMPLE_CHEMICAL", 150, 160], ["rhodesain", "SIMPLE_CHEMICAL", 232, 241], ["rhodesain", "SIMPLE_CHEMICAL", 301, 310], ["(c) rhodesain", "SIMPLE_CHEMICAL", 336, 349], ["vinyl sulfone", "SIMPLE_CHEMICAL", 369, 382], ["the ester cleavage of compound", "TREATMENT", 128, 158], ["enzymatic hydrolysis catalyzed", "TREATMENT", 178, 208], ["the target protease rhodesain", "TREATMENT", 212, 241]]], ["The reaction mixtures were subsequently analyzed by LC-MS.", [["The reaction mixtures", "TREATMENT", 0, 21]]], ["Unconverted ester 7 and acid 8 were eluted at t(8) =Reaction of Inhibitor 7 with a Low Molecular Weight ThiolSince cathepsins and rhodesain are cysteine proteases, we also investigated the interaction between the inhibitor 7 and a low molecular weight thiol (LMW thiol).", [["ester 7 and acid 8", "CHEMICAL", 12, 30], ["thiol", "CHEMICAL", 252, 257], ["LMW thiol", "CHEMICAL", 259, 268], ["ester", "CHEMICAL", 12, 17], ["rhodesain", "CHEMICAL", 130, 139], ["cysteine", "CHEMICAL", 144, 152], ["thiol", "CHEMICAL", 252, 257], ["thiol", "CHEMICAL", 263, 268], ["Unconverted ester 7", "SIMPLE_CHEMICAL", 0, 19], ["acid 8", "SIMPLE_CHEMICAL", 24, 30], ["cathepsins", "GENE_OR_GENE_PRODUCT", 115, 125], ["rhodesain", "SIMPLE_CHEMICAL", 130, 139], ["cysteine", "AMINO_ACID", 144, 152], ["LMW thiol", "SIMPLE_CHEMICAL", 259, 268], ["Low Molecular Weight ThiolSince cathepsins", "PROTEIN", 83, 125], ["cysteine proteases", "PROTEIN", 144, 162], ["Inhibitor", "TREATMENT", 64, 73], ["a Low Molecular Weight ThiolSince cathepsins", "TREATMENT", 81, 125], ["cysteine proteases", "TREATMENT", 144, 162], ["the inhibitor", "TREATMENT", 209, 222], ["a low molecular weight thiol (LMW thiol", "TREATMENT", 229, 268]]], ["The reaction of compound 7 was carried out with 2-phenylethanethiol (9) in the presence of a base in ethanol (Scheme 4).", [["2-phenylethanethiol", "CHEMICAL", 48, 67], ["ethanol", "CHEMICAL", 101, 108], ["2-phenylethanethiol", "CHEMICAL", 48, 67], ["ethanol", "CHEMICAL", 101, 108], ["compound 7", "SIMPLE_CHEMICAL", 16, 26], ["2-phenylethanethiol", "SIMPLE_CHEMICAL", 48, 67], ["ethanol", "SIMPLE_CHEMICAL", 101, 108], ["a base in ethanol (Scheme", "TREATMENT", 91, 116]]], ["All three possible reaction products resulting from substitution of the nitro-(10), fluoro-(11) and of both groups (12) were obtained in the experiments, in which the reaction temperature (rt or 80 \u00b0C), the amounts of thiol and base (excess or two equivalents each) and the reaction time (4 h, 16 h, 28 h) were varied.", [["nitro", "CHEMICAL", 72, 77], ["fluoro", "CHEMICAL", 84, 90], ["thiol", "CHEMICAL", 218, 223], ["nitro", "CHEMICAL", 72, 77], ["fluoro", "CHEMICAL", 84, 90], ["thiol", "CHEMICAL", 218, 223], ["nitro-(10)", "SIMPLE_CHEMICAL", 72, 82], ["fluoro-(11)", "SIMPLE_CHEMICAL", 84, 95], ["thiol", "SIMPLE_CHEMICAL", 218, 223], ["reaction products", "TREATMENT", 19, 36], ["the nitro", "TREATMENT", 68, 77], ["fluoro", "TREATMENT", 84, 90], ["thiol and base (excess", "TREATMENT", 218, 240], ["possible", "UNCERTAINTY", 10, 18], ["reaction products", "OBSERVATION", 19, 36], ["base", "ANATOMY_MODIFIER", 228, 232]]], ["The main product (ca.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["product", "OBSERVATION_MODIFIER", 9, 16], ["ca", "OBSERVATION", 18, 20]]], ["60-70%) detected in the 16 h reaction at 80 \u00b0C with a large excess of thiol and triethylamine was the double-substitution product (12) accompanied by small amounts of 10 and 11.", [["thiol", "CHEMICAL", 70, 75], ["triethylamine", "CHEMICAL", 80, 93], ["thiol", "CHEMICAL", 70, 75], ["triethylamine", "CHEMICAL", 80, 93], ["thiol", "SIMPLE_CHEMICAL", 70, 75], ["triethylamine", "SIMPLE_CHEMICAL", 80, 93], ["a large excess of thiol", "TREATMENT", 52, 75], ["triethylamine", "TREATMENT", 80, 93], ["the double-substitution product", "TREATMENT", 98, 129], ["large", "OBSERVATION_MODIFIER", 54, 59], ["small", "OBSERVATION_MODIFIER", 150, 155], ["amounts", "OBSERVATION_MODIFIER", 156, 163]]], ["At rt with two eq. base and thiol, ca.", [["thiol", "CHEMICAL", 28, 33], ["thiol", "CHEMICAL", 28, 33], ["thiol", "SIMPLE_CHEMICAL", 28, 33], ["two", "OBSERVATION_MODIFIER", 11, 14], ["eq", "OBSERVATION", 15, 17], ["thiol", "OBSERVATION_MODIFIER", 28, 33], ["ca", "OBSERVATION", 35, 37]]], ["70-80% unreacted starting material, accompanied by small amounts of all three reaction products (10-12), was detected.", [["unreacted starting material", "PROBLEM", 7, 34], ["unreacted", "OBSERVATION_MODIFIER", 7, 16], ["starting material", "OBSERVATION_MODIFIER", 17, 34], ["small", "OBSERVATION_MODIFIER", 51, 56], ["amounts", "OBSERVATION_MODIFIER", 57, 64], ["all", "OBSERVATION_MODIFIER", 68, 71], ["three", "OBSERVATION_MODIFIER", 72, 77], ["reaction", "OBSERVATION_MODIFIER", 78, 86], ["products", "OBSERVATION_MODIFIER", 87, 95]]], ["After 28 h at rt (2 eq. base and thiol), the amount of starting material decreased (to ca.", [["thiol", "CHEMICAL", 33, 38], ["thiol", "CHEMICAL", 33, 38], ["thiol", "SIMPLE_CHEMICAL", 33, 38], ["starting material", "PROBLEM", 55, 72], ["amount", "OBSERVATION_MODIFIER", 45, 51], ["decreased", "OBSERVATION_MODIFIER", 73, 82]]], ["40%) and the amounts of the three substitution products (10-12) increased (to ca.", [["the three substitution products", "TREATMENT", 24, 55]]], ["These reactions show that the chosen electrophilic aromatic moiety is indeed competent to undergo nucleophilic aromatic substitutions.Reaction of Inhibitor 7 with a Low Molecular Weight ThiolSince cathepsins and rhodesain are cysteine proteases, we also investigated the interaction between the inhibitor 7 and a low molecular weight thiol (LMW thiol).", [["thiol", "CHEMICAL", 334, 339], ["thiol", "CHEMICAL", 345, 350], ["rhodesain", "CHEMICAL", 212, 221], ["cysteine", "CHEMICAL", 226, 234], ["thiol", "CHEMICAL", 334, 339], ["thiol", "CHEMICAL", 345, 350], ["rhodesain", "SIMPLE_CHEMICAL", 212, 221], ["cysteine", "AMINO_ACID", 226, 234], ["LMW thiol", "SIMPLE_CHEMICAL", 341, 350], ["Low Molecular Weight ThiolSince cathepsins", "PROTEIN", 165, 207], ["cysteine proteases", "PROTEIN", 226, 244], ["the chosen electrophilic aromatic moiety", "PROBLEM", 26, 66], ["nucleophilic aromatic substitutions", "PROBLEM", 98, 133], ["Inhibitor", "TREATMENT", 146, 155], ["a Low Molecular Weight ThiolSince cathepsins", "TREATMENT", 163, 207], ["cysteine proteases", "TREATMENT", 226, 244], ["the inhibitor", "TREATMENT", 291, 304], ["a low molecular weight thiol (LMW thiol", "TREATMENT", 311, 350], ["aromatic moiety", "OBSERVATION", 51, 66], ["nucleophilic", "OBSERVATION", 98, 110], ["aromatic substitutions", "OBSERVATION", 111, 133]]], ["The reaction of compound 7 was carried out with 2-phenylethanethiol (9) in the presence of a base in ethanol (Scheme 4).", [["2-phenylethanethiol", "CHEMICAL", 48, 67], ["ethanol", "CHEMICAL", 101, 108], ["2-phenylethanethiol", "CHEMICAL", 48, 67], ["ethanol", "CHEMICAL", 101, 108], ["compound 7", "SIMPLE_CHEMICAL", 16, 26], ["2-phenylethanethiol", "SIMPLE_CHEMICAL", 48, 67], ["ethanol", "SIMPLE_CHEMICAL", 101, 108], ["a base in ethanol (Scheme", "TREATMENT", 91, 116]]], ["All three possible reaction products resulting from substitution of the nitro-(10), fluoro-(11) and of both groups (12) were obtained in the experiments, in which the reaction temperature (rt or 80 \u2022 C), the amounts of thiol and base (excess or two equivalents each) and the reaction time (4 h, 16 h, 28 h) were varied.", [["nitro", "CHEMICAL", 72, 77], ["fluoro", "CHEMICAL", 84, 90], ["thiol", "CHEMICAL", 219, 224], ["nitro", "CHEMICAL", 72, 77], ["fluoro", "CHEMICAL", 84, 90], ["thiol", "CHEMICAL", 219, 224], ["nitro-(10)", "SIMPLE_CHEMICAL", 72, 82], ["fluoro-(11)", "SIMPLE_CHEMICAL", 84, 95], ["thiol", "SIMPLE_CHEMICAL", 219, 224], ["reaction products", "TREATMENT", 19, 36], ["the nitro", "TREATMENT", 68, 77], ["fluoro", "TREATMENT", 84, 90], ["the reaction temperature", "TEST", 163, 187], ["thiol and base (excess", "TREATMENT", 219, 241], ["possible", "UNCERTAINTY", 10, 18], ["reaction products", "OBSERVATION", 19, 36], ["base", "ANATOMY_MODIFIER", 229, 233]]], ["The main product (ca.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["product", "OBSERVATION_MODIFIER", 9, 16], ["ca", "OBSERVATION", 18, 20]]], ["60-70%) detected in the 16 h reaction at 80 \u2022 C with a large excess of thiol and triethylamine was the double-substitution product (12) accompanied by small amounts of 10 and 11.", [["thiol", "CHEMICAL", 71, 76], ["triethylamine", "CHEMICAL", 81, 94], ["thiol", "CHEMICAL", 71, 76], ["triethylamine", "CHEMICAL", 81, 94], ["thiol", "SIMPLE_CHEMICAL", 71, 76], ["triethylamine", "SIMPLE_CHEMICAL", 81, 94], ["a large excess of thiol", "TREATMENT", 53, 76], ["triethylamine", "TREATMENT", 81, 94], ["the double-substitution product", "TREATMENT", 99, 130], ["small", "OBSERVATION_MODIFIER", 151, 156]]], ["At rt with two eq. base and thiol, ca.", [["thiol", "CHEMICAL", 28, 33], ["thiol", "CHEMICAL", 28, 33], ["thiol", "SIMPLE_CHEMICAL", 28, 33], ["two", "OBSERVATION_MODIFIER", 11, 14], ["eq", "OBSERVATION", 15, 17], ["thiol", "OBSERVATION_MODIFIER", 28, 33], ["ca", "OBSERVATION", 35, 37]]], ["70-80% unreacted starting material, accompanied by small amounts of all three reaction products (10-12), was detected.", [["unreacted starting material", "PROBLEM", 7, 34], ["unreacted", "OBSERVATION_MODIFIER", 7, 16], ["starting material", "OBSERVATION_MODIFIER", 17, 34], ["small", "OBSERVATION_MODIFIER", 51, 56], ["amounts", "OBSERVATION_MODIFIER", 57, 64], ["all", "OBSERVATION_MODIFIER", 68, 71], ["three", "OBSERVATION_MODIFIER", 72, 77], ["reaction", "OBSERVATION_MODIFIER", 78, 86], ["products", "OBSERVATION_MODIFIER", 87, 95]]], ["After 28 h at rt (2 eq. base and thiol), the amount of starting material decreased (to ca.", [["thiol", "CHEMICAL", 33, 38], ["thiol", "CHEMICAL", 33, 38], ["thiol", "SIMPLE_CHEMICAL", 33, 38], ["starting material", "PROBLEM", 55, 72], ["amount", "OBSERVATION_MODIFIER", 45, 51], ["decreased", "OBSERVATION_MODIFIER", 73, 82]]], ["40%) and the amounts of the three substitution products (10-12) increased (to ca.", [["the three substitution products", "TREATMENT", 24, 55]]], ["These reactions show that the chosen electrophilic aromatic moiety is indeed competent to undergo nucleophilic aromatic substitutions.Reaction of Inhibitor 7 with a Low Molecular Weight ThiolThe regiochemistry of the substitution in product 12 could not be unequivocally determined by the usual 2D NMR methods, so that DFT calculations and a DP4-probability analysis were performed.", [["the chosen electrophilic aromatic moiety", "PROBLEM", 26, 66], ["nucleophilic aromatic substitutions", "PROBLEM", 98, 133], ["Inhibitor", "TREATMENT", 146, 155], ["a Low Molecular Weight Thiol", "TREATMENT", 163, 191], ["the substitution in product", "TREATMENT", 213, 240], ["DFT calculations", "TEST", 319, 335], ["a DP4-probability analysis", "TEST", 340, 366], ["aromatic moiety", "OBSERVATION", 51, 66], ["nucleophilic", "OBSERVATION", 98, 110], ["aromatic substitutions", "OBSERVATION", 111, 133]]], ["The observed NMR chemical shifts were compared with those of values for both possible regioisomers computed by DFT calculations.", [["The observed NMR chemical shifts", "PROBLEM", 0, 32], ["DFT calculations", "TEST", 111, 127], ["chemical shifts", "OBSERVATION", 17, 32]]], ["Conformational analyses were performed on a PM6 (Parametric Method 6) [51] or MMFF (Merck Molecular Force Field) [52] level of theory and the geometries of all conformers found were subsequently reoptimized [B3LYP/6-31G(d)] [53] [54] [55] [56] [57] [58] [59] .", [["6-31G(d)] [53] [54] [55] [56] [57] [58] [59]", "SIMPLE_CHEMICAL", 214, 258], ["Conformational analyses", "TEST", 0, 23], ["a PM6 (Parametric Method", "TREATMENT", 42, 66], ["B3LYP", "TEST", 208, 213]]], ["For the calculation of the NMR shielding tensors, the mPW1PW91 [60] functional was used in combination with the 6-31 + G(d,p) [57] [58] [59] basis set and the gauge-independent atomic orbital (GIAO) method [61] .", [["the NMR shielding tensors", "TREATMENT", 23, 48], ["basis set", "TEST", 141, 150], ["the gauge", "TEST", 155, 164], ["atomic orbital", "ANATOMY", 177, 191]]], ["For this computation, undirected solvent effects were taken into account using the integral equation formalism polarizable continuum model (IEFPCM) [62] .", [["undirected solvent effects", "TREATMENT", 22, 48]]], ["After Boltzmann weighting, the DP4+ probabilities [63] (see Supplementary Material) were calculated, which unambiguously show that the most likely regioisomer is the one with both thioether moieties in para-position to each other (12) .", [["thioether", "CHEMICAL", 180, 189], ["thioether", "CHEMICAL", 180, 189], ["DP4", "PROTEIN", 31, 34], ["Boltzmann weighting", "TEST", 6, 25], ["both thioether moieties", "TREATMENT", 175, 198], ["most likely", "UNCERTAINTY", 135, 146]]], ["The regiochemistry of the substitution in product 12 could not be unequivocally determined by the usual 2D NMR methods, so that DFT calculations and a DP4-probability analysis were performed.", [["the usual 2D NMR methods", "TEST", 94, 118], ["DFT calculations", "TEST", 128, 144], ["a DP4-probability analysis", "TEST", 149, 175]]], ["The observed NMR chemical shifts were compared with those of values for both possible regioisomers computed by DFT calculations.", [["The observed NMR chemical shifts", "PROBLEM", 0, 32], ["DFT calculations", "TEST", 111, 127], ["chemical shifts", "OBSERVATION", 17, 32]]], ["Conformational analyses were performed on a PM6 (Parametric Method 6) [51] or MMFF (Merck Molecular Force Field) [52] level of theory and the geometries of all conformers found were subsequently reoptimized [B3LYP/6-31G(d)] [53] [54] [55] [56] [57] [58] [59] .", [["6-31G(d)] [53] [54] [55] [56] [57] [58] [59]", "SIMPLE_CHEMICAL", 214, 258], ["Conformational analyses", "TEST", 0, 23], ["a PM6 (Parametric Method", "TREATMENT", 42, 66], ["B3LYP", "TEST", 208, 213]]], ["For the calculation of the NMR shielding tensors, the mPW1PW91 [60] functional was used in combination with the 6-31 + G(d,p) [57] [58] [59] basis set and the gauge-independent atomic orbital (GIAO) method [61] .", [["the NMR shielding tensors", "TREATMENT", 23, 48], ["basis set", "TEST", 141, 150], ["the gauge", "TEST", 155, 164], ["atomic orbital", "ANATOMY", 177, 191]]], ["For this computation, undirected solvent effects were taken into account using the integral equation formalism polarizable continuum model (IEFPCM) [62] .", [["undirected solvent effects", "TREATMENT", 22, 48]]], ["After Boltzmann weighting, the DP4+ probabilities [63] (see Supplementary Material) were calculated, which unambiguously show that the most likely regioisomer is the one with both thioether moieties in paraposition to each other (12) .Reaction of Inhibitor 7 with a Low Molecular Weight ThiolHigh level quantum chemical calculations for appropriate model systems are often very helpful to understand the situation in an enzyme [28, [64] [65] [66] .", [["thioether", "CHEMICAL", 180, 189], ["thioether", "CHEMICAL", 180, 189], ["DP4", "PROTEIN", 31, 34], ["Boltzmann weighting", "TEST", 6, 25], ["Inhibitor", "TREATMENT", 247, 256], ["a Low Molecular Weight ThiolHigh level quantum chemical calculations", "TREATMENT", 264, 332], ["an enzyme", "TEST", 417, 426], ["most likely", "UNCERTAINTY", 135, 146]]], ["Hence, to shed some light on possible reaction intermediates, we also computed the relative stabilities of the involved Meisenheimer complexes in a polar solvent.", [["Meisenheimer complexes", "PROTEIN", 120, 142], ["reaction intermediates", "PROBLEM", 38, 60], ["a polar solvent", "TREATMENT", 146, 161]]], ["To mimic the polar environment, we used the IEFPCM approach for a water environment [62] .", [["the IEFPCM approach", "TREATMENT", 40, 59]]], ["In all model systems, the inhibitor was approximated by the substituted benzene ring.", [["benzene", "CHEMICAL", 72, 79], ["benzene", "CHEMICAL", 72, 79], ["benzene", "SIMPLE_CHEMICAL", 72, 79], ["the inhibitor", "TREATMENT", 22, 35], ["the substituted benzene ring", "TREATMENT", 56, 84], ["benzene ring", "OBSERVATION", 72, 84]]], ["For all calculations the 6-31 + G* basis sets were employed.", [["all calculations", "TEST", 4, 20]]], ["High level quantum chemical calculations for appropriate model systems are often very helpful to understand the situation in an enzyme [28, [64] [65] [66] .", [["High level quantum chemical calculations", "TREATMENT", 0, 40], ["an enzyme", "TEST", 125, 134]]], ["Hence, to shed some light on possible reaction intermediates, we also computed the relative stabilities of the involved Meisenheimer complexes in a polar solvent.", [["Meisenheimer complexes", "PROTEIN", 120, 142], ["reaction intermediates", "PROBLEM", 38, 60], ["a polar solvent", "TREATMENT", 146, 161]]], ["To mimic the polar environment, we used the IEFPCM approach for a water environment [62] .", [["the IEFPCM approach", "TREATMENT", 40, 59]]], ["In all model systems, the inhibitor was approximated by the substituted benzene ring.", [["benzene", "CHEMICAL", 72, 79], ["benzene", "CHEMICAL", 72, 79], ["benzene", "SIMPLE_CHEMICAL", 72, 79], ["the inhibitor", "TREATMENT", 22, 35], ["the substituted benzene ring", "TREATMENT", 56, 84], ["benzene ring", "OBSERVATION", 72, 84]]], ["The model system without an imidazole ring mimics the situation of the reaction with 2-phenylethanethiol (9) in the presence of a base in ethanol, in which the reaction can be viewed as a simple thiolate attack at the substituted ring.", [["imidazole", "CHEMICAL", 28, 37], ["2-phenylethanethiol", "CHEMICAL", 85, 104], ["ethanol", "CHEMICAL", 138, 145], ["imidazole", "CHEMICAL", 28, 37], ["2-phenylethanethiol", "CHEMICAL", 85, 104], ["ethanol", "CHEMICAL", 138, 145], ["2-phenylethanethiol (9)", "SIMPLE_CHEMICAL", 85, 108], ["ethanol", "SIMPLE_CHEMICAL", 138, 145], ["an imidazole ring", "TREATMENT", 25, 42], ["the reaction", "PROBLEM", 67, 79], ["a simple thiolate attack at the substituted ring", "TREATMENT", 186, 234], ["imidazole ring", "OBSERVATION", 28, 42], ["substituted ring", "OBSERVATION", 218, 234]]], ["The corresponding complexes are depicted in Figure 6 in the row \"only thiolate\".", [["thiolate", "CHEMICAL", 70, 78], ["complexes", "OBSERVATION_MODIFIER", 18, 27]]], ["CX distance (X = F, NO 2 , H) of 1.9 \u00c5.", [["NO", "CHEMICAL", 20, 22], ["NO 2 , H", "CHEMICAL", 20, 28], ["CX distance", "TEST", 0, 11]]], ["The resulting complexes represent Meisenheimer complexes as can be deduced from the distances: the distances R(S . . .", [["Meisenheimer complexes", "PROTEIN", 34, 56], ["Meisenheimer complexes", "PROBLEM", 34, 56], ["Meisenheimer complexes", "OBSERVATION", 34, 56]]], ["CX) remain at about 1.9 \u00c5 and the distances R(C Ar . . .", [["CX", "TEST", 0, 2]]], ["X) are already considerably elongated.", [["considerably", "OBSERVATION_MODIFIER", 15, 27], ["elongated", "OBSERVATION", 28, 37]]], ["According to the more accurate MP2 or SCS-MP2 computations, the Meisenheimer complexes represent stable minima on the hypersurface, which lie about 4-13 kcal/mol lower than the reactants.", [["MP2", "DNA", 31, 34], ["MP2", "DNA", 42, 45], ["Meisenheimer complexes", "PROTEIN", 64, 86], ["stable", "OBSERVATION_MODIFIER", 97, 103], ["minima", "OBSERVATION", 104, 110]]], ["The computations also indicate a stable pre-complex stabilized by a hydrogen bond between the NH group and the attacking thiolate, which according to the more accurate MP2-and SCS-MP2-calculations, is similarly stable as the Meisenheimer complexes.", [["NH", "CHEMICAL", 94, 96], ["hydrogen", "CHEMICAL", 68, 76], ["NH", "CHEMICAL", 94, 96], ["thiolate", "CHEMICAL", 121, 129], ["Meisenheimer complexes", "PROTEIN", 225, 247], ["stable", "OBSERVATION_MODIFIER", 33, 39], ["stable", "OBSERVATION_MODIFIER", 211, 217]]], ["It should be noted that wB97XD considerably underestimates the stability of the Meisenheimer complexes.", [["Meisenheimer complexes", "PROTEIN", 80, 102], ["stability", "OBSERVATION", 63, 72]]], ["The computations are in good agreement with the experiment, which finds S N Ar reactions between 2-phenylethanethiol (9) in the presence of a base in ethanol at rt.", [["S N Ar", "CHEMICAL", 72, 78], ["2-phenylethanethiol (9", "CHEMICAL", 97, 119], ["ethanol", "CHEMICAL", 150, 157], ["S N", "CHEMICAL", 72, 75], ["2-phenylethanethiol", "CHEMICAL", 97, 116], ["ethanol", "CHEMICAL", 150, 157], ["S N Ar", "SIMPLE_CHEMICAL", 72, 78], ["2-phenylethanethiol", "SIMPLE_CHEMICAL", 97, 116], ["ethanol", "SIMPLE_CHEMICAL", 150, 157], ["S N Ar reactions", "PROBLEM", 72, 88]]], ["Figure 6 also contains the 19 F NMR shifts relative to the value computed for the inhibitor.", [["the 19 F NMR shifts", "PROBLEM", 23, 42], ["the value", "TEST", 55, 64], ["the inhibitor", "TREATMENT", 78, 91], ["19 F", "OBSERVATION_MODIFIER", 27, 31]]], ["The computed variation upon the formation of the Meisenheimer complexes are magnitudes larger than the variation found experimentally for a possible inhibitor-enzyme complex (\u2248 1 ppm).", [["Meisenheimer complexes", "PROTEIN", 49, 71], ["enzyme complex", "PROTEIN", 159, 173], ["magnitudes", "OBSERVATION_MODIFIER", 76, 86], ["larger", "OBSERVATION_MODIFIER", 87, 93]]], ["Possible reactions between the substituted aromatic ring and the catalytic dyad of the enzyme differ from the solvent reaction in several ways.", [["catalytic dyad", "PROTEIN", 65, 79], ["enzyme", "PROTEIN", 87, 93], ["reactions", "PROBLEM", 9, 18], ["the substituted aromatic ring", "TREATMENT", 27, 56], ["the enzyme", "TEST", 83, 93], ["the solvent reaction", "PROBLEM", 106, 126], ["aromatic ring", "OBSERVATION", 43, 56], ["solvent reaction", "OBSERVATION", 110, 126]]], ["Besides steric restrictions, the thiolate group of the active-site cysteine residue is always stabilized by a strong salt bridge to the positively charged imidazolium ring of the active-site histidine residue, which might reduce the thiolate reactivity.", [["thiolate", "CHEMICAL", 33, 41], ["imidazolium", "CHEMICAL", 155, 166], ["histidine", "CHEMICAL", 191, 200], ["thiolate", "CHEMICAL", 33, 41], ["cysteine", "CHEMICAL", 67, 75], ["imidazolium", "CHEMICAL", 155, 166], ["histidine", "CHEMICAL", 191, 200], ["cysteine", "AMINO_ACID", 67, 75], ["histidine", "AMINO_ACID", 191, 200], ["steric restrictions", "TREATMENT", 8, 27], ["the active-site cysteine residue", "PROBLEM", 51, 83], ["a strong salt bridge", "TREATMENT", 108, 128], ["the positively charged imidazolium ring", "TREATMENT", 132, 171], ["histidine residue", "PROBLEM", 191, 208], ["steric restrictions", "OBSERVATION", 8, 27], ["active", "OBSERVATION_MODIFIER", 55, 61], ["cysteine residue", "OBSERVATION", 67, 83], ["active", "OBSERVATION_MODIFIER", 179, 185], ["histidine residue", "OBSERVATION", 191, 208]]], ["To mimic this situation, we added a positively charged imidazolium ring to the model system.", [["imidazolium", "CHEMICAL", 55, 66], ["imidazolium", "CHEMICAL", 55, 66], ["a positively charged imidazolium ring", "TREATMENT", 34, 71]]], ["In the first calculation, we put the thiolate at a distance of about 1.9 \u00c5 from the attacked carbon center of the aromatic ring and performed a full geometry optimization.", [["thiolate", "CHEMICAL", 37, 45], ["carbon", "CHEMICAL", 93, 99], ["a full geometry optimization", "TREATMENT", 142, 170], ["aromatic ring", "OBSERVATION", 114, 127]]], ["The resulting complexes are depicted in Figure 6 as \"thiolate and imidazolium: full optimization\".", [["imidazolium", "CHEMICAL", 66, 77], ["thiolate", "CHEMICAL", 53, 61], ["imidazolium", "CHEMICAL", 66, 77], ["thiolate", "SIMPLE_CHEMICAL", 53, 61], ["imidazolium", "SIMPLE_CHEMICAL", 66, 77]]], ["The more reliable MP2-or SCS-MP2-computations predict that the resulting complexes are stable with respect to the fragmentation into the inhibitor and thiolate/imidazolium complex.", [["thiolate/imidazolium", "CHEMICAL", 151, 171], ["thiolate", "CHEMICAL", 151, 159], ["imidazolium", "CHEMICAL", 160, 171], ["thiolate/imidazolium complex", "SIMPLE_CHEMICAL", 151, 179], ["MP2", "DNA", 18, 21], ["MP2", "DNA", 29, 32], ["MP2", "TEST", 18, 21], ["the inhibitor and thiolate/imidazolium complex", "TREATMENT", 133, 179], ["stable", "OBSERVATION_MODIFIER", 87, 93], ["fragmentation", "OBSERVATION", 114, 127]]], ["The computed complexes, however, are not Meisenheimer complexes as found for the situation without the imidazolium (only thiolate).", [["imidazolium", "CHEMICAL", 103, 114], ["imidazolium", "CHEMICAL", 103, 114], ["thiolate", "CHEMICAL", 121, 129], ["imidazolium", "SIMPLE_CHEMICAL", 103, 114], ["Meisenheimer complexes", "PROTEIN", 41, 63], ["the imidazolium", "TREATMENT", 99, 114]]], ["CX) distances are about 3.9-4.0 \u00c5 and the R(C Ar . . .", [["CX", "TEST", 0, 2], ["distances", "TEST", 4, 13]]], ["X) are not elongated.", [["elongated", "PROBLEM", 11, 20], ["not", "UNCERTAINTY", 7, 10], ["elongated", "OBSERVATION_MODIFIER", 11, 20]]], ["Nevertheless, the stability of this complex upon fragmentation into inhibitor and thiolate/imidazolium complex is about 20 kcal/mol, i.e., they are even more stable than the Meisenheimer complexes found for the \"only thiolate\" situation.", [["thiolate", "CHEMICAL", 82, 90], ["imidazolium", "CHEMICAL", 91, 102], ["thiolate", "CHEMICAL", 82, 90], ["imidazolium", "CHEMICAL", 91, 102], ["thiolate", "CHEMICAL", 217, 225], ["thiolate/imidazolium complex", "SIMPLE_CHEMICAL", 82, 110], ["Meisenheimer complexes", "PROTEIN", 174, 196], ["inhibitor and thiolate/imidazolium complex", "TREATMENT", 68, 110], ["stability", "OBSERVATION_MODIFIER", 18, 27], ["stable", "OBSERVATION_MODIFIER", 158, 164]]], ["It should be noted that the situation found for the attack at C\u2212NO 2 does not reflect the situation in the enzyme, because the thiolate and the imidazolium ring interchange their positions during the full optimization to maximize the interaction energy.", [["imidazolium", "CHEMICAL", 144, 155], ["C\u2212NO 2", "CHEMICAL", 62, 68], ["thiolate", "CHEMICAL", 127, 135], ["imidazolium", "CHEMICAL", 144, 155], ["thiolate", "SIMPLE_CHEMICAL", 127, 135], ["the enzyme", "TEST", 103, 113], ["the thiolate and the imidazolium ring", "TREATMENT", 123, 160], ["the full optimization", "TREATMENT", 196, 217], ["the interaction energy", "PROBLEM", 230, 252]]], ["The same holds true for the attack at C\u2212F due to the orientation of the substituted ring.", [["C\u2212F", "CHEMICAL", 38, 41], ["the attack at C\u2212F", "PROBLEM", 24, 41], ["the substituted ring", "TREATMENT", 68, 88], ["substituted ring", "OBSERVATION", 72, 88]]], ["Both the pre-complex and the situation found for the attack at the CH group of the ring could also take place in the enzyme (see Section 2.7).", [["CH", "CHEMICAL", 67, 69], ["enzyme", "PROTEIN", 117, 123], ["the enzyme", "TEST", 113, 123]]], ["To get more insights, we also built a complex in which we fixed the S-CX bond lengths to about 1.9 \u00c5, i.e., we enforced a kind of Meisenheimer complex in which the positively charged imidazolium is present.", [["imidazolium", "CHEMICAL", 183, 194], ["S-CX", "CHEMICAL", 68, 72], ["imidazolium", "CHEMICAL", 183, 194], ["imidazolium", "SIMPLE_CHEMICAL", 183, 194], ["Meisenheimer complex", "PROTEIN", 130, 150], ["the positively charged imidazolium", "TREATMENT", 160, 194], ["charged imidazolium", "OBSERVATION", 175, 194]]], ["According to MP2 or SCS-MP2, the resulting complexes ( Figure 6 : thiolate and imidazolium: R(S\u2212CX fixed at 1.9 \u00c5)) are 4-10 kcal/mol less stable than the complex obtained by the full optimization.", [["imidazolium", "CHEMICAL", 79, 90], ["thiolate", "CHEMICAL", 66, 74], ["imidazolium", "CHEMICAL", 79, 90], ["S\u2212CX", "CHEMICAL", 94, 98], ["Figure 6 : thiolate", "SIMPLE_CHEMICAL", 55, 74], ["imidazolium: R", "SIMPLE_CHEMICAL", 79, 93], ["MP2", "DNA", 13, 16], ["MP2", "DNA", 24, 27], ["MP2", "TEST", 24, 27], ["Figure", "TEST", 55, 61], ["thiolate", "TEST", 66, 74], ["imidazolium", "TEST", 79, 90], ["S\u2212CX", "TEST", 94, 98]]], ["This indicates that a thiolate/imidazolium complex should not be able to form a Meisenheimer complex.", [["thiolate", "CHEMICAL", 22, 30], ["imidazolium", "CHEMICAL", 31, 42], ["thiolate", "CHEMICAL", 22, 30], ["imidazolium", "CHEMICAL", 31, 42], ["thiolate/imidazolium complex", "SIMPLE_CHEMICAL", 22, 50], ["Meisenheimer complex", "PROTEIN", 80, 100], ["a thiolate/imidazolium complex", "TREATMENT", 20, 50]]], ["Again, the 19 F NMR shifts were computed.", [["the 19 F NMR shifts", "TEST", 7, 26]]], ["Their variations with respect to the 19 F NMR shift of the pure inhibitor are also given in Figure 6 .", [["the pure inhibitor", "TREATMENT", 55, 73]]], ["It can be seen that the NMR shift variations found for the complexes are considerably smaller than those found for the corresponding Meisenheimer complexes.", [["Meisenheimer complexes", "PROTEIN", 133, 155], ["the NMR shift variations", "TEST", 20, 44], ["considerably", "OBSERVATION_MODIFIER", 73, 85], ["smaller", "OBSERVATION_MODIFIER", 86, 93]]], ["Furthermore, they are of similar size as the experimental shift difference.", [["similar", "OBSERVATION_MODIFIER", 25, 32], ["size", "OBSERVATION_MODIFIER", 33, 37], ["experimental shift", "OBSERVATION", 45, 63], ["difference", "OBSERVATION_MODIFIER", 64, 74]]], ["The comparison between the employed theoretical approaches clearly shows that the DFT functional \u03c9B97XD underestimates the stability of the complexes by up to 10 kcal/mol.", [["the DFT functional", "TEST", 78, 96], ["stability", "OBSERVATION_MODIFIER", 123, 132]]], ["Our model calculations indicate that the catalytic dyad of the enzyme, mimicked by a thiolate/imidazolium complex, behaves differently than a single attacking thiolate.", [["imidazolium", "CHEMICAL", 94, 105], ["thiolate", "CHEMICAL", 85, 93], ["imidazolium", "CHEMICAL", 94, 105], ["thiolate", "CHEMICAL", 159, 167], ["Our model calculations", "TEST", 0, 22], ["the enzyme", "TEST", 59, 69], ["a thiolate/imidazolium complex", "TREATMENT", 83, 113], ["a single attacking thiolate", "TREATMENT", 140, 167]]], ["Consequently, the formation of a Meisenheimer complex would not be expected for the enzyme, but instead, the formation of a quite stable complex with larger distances between the catalytic dyad and the substituted aromatic ring would be expected.", [["Meisenheimer complex", "PROTEIN", 33, 53], ["enzyme", "PROTEIN", 84, 90], ["catalytic dyad", "PROTEIN", 179, 193], ["a Meisenheimer complex", "PROBLEM", 31, 53], ["the enzyme", "TEST", 80, 90], ["the substituted aromatic ring", "TREATMENT", 198, 227], ["stable", "OBSERVATION_MODIFIER", 130, 136], ["larger", "OBSERVATION_MODIFIER", 150, 156], ["aromatic ring", "OBSERVATION", 214, 227]]], ["From the orientation of the fragments, it resembles a \u03c0-complex.", [["fragments", "ANATOMY", 28, 37], ["\u03c0-complex", "PROTEIN", 54, 63], ["fragments", "OBSERVATION", 28, 37], ["\u03c0-complex", "OBSERVATION_MODIFIER", 54, 63]]], ["Despite this relatively long distance, the complex is quite stable.", [["relatively", "OBSERVATION_MODIFIER", 13, 23], ["long", "OBSERVATION_MODIFIER", 24, 28], ["complex", "OBSERVATION_MODIFIER", 43, 50], ["quite", "OBSERVATION_MODIFIER", 54, 59], ["stable", "OBSERVATION_MODIFIER", 60, 66]]], ["The magnitudes of the computed NMR shifts also indicate that a \u03c0instead of a Meisenheimer complex is formed.Theoretical Investigations of the Enzyme-Inhibitor ComplexDocking studies using the crystal structure of rhodesain (pdb 2p7u) were performed with acid 8 and its benzyl ester 7 to understand the molecular basis of the observed enzyme inhibition by acid 8 and of the observed enzymatic hydrolysis of ester 7 in more detail.", [["benzyl ester", "CHEMICAL", 269, 281], ["ester", "CHEMICAL", 406, 411], ["rhodesain", "CHEMICAL", 213, 222], ["benzyl ester", "CHEMICAL", 269, 281], ["ester", "CHEMICAL", 406, 411], ["rhodesain", "SIMPLE_CHEMICAL", 213, 222], ["benzyl ester 7", "SIMPLE_CHEMICAL", 269, 283], ["ester 7", "SIMPLE_CHEMICAL", 406, 413], ["Meisenheimer complex", "PROTEIN", 77, 97], ["pdb 2p7u", "PROTEIN", 224, 232], ["the computed NMR shifts", "TEST", 18, 41], ["a Meisenheimer complex", "PROBLEM", 75, 97], ["Theoretical Investigations", "TEST", 108, 134], ["the Enzyme", "TEST", 138, 148], ["ComplexDocking studies", "TEST", 159, 181], ["acid", "TEST", 254, 258], ["its benzyl ester", "TREATMENT", 265, 281]]], ["The detailed procedure is given in the Supplementary Material.Theoretical Investigations of the Enzyme-Inhibitor ComplexFor the benzyl ester 7, three different kinds of poses were found.", [["benzyl ester", "CHEMICAL", 128, 140], ["benzyl ester", "CHEMICAL", 128, 140], ["benzyl ester 7", "SIMPLE_CHEMICAL", 128, 142], ["The detailed procedure", "TREATMENT", 0, 22], ["Theoretical Investigations", "TEST", 62, 88], ["the Enzyme", "TEST", 92, 102], ["the benzyl ester", "TREATMENT", 124, 140]]], ["In the highest ranked pose (i.e., the pose with the most negative score of -20.56), the electrophilic aromatic ring binds to the S1 pocket and is not close to the cysteine (see Figure S3 in the Supplementary Material for more details).", [["cysteine", "CHEMICAL", 163, 171], ["cysteine", "AMINO_ACID", 163, 171], ["S1 pocket", "PROTEIN", 129, 138], ["electrophilic", "OBSERVATION", 88, 101], ["aromatic ring", "OBSERVATION", 102, 115], ["S1", "ANATOMY", 129, 131], ["pocket", "ANATOMY_MODIFIER", 132, 138]]], ["In various other highly stable poses, this inhibitor moiety sits in the active site and hence is close to the active site cysteine (score -18.26, see Figure S4 in the Supplementary Material for more details).", [["cysteine", "CHEMICAL", 122, 130], ["cysteine", "AMINO_ACID", 122, 130], ["this inhibitor moiety", "TREATMENT", 38, 59], ["score", "TEST", 132, 137], ["highly", "OBSERVATION_MODIFIER", 17, 23], ["stable", "OBSERVATION", 24, 30]]], ["Additionally, multiple poses with a substrate-like orientation of compound 7 were predicted with the benzyl ester being in a position close to the cysteine (distance 3.2 \u00c5, score -13.77, Figure 7 ).", [["benzyl ester", "CHEMICAL", 101, 113], ["benzyl ester", "CHEMICAL", 101, 113], ["cysteine", "CHEMICAL", 147, 155], ["benzyl ester", "SIMPLE_CHEMICAL", 101, 113], ["cysteine", "AMINO_ACID", 147, 155], ["the benzyl ester", "TREATMENT", 97, 113], ["score", "TEST", 173, 178], ["multiple", "OBSERVATION_MODIFIER", 14, 22]]], ["In this orientation, the ester carbonyl carbon atom is in a suitable position for nucleophilic attack initiating the hydrolysis of the ester.", [["ester carbonyl", "CHEMICAL", 25, 39], ["ester carbonyl carbon", "CHEMICAL", 25, 46], ["ester", "CHEMICAL", 135, 140], ["ester carbonyl", "SIMPLE_CHEMICAL", 25, 39], ["ester", "SIMPLE_CHEMICAL", 135, 140], ["the ester carbonyl carbon atom", "TREATMENT", 21, 51], ["nucleophilic attack", "PROBLEM", 82, 101]]], ["Our model calculations indicate that the catalytic dyad of the enzyme, mimicked by a thiolate/imidazolium complex, behaves differently than a single attacking thiolate.", [["imidazolium", "CHEMICAL", 94, 105], ["thiolate", "CHEMICAL", 85, 93], ["imidazolium", "CHEMICAL", 94, 105], ["thiolate", "CHEMICAL", 159, 167], ["Our model calculations", "TEST", 0, 22], ["the enzyme", "TEST", 59, 69], ["a thiolate/imidazolium complex", "TREATMENT", 83, 113], ["a single attacking thiolate", "TREATMENT", 140, 167]]], ["Consequently, the formation of a Meisenheimer complex would not be expected for the enzyme, but instead, the formation of a quite stable complex with larger distances between the catalytic dyad and the substituted aromatic ring would be expected.", [["Meisenheimer complex", "PROTEIN", 33, 53], ["enzyme", "PROTEIN", 84, 90], ["catalytic dyad", "PROTEIN", 179, 193], ["a Meisenheimer complex", "PROBLEM", 31, 53], ["the enzyme", "TEST", 80, 90], ["the substituted aromatic ring", "TREATMENT", 198, 227], ["stable", "OBSERVATION_MODIFIER", 130, 136], ["larger", "OBSERVATION_MODIFIER", 150, 156], ["aromatic ring", "OBSERVATION", 214, 227]]], ["From the orientation of the fragments, it resembles a \u03c0-complex.", [["fragments", "ANATOMY", 28, 37], ["\u03c0-complex", "PROTEIN", 54, 63], ["fragments", "OBSERVATION", 28, 37], ["\u03c0-complex", "OBSERVATION_MODIFIER", 54, 63]]], ["Despite this relatively long distance, the complex is quite stable.", [["relatively", "OBSERVATION_MODIFIER", 13, 23], ["long", "OBSERVATION_MODIFIER", 24, 28], ["complex", "OBSERVATION_MODIFIER", 43, 50], ["quite", "OBSERVATION_MODIFIER", 54, 59], ["stable", "OBSERVATION_MODIFIER", 60, 66]]], ["The magnitudes of the computed NMR shifts also indicate that a \u03c0-instead of a Meisenheimer complex is formed.Theoretical Investigations of the Enzyme-Inhibitor ComplexDocking studies using the crystal structure of rhodesain (pdb 2p7u) were performed with acid 8 and its benzyl ester 7 to understand the molecular basis of the observed enzyme inhibition by acid 8 and of the observed enzymatic hydrolysis of ester 7 in more detail.", [["benzyl ester", "CHEMICAL", 270, 282], ["ester", "CHEMICAL", 407, 412], ["rhodesain", "CHEMICAL", 214, 223], ["benzyl ester", "CHEMICAL", 270, 282], ["ester", "CHEMICAL", 407, 412], ["rhodesain", "SIMPLE_CHEMICAL", 214, 223], ["benzyl ester 7", "SIMPLE_CHEMICAL", 270, 284], ["ester 7", "SIMPLE_CHEMICAL", 407, 414], ["Meisenheimer complex", "PROTEIN", 78, 98], ["pdb 2p7u", "PROTEIN", 225, 233], ["the computed NMR shifts", "TEST", 18, 41], ["a Meisenheimer complex", "TREATMENT", 76, 98], ["Theoretical Investigations", "TEST", 109, 135], ["the Enzyme", "TEST", 139, 149], ["ComplexDocking studies", "TEST", 160, 182], ["acid", "TEST", 255, 259], ["its benzyl ester", "TREATMENT", 266, 282]]], ["The detailed procedure is given in the Supplementary Material.Theoretical Investigations of the Enzyme-Inhibitor ComplexFor the benzyl ester 7, three different kinds of poses were found.", [["benzyl ester", "CHEMICAL", 128, 140], ["benzyl ester", "CHEMICAL", 128, 140], ["benzyl ester 7", "SIMPLE_CHEMICAL", 128, 142], ["The detailed procedure", "TREATMENT", 0, 22], ["Theoretical Investigations", "TEST", 62, 88], ["the Enzyme", "TEST", 92, 102], ["the benzyl ester", "TREATMENT", 124, 140]]], ["In the highest ranked pose (i.e., the pose with the most negative score of -20.56), the electrophilic aromatic ring binds to the S1\u2032 pocket and is not close to the cysteine (see Figure SI Additionally, multiple poses with a substrate-like orientation of compound 7 were predicted with the benzyl ester being in a position close to the cysteine (distance 3.2 \u00c5, score -13.77, Figure 7 ).", [["cysteine", "CHEMICAL", 164, 172], ["benzyl ester", "CHEMICAL", 289, 301], ["cysteine", "CHEMICAL", 164, 172], ["benzyl ester", "CHEMICAL", 289, 301], ["cysteine", "CHEMICAL", 335, 343], ["cysteine", "AMINO_ACID", 164, 172], ["benzyl ester", "SIMPLE_CHEMICAL", 289, 301], ["cysteine", "AMINO_ACID", 335, 343], ["S1\u2032 pocket", "PROTEIN", 129, 139], ["the electrophilic aromatic ring binds", "PROBLEM", 84, 121], ["the benzyl ester", "TREATMENT", 285, 301], ["score", "TEST", 361, 366], ["electrophilic", "OBSERVATION", 88, 101], ["aromatic ring", "OBSERVATION", 102, 115], ["S1", "ANATOMY", 129, 131], ["pocket", "OBSERVATION_MODIFIER", 133, 139]]], ["In this orientation, the ester carbonyl carbon atom is in a suitable position for nucleophilic attack initiating the hydrolysis of the ester.", [["ester carbonyl", "CHEMICAL", 25, 39], ["ester carbonyl carbon", "CHEMICAL", 25, 46], ["ester", "CHEMICAL", 135, 140], ["ester carbonyl", "SIMPLE_CHEMICAL", 25, 39], ["ester", "SIMPLE_CHEMICAL", 135, 140], ["the ester carbonyl carbon atom", "TREATMENT", 21, 51], ["nucleophilic attack", "PROBLEM", 82, 101]]], ["In this reverse, i.e., substrate-like orientation, the carbonyl oxygen of the ester group points towards Gln-19.", [["oxygen", "CHEMICAL", 64, 70], ["ester", "CHEMICAL", 78, 83], ["Gln-19", "CHEMICAL", 105, 111], ["carbonyl", "CHEMICAL", 55, 63], ["oxygen", "CHEMICAL", 64, 70], ["ester", "CHEMICAL", 78, 83], ["Gln", "CHEMICAL", 105, 108], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 55, 70], ["ester", "SIMPLE_CHEMICAL", 78, 83], ["Gln-19", "SIMPLE_CHEMICAL", 105, 111], ["the carbonyl oxygen", "TREATMENT", 51, 70], ["Gln", "TEST", 105, 108]]], ["The benzyl group extends into the S1\u2032 pocket and the leucine residue is located in the S1 pocket.", [["benzyl", "CHEMICAL", 4, 10], ["leucine", "CHEMICAL", 53, 60], ["benzyl", "CHEMICAL", 4, 10], ["leucine", "CHEMICAL", 53, 60], ["benzyl", "SIMPLE_CHEMICAL", 4, 10], ["leucine", "AMINO_ACID", 53, 60], ["S1\u2032 pocket", "PROTEIN", 34, 44], ["S1 pocket", "PROTEIN", 87, 96], ["The benzyl group", "TREATMENT", 0, 16], ["the leucine residue", "PROBLEM", 49, 68], ["benzyl group", "OBSERVATION", 4, 16], ["S1", "ANATOMY", 34, 36], ["pocket", "OBSERVATION_MODIFIER", 38, 44], ["leucine residue", "OBSERVATION", 53, 68], ["S1", "ANATOMY", 87, 89], ["pocket", "ANATOMY_MODIFIER", 90, 96]]], ["The phenylalanine side chain occupies the S2 pocket, and the aromatic ring is placed in the S3 pocket.Theoretical Investigations of the Enzyme-Inhibitor ComplexTo investigate the stability of the poses in more detail, three MD simulations for each pose were performed.", [["phenylalanine", "CHEMICAL", 4, 17], ["phenylalanine", "CHEMICAL", 4, 17], ["phenylalanine", "AMINO_ACID", 4, 17], ["phenylalanine side chain", "PROTEIN", 4, 28], ["S2 pocket", "PROTEIN", 42, 51], ["S3 pocket", "PROTEIN", 92, 101], ["Enzyme", "PROTEIN", 136, 142], ["The phenylalanine side chain", "TREATMENT", 0, 28], ["the S2 pocket", "PROBLEM", 38, 51], ["the aromatic ring", "TREATMENT", 57, 74], ["Theoretical Investigations", "TEST", 102, 128], ["the Enzyme-Inhibitor", "TREATMENT", 132, 152], ["phenylalanine", "OBSERVATION", 4, 17], ["S2", "OBSERVATION_MODIFIER", 42, 44], ["pocket", "OBSERVATION_MODIFIER", 45, 51], ["aromatic ring", "OBSERVATION", 61, 74], ["S3 pocket", "OBSERVATION", 92, 101]]], ["The poses in which the electrophilic aromatic ring sits in the active site were found to be S3 S2 S1 S1' In this reverse, i.e., substrate-like orientation, the carbonyl oxygen of the ester group points towards Gln-19.", [["oxygen", "CHEMICAL", 169, 175], ["ester", "CHEMICAL", 183, 188], ["Gln-19", "CHEMICAL", 210, 216], ["carbonyl", "CHEMICAL", 160, 168], ["oxygen", "CHEMICAL", 169, 175], ["ester", "CHEMICAL", 183, 188], ["Gln", "CHEMICAL", 210, 213], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 160, 175], ["ester", "SIMPLE_CHEMICAL", 183, 188], ["Gln-19", "SIMPLE_CHEMICAL", 210, 216], ["S3 S2 S1 S1'", "PROTEIN", 92, 104], ["the electrophilic aromatic ring sits", "TREATMENT", 19, 55], ["the carbonyl oxygen", "TREATMENT", 156, 175], ["Gln", "TEST", 210, 213], ["electrophilic", "OBSERVATION", 23, 36], ["aromatic ring", "OBSERVATION", 37, 50]]], ["The benzyl group extends into the S1 pocket and the leucine residue is located in the S1 pocket.", [["benzyl", "CHEMICAL", 4, 10], ["leucine", "CHEMICAL", 52, 59], ["benzyl", "CHEMICAL", 4, 10], ["leucine", "CHEMICAL", 52, 59], ["benzyl", "SIMPLE_CHEMICAL", 4, 10], ["leucine", "AMINO_ACID", 52, 59], ["S1 pocket", "PROTEIN", 34, 43], ["S1 pocket", "PROTEIN", 86, 95], ["The benzyl group", "TREATMENT", 0, 16], ["the leucine residue", "PROBLEM", 48, 67], ["benzyl group", "OBSERVATION", 4, 16], ["S1", "ANATOMY", 34, 36], ["pocket", "ANATOMY_MODIFIER", 37, 43], ["leucine residue", "OBSERVATION", 52, 67], ["S1", "ANATOMY", 86, 88], ["pocket", "ANATOMY_MODIFIER", 89, 95]]], ["The phenylalanine side chain occupies the S2 pocket, and the aromatic ring is placed in the S3 pocket.GLY-66To investigate the stability of the poses in more detail, three MD simulations for each pose were performed.", [["phenylalanine", "CHEMICAL", 4, 17], ["GLY-66To", "CHEMICAL", 102, 110], ["phenylalanine", "CHEMICAL", 4, 17], ["GLY-66To", "CHEMICAL", 102, 110], ["phenylalanine", "AMINO_ACID", 4, 17], ["GLY-66To", "GENE_OR_GENE_PRODUCT", 102, 110], ["phenylalanine side chain", "PROTEIN", 4, 28], ["S2 pocket", "PROTEIN", 42, 51], ["S3 pocket", "PROTEIN", 92, 101], ["The phenylalanine side chain", "TREATMENT", 0, 28], ["the S2 pocket", "PROBLEM", 38, 51], ["the aromatic ring", "TREATMENT", 57, 74], ["phenylalanine", "OBSERVATION", 4, 17], ["S2", "OBSERVATION_MODIFIER", 42, 44], ["pocket", "OBSERVATION_MODIFIER", 45, 51], ["aromatic ring", "OBSERVATION", 61, 74], ["S3 pocket", "OBSERVATION", 92, 101], ["stability", "OBSERVATION_MODIFIER", 127, 136]]], ["The poses in which the electrophilic aromatic ring sits in the active site were found to be quite stable, although in some cases parts of the inhibitor left the enzyme.", [["enzyme", "PROTEIN", 161, 167], ["the electrophilic aromatic ring sits", "TREATMENT", 19, 55], ["electrophilic", "OBSERVATION", 23, 36], ["aromatic ring", "OBSERVATION", 37, 50], ["sits", "OBSERVATION", 51, 55], ["active site", "OBSERVATION", 63, 74], ["stable", "OBSERVATION_MODIFIER", 98, 104]]], ["However, the enzyme-inhibitor complex never split up completely.", [["enzyme-inhibitor complex", "PROTEIN", 13, 37], ["the enzyme-inhibitor complex", "PROBLEM", 9, 37]]], ["Furthermore, the distances between the cysteine moiety and the aromatic ring remained at distances above 4.5 \u00c5, i.e., for these poses, an attack at the substituted aromatic ring is unlikely.GLY-66MD simulations were also performed for the reverse, i.e., substrate-like binding mode given in Figure 7 .", [["cysteine", "CHEMICAL", 39, 47], ["GLY", "CHEMICAL", 190, 193], ["cysteine", "CHEMICAL", 39, 47], ["cysteine", "AMINO_ACID", 39, 47], ["GLY", "SIMPLE_CHEMICAL", 190, 193], ["the cysteine moiety", "TREATMENT", 35, 54], ["an attack at the substituted aromatic ring", "PROBLEM", 135, 177], ["simulations", "TEST", 199, 210], ["moiety", "OBSERVATION_MODIFIER", 48, 54], ["aromatic ring", "OBSERVATION", 63, 76], ["aromatic ring", "OBSERVATION", 164, 177], ["unlikely", "UNCERTAINTY", 181, 189]]], ["These simulations indicate a moderately stable complex.", [["a moderately stable complex", "PROBLEM", 27, 54], ["moderately", "OBSERVATION_MODIFIER", 29, 39], ["stable", "OBSERVATION_MODIFIER", 40, 46], ["complex", "OBSERVATION", 47, 54]]], ["However, as shown in Figure 8a , the distance between the cysteine moiety and the ester group increases along the simulation time.", [["cysteine", "CHEMICAL", 58, 66], ["ester", "CHEMICAL", 82, 87], ["cysteine", "CHEMICAL", 58, 66], ["ester", "CHEMICAL", 82, 87], ["cysteine moiety", "SIMPLE_CHEMICAL", 58, 73], ["ester", "SIMPLE_CHEMICAL", 82, 87], ["the cysteine moiety", "TREATMENT", 54, 73], ["the ester group", "TREATMENT", 78, 93], ["moiety", "OBSERVATION_MODIFIER", 67, 73], ["ester", "OBSERVATION_MODIFIER", 82, 87]]], ["Nevertheless, the ester may remain sufficiently long within the active site for an attack at the carbonyl carbon followed by ester hydrolysis.", [["ester", "CHEMICAL", 18, 23], ["carbonyl carbon", "CHEMICAL", 97, 112], ["ester", "CHEMICAL", 125, 130], ["ester", "CHEMICAL", 18, 23], ["carbonyl carbon", "CHEMICAL", 97, 112], ["ester", "CHEMICAL", 125, 130], ["ester", "SIMPLE_CHEMICAL", 18, 23], ["carbonyl carbon", "SIMPLE_CHEMICAL", 97, 112], ["ester", "SIMPLE_CHEMICAL", 125, 130], ["the carbonyl carbon", "TREATMENT", 93, 112], ["ester hydrolysis", "PROBLEM", 125, 141]]], ["To investigate possible differences between the ester and the acid we performed an MD simulation starting from the pose given in Figure 7 , but replaced the ester group by the corresponding acid group.", [["ester", "CHEMICAL", 48, 53], ["ester", "CHEMICAL", 157, 162], ["ester", "CHEMICAL", 48, 53], ["ester", "CHEMICAL", 157, 162], ["ester", "SIMPLE_CHEMICAL", 48, 53], ["ester", "SIMPLE_CHEMICAL", 157, 162]]], ["Figure 8b shows that in this case, the inhibitor leaves the enzyme rapidly and the enzyme-inhibitor complex splits up completely.", [["enzyme", "PROTEIN", 60, 66], ["enzyme-inhibitor complex", "PROTEIN", 83, 107], ["the inhibitor", "TREATMENT", 35, 48], ["the enzyme", "TEST", 56, 66], ["the enzyme", "TEST", 79, 89]]], ["The behavior may result from the repulsion between the negatively charged carboxylate and the negatively charged thiolate moiety of Cys-25.GLY-66Molecules 2020, 25, x FOR PEER REVIEW 13 of 23 quite stable, although in some cases parts of the inhibitor left the enzyme.", [["carboxylate", "CHEMICAL", 74, 85], ["Cys-25", "CHEMICAL", 132, 138], ["GLY-66Molecules", "CHEMICAL", 139, 154], ["carboxylate", "CHEMICAL", 74, 85], ["thiolate", "CHEMICAL", 113, 121], ["Cys", "CHEMICAL", 132, 135], ["GLY-66Molecules", "CHEMICAL", 139, 154], ["carboxylate", "SIMPLE_CHEMICAL", 74, 85], ["Cys-25", "SIMPLE_CHEMICAL", 132, 138], ["GLY-66Molecules", "SIMPLE_CHEMICAL", 139, 154], ["enzyme", "PROTEIN", 261, 267], ["the negatively charged carboxylate", "TREATMENT", 51, 85], ["Cys", "TEST", 132, 135], ["GLY", "TEST", 139, 142], ["PEER REVIEW", "TEST", 171, 182], ["stable", "OBSERVATION", 198, 204]]], ["However, the enzymeinhibitor complex never split up completely.", [["enzymeinhibitor", "GENE_OR_GENE_PRODUCT", 13, 28], ["enzymeinhibitor complex", "PROTEIN", 13, 36], ["the enzymeinhibitor complex", "PROBLEM", 9, 36]]], ["Furthermore, the distances between the cysteine moiety and the aromatic ring remained at distances above 4.5 \u00c5, i.e., for these poses, an attack at the substituted aromatic ring is unlikely.", [["cysteine", "CHEMICAL", 39, 47], ["cysteine", "CHEMICAL", 39, 47], ["cysteine", "AMINO_ACID", 39, 47], ["the cysteine moiety", "TREATMENT", 35, 54], ["an attack at the substituted aromatic ring", "PROBLEM", 135, 177], ["moiety", "OBSERVATION_MODIFIER", 48, 54], ["aromatic ring", "OBSERVATION", 63, 76], ["aromatic ring", "OBSERVATION", 164, 177], ["unlikely", "UNCERTAINTY", 181, 189]]], ["MD simulations were also performed for the reverse, i.e., substrate-like binding mode given in Figure 7 .", [["MD simulations", "TEST", 0, 14]]], ["These simulations indicate a moderately stable complex.", [["a moderately stable complex", "PROBLEM", 27, 54], ["moderately", "OBSERVATION_MODIFIER", 29, 39], ["stable", "OBSERVATION_MODIFIER", 40, 46], ["complex", "OBSERVATION", 47, 54]]], ["However, as shown in Figure 8a , the distance between the cysteine moiety and the ester group increases along the simulation time.", [["cysteine", "CHEMICAL", 58, 66], ["ester", "CHEMICAL", 82, 87], ["cysteine", "CHEMICAL", 58, 66], ["ester", "CHEMICAL", 82, 87], ["cysteine moiety", "SIMPLE_CHEMICAL", 58, 73], ["ester", "SIMPLE_CHEMICAL", 82, 87], ["the cysteine moiety", "TREATMENT", 54, 73], ["the ester group", "TREATMENT", 78, 93], ["moiety", "OBSERVATION_MODIFIER", 67, 73], ["ester", "OBSERVATION_MODIFIER", 82, 87]]], ["Nevertheless, the ester may remain sufficiently long within the active site for an attack at the carbonyl carbon followed by ester hydrolysis.", [["ester", "CHEMICAL", 18, 23], ["carbonyl carbon", "CHEMICAL", 97, 112], ["ester", "CHEMICAL", 125, 130], ["ester", "CHEMICAL", 18, 23], ["carbonyl carbon", "CHEMICAL", 97, 112], ["ester", "CHEMICAL", 125, 130], ["ester", "SIMPLE_CHEMICAL", 18, 23], ["carbonyl carbon", "SIMPLE_CHEMICAL", 97, 112], ["ester", "SIMPLE_CHEMICAL", 125, 130], ["the carbonyl carbon", "TREATMENT", 93, 112], ["ester hydrolysis", "PROBLEM", 125, 141]]], ["To investigate possible differences between the ester and the acid we performed an MD simulation starting from the pose given in Figure 7 , but replaced the ester group by the corresponding acid group.", [["ester", "CHEMICAL", 48, 53], ["ester", "CHEMICAL", 157, 162], ["ester", "CHEMICAL", 48, 53], ["ester", "CHEMICAL", 157, 162], ["ester", "SIMPLE_CHEMICAL", 48, 53], ["ester", "SIMPLE_CHEMICAL", 157, 162]]], ["Figure 8b shows that in this case, the inhibitor leaves the enzyme rapidly and the enzyme-inhibitor complex splits up completely.", [["enzyme", "PROTEIN", 60, 66], ["enzyme-inhibitor complex", "PROTEIN", 83, 107], ["the inhibitor", "TREATMENT", 35, 48], ["the enzyme", "TEST", 56, 66], ["the enzyme", "TEST", 79, 89]]], ["The behavior may result from the repulsion between the negatively charged carboxylate and the negatively charged thiolate moiety of Cys-25.", [["carboxylate", "CHEMICAL", 74, 85], ["Cys-25", "CHEMICAL", 132, 138], ["carboxylate", "CHEMICAL", 74, 85], ["thiolate", "CHEMICAL", 113, 121], ["Cys", "CHEMICAL", 132, 135], ["carboxylate", "SIMPLE_CHEMICAL", 74, 85], ["Cys-25", "SIMPLE_CHEMICAL", 132, 138], ["the negatively charged carboxylate", "TREATMENT", 51, 85], ["Cys", "TEST", 132, 135]]], ["For acid 8 in the highest ranked docking pose, the electrophilic aromatic ring was found to be located close to the nucleophilic cysteine (distance 2.7 \u00c5, score -18.03, Figure 9 ).", [["cysteine", "CHEMICAL", 129, 137], ["cysteine", "AMINO_ACID", 129, 137], ["acid", "TEST", 4, 8], ["distance", "TEST", 139, 147], ["score", "TEST", 155, 160], ["electrophilic", "OBSERVATION", 51, 64], ["aromatic ring", "OBSERVATION", 65, 78], ["nucleophilic cysteine", "OBSERVATION", 116, 137]]], ["The peptide backbone has interactions with Asp-161 and Gly-66, while the phenylalanine side chain occupies the hydrophobic S2 pocket.", [["Asp-161", "CHEMICAL", 43, 50], ["Gly-66", "CHEMICAL", 55, 61], ["phenylalanine", "CHEMICAL", 73, 86], ["Asp", "CHEMICAL", 43, 46], ["Gly", "CHEMICAL", 55, 58], ["phenylalanine", "CHEMICAL", 73, 86], ["Asp-161", "AMINO_ACID", 43, 50], ["Gly-66", "AMINO_ACID", 55, 61], ["phenylalanine", "AMINO_ACID", 73, 86], ["phenylalanine side chain", "PROTEIN", 73, 97], ["hydrophobic S2 pocket", "PROTEIN", 111, 132], ["Asp", "TEST", 43, 46], ["Gly", "TEST", 55, 58], ["the phenylalanine side chain", "TREATMENT", 69, 97], ["the hydrophobic S2 pocket", "PROBLEM", 107, 132], ["hydrophobic S2 pocket", "OBSERVATION", 111, 132]]], ["The leucine side-chain and the carboxylic acid group reside in the S3 pocket.", [["leucine", "CHEMICAL", 4, 11], ["carboxylic acid", "CHEMICAL", 31, 46], ["leucine", "CHEMICAL", 4, 11], ["carboxylic acid", "CHEMICAL", 31, 46], ["leucine", "AMINO_ACID", 4, 11], ["carboxylic acid", "SIMPLE_CHEMICAL", 31, 46], ["leucine side-chain", "PROTEIN", 4, 22], ["S3 pocket", "PROTEIN", 67, 76], ["The leucine side-chain", "TREATMENT", 0, 22], ["the carboxylic acid group", "TREATMENT", 27, 52], ["S3", "ANATOMY", 67, 69], ["pocket", "ANATOMY_MODIFIER", 70, 76]]], ["One nitro group forms hydrogen bonds to Gln-19.", [["nitro", "CHEMICAL", 4, 9], ["Gln-19", "CHEMICAL", 40, 46], ["nitro", "CHEMICAL", 4, 9], ["hydrogen", "CHEMICAL", 22, 30], ["Gln", "CHEMICAL", 40, 43], ["hydrogen bonds", "SIMPLE_CHEMICAL", 22, 36], ["Gln-19", "SIMPLE_CHEMICAL", 40, 46], ["Gln", "TEST", 40, 43]]], ["To investigate the stability of the binding pose, we performed various MD simulations, which indicated a very stable complex.", [["very", "OBSERVATION_MODIFIER", 105, 109], ["stable", "OBSERVATION", 110, 116]]], ["The corresponding fluctuations in the distances between the thiolate moiety and the CH-and CNO2-groups of the aromatic ring are depicted in Figures 10a and 10b , respectively.", [["thiolate", "CHEMICAL", 60, 68], ["CNO2", "CHEMICAL", 91, 95], ["thiolate", "CHEMICAL", 60, 68], ["CH", "CHEMICAL", 84, 86], ["CNO2", "CHEMICAL", 91, 95], ["thiolate moiety", "SIMPLE_CHEMICAL", 60, 75], ["the thiolate moiety", "TREATMENT", 56, 75], ["the CH", "TEST", 80, 86], ["fluctuations", "OBSERVATION_MODIFIER", 18, 30], ["thiolate", "OBSERVATION_MODIFIER", 60, 68], ["moiety", "OBSERVATION_MODIFIER", 69, 75], ["aromatic ring", "OBSERVATION", 110, 123]]], ["For acid 8 in the highest ranked docking pose, the electrophilic aromatic ring was found to be located close to the nucleophilic cysteine (distance 2.7 \u00c5, score -18.03, Figure 9 ).", [["cysteine", "CHEMICAL", 129, 137], ["cysteine", "AMINO_ACID", 129, 137], ["acid", "TEST", 4, 8], ["distance", "TEST", 139, 147], ["score", "TEST", 155, 160], ["electrophilic", "OBSERVATION", 51, 64], ["aromatic ring", "OBSERVATION", 65, 78], ["nucleophilic cysteine", "OBSERVATION", 116, 137]]], ["The peptide backbone has interactions with Asp-161 and Gly-66, while the phenylalanine side chain occupies the hydrophobic S2 pocket.", [["Asp-161", "CHEMICAL", 43, 50], ["Gly-66", "CHEMICAL", 55, 61], ["phenylalanine", "CHEMICAL", 73, 86], ["Asp", "CHEMICAL", 43, 46], ["Gly", "CHEMICAL", 55, 58], ["phenylalanine", "CHEMICAL", 73, 86], ["Asp-161", "AMINO_ACID", 43, 50], ["Gly-66", "AMINO_ACID", 55, 61], ["phenylalanine", "AMINO_ACID", 73, 86], ["phenylalanine side chain", "PROTEIN", 73, 97], ["hydrophobic S2 pocket", "PROTEIN", 111, 132], ["Asp", "TEST", 43, 46], ["Gly", "TEST", 55, 58], ["the phenylalanine side chain", "TREATMENT", 69, 97], ["the hydrophobic S2 pocket", "PROBLEM", 107, 132], ["hydrophobic S2 pocket", "OBSERVATION", 111, 132]]], ["The leucine side-chain and the carboxylic acid group reside in the S3 pocket.", [["leucine", "CHEMICAL", 4, 11], ["carboxylic acid", "CHEMICAL", 31, 46], ["leucine", "CHEMICAL", 4, 11], ["carboxylic acid", "CHEMICAL", 31, 46], ["leucine", "AMINO_ACID", 4, 11], ["carboxylic acid", "SIMPLE_CHEMICAL", 31, 46], ["leucine side-chain", "PROTEIN", 4, 22], ["S3 pocket", "PROTEIN", 67, 76], ["The leucine side-chain", "TREATMENT", 0, 22], ["the carboxylic acid group", "TREATMENT", 27, 52], ["S3", "ANATOMY", 67, 69], ["pocket", "ANATOMY_MODIFIER", 70, 76]]], ["One nitro group forms hydrogen bonds to Gln-19.", [["nitro", "CHEMICAL", 4, 9], ["Gln-19", "CHEMICAL", 40, 46], ["nitro", "CHEMICAL", 4, 9], ["hydrogen", "CHEMICAL", 22, 30], ["Gln", "CHEMICAL", 40, 43], ["hydrogen bonds", "SIMPLE_CHEMICAL", 22, 36], ["Gln-19", "SIMPLE_CHEMICAL", 40, 46], ["Gln", "TEST", 40, 43]]], ["To investigate the stability of the binding pose, we performed various MD simulations, which indicated a very stable complex.", [["very", "OBSERVATION_MODIFIER", 105, 109], ["stable", "OBSERVATION", 110, 116]]], ["The corresponding fluctuations in the distances between the thiolate moiety and the CH-and CNO 2 -groups of the aromatic ring are depicted in Figure 10a ,b, respectively.GLY-66Our model computations indicate a stable pre-complex that is stabilized by a strong hydrogen bond between the thiolate and the NH substituent of the aromatic ring.", [["thiolate", "CHEMICAL", 60, 68], ["CNO", "CHEMICAL", 91, 94], ["GLY-66Our", "CHEMICAL", 170, 179], ["NH", "CHEMICAL", 303, 305], ["thiolate", "CHEMICAL", 60, 68], ["CH", "CHEMICAL", 84, 86], ["CNO", "CHEMICAL", 91, 94], ["GLY-66Our", "CHEMICAL", 170, 179], ["hydrogen", "CHEMICAL", 260, 268], ["thiolate", "CHEMICAL", 286, 294], ["NH", "CHEMICAL", 303, 305], ["GLY-66Our", "SIMPLE_CHEMICAL", 170, 179], ["thiolate", "SIMPLE_CHEMICAL", 286, 294], ["the thiolate moiety", "TREATMENT", 56, 75], ["GLY", "TEST", 170, 173], ["a strong hydrogen bond between the thiolate", "TREATMENT", 251, 294], ["fluctuations", "OBSERVATION_MODIFIER", 18, 30], ["thiolate", "OBSERVATION_MODIFIER", 60, 68], ["moiety", "OBSERVATION_MODIFIER", 69, 75], ["aromatic ring", "OBSERVATION", 112, 125], ["stable", "OBSERVATION_MODIFIER", 210, 216], ["NH substituent", "OBSERVATION", 303, 317], ["aromatic ring", "OBSERVATION", 325, 338]]], ["To investigate whether this hydrogen bond is also important for the enzyme-inhibitor complex, we analyzed the distance Cys-S . . .", [["hydrogen", "CHEMICAL", 28, 36], ["Cys", "CHEMICAL", 119, 122], ["enzyme-inhibitor complex", "PROTEIN", 68, 92], ["this hydrogen bond", "PROBLEM", 23, 41], ["the enzyme-inhibitor complex", "TREATMENT", 64, 92]]], ["H-N between the sulfur center of Cys-25 and the proton of the NH substituent along our MD simulations.", [["H-N", "CHEMICAL", 0, 3], ["sulfur", "CHEMICAL", 16, 22], ["Cys-25", "CHEMICAL", 33, 39], ["H-N", "CHEMICAL", 0, 3], ["sulfur", "CHEMICAL", 16, 22], ["Cys", "CHEMICAL", 33, 36], ["NH", "CHEMICAL", 62, 64], ["H-N", "SIMPLE_CHEMICAL", 0, 3], ["sulfur", "SIMPLE_CHEMICAL", 16, 22], ["Cys-25", "SIMPLE_CHEMICAL", 33, 39], ["Cys", "TEST", 33, 36]]], ["The corresponding fluctuations are given in Figure 10c ,d for two MD simulations, which reflect the two different conformations that are adopted along these MD simulations.", [["fluctuations", "OBSERVATION_MODIFIER", 18, 30]]], ["Our model computations indicate a stable pre-complex that is stabilized by a strong hydrogen bond between the thiolate and the NH substituent of the aromatic ring.", [["NH", "CHEMICAL", 127, 129], ["hydrogen", "CHEMICAL", 84, 92], ["thiolate", "CHEMICAL", 110, 118], ["NH", "CHEMICAL", 127, 129], ["thiolate", "SIMPLE_CHEMICAL", 110, 118], ["Our model computations", "TEST", 0, 22], ["a strong hydrogen bond between the thiolate", "TREATMENT", 75, 118], ["stable", "OBSERVATION_MODIFIER", 34, 40], ["NH substituent", "OBSERVATION", 127, 141], ["aromatic ring", "OBSERVATION", 149, 162]]], ["To investigate whether this hydrogen bond is also important for the enzyme-inhibitor complex, we analyzed the distance Cys-S \u2026 H-N between the sulfur center of Cys-25 and the proton of the NH substituent along our MD simulations.", [["sulfur", "CHEMICAL", 143, 149], ["Cys-25", "CHEMICAL", 160, 166], ["hydrogen", "CHEMICAL", 28, 36], ["Cys", "CHEMICAL", 119, 122], ["S", "CHEMICAL", 123, 124], ["H-N", "CHEMICAL", 127, 130], ["sulfur", "CHEMICAL", 143, 149], ["Cys", "CHEMICAL", 160, 163], ["NH", "CHEMICAL", 189, 191], ["H-N", "SIMPLE_CHEMICAL", 127, 130], ["sulfur", "SIMPLE_CHEMICAL", 143, 149], ["Cys-25", "SIMPLE_CHEMICAL", 160, 166], ["enzyme-inhibitor complex", "PROTEIN", 68, 92], ["this hydrogen bond", "PROBLEM", 23, 41], ["the distance Cys", "TEST", 106, 122], ["Cys", "TEST", 160, 163]]], ["The corresponding fluctuations are given in Figures 10c, 10d for two MD simulations, which reflect the two different conformations that are adopted along these MD simulations.", [["fluctuations", "OBSERVATION_MODIFIER", 18, 30]]], ["Our model computations indicate a stable pre-complex that is stabilized by a strong hydrogen bond between the thiolate and the NH substituent of the aromatic ring.", [["NH", "CHEMICAL", 127, 129], ["hydrogen", "CHEMICAL", 84, 92], ["thiolate", "CHEMICAL", 110, 118], ["NH", "CHEMICAL", 127, 129], ["thiolate", "SIMPLE_CHEMICAL", 110, 118], ["Our model computations", "TEST", 0, 22], ["a strong hydrogen bond between the thiolate", "TREATMENT", 75, 118], ["stable", "OBSERVATION_MODIFIER", 34, 40], ["NH substituent", "OBSERVATION", 127, 141], ["aromatic ring", "OBSERVATION", 149, 162]]], ["To investigate whether this hydrogen bond is also important for the enzyme-inhibitor complex, we analyzed the distance Cys-S \u2026 H-N between the sulfur center of Cys-25 and the proton of the NH substituent along our MD simulations.", [["sulfur", "CHEMICAL", 143, 149], ["Cys-25", "CHEMICAL", 160, 166], ["hydrogen", "CHEMICAL", 28, 36], ["Cys", "CHEMICAL", 119, 122], ["S", "CHEMICAL", 123, 124], ["H-N", "CHEMICAL", 127, 130], ["sulfur", "CHEMICAL", 143, 149], ["Cys", "CHEMICAL", 160, 163], ["NH", "CHEMICAL", 189, 191], ["H-N", "SIMPLE_CHEMICAL", 127, 130], ["sulfur", "SIMPLE_CHEMICAL", 143, 149], ["Cys-25", "SIMPLE_CHEMICAL", 160, 166], ["enzyme-inhibitor complex", "PROTEIN", 68, 92], ["this hydrogen bond", "PROBLEM", 23, 41], ["the distance Cys", "TEST", 106, 122], ["Cys", "TEST", 160, 163]]], ["The corresponding fluctuations are given in Figures 10c, 10d for two MD simulations, which reflect the two different conformations that are adopted along these MD simulations.", [["fluctuations", "OBSERVATION_MODIFIER", 18, 30]]], ["Both conformations are depicted in Figure 11 . (c) (d) Within the pose depicted in Figure 9 , the Cys-S \u2026 H-N distance is around 4.5 \u00c5, i.e., all MD simulations started from that distance.", [["Cys", "CHEMICAL", 98, 101], ["S", "CHEMICAL", 102, 103], ["H-N", "CHEMICAL", 106, 109], ["the Cys", "TEST", 94, 101]]], ["For some MDs this conformation was kept for the whole simulation (Figure 10d , Figure 11 conformation with Cys-S \u2026 H-N = 4.4 \u00c5).", [["Cys", "CHEMICAL", 107, 110], ["H-N", "CHEMICAL", 115, 118], ["H", "PROTEIN", 115, 116], ["Cys-S", "TEST", 107, 112]]], ["In other cases (Figure 10c , Figure 11 conformation with Cys-S \u2026 H-N = 2.5 \u00c5), a presumably more stable conformation is adopted in which the Cys-S \u2026 H-N distance decreases strongly and fluctuates around 2.2 \u00c5, indicating a strong hydrogen bond.", [["Cys-S", "CHEMICAL", 141, 146], ["Cys", "CHEMICAL", 57, 60], ["H-N", "CHEMICAL", 65, 68], ["Cys", "CHEMICAL", 141, 144], ["S", "CHEMICAL", 145, 146], ["H", "CHEMICAL", 149, 150], ["N", "CHEMICAL", 151, 152], ["hydrogen", "CHEMICAL", 230, 238], ["H", "PROTEIN", 65, 66], ["Cys-S", "TEST", 57, 62], ["H", "TEST", 65, 66], ["the Cys", "TEST", 137, 144], ["a strong hydrogen bond", "PROBLEM", 221, 243], ["stable", "OBSERVATION", 97, 103], ["strong", "OBSERVATION_MODIFIER", 223, 229], ["hydrogen bond", "OBSERVATION", 230, 243]]], ["While the distance Cys-S \u2026 H-N strongly differs between both conformations, the A complete nucleophilic substitution reaction would lead to an irreversible inhibition because the eliminated group would diffuse away.", [["Cys", "CHEMICAL", 19, 22], ["H-N", "CHEMICAL", 27, 30], ["H-N", "PROTEIN", 27, 30], ["the distance Cys", "TEST", 6, 22], ["the A complete nucleophilic substitution reaction", "PROBLEM", 76, 125], ["an irreversible inhibition", "PROBLEM", 140, 166], ["nucleophilic substitution", "OBSERVATION", 91, 116]]], ["Consequently, for a reversible inhibition the reaction must get trapped in a minimum from which the elimination of the leaving group cannot happen.", [["a reversible inhibition the reaction", "PROBLEM", 18, 54]]], ["This minimum cannot be a Meisenheimer complex as found for the model system with a single attacking thiolate because in this complex, the bonds to the leaving groups are already elongated, i.e., an elimination could occur.", [["Meisenheimer complex", "PROTEIN", 25, 45], ["a single attacking thiolate", "TREATMENT", 81, 108], ["elongated", "OBSERVATION_MODIFIER", 178, 187]]], ["The \u03c0-complex found for the model system consisting of a thiolate/imidazolium unit instead of a single thiolate represents such a trap.", [["imidazolium", "CHEMICAL", 66, 77], ["thiolate", "CHEMICAL", 57, 65], ["imidazolium", "CHEMICAL", 66, 77], ["thiolate", "CHEMICAL", 103, 111], ["a thiolate/imidazolium unit", "TREATMENT", 55, 82], ["a single thiolate", "TREATMENT", 94, 111], ["a trap", "TREATMENT", 128, 134]]], ["It is more stable than the reactants and a further approach of the thiolate towards the inhibitor, which is necessary for an S N Ar reaction, cannot take place because the underlying potential is repulsive.", [["thiolate", "CHEMICAL", 67, 75], ["S N", "CHEMICAL", 125, 128], ["thiolate", "SIMPLE_CHEMICAL", 67, 75], ["the thiolate towards the inhibitor", "TREATMENT", 63, 97], ["an S N Ar reaction", "PROBLEM", 122, 140], ["more", "OBSERVATION_MODIFIER", 6, 10], ["stable", "OBSERVATION_MODIFIER", 11, 17], ["repulsive", "OBSERVATION", 196, 205]]], ["The question remains whether a similar situation exists for the enzyme.GLY-66In many cases the enzyme environment strongly influences the reactivity of a given inhibitor [71] [72] [73] .", [["GLY-66In", "CHEMICAL", 71, 79], ["GLY-66In", "CHEMICAL", 71, 79], ["GLY-66In", "GENE_OR_GENE_PRODUCT", 71, 79], ["enzyme", "PROTEIN", 64, 70], ["the enzyme", "TEST", 60, 70], ["GLY", "TEST", 71, 74], ["the enzyme environment", "TEST", 91, 113], ["a given inhibitor", "TREATMENT", 152, 169]]], ["To investigate the situation for the present question, possible reaction paths of the addition step of the thiolate moiety to the aromatic ring including the influence of the enzyme environment were computed.GLY-66For this instance, hybrid QM/MM computations were performed in which the most important part is described quantum-mechanically (QM) while the influence of the rest is taken into account by force field approaches (MM) using the ONIOM (own n-layered integrated molecular orbital and molecular mechanics) approach implemented in GAUSSIAN16 [69] .", [["thiolate", "CHEMICAL", 107, 115], ["GLY-66For", "CHEMICAL", 208, 217], ["thiolate", "CHEMICAL", 107, 115], ["GLY-66For", "CHEMICAL", 208, 217], ["the thiolate moiety", "TREATMENT", 103, 122], ["the enzyme environment", "TEST", 171, 193], ["GLY", "TEST", 208, 211], ["hybrid QM/MM computations", "TEST", 233, 258], ["the ONIOM (own n-layered integrated molecular orbital and molecular mechanics", "TREATMENT", 437, 514], ["aromatic ring", "OBSERVATION", 130, 143], ["orbital", "ANATOMY", 483, 490]]], ["It was described by SCS-MP2/6-31 + G* because the \u03c9B97XD values underestimated the effects in the model computation.", [["\u03c9B97XD", "SIMPLE_CHEMICAL", 50, 56], ["the \u03c9B97XD values", "TEST", 46, 63], ["the model computation", "TREATMENT", 94, 115]]], ["The influence of the rest of the enzyme (more than 5200 atoms) was included into the MM part, which was described by the AMBER16 force field.", [["enzyme", "PROTEIN", 33, 39], ["the enzyme", "TEST", 29, 39]]], ["The electrostatic embedding was employed to include possible polarization effects.", [["The electrostatic embedding", "TREATMENT", 0, 27], ["polarization effects", "PROBLEM", 61, 81], ["electrostatic embedding", "OBSERVATION", 4, 27], ["possible", "UNCERTAINTY", 52, 60], ["polarization effects", "OBSERVATION", 61, 81]]], ["For the calculations, some frames of the MD simulation performed for the complex of compound 8 and rhodesain were selected, and a full geometry optimization was conducted using QM/MM. The resulting geometry represents the starting point for a possible addition of the thiolate to the substituted aromatic ring as the first step of the S N Ar reaction.", [["rhodesain", "CHEMICAL", 99, 108], ["thiolate", "CHEMICAL", 268, 276], ["S N", "CHEMICAL", 335, 338], ["rhodesain", "SIMPLE_CHEMICAL", 99, 108], ["S N Ar", "SIMPLE_CHEMICAL", 335, 341], ["the calculations", "TEST", 4, 20], ["the MD simulation", "TEST", 37, 54], ["the thiolate", "TREATMENT", 264, 276], ["the substituted aromatic ring", "TREATMENT", 280, 309], ["the S N Ar reaction", "PROBLEM", 331, 350], ["aromatic ring", "OBSERVATION", 296, 309]]], ["We computed the minimal energy path of the addition by decreasing the distance between the thiolate and the two reachable carbon centers (C-H and C-NO 2 ).", [["NO", "CHEMICAL", 148, 150], ["thiolate", "CHEMICAL", 91, 99], ["carbon", "CHEMICAL", 122, 128], ["C-H", "CHEMICAL", 138, 141], ["C-NO 2", "CHEMICAL", 146, 152], ["thiolate", "SIMPLE_CHEMICAL", 91, 99], ["C-H", "SIMPLE_CHEMICAL", 138, 141], ["C-NO 2", "SIMPLE_CHEMICAL", 146, 152], ["C", "TEST", 146, 147], ["minimal", "OBSERVATION_MODIFIER", 16, 23], ["energy path", "OBSERVATION", 24, 35]]], ["For each distance all other geometrical degrees of freedom were optimized.", [["geometrical degrees", "OBSERVATION", 28, 47]]], ["Table 3 indeed indicates small minima in the reaction path.", [["small minima in the reaction path", "PROBLEM", 25, 58], ["small", "OBSERVATION_MODIFIER", 25, 30], ["minima", "OBSERVATION_MODIFIER", 31, 37], ["reaction path", "OBSERVATION", 45, 58]]], ["They appear at distances for R(S-CH) of about 3.1-3.3 \u00c5 or for R(S-CNO 2 ) of about 3.9 \u00c5, i.e., in the range of the complex of the model \"thiolate and imidazolium: full optimization\" (Figure 6 ).", [["imidazolium", "CHEMICAL", 152, 163], ["thiolate", "CHEMICAL", 139, 147], ["imidazolium", "CHEMICAL", 152, 163], ["thiolate", "SIMPLE_CHEMICAL", 139, 147], ["imidazolium", "SIMPLE_CHEMICAL", 152, 163], ["R(S-CH)", "TEST", 29, 36], ["R(S-CNO", "TEST", 63, 70]]], ["They seem to be shallower than in the corresponding model system.", [["seem to be", "UNCERTAINTY", 5, 15], ["shallower", "OBSERVATION", 16, 25]]], ["However, we expect that parts of the attractive forces between the catalytic dyad and the substituted ring are already taken into account by the force field used for the MD simulations or in the subsequent QM/MM geometry optimization, i.e., they already stabilize the minimum from which the computation of the reaction paths started.", [["catalytic dyad", "PROTEIN", 67, 81], ["the substituted ring", "TREATMENT", 86, 106], ["the subsequent QM/MM geometry optimization", "TREATMENT", 191, 233], ["the reaction paths", "TREATMENT", 306, 324]]], ["Nevertheless, beside the indicated strong Cys-S . . .", [["Cys", "CHEMICAL", 42, 45], ["Cys-S", "PROTEIN", 42, 47]]], ["H-N hydrogen bond (see above), the underlying interactions will contribute to the high inhibition potency of the acid 8 for rhodesain.", [["H", "CHEMICAL", 0, 1], ["rhodesain", "CHEMICAL", 124, 133], ["H-N", "CHEMICAL", 0, 3], ["hydrogen", "CHEMICAL", 4, 12], ["rhodesain", "CHEMICAL", 124, 133], ["rhodesain", "SIMPLE_CHEMICAL", 124, 133], ["rhodesain", "PROBLEM", 124, 133]]], ["As for the model system, the computations for the enzyme environment also find a repulsive reaction path, so that a Meisenheimer complex cannot be formed.", [["Meisenheimer complex", "PROTEIN", 116, 136], ["the enzyme environment", "TEST", 46, 68], ["a repulsive reaction path", "PROBLEM", 79, 104], ["a Meisenheimer complex", "TREATMENT", 114, 136]]], ["As a consequence, a complete substitution reaction cannot take place in the enzyme.GLY-66In summary, our QM/MM computations indicate that acid 8 and rhodesain form a very stable \u03c0-complex, which can explain the high inhibition potency of 8.", [["GLY-66In", "CHEMICAL", 83, 91], ["rhodesain", "CHEMICAL", 149, 158], ["GLY-66In", "CHEMICAL", 83, 91], ["rhodesain", "CHEMICAL", 149, 158], ["rhodesain", "SIMPLE_CHEMICAL", 149, 158], ["\u03c0-complex", "SIMPLE_CHEMICAL", 178, 187], ["enzyme", "PROTEIN", 76, 82], ["a complete substitution reaction", "PROBLEM", 18, 50], ["the enzyme", "TEST", 72, 82], ["our QM/MM computations", "TEST", 101, 123], ["acid", "TEST", 138, 142], ["very", "OBSERVATION_MODIFIER", 166, 170], ["stable", "OBSERVATION", 171, 177]]], ["Because the reaction path of the formation of a Meisenheimer complex is repulsive, a S N Ar reaction as found for the reaction of 2-phenylethanethiol with the ester 7 in the presence of a base in ethanol cannot take place in the enzyme.", [["Meisenheimer", "CHEMICAL", 48, 60], ["S N Ar", "CHEMICAL", 85, 91], ["2-phenylethanethiol", "CHEMICAL", 130, 149], ["ester", "CHEMICAL", 159, 164], ["ethanol", "CHEMICAL", 196, 203], ["S N", "CHEMICAL", 85, 88], ["2-phenylethanethiol", "CHEMICAL", 130, 149], ["ester", "CHEMICAL", 159, 164], ["ethanol", "CHEMICAL", 196, 203], ["Meisenheimer", "SIMPLE_CHEMICAL", 48, 60], ["S N Ar", "SIMPLE_CHEMICAL", 85, 91], ["2-phenylethanethiol", "SIMPLE_CHEMICAL", 130, 149], ["ester 7", "SIMPLE_CHEMICAL", 159, 166], ["ethanol", "SIMPLE_CHEMICAL", 196, 203], ["Meisenheimer complex", "PROTEIN", 48, 68], ["enzyme", "PROTEIN", 229, 235], ["a S N Ar reaction", "PROBLEM", 83, 100], ["the reaction", "PROBLEM", 114, 126], ["a base in ethanol", "TREATMENT", 186, 203], ["repulsive", "OBSERVATION", 72, 81]]], ["This explains why acid 8 is a reversible inhibitor.", [["a reversible inhibitor", "PROBLEM", 28, 50]]], ["The lower inhibitory potency of ester 7 is a consequence of the non-covalent interactions between inhibitor and enzyme, which prevent the formation of such a strong complex.T. b. brucei Cell Survival AssayEster 7 and acid 8 were tested for their anti-trypanosomal activity against T. brucei brucei using the ATPlite assay according to previously published procedures [74] .", [["Cell", "ANATOMY", 186, 190], ["ester", "CHEMICAL", 32, 37], ["AssayEster 7 and acid 8", "CHEMICAL", 200, 223], ["ester", "CHEMICAL", 32, 37], ["ester 7", "SIMPLE_CHEMICAL", 32, 39], ["T. b. brucei", "ORGANISM", 173, 185], ["Cell", "CELL", 186, 190], ["AssayEster 7", "ORGANISM", 200, 212], ["T. brucei brucei", "ORGANISM", 281, 297], ["enzyme", "PROTEIN", 112, 118], ["T. b. brucei", "SPECIES", 173, 185], ["T. brucei", "SPECIES", 281, 290], ["brucei", "SPECIES", 291, 297], ["T. b. brucei", "SPECIES", 173, 185], ["T. brucei brucei", "SPECIES", 281, 297], ["inhibitor", "TREATMENT", 98, 107], ["enzyme", "TEST", 112, 118], ["Survival AssayEster", "TREATMENT", 191, 210], ["T. brucei brucei", "PROBLEM", 281, 297], ["lower", "ANATOMY_MODIFIER", 4, 9], ["brucei Cell", "OBSERVATION", 179, 190], ["brucei brucei", "OBSERVATION", 284, 297]]], ["After 24 h, EC 50 values of 0.0953 (\u00b10.0402) \u00b5M for the ester 7 and 18.5 (\u00b14.97) \u00b5M for the acid 8 were found (Figure 12 ).", [["EC", "ANATOMY", 12, 14], ["ester", "CHEMICAL", 56, 61], ["ester", "CHEMICAL", 56, 61], ["EC", "CELL", 12, 14], ["EC", "TEST", 12, 14], ["the ester", "TEST", 52, 61], ["the acid 8", "TEST", 88, 98]]], ["The differences in anti-protease and anti-trypanosomal activity between the lipophilic ester 7 and the more hydrophilic acid 8 might be due to different cell permeabilities of the compounds.", [["cell", "ANATOMY", 153, 157], ["lipophilic ester", "CHEMICAL", 76, 92], ["hydrophilic acid", "CHEMICAL", 108, 124], ["ester", "CHEMICAL", 87, 92], ["lipophilic ester 7", "SIMPLE_CHEMICAL", 76, 94], ["cell", "CELL", 153, 157], ["anti-protease", "TREATMENT", 19, 32], ["the lipophilic ester", "TEST", 72, 92], ["different cell permeabilities of the compounds", "PROBLEM", 143, 189], ["different cell permeabilities", "OBSERVATION", 143, 172]]], ["With the acid 8 being the active protease inhibitor and the more lipophilic benzyl ester 7 being the better anti-trypanosomal compound that is converted to the active protease inhibitor 8 by the target enzyme itself, we presumably have discovered a new prodrug concept for anti-trypanosomal compounds targeting the major trypanosomal cysteine protease rhodesain.", [["benzyl ester", "CHEMICAL", 76, 88], ["benzyl ester", "CHEMICAL", 76, 88], ["cysteine", "CHEMICAL", 334, 342], ["lipophilic benzyl ester 7", "SIMPLE_CHEMICAL", 65, 90], ["anti-trypanosomal compounds", "SIMPLE_CHEMICAL", 273, 300], ["major trypanosomal cysteine protease rhodesain", "PROTEIN", 315, 361], ["the acid", "TREATMENT", 5, 13], ["the active protease inhibitor", "TREATMENT", 22, 51], ["the more lipophilic benzyl ester", "TREATMENT", 56, 88], ["the active protease inhibitor", "TREATMENT", 156, 185], ["a new prodrug concept", "TREATMENT", 247, 268], ["anti-trypanosomal compounds", "TREATMENT", 273, 300], ["the major trypanosomal cysteine protease rhodesain", "TREATMENT", 311, 361], ["trypanosomal cysteine protease", "OBSERVATION", 321, 351]]], ["These results are in agreement with previous findings [75] , which showed that especially rhodesain inhibitors with benzyl ester moieties display high anti-trypanosomal activity.T. b. brucei Cell Survival Assaythat a Meisenheimer complex cannot be formed.", [["Cell", "ANATOMY", 191, 195], ["benzyl ester", "CHEMICAL", 116, 128], ["benzyl ester", "CHEMICAL", 116, 128], ["rhodesain inhibitors", "SIMPLE_CHEMICAL", 90, 110], ["benzyl ester moieties", "SIMPLE_CHEMICAL", 116, 137], ["T. b. brucei", "ORGANISM", 178, 190], ["Cell", "CELL", 191, 195], ["Meisenheimer complex", "PROTEIN", 217, 237], ["T. b. brucei", "SPECIES", 178, 190], ["T. b. brucei", "SPECIES", 178, 190], ["rhodesain inhibitors", "TREATMENT", 90, 110], ["benzyl ester moieties", "TREATMENT", 116, 137], ["high anti-trypanosomal activity", "PROBLEM", 146, 177], ["a Meisenheimer complex", "TREATMENT", 215, 237], ["high", "OBSERVATION_MODIFIER", 146, 150], ["anti-trypanosomal activity", "OBSERVATION", 151, 177], ["brucei", "OBSERVATION", 184, 190]]], ["As a consequence, a complete substitution reaction cannot take place in the enzyme.T. b. brucei Cell Survival AssayIn summary, our QM/MM computations indicate that acid 8 and rhodesain form a very stable \u03c0-complex, which can explain the high inhibition potency of 8.", [["Cell", "ANATOMY", 96, 100], ["rhodesain", "CHEMICAL", 175, 184], ["rhodesain", "CHEMICAL", 175, 184], ["Cell", "CELL", 96, 100], ["rhodesain", "SIMPLE_CHEMICAL", 175, 184], ["\u03c0-complex", "SIMPLE_CHEMICAL", 204, 213], ["enzyme", "PROTEIN", 76, 82], ["T. b. brucei", "SPECIES", 83, 95], ["T. b. brucei", "SPECIES", 83, 95], ["a complete substitution reaction", "PROBLEM", 18, 50], ["the enzyme", "TEST", 72, 82], ["our QM/MM computations", "TEST", 127, 149], ["acid", "TEST", 164, 168], ["brucei Cell", "OBSERVATION", 89, 100], ["very", "OBSERVATION_MODIFIER", 192, 196], ["stable", "OBSERVATION", 197, 203]]], ["Because the reaction path of the formation of a Meisenheimer complex is repulsive, a SNAr reaction as found for the reaction of 2phenylethanethiol with the ester 7 in the presence of a base in ethanol cannot take place in the enzyme.", [["Meisenheimer", "CHEMICAL", 48, 60], ["2phenylethanethiol", "CHEMICAL", 128, 146], ["ester", "CHEMICAL", 156, 161], ["ethanol", "CHEMICAL", 193, 200], ["2phenylethanethiol", "CHEMICAL", 128, 146], ["ester", "CHEMICAL", 156, 161], ["ethanol", "CHEMICAL", 193, 200], ["Meisenheimer", "SIMPLE_CHEMICAL", 48, 60], ["SNAr", "SIMPLE_CHEMICAL", 85, 89], ["2phenylethanethiol", "SIMPLE_CHEMICAL", 128, 146], ["ester 7", "SIMPLE_CHEMICAL", 156, 163], ["ethanol", "SIMPLE_CHEMICAL", 193, 200], ["Meisenheimer complex", "PROTEIN", 48, 68], ["enzyme", "PROTEIN", 226, 232], ["a SNAr reaction", "PROBLEM", 83, 98], ["the enzyme", "TEST", 222, 232], ["repulsive", "OBSERVATION_MODIFIER", 72, 81], ["base", "ANATOMY_MODIFIER", 185, 189]]], ["This explains why acid 8 is a reversible inhibitor.", [["a reversible inhibitor", "PROBLEM", 28, 50]]], ["The lower inhibitory potency of ester 7 is a consequence of the non-covalent interactions between inhibitor and enzyme, which prevent the formation of such a strong complex.T. b. brucei Cell Survival AssayEster 7 and acid 8 were tested for their anti-trypanosomal activity against T. brucei brucei using the ATPlite assay according to previously published procedures [74] .", [["Cell", "ANATOMY", 186, 190], ["ester", "CHEMICAL", 32, 37], ["AssayEster 7 and acid 8", "CHEMICAL", 200, 223], ["ester", "CHEMICAL", 32, 37], ["ester 7", "SIMPLE_CHEMICAL", 32, 39], ["T. b. brucei", "ORGANISM", 173, 185], ["Cell", "CELL", 186, 190], ["AssayEster 7", "ORGANISM", 200, 212], ["T. brucei brucei", "ORGANISM", 281, 297], ["enzyme", "PROTEIN", 112, 118], ["T. b. brucei", "SPECIES", 173, 185], ["T. brucei", "SPECIES", 281, 290], ["brucei", "SPECIES", 291, 297], ["T. b. brucei", "SPECIES", 173, 185], ["T. brucei brucei", "SPECIES", 281, 297], ["inhibitor", "TREATMENT", 98, 107], ["enzyme", "TEST", 112, 118], ["Survival AssayEster", "TREATMENT", 191, 210], ["T. brucei brucei", "PROBLEM", 281, 297], ["lower", "ANATOMY_MODIFIER", 4, 9], ["brucei Cell", "OBSERVATION", 179, 190], ["brucei brucei", "OBSERVATION", 284, 297]]], ["After 24 h, EC50 values of 0.0953 (\u00b10.0402) \u00b5M for the ester 7 and 18.5 (\u00b14.97) \u00b5M for the acid 8 were found (Figure 12 ).", [["ester", "CHEMICAL", 55, 60], ["ester", "CHEMICAL", 55, 60], ["EC50 values", "TEST", 12, 23], ["the ester", "TEST", 51, 60], ["the acid 8", "TEST", 87, 97]]], ["The differences in anti-protease and anti-trypanosomal activity between the lipophilic ester 7 and the more hydrophilic acid 8 might be due to different cell permeabilities of the compounds.", [["cell", "ANATOMY", 153, 157], ["lipophilic ester", "CHEMICAL", 76, 92], ["hydrophilic acid", "CHEMICAL", 108, 124], ["ester", "CHEMICAL", 87, 92], ["lipophilic ester 7", "SIMPLE_CHEMICAL", 76, 94], ["cell", "CELL", 153, 157], ["anti-protease", "TREATMENT", 19, 32], ["the lipophilic ester", "TEST", 72, 92], ["different cell permeabilities of the compounds", "PROBLEM", 143, 189], ["different cell permeabilities", "OBSERVATION", 143, 172]]], ["With the acid 8 being the active protease inhibitor and the more lipophilic benzyl ester 7 being the better antitrypanosomal compound that is converted to the active protease inhibitor 8 by the target enzyme itself, we presumably have discovered a new prodrug concept for anti-trypanosomal compounds targeting the major trypanosomal cysteine protease rhodesain.", [["benzyl ester", "CHEMICAL", 76, 88], ["benzyl ester", "CHEMICAL", 76, 88], ["cysteine", "CHEMICAL", 333, 341], ["lipophilic benzyl ester 7", "SIMPLE_CHEMICAL", 65, 90], ["anti-trypanosomal compounds", "SIMPLE_CHEMICAL", 272, 299], ["major trypanosomal cysteine protease rhodesain", "PROTEIN", 314, 360], ["the acid", "TREATMENT", 5, 13], ["the active protease inhibitor", "TREATMENT", 22, 51], ["the more lipophilic benzyl ester", "TREATMENT", 56, 88], ["the active protease inhibitor", "TREATMENT", 155, 184], ["a new prodrug concept", "TREATMENT", 246, 267], ["anti-trypanosomal compounds", "TREATMENT", 272, 299], ["the major trypanosomal cysteine protease rhodesain", "TREATMENT", 310, 360], ["trypanosomal cysteine protease", "OBSERVATION", 320, 350]]], ["These results are in agreement with previous findings [75] , which showed that especially rhodesain inhibitors with benzyl ester moieties display high anti-trypanosomal activity.DiscussionThe realm of potentially S N Ar-reactive units as building blocks for protease inhibitors is still largely unexplored and as stated in the introduction part, only very few steps have been undertaken in this direction.", [["benzyl ester", "CHEMICAL", 116, 128], ["benzyl ester", "CHEMICAL", 116, 128], ["S N", "CHEMICAL", 213, 216], ["rhodesain inhibitors", "SIMPLE_CHEMICAL", 90, 110], ["benzyl ester moieties", "SIMPLE_CHEMICAL", 116, 137], ["rhodesain inhibitors", "TREATMENT", 90, 110], ["benzyl ester moieties", "TREATMENT", 116, 137], ["high anti-trypanosomal activity", "PROBLEM", 146, 177], ["S N Ar-reactive units", "TREATMENT", 213, 234], ["building blocks", "TREATMENT", 238, 253], ["protease inhibitors", "TREATMENT", 258, 277], ["high", "OBSERVATION_MODIFIER", 146, 150], ["anti-trypanosomal activity", "OBSERVATION", 151, 177]]], ["The evaluation of (hetero)aromatic electrophiles as possible inhibitory fragments or warheads for peptidic cysteine protease inhibitors is a first important step.", [["cysteine", "CHEMICAL", 107, 115], ["(hetero)aromatic electrophiles", "SIMPLE_CHEMICAL", 18, 48], ["The evaluation", "TEST", 0, 14], ["(hetero)aromatic electrophiles", "PROBLEM", 18, 48], ["inhibitory fragments", "PROBLEM", 61, 81], ["peptidic cysteine protease inhibitors", "TREATMENT", 98, 135]]], ["Among the inhibitors presented herein, which contain the dipeptide HN-l-Phe-l-Leu-OBn as the recognition unit for cathepsin L-like proteases, the 2-fluoro-3-nitro-substituted benzoic acid amide 4 and the 2-fluoro-4,5-dinitro-substituted aniline derivative 7 were discovered as very potent cathepsin L inhibitors.", [["Phe-l-Leu-OBn", "CHEMICAL", 72, 85], ["2-fluoro-3-nitro-substituted benzoic acid amide", "CHEMICAL", 146, 193], ["2-fluoro-4,5-dinitro-substituted aniline", "CHEMICAL", 204, 244], ["HN-l-Phe-l-Leu-OBn", "CHEMICAL", 67, 85], ["2-fluoro-3-nitro-substituted benzoic acid amide", "CHEMICAL", 146, 193], ["2-fluoro-4,5-dinitro-substituted aniline", "CHEMICAL", 204, 244], ["Phe-l-Leu-OBn", "SIMPLE_CHEMICAL", 72, 85], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 114, 125], ["2-fluoro-3-nitro-substituted benzoic acid amide 4", "SIMPLE_CHEMICAL", 146, 195], ["2-fluoro-4,5-dinitro-substituted aniline derivative 7", "SIMPLE_CHEMICAL", 204, 257], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 289, 300], ["cathepsin L-like proteases", "PROTEIN", 114, 140], ["the dipeptide HN", "TEST", 53, 69], ["cathepsin L", "TEST", 114, 125], ["nitro", "TREATMENT", 157, 162], ["substituted benzoic acid amide", "TREATMENT", 163, 193], ["the 2-fluoro", "TREATMENT", 200, 212], ["dinitro-substituted aniline derivative", "TREATMENT", 217, 255], ["potent cathepsin L inhibitors", "TREATMENT", 282, 311]]], ["Amide 4 additionally inhibits the trypanosomal cathepsin L-like protease rhodesain.", [["Amide 4", "CHEMICAL", 0, 7], ["Amide 4", "CHEMICAL", 0, 7], ["Amide 4", "SIMPLE_CHEMICAL", 0, 7], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 47, 58], ["trypanosomal cathepsin L-like protease rhodesain", "PROTEIN", 34, 82], ["Amide", "TREATMENT", 0, 5], ["the trypanosomal cathepsin L", "TREATMENT", 30, 58], ["protease rhodesain", "TREATMENT", 64, 82]]], ["The compounds were found to exhibit a competitive and reversible mode of inhibition.", [["a competitive and reversible mode of inhibition", "PROBLEM", 36, 83]]], ["As shown by NMR spectroscopy, mass spectrometry and hydrolysis assays, the benzyl ester 7 was found to be hydrolyzed to the free acid 8 by rhodesain to yield a highly potent reversible rhodesain inhibitor (K i = 4.0 nM).", [["benzyl ester", "CHEMICAL", 75, 87], ["rhodesain", "CHEMICAL", 139, 148], ["K", "CHEMICAL", 206, 207], ["benzyl ester", "CHEMICAL", 75, 87], ["rhodesain", "CHEMICAL", 139, 148], ["benzyl ester 7", "SIMPLE_CHEMICAL", 75, 89], ["rhodesain", "SIMPLE_CHEMICAL", 139, 148], ["rhodesain", "SIMPLE_CHEMICAL", 185, 194], ["NMR spectroscopy", "TEST", 12, 28], ["mass spectrometry", "TEST", 30, 47], ["hydrolysis assays", "TEST", 52, 69], ["a highly potent reversible rhodesain inhibitor", "PROBLEM", 158, 204], ["K i", "TEST", 206, 209]]], ["Thus, with the benzyl ester 7, we identified an unexpected prodrug that is converted into the active protease inhibitor by the target enzyme itself.", [["benzyl ester", "CHEMICAL", 15, 27], ["benzyl ester", "CHEMICAL", 15, 27], ["benzyl ester 7", "SIMPLE_CHEMICAL", 15, 29], ["the benzyl ester", "TREATMENT", 11, 27], ["the active protease inhibitor", "TREATMENT", 90, 119]]], ["This is supported by the T. b. brucei cell survival assays, which revealed the benzyl ester 7 as a compound with significantly enhanced anti-trypanosomal activity.", [["cell", "ANATOMY", 38, 42], ["benzyl ester", "CHEMICAL", 79, 91], ["benzyl ester", "CHEMICAL", 79, 91], ["b. brucei", "ORGANISM", 28, 37], ["cell", "CELL", 38, 42], ["benzyl ester 7", "SIMPLE_CHEMICAL", 79, 93], ["T. b. brucei", "SPECIES", 25, 37], ["T. b. brucei", "SPECIES", 25, 37], ["the T. b. brucei cell survival assays", "TEST", 21, 58], ["the benzyl ester", "TREATMENT", 75, 91], ["brucei cell", "OBSERVATION", 31, 42], ["anti-trypanosomal activity", "OBSERVATION", 136, 162]]], ["The serendipitous discovery of the dual mode of action of compound 8 implies that other ester-or even amide-type inhibitors may also react similarly.", [["ester", "CHEMICAL", 88, 93], ["ester", "CHEMICAL", 88, 93], ["amide", "CHEMICAL", 102, 107], ["ester", "SIMPLE_CHEMICAL", 88, 93], ["even amide-type inhibitors", "TREATMENT", 97, 123]]], ["The ester 7 performed S N Ar reactions with 2-phenylethanethiol in ethanol in the presence of a base.", [["ester", "CHEMICAL", 4, 9], ["S N Ar", "CHEMICAL", 22, 28], ["2-phenylethanethiol", "CHEMICAL", 44, 63], ["ethanol", "CHEMICAL", 67, 74], ["ester", "CHEMICAL", 4, 9], ["S N", "CHEMICAL", 22, 25], ["2-phenylethanethiol", "CHEMICAL", 44, 63], ["ethanol", "CHEMICAL", 67, 74], ["ester 7", "SIMPLE_CHEMICAL", 4, 11], ["S N Ar", "SIMPLE_CHEMICAL", 22, 28], ["2-phenylethanethiol", "SIMPLE_CHEMICAL", 44, 63], ["ethanol", "SIMPLE_CHEMICAL", 67, 74], ["S N Ar reactions", "TREATMENT", 22, 38], ["base", "ANATOMY_MODIFIER", 96, 100]]], ["Such a reaction is also expected for 8 because both possess the same substituted aromatic ring.", [["a reaction", "PROBLEM", 5, 15], ["aromatic ring", "OBSERVATION", 81, 94]]], ["However, because 8 acts as a reversible inhibitor, such a reaction cannot be the inhibition mechanism of rhodesain.DiscussionTo investigate possible inhibition mechanisms, QM computations for relevant model systems were performed.", [["rhodesain", "CHEMICAL", 105, 114], ["rhodesain", "CHEMICAL", 105, 114], ["rhodesain", "SIMPLE_CHEMICAL", 105, 114], ["a reversible inhibitor", "TREATMENT", 27, 49], ["a reaction", "PROBLEM", 56, 66], ["inhibition mechanisms", "PROBLEM", 149, 170], ["relevant model systems", "TEST", 192, 214]]], ["Docking and MD simulation were conducted to detect and investigate possible inhibitor-enzyme complexes of the compounds 7 and 8.", [["enzyme complexes", "PROTEIN", 86, 102], ["inhibitor-enzyme complexes of the compounds", "PROBLEM", 76, 119]]], ["Finally, QM/MM computations were carried out to get some insights into possible reactions between 8 and rhodesain.DiscussionThe model calculations show that a single attacking thiolate behaves completely different than a dyad consisting of a thiolate and a positively charged imidazolium ring.", [["imidazolium", "CHEMICAL", 276, 287], ["thiolate", "CHEMICAL", 176, 184], ["thiolate", "CHEMICAL", 242, 250], ["imidazolium", "CHEMICAL", 276, 287], ["rhodesain", "SIMPLE_CHEMICAL", 104, 113], ["imidazolium ring", "SIMPLE_CHEMICAL", 276, 292], ["QM/MM computations", "TEST", 9, 27], ["reactions", "PROBLEM", 80, 89], ["The model calculations", "TEST", 124, 146], ["a single attacking thiolate", "PROBLEM", 157, 184], ["a thiolate", "TREATMENT", 240, 250], ["a positively charged imidazolium ring", "TREATMENT", 255, 292], ["imidazolium ring", "OBSERVATION", 276, 292]]], ["The former is a model for the reaction of phenylethanethiol in ethanol in the presence of a base, while the latter mimics the catalytic dyad of the protease.", [["phenylethanethiol", "CHEMICAL", 42, 59], ["ethanol", "CHEMICAL", 63, 70], ["phenylethanethiol", "CHEMICAL", 42, 59], ["ethanol", "CHEMICAL", 63, 70], ["phenylethanethiol", "SIMPLE_CHEMICAL", 42, 59], ["ethanol", "SIMPLE_CHEMICAL", 63, 70], ["catalytic dyad", "PROTEIN", 126, 140], ["protease", "PROTEIN", 148, 156], ["phenylethanethiol in ethanol", "TREATMENT", 42, 70], ["the protease", "TREATMENT", 144, 156], ["base", "ANATOMY_MODIFIER", 92, 96]]], ["For a single thiolate, the computations predict stable Meisenheimer complexes, which is in line with the observed S N Ar reactions.", [["thiolate", "CHEMICAL", 13, 21], ["S N", "CHEMICAL", 114, 117], ["Meisenheimer complexes", "PROTEIN", 55, 77], ["a single thiolate", "TREATMENT", 4, 21]]], ["By contrast, for a thiolate/imidazolium dyad, a stable \u03c0-complex is found.", [["thiolate", "CHEMICAL", 19, 27], ["imidazolium", "CHEMICAL", 28, 39], ["thiolate", "CHEMICAL", 19, 27], ["imidazolium", "CHEMICAL", 28, 39], ["\u03c0-complex", "SIMPLE_CHEMICAL", 55, 64], ["\u03c0-complex", "PROTEIN", 55, 64], ["a thiolate/imidazolium dyad", "TREATMENT", 17, 44], ["stable", "OBSERVATION_MODIFIER", 48, 54]]], ["The reaction potential of a further approach towards a Meisenheimer complex is repulsive, i.e., the reaction cannot take place.", [["Meisenheimer", "SIMPLE_CHEMICAL", 55, 67], ["Meisenheimer complex", "PROTEIN", 55, 75], ["a further approach", "TREATMENT", 26, 44], ["the reaction", "PROBLEM", 96, 108], ["repulsive", "OBSERVATION", 79, 88]]], ["Consequently, while an irreversible reaction is predicted for a single thiolate, a reversible formation of a stable \u03c0-complex is computed for the thiolate/imidazolium dyad.", [["imidazolium", "CHEMICAL", 155, 166], ["thiolate", "CHEMICAL", 146, 154], ["imidazolium", "CHEMICAL", 155, 166], ["\u03c0-complex", "SIMPLE_CHEMICAL", 116, 125], ["thiolate/imidazolium dyad", "SIMPLE_CHEMICAL", 146, 171], ["an irreversible reaction", "PROBLEM", 20, 44], ["a reversible formation", "PROBLEM", 81, 103], ["the thiolate/imidazolium dyad", "TREATMENT", 142, 171], ["reversible", "OBSERVATION_MODIFIER", 83, 93], ["formation", "OBSERVATION", 94, 103], ["stable", "OBSERVATION_MODIFIER", 109, 115]]], ["Subsequent QM/MM computations simulating the reaction of 8 with rhodesain indicate a similar situation.", [["rhodesain", "CHEMICAL", 64, 73], ["rhodesain", "CHEMICAL", 64, 73], ["rhodesain", "SIMPLE_CHEMICAL", 64, 73], ["Subsequent QM/MM computations", "TREATMENT", 0, 29], ["the reaction", "TEST", 41, 53]]], ["Hence, we expect that an S N Ar reaction of acid 8 with rhodesain does not take place because the reaction is trapped in a very stable \u03c0-complex.", [["acid 8", "CHEMICAL", 44, 50], ["rhodesain", "CHEMICAL", 56, 65], ["S N", "CHEMICAL", 25, 28], ["rhodesain", "CHEMICAL", 56, 65], ["rhodesain", "SIMPLE_CHEMICAL", 56, 65], ["\u03c0-complex", "SIMPLE_CHEMICAL", 135, 144], ["\u03c0-complex", "PROTEIN", 135, 144], ["an S N Ar reaction of acid", "TREATMENT", 22, 48], ["rhodesain", "TREATMENT", 56, 65], ["the reaction", "PROBLEM", 94, 106], ["very", "OBSERVATION_MODIFIER", 123, 127], ["stable", "OBSERVATION_MODIFIER", 128, 134]]], ["The complex seems to receive additional stability through a strong hydrogen bridge between the thiolate group of Cys-25 and the NH-substituent of the aromatic ring.DiscussionThe conducted docking and MD simulations reveal several stable complexes between ester 7 and rhodesain, in which the substituted aromatic ring sits in the active site, i.e., in close vicinity to the reactive dyad.", [["thiolate", "CHEMICAL", 95, 103], ["Cys-25", "CHEMICAL", 113, 119], ["ester", "CHEMICAL", 255, 260], ["rhodesain", "CHEMICAL", 267, 276], ["hydrogen", "CHEMICAL", 67, 75], ["thiolate", "CHEMICAL", 95, 103], ["Cys", "CHEMICAL", 113, 116], ["NH", "CHEMICAL", 128, 130], ["ester", "CHEMICAL", 255, 260], ["rhodesain", "CHEMICAL", 267, 276], ["thiolate", "SIMPLE_CHEMICAL", 95, 103], ["Cys-25", "SIMPLE_CHEMICAL", 113, 119], ["NH-substituent", "SIMPLE_CHEMICAL", 128, 142], ["ester 7", "SIMPLE_CHEMICAL", 255, 262], ["rhodesain", "SIMPLE_CHEMICAL", 267, 276], ["a strong hydrogen bridge", "TREATMENT", 58, 82], ["Cys", "TEST", 113, 116], ["MD simulations", "TEST", 200, 214], ["the substituted aromatic ring sits", "TREATMENT", 287, 321], ["stability", "OBSERVATION", 40, 49], ["aromatic ring", "OBSERVATION", 150, 163], ["several", "OBSERVATION_MODIFIER", 222, 229], ["stable", "OBSERVATION_MODIFIER", 230, 236], ["aromatic ring sits", "OBSERVATION", 303, 321], ["active", "OBSERVATION_MODIFIER", 329, 335], ["site", "OBSERVATION_MODIFIER", 336, 340], ["reactive dyad", "OBSERVATION", 373, 386]]], ["Nevertheless, reactions are not expected because MD simulations show that the distances are still too large.", [["large", "OBSERVATION", 102, 107]]], ["Additionally, no indication for the formation of a stable \u03c0-complex or the thiolate-NH bridge is seen.", [["thiolate-NH", "CHEMICAL", 75, 86], ["thiolate", "CHEMICAL", 75, 83], ["NH", "CHEMICAL", 84, 86], ["\u03c0-complex", "SIMPLE_CHEMICAL", 58, 67], ["thiolate-NH", "SIMPLE_CHEMICAL", 75, 86], ["NH bridge", "PROTEIN", 84, 93], ["the thiolate-NH bridge", "TREATMENT", 71, 93], ["no indication for", "UNCERTAINTY", 14, 31], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["\u03c0-complex", "OBSERVATION", 58, 67], ["thiolate", "OBSERVATION_MODIFIER", 75, 83], ["NH bridge", "OBSERVATION", 84, 93]]], ["Hence, we expect that these complexes are less stable, which nicely explains the lower inhibitory potency of ester 7 compared to acid 8.", [["ester", "CHEMICAL", 109, 114], ["ester", "CHEMICAL", 109, 114], ["ester 7", "SIMPLE_CHEMICAL", 109, 116], ["less", "OBSERVATION_MODIFIER", 42, 46], ["stable", "OBSERVATION_MODIFIER", 47, 53]]], ["Docking also predicts a reverse, substrate-like binding pose, which is ideal for the hydrolysis of the ester through rhodesain.", [["ester", "CHEMICAL", 103, 108], ["rhodesain", "CHEMICAL", 117, 126], ["ester", "CHEMICAL", 103, 108], ["rhodesain", "CHEMICAL", 117, 126], ["ester", "SIMPLE_CHEMICAL", 103, 108], ["rhodesain", "SIMPLE_CHEMICAL", 117, 126]]], ["MD simulations find this pose to be reasonably stable.", [["stable", "OBSERVATION", 47, 53]]], ["For the acid 8 in rhodesain, docking and MD find very stable complexes in which the substituted aromatic ring and the catalytic Cys-25/His-162 dyad are sufficiently close.", [["Cys", "CHEMICAL", 128, 131], ["His", "CHEMICAL", 135, 138], ["rhodesain", "SIMPLE_CHEMICAL", 18, 27], ["catalytic Cys-25/His-162 dyad", "PROTEIN", 118, 147], ["the acid", "TEST", 4, 12], ["the substituted aromatic ring", "TREATMENT", 80, 109], ["the catalytic Cys", "TEST", 114, 131], ["stable", "OBSERVATION", 54, 60], ["aromatic ring", "OBSERVATION", 96, 109]]], ["However, as described above, the reaction path towards the Meisenheimer complex only exhibits shallow minima for large distances (R(S-CH) or R(S-CNO 2 ) \u2248 3.1 -4.0 \u00c5) while it is repulsive for a further approach.", [["CH", "CHEMICAL", 134, 136], ["Meisenheimer complex", "PROTEIN", 59, 79], ["large distances", "PROBLEM", 113, 128], ["a further approach", "TREATMENT", 193, 211], ["shallow minima", "OBSERVATION", 94, 108], ["repulsive", "OBSERVATION", 179, 188]]], ["This finding is in line with the reversible inhibition of rhodesain by acid 8.DiscussionIn summary, with the benzyl ester 7, we present an efficient prodrug that has a strong anti-trypanosomal effect and inhibits the trypanosomal protease rhodesain in vitro via the hydrolysis and subsequent reversible binding of the hydrolysis product 8 via a \u03c0-complex.", [["benzyl ester", "CHEMICAL", 109, 121], ["rhodesain", "CHEMICAL", 239, 248], ["benzyl ester", "CHEMICAL", 109, 121], ["rhodesain", "SIMPLE_CHEMICAL", 58, 67], ["benzyl ester 7", "SIMPLE_CHEMICAL", 109, 123], ["rhodesain", "SIMPLE_CHEMICAL", 239, 248], ["trypanosomal protease", "PROTEIN", 217, 238], ["\u03c0-complex", "PROTEIN", 345, 354], ["a strong anti-trypanosomal effect", "PROBLEM", 166, 199], ["the trypanosomal protease rhodesain", "TREATMENT", 213, 248], ["the hydrolysis", "PROBLEM", 262, 276], ["the hydrolysis product", "TREATMENT", 314, 336], ["reversible", "OBSERVATION_MODIFIER", 33, 43], ["inhibition", "OBSERVATION_MODIFIER", 44, 54], ["reversible binding", "OBSERVATION", 292, 310]]], ["In future studies, we will address the question if esters other than benzyl can also be used as prodrugs.See Supplementary Materials.Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/6/1451/ s1: Syntheses and analytical data of the compounds; Analysis of the reaction products of the reaction with low-molecular weight thiol; Calculation of the chemical shifts/determination of the regiochemistry of the addition products; Mass spectrometry; NMR material and methods; Enzyme and hydrolysis assays; T. b. brucei cell survival assay; Docking procedures; NMR spectra of the compounds.", [["cell", "ANATOMY", 557, 561], ["benzyl", "CHEMICAL", 69, 75], ["thiol", "CHEMICAL", 365, 370], ["esters", "CHEMICAL", 51, 57], ["benzyl", "CHEMICAL", 69, 75], ["thiol", "CHEMICAL", 365, 370], ["esters", "SIMPLE_CHEMICAL", 51, 57], ["benzyl", "SIMPLE_CHEMICAL", 69, 75], ["cell", "CELL", 557, 561], ["s1", "DNA", 237, 239], ["T. b. brucei", "SPECIES", 544, 556], ["T. b. brucei", "SPECIES", 544, 556], ["future studies", "TEST", 3, 17], ["benzyl", "TREATMENT", 69, 75], ["prodrugs", "TREATMENT", 96, 104], ["analytical data", "TEST", 255, 270], ["the compounds", "TEST", 274, 287], ["the reaction products", "TREATMENT", 301, 322], ["the reaction", "PROBLEM", 326, 338], ["low-molecular weight thiol", "TREATMENT", 344, 370], ["the addition products", "TREATMENT", 446, 467], ["Mass spectrometry", "PROBLEM", 469, 486], ["NMR material", "TEST", 488, 500], ["methods", "TEST", 505, 512], ["Enzyme", "TEST", 514, 520], ["hydrolysis assays", "TEST", 525, 542], ["survival assay", "TEST", 562, 576], ["Docking procedures", "TEST", 578, 596]]]], "298a7352748c4834d85b793f46eb4848d91b1ce8": [["IntroductionDuring the past decades, widespread application of fluoroaromatic compounds as agrochemicals and pharmaceuticals has lead to an increased occurrence of environmental contaminants containing fluorine (Key et al. 1997) .", [["fluorine", "CHEMICAL", 202, 210], ["fluorine", "CHEMICAL", 202, 210], ["fluoroaromatic compounds", "SIMPLE_CHEMICAL", 63, 87], ["fluorine", "SIMPLE_CHEMICAL", 202, 210], ["fluoroaromatic compounds", "TREATMENT", 63, 87], ["pharmaceuticals", "TREATMENT", 109, 124], ["widespread", "OBSERVATION_MODIFIER", 37, 47], ["fluoroaromatic compounds", "OBSERVATION", 63, 87], ["increased", "OBSERVATION_MODIFIER", 140, 149], ["environmental contaminants", "OBSERVATION", 164, 190]]], ["The stability of the carbon-fluorine bond (116 kcal/mol in CH 3 F, compared to 81 kcal/mol for the carbon-chlorine bond in CH 3 Cl) makes most fluorinecontaining compounds much more resistant to biodegradation than their unsubstituted analogs (Key et al. 1997) .", [["carbon-fluorine", "CHEMICAL", 21, 36], ["carbon-chlorine", "CHEMICAL", 99, 114], ["CH 3 Cl", "CHEMICAL", 123, 130], ["carbon", "CHEMICAL", 21, 27], ["fluorine", "CHEMICAL", 28, 36], ["CH 3 F", "CHEMICAL", 59, 65], ["carbon", "CHEMICAL", 99, 105], ["chlorine", "CHEMICAL", 106, 114], ["CH 3 Cl", "CHEMICAL", 123, 130], ["fluorinecontaining", "CHEMICAL", 143, 161], ["carbon-fluorine", "SIMPLE_CHEMICAL", 21, 36], ["carbon-chlorine", "SIMPLE_CHEMICAL", 99, 114], ["CH 3 Cl", "SIMPLE_CHEMICAL", 123, 130], ["fluorinecontaining compounds", "SIMPLE_CHEMICAL", 143, 171], ["the carbon-fluorine bond (116 kcal/mol in CH 3 F", "TREATMENT", 17, 65], ["the carbon-chlorine bond in CH", "TREATMENT", 95, 125], ["most fluorinecontaining compounds", "PROBLEM", 138, 171], ["stability", "OBSERVATION_MODIFIER", 4, 13]]], ["Furthermore, the van der Waals radius of fluorine is small (1.47 \u00c5, in between that of a hydrogen and an oxygen).", [["fluorine", "CHEMICAL", 41, 49], ["hydrogen", "CHEMICAL", 89, 97], ["oxygen", "CHEMICAL", 105, 111], ["fluorine", "CHEMICAL", 41, 49], ["hydrogen", "CHEMICAL", 89, 97], ["oxygen", "CHEMICAL", 105, 111], ["fluorine", "SIMPLE_CHEMICAL", 41, 49], ["hydrogen", "SIMPLE_CHEMICAL", 89, 97], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["the van der Waals radius of fluorine", "TREATMENT", 13, 49], ["a hydrogen", "TREATMENT", 87, 97], ["an oxygen)", "TREATMENT", 102, 112], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["Yet, the electronegativity of fluorine causes strong polarization of C-F bonds, and fluorine substituents may be involved in biological interactions (Howard et al. 1996) .IntroductionRegardless of the recalcitrance of most fluoroaromatics to biodegradation, several bacterial cultures have been described that aerobically degrade fluorobenzoic acids (Oltmanns et al. 1989; Engesser et al. 1980; Harper and Blakley 1971; Schlomann et al. 1990 ).", [["fluorine", "CHEMICAL", 30, 38], ["fluorine", "CHEMICAL", 84, 92], ["fluorobenzoic acids", "CHEMICAL", 330, 349], ["fluorine", "CHEMICAL", 30, 38], ["C-F", "CHEMICAL", 69, 72], ["fluorine", "CHEMICAL", 84, 92], ["fluoroaromatics", "CHEMICAL", 223, 238], ["fluorobenzoic acids", "CHEMICAL", 330, 349], ["fluorine", "SIMPLE_CHEMICAL", 30, 38], ["C-F bonds", "SIMPLE_CHEMICAL", 69, 78], ["fluorine substituents", "SIMPLE_CHEMICAL", 84, 105], ["fluoroaromatics", "SIMPLE_CHEMICAL", 223, 238], ["fluorobenzoic acids", "SIMPLE_CHEMICAL", 330, 349], ["bacterial cultures", "CELL_LINE", 266, 284], ["fluorine", "TREATMENT", 30, 38], ["fluorine substituents", "TREATMENT", 84, 105], ["several bacterial cultures", "TEST", 258, 284]]], ["Research on bacterial fluorophenol degradation has been limited to studies with whole cells, cell extracts, or purified enzymes from Rhodococcus species that were obtained by enrichment with other aromatic compounds as a growth substrate (Boersma et al. , 2001 Bondar et al. 1998 Bondar et al. , 1999 Finkelstein et al. 2000) .", [["cells", "ANATOMY", 86, 91], ["cell extracts", "ANATOMY", 93, 106], ["fluorophenol", "CHEMICAL", 22, 34], ["fluorophenol", "CHEMICAL", 22, 34], ["fluorophenol", "SIMPLE_CHEMICAL", 22, 34], ["cells", "CELL", 86, 91], ["cell extracts", "ORGANISM_SUBSTANCE", 93, 106], ["Rhodococcus species", "ORGANISM", 133, 152], ["whole cells", "CELL_TYPE", 80, 91], ["purified enzymes", "PROTEIN", 111, 127], ["bacterial fluorophenol degradation", "PROBLEM", 12, 46], ["whole cells", "PROBLEM", 80, 91], ["cell extracts", "TEST", 93, 106], ["purified enzymes", "TEST", 111, 127], ["Rhodococcus species", "PROBLEM", 133, 152], ["bacterial fluorophenol", "OBSERVATION", 12, 34]]], ["The fluorobenzene-degrading organism Rhizobiales F11 could grow on 4-fluorophenol (4-FP), but information on the pathway of 4-FP metabolism is lacking.IntroductionCometabolic degradation of difluorophenols and trifluorophenols by several Rhodococcus species is initiated by a phenol hydroxylase that catalyzes ortho-hydroxylation, resulting in the formation of the respective fluorocatechol, which is then cleaved by an intradiol dioxygenase to produce fluoromuconate (Bondar et al. 1998 ).", [["fluorobenzene", "CHEMICAL", 4, 17], ["Rhizobiales", "CHEMICAL", 37, 48], ["4-fluorophenol", "CHEMICAL", 67, 81], ["4-FP", "CHEMICAL", 83, 87], ["4-FP", "CHEMICAL", 124, 128], ["difluorophenols", "CHEMICAL", 190, 205], ["trifluorophenols", "CHEMICAL", 210, 226], ["phenol", "CHEMICAL", 276, 282], ["ortho-hydroxylation", "CHEMICAL", 310, 329], ["fluorocatechol", "CHEMICAL", 376, 390], ["fluoromuconate", "CHEMICAL", 453, 467], ["fluorobenzene", "CHEMICAL", 4, 17], ["4-fluorophenol", "CHEMICAL", 67, 81], ["4-FP", "CHEMICAL", 83, 87], ["4-FP", "CHEMICAL", 124, 128], ["difluorophenols", "CHEMICAL", 190, 205], ["trifluorophenols", "CHEMICAL", 210, 226], ["phenol", "CHEMICAL", 276, 282], ["fluorocatechol", "CHEMICAL", 376, 390], ["intradiol", "CHEMICAL", 420, 429], ["fluoromuconate", "CHEMICAL", 453, 467], ["fluorobenzene", "SIMPLE_CHEMICAL", 4, 17], ["4-fluorophenol", "SIMPLE_CHEMICAL", 67, 81], ["4-FP", "SIMPLE_CHEMICAL", 83, 87], ["4-FP", "SIMPLE_CHEMICAL", 124, 128], ["difluorophenols", "SIMPLE_CHEMICAL", 190, 205], ["trifluorophenols", "SIMPLE_CHEMICAL", 210, 226], ["phenol hydroxylase", "GENE_OR_GENE_PRODUCT", 276, 294], ["ortho-hydroxylation", "SIMPLE_CHEMICAL", 310, 329], ["fluorocatechol", "SIMPLE_CHEMICAL", 376, 390], ["intradiol", "SIMPLE_CHEMICAL", 420, 429], ["fluoromuconate", "SIMPLE_CHEMICAL", 453, 467], ["phenol hydroxylase", "PROTEIN", 276, 294], ["The fluorobenzene", "TEST", 0, 17], ["the pathway", "TEST", 109, 120], ["IntroductionCometabolic degradation", "TREATMENT", 151, 186], ["difluorophenols", "TREATMENT", 190, 205], ["trifluorophenols", "TREATMENT", 210, 226], ["several Rhodococcus species", "PROBLEM", 230, 257], ["a phenol hydroxylase", "TREATMENT", 274, 294], ["ortho-hydroxylation", "TREATMENT", 310, 329], ["an intradiol dioxygenase", "TREATMENT", 417, 441], ["Rhodococcus species", "OBSERVATION", 238, 257]]], ["Conversion of 4-FP by whole cells of the phenol-degrading organism Rhodococcus opacus 1cp resulted in the formation of 4fluorocatechol, 1,2,3-trihydroxy-5-fluorobenzene, and fluoromuconates (Finkelstein et al. 2000) .", [["whole cells", "ANATOMY", 22, 33], ["4-FP", "CHEMICAL", 14, 18], ["phenol", "CHEMICAL", 41, 47], ["Rhodococcus opacus 1cp", "CHEMICAL", 67, 89], ["4fluorocatechol", "CHEMICAL", 119, 134], ["1,2,3-trihydroxy-5-fluorobenzene", "CHEMICAL", 136, 168], ["fluoromuconates", "CHEMICAL", 174, 189], ["4-FP", "CHEMICAL", 14, 18], ["phenol", "CHEMICAL", 41, 47], ["4fluorocatechol", "CHEMICAL", 119, 134], ["1,2,3-trihydroxy-5-fluorobenzene", "CHEMICAL", 136, 168], ["fluoromuconates", "CHEMICAL", 174, 189], ["4-FP", "SIMPLE_CHEMICAL", 14, 18], ["cells", "CELL", 28, 33], ["phenol", "SIMPLE_CHEMICAL", 41, 47], ["Rhodococcus opacus", "ORGANISM", 67, 85], ["4fluorocatechol", "SIMPLE_CHEMICAL", 119, 134], ["1,2,3-trihydroxy-5-fluorobenzene", "SIMPLE_CHEMICAL", 136, 168], ["fluoromuconates", "SIMPLE_CHEMICAL", 174, 189], ["Rhodococcus opacus", "SPECIES", 67, 85], ["Rhodococcus opacus", "SPECIES", 67, 85], ["4fluorocatechol", "TEST", 119, 134], ["trihydroxy", "TEST", 142, 152], ["fluorobenzene", "TREATMENT", 155, 168], ["fluoromuconates", "TREATMENT", 174, 189]]], ["Yeasts and fungi that are able to cometabolically transform fluorinated phenols have also been described.", [["Yeasts", "ANATOMY", 0, 6], ["fluorinated phenols", "CHEMICAL", 60, 79], ["fluorinated phenols", "CHEMICAL", 60, 79], ["Yeasts", "ORGANISM_SUBSTANCE", 0, 6], ["fluorinated phenols", "SIMPLE_CHEMICAL", 60, 79], ["Yeasts and fungi", "PROBLEM", 0, 16], ["fungi", "OBSERVATION", 11, 16], ["fluorinated phenols", "OBSERVATION", 60, 79]]], ["Whole cells of Exophiala jeanselmei transformed 4-FP into 4-fluorocatechol and 3fluoromuconate .", [["Whole cells", "ANATOMY", 0, 11], ["4-FP", "CHEMICAL", 48, 52], ["4-fluorocatechol", "CHEMICAL", 58, 74], ["3fluoromuconate", "CHEMICAL", 79, 94], ["4-FP", "CHEMICAL", 48, 52], ["4-fluorocatechol", "CHEMICAL", 58, 74], ["3fluoromuconate", "CHEMICAL", 79, 94], ["cells", "CELL", 6, 11], ["Exophiala jeanselmei", "ORGANISM", 15, 35], ["4-FP", "SIMPLE_CHEMICAL", 48, 52], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 58, 74], ["3fluoromuconate", "SIMPLE_CHEMICAL", 79, 94], ["Exophiala jeanselmei", "SPECIES", 15, 35], ["Exophiala jeanselmei", "SPECIES", 15, 35], ["Whole cells", "TEST", 0, 11], ["Exophiala jeanselmei", "TEST", 15, 35], ["3fluoromuconate", "TREATMENT", 79, 94], ["Exophiala jeanselmei", "OBSERVATION", 15, 35]]], ["Penicillium frequentans metabolized monofluorophenols in the presence of glucose or phenol.", [["frequentans", "CHEMICAL", 12, 23], ["monofluorophenols", "CHEMICAL", 36, 53], ["glucose", "CHEMICAL", 73, 80], ["phenol", "CHEMICAL", 84, 90], ["monofluorophenols", "CHEMICAL", 36, 53], ["glucose", "CHEMICAL", 73, 80], ["phenol", "CHEMICAL", 84, 90], ["Penicillium frequentans", "ORGANISM", 0, 23], ["monofluorophenols", "SIMPLE_CHEMICAL", 36, 53], ["glucose", "SIMPLE_CHEMICAL", 73, 80], ["phenol", "SIMPLE_CHEMICAL", 84, 90], ["Penicillium frequentans", "SPECIES", 0, 23], ["Penicillium", "TREATMENT", 0, 11], ["phenol", "TREATMENT", 84, 90]]], ["The metabolism of meta-or parafluorophenols yielded the corresponding catechol and 4-carboxymethylenebut-2-en-4-olide (Hofrichter and Schreibner 1993; Hofrichter et al. 1994) .", [["meta-or parafluorophenols", "CHEMICAL", 18, 43], ["catechol", "CHEMICAL", 70, 78], ["4-carboxymethylenebut-2-en-4-olide", "CHEMICAL", 83, 117], ["meta-or parafluorophenols", "CHEMICAL", 18, 43], ["catechol", "CHEMICAL", 70, 78], ["4-carboxymethylenebut-2-en-4-olide", "CHEMICAL", 83, 117], ["Hofrichter", "CHEMICAL", 119, 129], ["meta-or parafluorophenols", "SIMPLE_CHEMICAL", 18, 43], ["catechol", "SIMPLE_CHEMICAL", 70, 78], ["4-carboxymethylenebut-2-en-4-olide", "SIMPLE_CHEMICAL", 83, 117], ["Hofrichter", "SIMPLE_CHEMICAL", 119, 129], ["meta-or parafluorophenols", "PROBLEM", 18, 43], ["the corresponding catechol", "TEST", 52, 78]]], ["None of these organisms could utilize fluorophenols as a growth substrate.IntroductionTo our knowledge, studies on the metabolism of fluorophenols by a bacterial culture that is capable of using such as compound as a sole source of carbon and energy have not been reported.", [["fluorophenols", "CHEMICAL", 38, 51], ["fluorophenols", "CHEMICAL", 133, 146], ["fluorophenols", "CHEMICAL", 38, 51], ["fluorophenols", "CHEMICAL", 133, 146], ["carbon", "CHEMICAL", 232, 238], ["fluorophenols", "SIMPLE_CHEMICAL", 38, 51], ["fluorophenols", "SIMPLE_CHEMICAL", 133, 146], ["carbon", "SIMPLE_CHEMICAL", 232, 238], ["these organisms", "PROBLEM", 8, 23], ["fluorophenols", "TREATMENT", 38, 51], ["a growth substrate", "PROBLEM", 55, 73], ["fluorophenols", "TREATMENT", 133, 146], ["a bacterial culture", "TEST", 150, 169]]], ["In the present paper, we describe the isolation and characterization of a bacterial strain growing on 4-FP as the sole source of carbon and energy.", [["4-FP", "CHEMICAL", 102, 106], ["4-FP", "CHEMICAL", 102, 106], ["carbon", "CHEMICAL", 129, 135], ["4-FP", "SIMPLE_CHEMICAL", 102, 106], ["carbon", "SIMPLE_CHEMICAL", 129, 135], ["a bacterial strain", "PROBLEM", 72, 90], ["bacterial strain", "OBSERVATION", 74, 90]]], ["Based on the identification of several intermediates, a metabolic route for the degradation of 4-FP by this strain is proposed.Materials and methodsMedia and growth conditions NB medium contained 8 g of Nutrient Broth (Difco) per liter.", [["4-FP", "CHEMICAL", 95, 99], ["4-FP", "CHEMICAL", 95, 99], ["4-FP", "SIMPLE_CHEMICAL", 95, 99], ["methodsMedia", "TREATMENT", 141, 153], ["Nutrient Broth (Difco)", "TREATMENT", 203, 225]]], ["Mineral salts medium (MM) contained per liter 5.3 g Na 2 HPO 4 12H 2 O, 1.4 g KH 2 PO 4 , 0.2 g MgSO 4 7H 2 O, 0.5 g (NH 4 ) 2 SO 4 , 5 ml trace metals solution (Janssen et al. 1985) , and 10 mg of yeast extract (Difco Laboratories).", [["Mineral salts", "CHEMICAL", 0, 13], ["MM", "CHEMICAL", 22, 24], ["Na", "CHEMICAL", 52, 54], ["MgSO 4 7H 2 O", "CHEMICAL", 96, 109], ["Na 2 HPO", "CHEMICAL", 52, 60], ["MgSO", "CHEMICAL", 96, 100], ["(NH 4 ) 2 SO 4", "CHEMICAL", 117, 131], ["Mineral salts", "SIMPLE_CHEMICAL", 0, 13], ["yeast", "SPECIES", 198, 203], ["yeast", "SPECIES", 198, 203], ["Mineral salts medium (MM)", "TREATMENT", 0, 25], ["Na", "TEST", 52, 54], ["HPO", "TEST", 57, 60], ["MgSO", "TEST", 96, 100]]], ["When required, the solid medium was obtained by adding 15 g/l of Difco agar.", [["Difco agar", "TREATMENT", 65, 75]]], ["Strain IF1 was grown at 30\u00b0C on a rotary shaker (180 rpm).", [["IF1", "GENE_OR_GENE_PRODUCT", 7, 10], ["IF1", "PROTEIN", 7, 10], ["Strain IF1", "PROBLEM", 0, 10], ["a rotary shaker", "TREATMENT", 32, 47]]], ["Cultures were grown in 100-ml flasks filled to 25% of their volume and were closed with Teflon-lined screw caps.", [["Teflon", "CHEMICAL", 88, 94], ["Cultures", "TEST", 0, 8], ["Teflon-lined screw caps", "TREATMENT", 88, 111], ["screw caps", "OBSERVATION", 101, 111]]], ["E. coli cells were grown in Luria-Bertani medium (LB) at 37\u00b0C on a rotary shaker.Materials and methodsEnrichment and isolation of 4-FP-degrading cultures A variety of soil samples, collected from different sites in The Netherlands that are contaminated with halogenated aliphatic compounds (such as monochlorobenzene, hexachlor-obenzene, and trichloropropane), were used as the initial inoculum for the 4-FP enrichments.", [["cells", "ANATOMY", 8, 13], ["soil samples", "ANATOMY", 167, 179], ["4-FP", "CHEMICAL", 130, 134], ["halogenated aliphatic", "CHEMICAL", 258, 279], ["monochlorobenzene, hexachlor-obenzene", "CHEMICAL", 299, 336], ["trichloropropane", "CHEMICAL", 342, 358], ["4-FP", "CHEMICAL", 130, 134], ["monochlorobenzene", "CHEMICAL", 299, 316], ["hexachlor-obenzene", "CHEMICAL", 318, 336], ["trichloropropane", "CHEMICAL", 342, 358], ["4-FP", "CHEMICAL", 403, 407], ["E. coli cells", "CELL", 0, 13], ["4-FP", "SIMPLE_CHEMICAL", 130, 134], ["soil samples", "CANCER", 167, 179], ["monochlorobenzene", "SIMPLE_CHEMICAL", 299, 316], ["hexachlor-obenzene", "SIMPLE_CHEMICAL", 318, 336], ["trichloropropane", "SIMPLE_CHEMICAL", 342, 358], ["4-FP", "SIMPLE_CHEMICAL", 403, 407], ["E. coli cells", "CELL_LINE", 0, 13], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli cells", "PROBLEM", 0, 13], ["methodsEnrichment", "TEST", 95, 112], ["degrading cultures", "TEST", 135, 153], ["soil samples", "TEST", 167, 179], ["halogenated aliphatic compounds", "TREATMENT", 258, 289], ["monochlorobenzene", "TREATMENT", 299, 316], ["hexachlor-obenzene", "TREATMENT", 318, 336], ["trichloropropane", "TREATMENT", 342, 358], ["the 4-FP enrichments", "TREATMENT", 399, 419], ["coli cells", "OBSERVATION", 3, 13], ["aliphatic compounds", "OBSERVATION", 270, 289]]], ["The soil samples were used to inoculate flasks containing 30 ml of sterile minimal salts medium and 1 mM of 4-FP, supplied in the liquid phase as the sole carbon and energy source.", [["soil samples", "ANATOMY", 4, 16], ["4-FP", "CHEMICAL", 108, 112], ["4-FP", "CHEMICAL", 108, 112], ["carbon", "CHEMICAL", 155, 161], ["soil samples", "ORGANISM_SUBSTANCE", 4, 16], ["4-FP", "SIMPLE_CHEMICAL", 108, 112], ["carbon", "SIMPLE_CHEMICAL", 155, 161], ["The soil samples", "TREATMENT", 0, 16], ["sterile minimal salts medium", "TREATMENT", 67, 95]]], ["The cultures were incubated at room temperature on a rotary shaker (150 rpm), and 40% of the suspension was transferred to a new flask containing fresh medium every 15 days.", [["cultures", "ANATOMY", 4, 12], ["The cultures", "TEST", 0, 12], ["the suspension", "TREATMENT", 89, 103], ["a new flask containing fresh medium", "TREATMENT", 123, 158]]], ["During this time, growth (optical density at 600 nm) and liberation of fluoride were monitored.", [["fluoride", "CHEMICAL", 71, 79], ["fluoride", "CHEMICAL", 71, 79], ["fluoride", "SIMPLE_CHEMICAL", 71, 79], ["liberation of fluoride", "TREATMENT", 57, 79]]], ["Samples of the enrichment culture were periodically spread onto minimal salts agar plates containing 1 mM 4-FP and onto NB plates as soon as growth on 4-FP was established.", [["Samples", "ANATOMY", 0, 7], ["4-FP", "CHEMICAL", 106, 110], ["4-FP", "CHEMICAL", 106, 110], ["4-FP", "CHEMICAL", 151, 155], ["4-FP", "SIMPLE_CHEMICAL", 106, 110], ["4-FP", "SIMPLE_CHEMICAL", 151, 155], ["the enrichment culture", "TEST", 11, 33], ["minimal salts agar plates", "TREATMENT", 64, 89], ["NB plates", "TREATMENT", 120, 129]]], ["Pure cultures were obtained by repetitive streaking onto solid MM containing 4-FP and tested separately for growth on 1 mM 4-FP liquid medium.", [["4-FP", "CHEMICAL", 77, 81], ["4-FP", "CHEMICAL", 123, 127], ["4-FP", "CHEMICAL", 77, 81], ["4-FP", "CHEMICAL", 123, 127], ["solid MM", "CANCER", 57, 65], ["4-FP", "SIMPLE_CHEMICAL", 77, 81], ["4-FP", "SIMPLE_CHEMICAL", 123, 127], ["Pure cultures", "TEST", 0, 13]]], ["Growth and fluoride release were again monitored to verify 4-FP degradation.", [["fluoride", "CHEMICAL", 11, 19], ["fluoride", "CHEMICAL", 11, 19], ["4-FP", "CHEMICAL", 59, 63], ["fluoride", "SIMPLE_CHEMICAL", 11, 19], ["4-FP", "SIMPLE_CHEMICAL", 59, 63], ["Growth and fluoride release", "TREATMENT", 0, 27]]], ["Strains capable of 4-FP degradation as a sole source of carbon and energy were used for further experiments.", [["4-FP", "CHEMICAL", 19, 23], ["4-FP", "CHEMICAL", 19, 23], ["carbon", "CHEMICAL", 56, 62], ["4-FP", "SIMPLE_CHEMICAL", 19, 23], ["carbon", "SIMPLE_CHEMICAL", 56, 62], ["carbon and energy", "TREATMENT", 56, 73]]], ["Strain IF1 was deposited at Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands, under accession number NCCB 100218.Materials and methodsSequencing of the 16S rRNA gene For cloning of the 16S ribosomal ribonucleic acid (rRNA) gene, a single colony of strain IF1 was directly used for polymerase chain reaction (PCR) amplification.", [["colony", "ANATOMY", 252, 258], ["NCCB 100218", "CHEMICAL", 115, 126], ["ribonucleic acid", "CHEMICAL", 213, 229], ["IF1", "GENE_OR_GENE_PRODUCT", 7, 10], ["16S ribosomal ribonucleic acid", "GENE_OR_GENE_PRODUCT", 199, 229], ["IF1", "GENE_OR_GENE_PRODUCT", 269, 272], ["IF1", "PROTEIN", 7, 10], ["16S rRNA gene", "DNA", 166, 179], ["16S ribosomal ribonucleic acid (rRNA) gene", "DNA", 199, 241], ["IF1", "PROTEIN", 269, 272], ["Strain IF1", "PROBLEM", 0, 10], ["methodsSequencing", "TEST", 141, 158], ["the 16S ribosomal ribonucleic acid", "TEST", 195, 229], ["a single colony of strain IF1", "PROBLEM", 243, 272], ["polymerase chain reaction", "PROBLEM", 295, 320], ["PCR", "TEST", 322, 325]]], ["The primers 63f (5\u2032-CAGGCCTAAC ACATGCAAGTC-3\u2032) and 1387r (5\u2032-GGGCGGWGTGTA CAAGGC-3\u2032; Marchesi et al. 1998) were used for PCR amplification.", [["The primers", "TEST", 0, 11], ["ACATGCAAGTC", "TEST", 31, 42], ["CAAGGC", "TEST", 74, 80], ["PCR amplification", "TEST", 121, 138]]], ["The PCR reaction mixture (50 \u03bcl) contained Taq PCR buffer, 2.5 mM MgCl 2 , 20 pmol of each appropriate primer, 200 mM of each deoxyribonucleotide triphosphate, 1 U Taq DNA polymerase, and biomass of strain IF1.", [["MgCl", "CHEMICAL", 66, 70], ["deoxyribonucleotide triphosphate", "CHEMICAL", 126, 158], ["MgCl", "CHEMICAL", 66, 70], ["deoxyribonucleotide triphosphate", "CHEMICAL", 126, 158], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["IF1", "GENE_OR_GENE_PRODUCT", 206, 209], ["IF1", "PROTEIN", 206, 209], ["The PCR reaction mixture", "TEST", 0, 24], ["Taq PCR buffer", "TREATMENT", 43, 57], ["MgCl", "TEST", 66, 70], ["deoxyribonucleotide triphosphate", "TEST", 126, 158], ["Taq DNA polymerase", "TEST", 164, 182], ["strain IF1", "PROBLEM", 199, 209]]], ["The PCR conditions were 94\u00b0C for 10 min followed by 1 min at 95\u00b0C, 1 min at 55\u00b0C, 1.5 min at 72\u00b0C, and 5 min at 72\u00b0C. The resulting fragments were cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA) and transformed into E. coli TOP10 cells.", [["fragments", "ANATOMY", 132, 141], ["cells", "ANATOMY", 242, 247], ["TOPO", "GENE_OR_GENE_PRODUCT", 168, 172], ["Carlsbad, CA", "ORGANISM", 193, 205], ["E. coli", "ORGANISM", 228, 235], ["TOP10 cells", "CELL", 236, 247], ["pCR4", "DNA", 163, 167], ["TOPO vector", "DNA", 168, 179], ["E. coli TOP10 cells", "CELL_LINE", 228, 247], ["E. coli", "SPECIES", 228, 235], ["E. coli", "SPECIES", 228, 235], ["The PCR conditions", "TEST", 0, 18], ["The resulting fragments", "PROBLEM", 118, 141], ["the pCR4", "TEST", 159, 167], ["fragments", "OBSERVATION", 132, 141], ["coli TOP10 cells", "OBSERVATION", 231, 247]]], ["The transformed cells were plated on LB plates containing 0.5 mg/ml of ampicillin, and the positive colonies were used for plasmid isolation and sequencing.Materials and methodsPhylogenetic analysis Alignments of the 16S rRNA gene were made using sequences downloaded from the Ribosomal database project II (RDP II; Cole et al. 2005) , after searching for nearest neighbors using the sequence match tool.", [["cells", "ANATOMY", 16, 21], ["colonies", "ANATOMY", 100, 108], ["plasmid", "ANATOMY", 123, 130], ["ampicillin", "CHEMICAL", 71, 81], ["ampicillin", "CHEMICAL", 71, 81], ["cells", "CELL", 16, 21], ["ampicillin", "SIMPLE_CHEMICAL", 71, 81], ["transformed cells", "CELL_LINE", 4, 21], ["16S rRNA gene", "DNA", 217, 230], ["The transformed cells", "TREATMENT", 0, 21], ["LB plates", "TREATMENT", 37, 46], ["ampicillin", "TREATMENT", 71, 81], ["the positive colonies", "PROBLEM", 87, 108], ["plasmid isolation", "TREATMENT", 123, 140], ["Phylogenetic analysis", "TEST", 177, 198], ["positive colonies", "OBSERVATION", 91, 108]]], ["Further searches were conducted using BLAST and FASTA of the European Molecular Biology Laboratory (EMBL) database for 16S rRNA gene sequences that are closely related to the 16S rRNA gene of strain IF1 but not available from the RDP II.", [["IF1", "GENE_OR_GENE_PRODUCT", 199, 202], ["16S rRNA gene sequences", "DNA", 119, 142], ["16S rRNA gene", "DNA", 175, 188], ["IF1", "PROTEIN", 199, 202], ["RDP II", "PROTEIN", 230, 236], ["Further searches", "TEST", 0, 16], ["16S rRNA gene sequences", "TEST", 119, 142], ["strain IF1", "PROBLEM", 192, 202]]], ["Alignments were subsequently made using the profile alignment option in ClustalX (Thompson et al. 1997) , refined using BioEdit ver 7.0.5.2 (Hall 1999) , and subsequently parsed through Gblock (Castresana 2000) to remove ambiguously aligned sections and increase the robustness of the data.", [["sections", "ANATOMY", 241, 249], ["sections", "MULTI-TISSUE_STRUCTURE", 241, 249]]], ["Phylogenetic trees were determined using the neighbor-joining (NJ) method.", [["Phylogenetic trees", "PROBLEM", 0, 18], ["the neighbor-joining (NJ) method", "TREATMENT", 41, 73]]], ["Evolutionary distances for the global tree were calculated using the Kimura-2-parameter model with a transition/ transversion ratio of 2 ( Fig. 1) .", [["the Kimura", "TEST", 65, 75], ["a transition/ transversion ratio", "TEST", 99, 131], ["global", "ANATOMY_MODIFIER", 31, 37], ["tree", "ANATOMY_MODIFIER", 38, 42]]], ["All NJ trees were tested statistically by means of bootstrap analysis.Materials and methodsPreparation of cell extracts Cells were grown in MM with 4 mM 4-FP, harvested by centrifugation at 5,000\u00d7g for 15 min, washed with ice-cold TD buffer (0.1 M Tris-HCl, pH 7.5, and 0.1 M 1,4-dithiothreitol), and stored at \u221220\u00b0C until further use.", [["cell extracts", "ANATOMY", 106, 119], ["Cells", "ANATOMY", 120, 125], ["MM", "ANATOMY", 140, 142], ["4-FP", "CHEMICAL", 153, 157], ["Tris-HCl", "CHEMICAL", 248, 256], ["1,4-dithiothreitol", "CHEMICAL", 276, 294], ["4-FP", "CHEMICAL", 153, 157], ["Tris-HCl", "CHEMICAL", 248, 256], ["1,4-dithiothreitol", "CHEMICAL", 276, 294], ["cell extracts", "CELL", 106, 119], ["Cells", "CELL", 120, 125], ["4-FP", "SIMPLE_CHEMICAL", 153, 157], ["Tris-HCl", "SIMPLE_CHEMICAL", 248, 256], ["1,4-dithiothreitol", "SIMPLE_CHEMICAL", 276, 294], ["All NJ trees", "TREATMENT", 0, 12], ["bootstrap analysis", "TEST", 51, 69], ["Materials", "TREATMENT", 70, 79], ["cell extracts Cells", "TREATMENT", 106, 125], ["cold TD buffer", "TREATMENT", 226, 240], ["Tris", "TEST", 248, 252], ["pH", "TEST", 258, 260]]], ["The frozen cells were thawed, resuspended in TD buffer, and incubated with lysozyme (50 mg/ml) for 1 h at 30\u00b0C. A French press was used to disrupt the cells, and the crude extracts were centrifuged at 10,000\u00d7g for 15 min to separate the soluble from the particulate fraction.", [["cells", "ANATOMY", 11, 16], ["cells", "ANATOMY", 151, 156], ["extracts", "ANATOMY", 172, 180], ["cells", "CELL", 11, 16], ["lysozyme", "GENE_OR_GENE_PRODUCT", 75, 83], ["cells", "CELL", 151, 156], ["extracts", "ORGANISM_SUBSTANCE", 172, 180], ["frozen cells", "CELL_TYPE", 4, 16], ["lysozyme", "PROTEIN", 75, 83], ["The frozen cells", "TREATMENT", 0, 16], ["lysozyme", "TREATMENT", 75, 83], ["A French press", "TREATMENT", 112, 126], ["the crude extracts", "TREATMENT", 162, 180], ["frozen cells", "OBSERVATION", 4, 16], ["particulate fraction", "OBSERVATION", 254, 274]]], ["The supernatant was used for further experiments.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15]]], ["Protein concentrations were determined with the Biorad protein assay kit.Materials and methodsEnzyme assays Catechol 1,2-dioxygenase and catechol 2,3dioxygenase activities were measured spectrophotometrically at 260 and 375 nm, respectively.", [["Catechol 1,2-dioxygenase", "CHEMICAL", 108, 132], ["catechol", "CHEMICAL", 137, 145], ["Catechol", "CHEMICAL", 108, 116], ["catechol", "CHEMICAL", 137, 145], ["Catechol 1,2-dioxygenase", "GENE_OR_GENE_PRODUCT", 108, 132], ["catechol 2,3dioxygenase", "GENE_OR_GENE_PRODUCT", 137, 160], ["Catechol 1,2-dioxygenase", "PROTEIN", 108, 132], ["Protein concentrations", "TEST", 0, 22], ["the Biorad protein assay kit", "TEST", 44, 72], ["Enzyme assays", "TEST", 94, 107], ["Catechol", "TEST", 108, 116], ["dioxygenase", "TEST", 121, 132], ["catechol 2,3dioxygenase activities", "TEST", 137, 171]]], ["The reaction mixtures contained 0.1 mM catechol, TD buffer, and cellfree extract (0.1 mg of protein) in a final volume of 1 ml.", [["catechol", "CHEMICAL", 39, 47], ["cellfree extract", "CHEMICAL", 64, 80], ["catechol", "CHEMICAL", 39, 47], ["catechol", "SIMPLE_CHEMICAL", 39, 47], ["TD", "SIMPLE_CHEMICAL", 49, 51], ["The reaction mixtures", "TEST", 0, 21], ["0.1 mM catechol", "TREATMENT", 32, 47], ["TD buffer, and cellfree extract", "TREATMENT", 49, 80]]], ["4-Fluorocatechol 1,2-dioxygenase was measured as catechol 1,2-dioxygenase but with 4-fluorocatechol instead of catechol as the substrate.Materials and methodsThe 4-FP monooxygenase activity was measured spectrophotometrically by following the consumption of NADH at 340 nm in a reaction mixture containing cellfree extract (0.1 mg protein), 0.1 mM 4-FP, 0.1 mM NADH, and buffer in a total volume of 1 ml.", [["4-Fluorocatechol 1,2-dioxygenase", "CHEMICAL", 0, 32], ["catechol 1,2-dioxygenase", "CHEMICAL", 49, 73], ["4-fluorocatechol", "CHEMICAL", 83, 99], ["catechol", "CHEMICAL", 111, 119], ["4-FP", "CHEMICAL", 162, 166], ["NADH", "CHEMICAL", 258, 262], ["cellfree extract", "CHEMICAL", 306, 322], ["4-FP", "CHEMICAL", 348, 352], ["NADH", "CHEMICAL", 361, 365], ["4-Fluorocatechol", "CHEMICAL", 0, 16], ["catechol", "CHEMICAL", 49, 57], ["4-fluorocatechol", "CHEMICAL", 83, 99], ["catechol", "CHEMICAL", 111, 119], ["4-FP", "CHEMICAL", 162, 166], ["NADH", "CHEMICAL", 258, 262], ["4-FP", "CHEMICAL", 348, 352], ["NADH", "CHEMICAL", 361, 365], ["4-Fluorocatechol 1,2-dioxygenase", "SIMPLE_CHEMICAL", 0, 32], ["catechol 1,2-dioxygenase", "SIMPLE_CHEMICAL", 49, 73], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 83, 99], ["catechol", "SIMPLE_CHEMICAL", 111, 119], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 162, 180], ["NADH", "SIMPLE_CHEMICAL", 258, 262], ["4-FP", "SIMPLE_CHEMICAL", 348, 352], ["NADH", "SIMPLE_CHEMICAL", 361, 365], ["Fluorocatechol 1,2-dioxygenase", "PROTEIN", 2, 32], ["catechol 1,2-dioxygenase", "PROTEIN", 49, 73], ["Fluorocatechol", "TEST", 2, 16], ["catechol", "TEST", 49, 57], ["catechol", "TREATMENT", 111, 119], ["The 4-FP monooxygenase activity", "TEST", 158, 189], ["a reaction mixture", "TREATMENT", 276, 294], ["cellfree extract", "TREATMENT", 306, 322], ["buffer in a total volume", "TREATMENT", 371, 395]]], ["The observed rates were corrected for substrate-independent NADH oxidation.Materials and methodsHydroxymuconic semialdehyde dehydrogenase was measured at 375 nm.", [["NADH", "CHEMICAL", 60, 64], ["Hydroxymuconic semialdehyde", "CHEMICAL", 96, 123], ["NADH", "CHEMICAL", 60, 64], ["Hydroxymuconic semialdehyde", "CHEMICAL", 96, 123], ["NADH", "SIMPLE_CHEMICAL", 60, 64], ["Hydroxymuconic semialdehyde dehydrogenase", "GENE_OR_GENE_PRODUCT", 96, 137], ["Hydroxymuconic semialdehyde dehydrogenase", "PROTEIN", 96, 137], ["methodsHydroxymuconic semialdehyde dehydrogenase", "TEST", 89, 137], ["NADH oxidation", "OBSERVATION", 60, 74]]], ["Reaction mixtures contained (in a final volume of 1 ml) about 0.05 mM freshly prepared hydroxymuconic semialdehyde, TD buffer, 0.1 mM NAD, and cell-free extract (0.1 mg of protein).", [["cell", "ANATOMY", 143, 147], ["extract", "ANATOMY", 153, 160], ["hydroxymuconic semialdehyde", "CHEMICAL", 87, 114], ["NAD", "CHEMICAL", 134, 137], ["hydroxymuconic semialdehyde", "CHEMICAL", 87, 114], ["NAD", "CHEMICAL", 134, 137], ["hydroxymuconic semialdehyde", "SIMPLE_CHEMICAL", 87, 114], ["NAD", "SIMPLE_CHEMICAL", 134, 137], ["cell", "CELL", 143, 147], ["Reaction mixtures", "PROBLEM", 0, 17], ["TD buffer", "TREATMENT", 116, 125], ["cell-free extract", "TREATMENT", 143, 160]]], ["Hydroxymuconic semialdehyde was obtained by incubation of catechol with the cell-free extract of Pseudomonas putida mt-2 as described previously (Mars et al. 1998 Hydroquinone dioxygenase was assayed spectrophotometrically by monitoring the change in absorbance between 230 and 330 nm in a reaction mixture of 1 ml final volume containing 0.1 mM hydroquinone, TD buffer, and cell-free extract (0.1 mg of protein).", [["cell", "ANATOMY", 76, 80], ["cell", "ANATOMY", 375, 379], ["extract", "ANATOMY", 385, 392], ["Hydroxymuconic semialdehyde", "CHEMICAL", 0, 27], ["catechol", "CHEMICAL", 58, 66], ["Hydroquinone", "CHEMICAL", 163, 175], ["hydroquinone", "CHEMICAL", 346, 358], ["Hydroxymuconic semialdehyde", "CHEMICAL", 0, 27], ["catechol", "CHEMICAL", 58, 66], ["Hydroquinone", "CHEMICAL", 163, 175], ["hydroquinone", "CHEMICAL", 346, 358], ["Hydroxymuconic semialdehyde", "SIMPLE_CHEMICAL", 0, 27], ["catechol", "SIMPLE_CHEMICAL", 58, 66], ["cell", "CELL", 76, 80], ["Pseudomonas putida", "ORGANISM", 97, 115], ["mt-2", "GENE_OR_GENE_PRODUCT", 116, 120], ["Hydroquinone dioxygenase", "GENE_OR_GENE_PRODUCT", 163, 187], ["hydroquinone", "SIMPLE_CHEMICAL", 346, 358], ["cell", "CELL", 375, 379], ["Pseudomonas putida", "SPECIES", 97, 115], ["Pseudomonas putida", "SPECIES", 97, 115], ["Hydroxymuconic semialdehyde", "TREATMENT", 0, 27], ["Pseudomonas putida mt", "PROBLEM", 97, 118], ["Hydroquinone dioxygenase", "TREATMENT", 163, 187], ["the change in absorbance", "PROBLEM", 237, 261], ["a reaction mixture", "TREATMENT", 288, 306], ["0.1 mM hydroquinone", "TREATMENT", 339, 358], ["TD buffer", "TREATMENT", 360, 369], ["cell-free extract", "TREATMENT", 375, 392], ["Pseudomonas", "OBSERVATION", 97, 108]]], ["Hydroquinone hydroxylase and hydroxyquinol dioxygenase were assayed by using a fiber optic oxygen sensor.", [["Hydroquinone", "CHEMICAL", 0, 12], ["hydroxyquinol", "CHEMICAL", 29, 42], ["oxygen", "CHEMICAL", 91, 97], ["Hydroquinone", "CHEMICAL", 0, 12], ["hydroxyquinol", "CHEMICAL", 29, 42], ["oxygen", "CHEMICAL", 91, 97], ["Hydroquinone hydroxylase", "GENE_OR_GENE_PRODUCT", 0, 24], ["hydroxyquinol dioxygenase", "GENE_OR_GENE_PRODUCT", 29, 54], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["Hydroquinone hydroxylase", "PROTEIN", 0, 24], ["hydroxyquinol dioxygenase", "PROTEIN", 29, 54], ["Hydroquinone hydroxylase", "TREATMENT", 0, 24], ["hydroxyquinol dioxygenase", "TREATMENT", 29, 54], ["a fiber optic oxygen sensor", "TREATMENT", 77, 104]]], ["Reaction mixtures contained 1 mM of substrate, MM, and cell suspension (0.5 mg/ml protein) in a final volume of 1.25 ml.Materials and methodsOxygen uptake measurements Strain IF1 was grown with glucose or 4-FP as the sole carbon source and harvested by centrifugation at 6,000\u00d7g for 15 min at 4\u00b0C. Cells were resuspended in MM, and O 2 consumption was measured with a fiber optic oxygen sensor (MOPS-1, ProSense BV, Hannover, Germany).", [["MM", "ANATOMY", 47, 49], ["cell", "ANATOMY", 55, 59], ["Cells", "ANATOMY", 298, 303], ["MM", "ANATOMY", 324, 326], ["Oxygen", "CHEMICAL", 141, 147], ["glucose", "CHEMICAL", 194, 201], ["4-FP", "CHEMICAL", 205, 209], ["oxygen", "CHEMICAL", 380, 386], ["Oxygen", "CHEMICAL", 141, 147], ["glucose", "CHEMICAL", 194, 201], ["4-FP", "CHEMICAL", 205, 209], ["carbon", "CHEMICAL", 222, 228], ["O 2", "CHEMICAL", 332, 335], ["oxygen", "CHEMICAL", 380, 386], ["cell", "CELL", 55, 59], ["Oxygen", "SIMPLE_CHEMICAL", 141, 147], ["IF1", "GENE_OR_GENE_PRODUCT", 175, 178], ["glucose", "SIMPLE_CHEMICAL", 194, 201], ["4-FP", "SIMPLE_CHEMICAL", 205, 209], ["Cells", "CELL", 298, 303], ["MM", "CELL", 324, 326], ["O 2", "SIMPLE_CHEMICAL", 332, 335], ["oxygen", "SIMPLE_CHEMICAL", 380, 386], ["IF1", "PROTEIN", 175, 178], ["Reaction mixtures", "TREATMENT", 0, 17], ["substrate, MM, and cell suspension", "TREATMENT", 36, 70], ["Oxygen uptake measurements", "TEST", 141, 167], ["glucose", "TEST", 194, 201], ["a fiber optic oxygen sensor (MOPS", "TREATMENT", 366, 399]]], ["All reactions were performed in a stirred vessel at room temperature.", [["vessel", "ANATOMY", 42, 48], ["vessel", "MULTI-TISSUE_STRUCTURE", 42, 48], ["All reactions", "PROBLEM", 0, 13], ["vessel", "ANATOMY", 42, 48]]], ["The reaction mixtures contained 1 mM of substrate (4-FP, hydroquinone, 4fluorocatechol, hydroxyquinol, or catechol), MM, and cell suspension (0.5 mg/ml protein) in a final volume of 1.25 ml.Materials and methodsAnalytical methods For capillary gas chromatography (GC), 4 ml samples were extracted with 1 ml of diethyl ether.", [["MM", "ANATOMY", 117, 119], ["cell", "ANATOMY", 125, 129], ["samples", "ANATOMY", 274, 281], ["4-FP, hydroquinone, 4fluorocatechol", "CHEMICAL", 51, 86], ["hydroxyquinol", "CHEMICAL", 88, 101], ["catechol", "CHEMICAL", 106, 114], ["MM", "CHEMICAL", 117, 119], ["diethyl ether", "CHEMICAL", 310, 323], ["4-FP", "CHEMICAL", 51, 55], ["hydroquinone", "CHEMICAL", 57, 69], ["4fluorocatechol", "CHEMICAL", 71, 86], ["hydroxyquinol", "CHEMICAL", 88, 101], ["catechol", "CHEMICAL", 106, 114], ["diethyl ether", "CHEMICAL", 310, 323], ["4-FP", "SIMPLE_CHEMICAL", 51, 55], ["hydroquinone", "SIMPLE_CHEMICAL", 57, 69], ["4fluorocatechol", "SIMPLE_CHEMICAL", 71, 86], ["hydroxyquinol", "SIMPLE_CHEMICAL", 88, 101], ["catechol", "SIMPLE_CHEMICAL", 106, 114], ["MM", "SIMPLE_CHEMICAL", 117, 119], ["cell", "CELL", 125, 129], ["capillary", "TISSUE", 234, 243], ["diethyl ether", "SIMPLE_CHEMICAL", 310, 323], ["The reaction mixtures", "TEST", 0, 21], ["substrate", "TEST", 40, 49], ["hydroquinone", "TREATMENT", 57, 69], ["fluorocatechol", "TREATMENT", 72, 86], ["hydroxyquinol", "TREATMENT", 88, 101], ["catechol", "TREATMENT", 106, 114], ["MM, and cell suspension", "TREATMENT", 117, 140], ["Analytical methods", "TEST", 211, 229], ["capillary gas chromatography", "TEST", 234, 262], ["diethyl ether", "TREATMENT", 310, 323]]], ["A model 6890 gas chromatograph (Hewlett-Packard) equipped with a flame ionization detector and a HP-5 column (Agilent 19091J-413, 30 m\u00d70.25 mm\u00d70.25 \u03bcm) were used for the analysis.", [["A model 6890 gas chromatograph", "TEST", 0, 30], ["a flame ionization detector", "TEST", 63, 90], ["a HP", "TEST", 95, 99], ["Agilent", "TEST", 110, 117], ["the analysis", "TEST", 166, 178]]], ["GC-mass spectrometry (MS) analysis was carried out with a model 5973 mass selective detector (Hewlett-Packard) coupled to a HP 6890 series injector and a HP1 column (Agilent 19091Z-433; 30 m\u00d7 0.25 mm\u00d70.25 \u03bcm).", [["19091Z-433", "CHEMICAL", 174, 184], ["GC-mass spectrometry", "TEST", 0, 20], ["MS) analysis", "TEST", 22, 34], ["a HP1 column", "TEST", 152, 164], ["Agilent", "TEST", 166, 173], ["mass", "OBSERVATION", 3, 7]]], ["High-performance liquid chromatography (HPLC) was carried out using a Chrompack C18 column (10 cm\u00d75 mm) connected to a Jasco UV-1575 detector, which monitored absorbance at 214 and 254 nm, and operated with Jasco PU-980 pumps and a Jasco AS-1555 sampler.", [["UV-1575", "CHEMICAL", 125, 132], ["a Chrompack C18 column", "TREATMENT", 68, 90], ["a Jasco UV", "TEST", 117, 127], ["Jasco PU", "TREATMENT", 207, 215]]], ["The mobile phase was water/acetonitrile (70:30), 5 mM potassium phosphate (pH=3), and 340 mg/l sodium dodecyl sulfate, and the flow rate was 1 ml/min.Materials and methodsLiquid chromatography (LC)-MS was carried out with a ZMD Micromass spectrometer, equipped with a XTerra MS, Symmetry Shield C8 column (4.6\u00d7150 mm), a Waters 996 photodiode array detector, and a Waters 2690 separations module.", [["potassium phosphate", "CHEMICAL", 54, 73], ["sodium dodecyl sulfate", "CHEMICAL", 95, 117], ["acetonitrile", "CHEMICAL", 27, 39], ["potassium phosphate", "CHEMICAL", 54, 73], ["sodium dodecyl sulfate", "CHEMICAL", 95, 117], ["acetonitrile", "SIMPLE_CHEMICAL", 27, 39], ["potassium phosphate", "SIMPLE_CHEMICAL", 54, 73], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 95, 117], ["water/acetonitrile", "TREATMENT", 21, 39], ["5 mM potassium phosphate", "TREATMENT", 49, 73], ["pH", "TEST", 75, 77], ["340 mg/l sodium dodecyl sulfate", "TREATMENT", 86, 117], ["the flow rate", "TEST", 123, 136], ["methodsLiquid chromatography", "TEST", 164, 192], ["MS", "PROBLEM", 198, 200], ["a ZMD Micromass spectrometer", "TEST", 222, 250], ["a XTerra MS", "TEST", 266, 277], ["Symmetry Shield C8 column", "TEST", 279, 304], ["a Waters 996 photodiode array detector", "TREATMENT", 319, 357], ["a Waters 2690 separations module", "TREATMENT", 363, 395]]], ["Samples of 20 \u03bcl were analyzed, and compounds were isocratically eluted at a flow rate of 1 ml/min with a solution of water/acetonitrile (80:20) and 10 mM formic acid.Materials and methodsConcentrations of free fluoride in the culture supernatants were measured with a fluoride electrode (model 96-09, Thermo Russell, Scotland).", [["Samples", "ANATOMY", 0, 7], ["supernatants", "ANATOMY", 235, 247], ["acetonitrile", "CHEMICAL", 124, 136], ["formic acid", "CHEMICAL", 155, 166], ["fluoride", "CHEMICAL", 211, 219], ["fluoride", "CHEMICAL", 269, 277], ["acetonitrile", "CHEMICAL", 124, 136], ["formic acid", "CHEMICAL", 155, 166], ["fluoride", "CHEMICAL", 211, 219], ["fluoride", "CHEMICAL", 269, 277], ["water", "SIMPLE_CHEMICAL", 118, 123], ["acetonitrile", "SIMPLE_CHEMICAL", 124, 136], ["formic acid", "SIMPLE_CHEMICAL", 155, 166], ["fluoride", "SIMPLE_CHEMICAL", 211, 219], ["fluoride", "SIMPLE_CHEMICAL", 269, 277], ["Samples", "TEST", 0, 7], ["a flow rate", "TEST", 75, 86], ["a solution of water/acetonitrile", "TREATMENT", 104, 136], ["10 mM formic acid", "TREATMENT", 149, 166], ["free fluoride", "TREATMENT", 206, 219], ["the culture supernatants", "TEST", 223, 247], ["a fluoride electrode", "TEST", 267, 287]]], ["Fresh sodium fluoride standards were prepared for calibration curves.Materials and methodsChemicals 4-FP (>98%) was obtained from Sigma-Aldrich (Steinheim, Germany).", [["sodium fluoride", "CHEMICAL", 6, 21], ["4-FP", "CHEMICAL", 100, 104], ["sodium fluoride", "CHEMICAL", 6, 21], ["4-FP", "CHEMICAL", 100, 104], ["sodium fluoride", "SIMPLE_CHEMICAL", 6, 21], ["4-FP", "SIMPLE_CHEMICAL", 100, 104], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 130, 143], ["Fresh sodium fluoride standards", "TREATMENT", 0, 31], ["calibration curves", "TEST", 50, 68], ["Chemicals", "TEST", 90, 99], ["FP", "TEST", 102, 104]]], ["The compound 4-fluorocatechol was kindly provided by Dr. Erik de Vries.", [["4-fluorocatechol", "CHEMICAL", 13, 29], ["4-fluorocatechol", "CHEMICAL", 13, 29], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 13, 29]]], ["Purity of 4-FP, 4fluorocatechol, and hydroquinone was checked by HPLC.Materials and methodsNucleotide sequence accession numbers The 16S rRNA sequence of strain IF1 was deposited at GenBank with the accession no. DQ425093.ResultsIsolation of a 4-FP-degrading bacterium To obtain a bacterial culture that is able to use 4-FP as carbon and energy source for growth, enrichments were performed and followed over time.", [["4-FP", "CHEMICAL", 10, 14], ["4fluorocatechol", "CHEMICAL", 16, 31], ["hydroquinone", "CHEMICAL", 37, 49], ["DQ425093", "CHEMICAL", 213, 221], ["4-FP", "CHEMICAL", 244, 248], ["4-FP", "CHEMICAL", 319, 323], ["4-FP", "CHEMICAL", 10, 14], ["4fluorocatechol", "CHEMICAL", 16, 31], ["hydroquinone", "CHEMICAL", 37, 49], ["DQ425093", "CHEMICAL", 213, 221], ["4-FP", "CHEMICAL", 244, 248], ["4-FP", "CHEMICAL", 319, 323], ["carbon", "CHEMICAL", 327, 333], ["4-FP", "SIMPLE_CHEMICAL", 10, 14], ["4fluorocatechol", "SIMPLE_CHEMICAL", 16, 31], ["hydroquinone", "SIMPLE_CHEMICAL", 37, 49], ["IF1", "GENE_OR_GENE_PRODUCT", 161, 164], ["DQ425093", "SIMPLE_CHEMICAL", 213, 221], ["4-FP", "SIMPLE_CHEMICAL", 244, 248], ["4-FP", "SIMPLE_CHEMICAL", 319, 323], ["carbon", "SIMPLE_CHEMICAL", 327, 333], ["16S rRNA sequence", "DNA", 133, 150], ["IF1", "PROTEIN", 161, 164], ["Purity", "TEST", 0, 6], ["4fluorocatechol", "TREATMENT", 16, 31], ["hydroquinone", "TREATMENT", 37, 49], ["The 16S rRNA sequence", "TEST", 129, 150], ["strain IF1", "PROBLEM", 154, 164], ["degrading bacterium", "PROBLEM", 249, 268], ["a bacterial culture", "TEST", 279, 298]]], ["Two months of selective enrichment by repeated transfer of samples from a culture that displayed growth on 4-FP to fresh 4-FP containing media resulted in a microbial consortium that was capable of growth on 4-FP as a sole source of carbon and energy.", [["samples", "ANATOMY", 59, 66], ["4-FP", "CHEMICAL", 107, 111], ["4-FP", "CHEMICAL", 121, 125], ["4-FP", "CHEMICAL", 208, 212], ["4-FP", "CHEMICAL", 107, 111], ["4-FP", "CHEMICAL", 121, 125], ["4-FP", "CHEMICAL", 208, 212], ["carbon", "CHEMICAL", 233, 239], ["4-FP", "SIMPLE_CHEMICAL", 107, 111], ["4-FP", "SIMPLE_CHEMICAL", 121, 125], ["4-FP", "SIMPLE_CHEMICAL", 208, 212], ["carbon", "SIMPLE_CHEMICAL", 233, 239], ["a culture", "TEST", 72, 81], ["a microbial consortium", "PROBLEM", 155, 177], ["selective", "OBSERVATION_MODIFIER", 14, 23], ["enrichment", "OBSERVATION", 24, 34], ["growth", "OBSERVATION_MODIFIER", 97, 103], ["microbial consortium", "OBSERVATION", 157, 177]]], ["Samples of the consortium were repeatedly plated onto NB agar plates and MM agar plates containing 4-FP.", [["Samples", "ANATOMY", 0, 7], ["Samples of the consortium", "TEST", 0, 25], ["NB agar plates", "TEST", 54, 68], ["MM agar plates", "TEST", 73, 87]]], ["This procedure resulted in the isolation of three pure strains named IF1, IF2, and IF3.", [["IF1", "GENE_OR_GENE_PRODUCT", 69, 72], ["IF2", "GENE_OR_GENE_PRODUCT", 74, 77], ["IF3", "GENE_OR_GENE_PRODUCT", 83, 86], ["IF1", "PROTEIN", 69, 72], ["IF2", "PROTEIN", 74, 77], ["IF3", "PROTEIN", 83, 86], ["This procedure", "TREATMENT", 0, 14]]], ["The strains were restreaked on MM supplemented with 4-FP and inoculated in liquid cultures with 1 mM 4-FP.", [["MM", "ANATOMY", 31, 33], ["4-FP", "CHEMICAL", 52, 56], ["4-FP", "CHEMICAL", 52, 56], ["4-FP.", "CHEMICAL", 101, 106], ["4-FP", "SIMPLE_CHEMICAL", 52, 56], ["The strains", "PROBLEM", 0, 11], ["liquid cultures", "TEST", 75, 90]]], ["Fluoride liberation was observed for all three strains but not in control incubations to which no bacterial inoculum was added.", [["Fluoride", "CHEMICAL", 0, 8], ["Fluoride", "CHEMICAL", 0, 8], ["Fluoride", "SIMPLE_CHEMICAL", 0, 8], ["Fluoride liberation", "TREATMENT", 0, 19], ["all three strains", "PROBLEM", 37, 54], ["bacterial inoculum", "PROBLEM", 98, 116], ["liberation", "OBSERVATION", 9, 19], ["bacterial inoculum", "OBSERVATION", 98, 116]]], ["All the three strains showed growth, as monitored at 600 nm, and thus were able to use 4-FP as a sole carbon and energy source.", [["4-FP", "CHEMICAL", 87, 91], ["4-FP", "CHEMICAL", 87, 91], ["carbon", "CHEMICAL", 102, 108], ["4-FP", "SIMPLE_CHEMICAL", 87, 91], ["carbon", "SIMPLE_CHEMICAL", 102, 108], ["growth", "OBSERVATION_MODIFIER", 29, 35]]], ["After 5 days of incubation in liquid culture supplied with 1 mM 4-FP, strain IF1 reached 100% fluoride release and an optical density (OD) of 0.119 at 600 nm.", [["4-FP", "CHEMICAL", 64, 68], ["fluoride", "CHEMICAL", 94, 102], ["4-FP", "CHEMICAL", 64, 68], ["fluoride", "CHEMICAL", 94, 102], ["4-FP", "SIMPLE_CHEMICAL", 64, 68], ["IF1", "GENE_OR_GENE_PRODUCT", 77, 80], ["fluoride", "SIMPLE_CHEMICAL", 94, 102], ["IF1", "PROTEIN", 77, 80], ["incubation in liquid culture", "TEST", 16, 44], ["strain IF1", "TREATMENT", 70, 80], ["an optical density", "TEST", 115, 133], ["optical", "OBSERVATION_MODIFIER", 118, 125], ["density", "OBSERVATION", 126, 133]]], ["Strain IF2 released 76% of the fluorine and reached an OD 600 of 0.09, while strain IF3 reached an OD of 0.076 and released 54% of the theoretical amount of fluoride ions.", [["fluorine", "CHEMICAL", 31, 39], ["fluoride ions", "CHEMICAL", 157, 170], ["fluorine", "CHEMICAL", 31, 39], ["fluoride", "CHEMICAL", 157, 165], ["IF2", "GENE_OR_GENE_PRODUCT", 7, 10], ["fluorine", "SIMPLE_CHEMICAL", 31, 39], ["fluoride ions", "SIMPLE_CHEMICAL", 157, 170], ["IF2", "PROTEIN", 7, 10], ["Strain IF2", "TEST", 0, 10], ["the fluorine", "TEST", 27, 39], ["strain IF3", "TEST", 77, 87], ["fluoride ions", "TREATMENT", 157, 170], ["amount", "OBSERVATION_MODIFIER", 147, 153], ["fluoride ions", "OBSERVATION", 157, 170]]], ["When a mixed culture of the three strains in liquid media was used, an OD 600 of 0.217 and 100% fluorine release were measured after 4 days.", [["fluorine", "CHEMICAL", 96, 104], ["fluorine", "CHEMICAL", 96, 104], ["fluorine", "SIMPLE_CHEMICAL", 96, 104], ["a mixed culture", "TEST", 5, 20], ["liquid media", "TREATMENT", 45, 57]]], ["Apparently, the mixed culture contained, even after prolonged adaptation, organisms with varying efficiencies of 4-FP utilization.", [["4-FP", "CHEMICAL", 113, 117], ["4-FP", "CHEMICAL", 113, 117], ["4-FP", "SIMPLE_CHEMICAL", 113, 117], ["the mixed culture", "TEST", 12, 29], ["organisms", "PROBLEM", 74, 83], ["varying efficiencies", "PROBLEM", 89, 109]]], ["Because strain IF1 showed the highest degradation rates combined with stoichiometric release of fluoride, this organism was chosen for further studies.ResultsMicrobiological characterization Strain IF1 is a Grampositive motile bacterium with a rhodococcus lifecycle.", [["fluoride", "CHEMICAL", 96, 104], ["fluoride", "CHEMICAL", 96, 104], ["IF1", "GENE_OR_GENE_PRODUCT", 15, 18], ["fluoride", "SIMPLE_CHEMICAL", 96, 104], ["IF1", "GENE_OR_GENE_PRODUCT", 198, 201], ["rhodococcus", "SIMPLE_CHEMICAL", 244, 255], ["IF1", "PROTEIN", 15, 18], ["IF1", "PROTEIN", 198, 201], ["strain IF1", "PROBLEM", 8, 18], ["the highest degradation rates", "PROBLEM", 26, 55], ["stoichiometric release of fluoride", "TREATMENT", 70, 104], ["this organism", "PROBLEM", 106, 119], ["further studies", "TEST", 135, 150], ["Microbiological characterization Strain IF1", "TEST", 158, 201], ["a Grampositive motile bacterium", "PROBLEM", 205, 236], ["rhodococcus lifecycle", "OBSERVATION", 244, 265]]], ["The optimal temperature for growth is 30\u00b0C. The 16S rRNA gene sequence was determined.", [["rRNA", "CELLULAR_COMPONENT", 52, 56], ["16S rRNA gene sequence", "DNA", 48, 70], ["The 16S rRNA gene sequence", "TEST", 44, 70]]], ["Initial searches against the RDP II and EMBL rRNA databases resulted in very close associations with members of the genus Arthrobacter, the closest of which were the quinaldine-degrading strain Arthrobacter sp.", [["quinaldine", "CHEMICAL", 166, 176], ["quinaldine", "CHEMICAL", 166, 176], ["RDP II", "GENE_OR_GENE_PRODUCT", 29, 35], ["quinaldine", "SIMPLE_CHEMICAL", 166, 176], ["Arthrobacter sp", "ORGANISM", 194, 209], ["RDP II and EMBL rRNA databases", "DNA", 29, 59], ["EMBL rRNA databases", "TEST", 40, 59], ["the genus Arthrobacter", "PROBLEM", 112, 134]]], ["KA1-1 (Overhage et al. 2005 ) and the 4-nitroguaiacol-degrading actinobacterium Arthrobacter nitroguajacolicus sp. nov (Kotouckova et al. 2004 ).", [["4-nitroguaiacol", "CHEMICAL", 38, 53], ["4-nitroguaiacol", "CHEMICAL", 38, 53], ["4-nitroguaiacol", "SIMPLE_CHEMICAL", 38, 53], ["Arthrobacter nitroguajacolicus sp", "ORGANISM", 80, 113], ["Arthrobacter nitroguajacolicus", "SPECIES", 80, 110], ["Arthrobacter nitroguajacolicus", "SPECIES", 80, 110], ["KA1", "TEST", 0, 3], ["nitroguaiacol", "TREATMENT", 40, 53]]], ["The 16S rRNA gene sequences of these organisms were greater than 99% identical to IF1's.", [["IF1", "GENE_OR_GENE_PRODUCT", 82, 85], ["16S rRNA gene sequences", "DNA", 4, 27], ["IF1", "PROTEIN", 82, 85], ["The 16S rRNA gene sequences", "TEST", 0, 27], ["these organisms", "TEST", 31, 46], ["IF1's", "TEST", 82, 87], ["greater", "OBSERVATION_MODIFIER", 52, 59]]], ["The phylogenetic analysis places the isolates in the phylum Actinobacteria and the genus Arthrobacter (Fig. 1) .", [["The phylogenetic analysis", "TEST", 0, 25], ["the isolates", "TEST", 33, 45], ["the phylum Actinobacteria", "TEST", 49, 74], ["the genus Arthrobacter", "TEST", 79, 101], ["phylum Actinobacteria", "OBSERVATION", 53, 74]]], ["The subtree that were obtained shows the detailed relationship of isolate IF1 to other members of the genus Arthrobacter.", [["IF1", "GENE_OR_GENE_PRODUCT", 74, 77], ["IF1", "PROTEIN", 74, 77], ["genus Arthrobacter", "OBSERVATION", 102, 120]]], ["The topologies of all the trees that were obtained during statistical analysis were in agreement and clearly placed this isolate in the genus Arthrobacter (data not shown).", [["statistical analysis", "TEST", 58, 78], ["the genus Arthrobacter", "TEST", 132, 154]]], ["Furthermore, the change in form during the growth cycle between rod and coccus is typical of the lifecycle of the Arthrobacter genus.ResultsCatabolic activities of Arthrobacter sp. strain IF1 To study the degradation potential of strain IF1, a range of organic compounds were tested as growth substrates.", [["Arthrobacter genus", "ORGANISM", 114, 132], ["Arthrobacter sp", "ORGANISM", 164, 179], ["IF1", "GENE_OR_GENE_PRODUCT", 188, 191], ["IF1", "GENE_OR_GENE_PRODUCT", 237, 240], ["IF1", "PROTEIN", 188, 191], ["IF1", "PROTEIN", 237, 240], ["the growth cycle between rod and coccus", "PROBLEM", 39, 78], ["Arthrobacter sp", "PROBLEM", 164, 179], ["strain IF1", "PROBLEM", 181, 191], ["strain IF1", "PROBLEM", 230, 240], ["organic compounds", "PROBLEM", 253, 270], ["coccus", "OBSERVATION", 72, 78], ["Arthrobacter genus", "OBSERVATION", 114, 132], ["IF1", "OBSERVATION", 188, 191]]], ["Cells were inoculated into MM, and different organic substrates were added at a concentration of 1 mM.", [["Cells", "ANATOMY", 0, 5], ["MM", "ANATOMY", 27, 29], ["Cells", "CELL", 0, 5], ["MM", "CANCER", 27, 29], ["Cells", "TEST", 0, 5], ["different organic substrates", "PROBLEM", 35, 63]]], ["After 72-h incubation growth, substrate disappearance and halide release were measured.ResultsGrowth and substrate removal were found when catechol, hydroquinone, hydroxyquinol, benzoate, phenol, 4-fluorocinnamic acid, and 4-nitrophenol were used as substrates.", [["catechol", "CHEMICAL", 139, 147], ["hydroquinone", "CHEMICAL", 149, 161], ["hydroxyquinol", "CHEMICAL", 163, 176], ["benzoate", "CHEMICAL", 178, 186], ["phenol", "CHEMICAL", 188, 194], ["4-fluorocinnamic acid", "CHEMICAL", 196, 217], ["4-nitrophenol", "CHEMICAL", 223, 236], ["halide", "CHEMICAL", 58, 64], ["catechol", "CHEMICAL", 139, 147], ["hydroquinone", "CHEMICAL", 149, 161], ["hydroxyquinol", "CHEMICAL", 163, 176], ["benzoate", "CHEMICAL", 178, 186], ["phenol", "CHEMICAL", 188, 194], ["4-fluorocinnamic acid", "CHEMICAL", 196, 217], ["4-nitrophenol", "CHEMICAL", 223, 236], ["halide", "SIMPLE_CHEMICAL", 58, 64], ["catechol", "SIMPLE_CHEMICAL", 139, 147], ["hydroquinone", "SIMPLE_CHEMICAL", 149, 161], ["hydroxyquinol", "SIMPLE_CHEMICAL", 163, 176], ["benzoate", "SIMPLE_CHEMICAL", 178, 186], ["phenol", "SIMPLE_CHEMICAL", 188, 194], ["4-fluorocinnamic acid", "SIMPLE_CHEMICAL", 196, 217], ["4-nitrophenol", "SIMPLE_CHEMICAL", 223, 236], ["halide release", "TREATMENT", 58, 72], ["substrate removal", "TREATMENT", 105, 122], ["catechol", "TEST", 139, 147], ["hydroquinone", "TREATMENT", 149, 161], ["hydroxyquinol", "TREATMENT", 163, 176], ["benzoate", "TREATMENT", 178, 186], ["phenol", "TREATMENT", 188, 194], ["fluorocinnamic acid", "TREATMENT", 198, 217], ["nitrophenol", "TREATMENT", 225, 236]]], ["The organism did not grow on 2-fluorophenol, 3fluorophenol, 4-chlorophenol, 4-bromophenol, 4-iodophenol, fluoroacetate, trifluoroacetate, fluoroacetamide, trifluoroethanol, or on 2-bromoethanol.", [["2-fluorophenol", "CHEMICAL", 29, 43], ["3fluorophenol", "CHEMICAL", 45, 58], ["4-chlorophenol", "CHEMICAL", 60, 74], ["4-bromophenol", "CHEMICAL", 76, 89], ["4-iodophenol", "CHEMICAL", 91, 103], ["fluoroacetate", "CHEMICAL", 105, 118], ["trifluoroacetate", "CHEMICAL", 120, 136], ["fluoroacetamide", "CHEMICAL", 138, 153], ["trifluoroethanol", "CHEMICAL", 155, 171], ["2-bromoethanol", "CHEMICAL", 179, 193], ["2-fluorophenol", "CHEMICAL", 29, 43], ["3fluorophenol", "CHEMICAL", 45, 58], ["4-chlorophenol", "CHEMICAL", 60, 74], ["4-bromophenol", "CHEMICAL", 76, 89], ["4-iodophenol", "CHEMICAL", 91, 103], ["fluoroacetate", "CHEMICAL", 105, 118], ["trifluoroacetate", "CHEMICAL", 120, 136], ["fluoroacetamide", "CHEMICAL", 138, 153], ["trifluoroethanol", "CHEMICAL", 155, 171], ["2-bromoethanol", "CHEMICAL", 179, 193], ["2-fluorophenol", "SIMPLE_CHEMICAL", 29, 43], ["3fluorophenol", "SIMPLE_CHEMICAL", 45, 58], ["4-chlorophenol", "SIMPLE_CHEMICAL", 60, 74], ["4-bromophenol", "SIMPLE_CHEMICAL", 76, 89], ["4-iodophenol", "SIMPLE_CHEMICAL", 91, 103], ["fluoroacetate", "SIMPLE_CHEMICAL", 105, 118], ["trifluoroacetate", "SIMPLE_CHEMICAL", 120, 136], ["fluoroacetamide", "SIMPLE_CHEMICAL", 138, 153], ["trifluoroethanol", "SIMPLE_CHEMICAL", 155, 171], ["2-bromoethanol", "SIMPLE_CHEMICAL", 179, 193], ["fluorophenol", "TREATMENT", 31, 43], ["3fluorophenol", "TREATMENT", 45, 58], ["chlorophenol", "TREATMENT", 62, 74], ["bromophenol", "TREATMENT", 78, 89], ["iodophenol", "TREATMENT", 93, 103], ["fluoroacetate", "TREATMENT", 105, 118], ["trifluoroacetate", "TREATMENT", 120, 136], ["fluoroacetamide", "TREATMENT", 138, 153], ["trifluoroethanol", "TREATMENT", 155, 171], ["bromoethanol", "TREATMENT", 181, 193]]], ["The fact that strain IF1 is capable of growth on catechol, hydroquinone, and hydroxyquinol but not on 4-fluorocatechol indicates that 4-fluorocatechol is not the most likely intermediate in the 4-FP pathway, although toxic effects could also play a role.ResultsTo test the range of 4-FP concentrations tolerated by strain IF1, experiments were conducted in sealed flasks with 4-FP at concentrations of 1 to 7 mM as a sole carbon and energy source.", [["catechol", "CHEMICAL", 49, 57], ["hydroquinone", "CHEMICAL", 59, 71], ["hydroxyquinol", "CHEMICAL", 77, 90], ["4-fluorocatechol", "CHEMICAL", 102, 118], ["4-fluorocatechol", "CHEMICAL", 134, 150], ["4-FP", "CHEMICAL", 282, 286], ["4-FP", "CHEMICAL", 376, 380], ["catechol", "CHEMICAL", 49, 57], ["hydroquinone", "CHEMICAL", 59, 71], ["hydroxyquinol", "CHEMICAL", 77, 90], ["4-fluorocatechol", "CHEMICAL", 102, 118], ["4-fluorocatechol", "CHEMICAL", 134, 150], ["4-FP", "CHEMICAL", 194, 198], ["4-FP", "CHEMICAL", 282, 286], ["4-FP", "CHEMICAL", 376, 380], ["carbon", "CHEMICAL", 422, 428], ["IF1", "GENE_OR_GENE_PRODUCT", 21, 24], ["catechol", "SIMPLE_CHEMICAL", 49, 57], ["hydroquinone", "SIMPLE_CHEMICAL", 59, 71], ["hydroxyquinol", "SIMPLE_CHEMICAL", 77, 90], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 102, 118], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 134, 150], ["4-FP", "SIMPLE_CHEMICAL", 194, 198], ["4-FP", "SIMPLE_CHEMICAL", 282, 286], ["IF1", "GENE_OR_GENE_PRODUCT", 322, 325], ["4-FP", "SIMPLE_CHEMICAL", 376, 380], ["carbon", "SIMPLE_CHEMICAL", 422, 428], ["IF1", "PROTEIN", 21, 24], ["IF1", "PROTEIN", 322, 325], ["strain IF1", "PROBLEM", 14, 24], ["catechol", "TREATMENT", 49, 57], ["hydroquinone", "TREATMENT", 59, 71], ["hydroxyquinol", "TREATMENT", 77, 90], ["fluorocatechol", "TREATMENT", 136, 150], ["toxic effects", "PROBLEM", 217, 230]]], ["Control assays without 4-FP showed no growth or release of fluoride, and sterile controls showed no abiotic loss of 4-FP.", [["4-FP", "CHEMICAL", 23, 27], ["fluoride", "CHEMICAL", 59, 67], ["4-FP", "CHEMICAL", 23, 27], ["fluoride", "CHEMICAL", 59, 67], ["4-FP", "SIMPLE_CHEMICAL", 23, 27], ["fluoride", "SIMPLE_CHEMICAL", 59, 67], ["Control assays", "TEST", 0, 14], ["fluoride", "TREATMENT", 59, 67], ["sterile controls", "TEST", 73, 89], ["abiotic loss", "PROBLEM", 100, 112], ["no", "UNCERTAINTY", 97, 99], ["abiotic loss", "OBSERVATION", 100, 112]]], ["Between 1 and 4 mM 4-FP, the substrate was completely consumed, stoichiometric release of fluoride was observed, and biomass increased linearly with the amount of 4-FP added (Fig. 2a) .", [["4-FP", "CHEMICAL", 19, 23], ["fluoride", "CHEMICAL", 90, 98], ["4-FP", "CHEMICAL", 163, 167], ["4-FP", "CHEMICAL", 19, 23], ["fluoride", "CHEMICAL", 90, 98], ["4-FP", "CHEMICAL", 163, 167], ["4-FP", "SIMPLE_CHEMICAL", 19, 23], ["fluoride", "SIMPLE_CHEMICAL", 90, 98], ["4-FP", "SIMPLE_CHEMICAL", 163, 167], ["fluoride", "TREATMENT", 90, 98], ["biomass", "PROBLEM", 117, 124], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["linearly", "OBSERVATION_MODIFIER", 135, 143], ["amount", "OBSERVATION_MODIFIER", 153, 159]]], ["This indicates that the degradation of 4-FP by strain IF1 does not give large amounts of fluorinated dead-end products.", [["4-FP", "CHEMICAL", 39, 43], ["4-FP", "CHEMICAL", 39, 43], ["4-FP", "SIMPLE_CHEMICAL", 39, 43], ["IF1", "GENE_OR_GENE_PRODUCT", 54, 57], ["IF1", "PROTEIN", 54, 57], ["the degradation", "PROBLEM", 20, 35], ["fluorinated dead-end products", "TREATMENT", 89, 118]]], ["Concentrations of 4-FP above 4 mM caused a toxic effect on the growth of IF1 (Fig. 2b) .", [["4-FP", "CHEMICAL", 18, 22], ["4-FP", "CHEMICAL", 18, 22], ["4-FP", "SIMPLE_CHEMICAL", 18, 22], ["IF1", "GENE_OR_GENE_PRODUCT", 73, 76], ["IF1", "PROTEIN", 73, 76], ["Concentrations", "TEST", 0, 14], ["a toxic effect", "PROBLEM", 41, 55], ["toxic effect", "OBSERVATION_MODIFIER", 43, 55]]], ["The use of 5 mM 4-FP promoted growth, but a longer lag time was observed.", [["4-FP", "CHEMICAL", 16, 20], ["4-FP", "CHEMICAL", 16, 20], ["4-FP", "SIMPLE_CHEMICAL", 16, 20], ["5 mM 4-FP promoted growth", "TREATMENT", 11, 36]]], ["At 7 mM 4-FP, no growth occurred even after 15 days of incubation.ResultsGrowth on 4-FP and formation of metabolites A batch culture of strain IF1 supplied with 1 mM 4-FP as the only source of carbon and energy was monitored in time.", [["4-FP", "CHEMICAL", 8, 12], ["4-FP", "CHEMICAL", 83, 87], ["4-FP", "CHEMICAL", 166, 170], ["4-FP", "CHEMICAL", 8, 12], ["4-FP", "CHEMICAL", 83, 87], ["4-FP", "CHEMICAL", 166, 170], ["carbon", "CHEMICAL", 193, 199], ["4-FP", "SIMPLE_CHEMICAL", 8, 12], ["4-FP", "SIMPLE_CHEMICAL", 83, 87], ["IF1", "GENE_OR_GENE_PRODUCT", 143, 146], ["4-FP", "SIMPLE_CHEMICAL", 166, 170], ["carbon", "SIMPLE_CHEMICAL", 193, 199], ["IF1", "PROTEIN", 143, 146], ["growth", "PROBLEM", 17, 23], ["incubation", "TREATMENT", 55, 65], ["metabolites", "TEST", 105, 116], ["A batch culture", "TEST", 117, 132], ["strain IF1", "PROBLEM", 136, 146], ["no", "UNCERTAINTY", 14, 16], ["growth", "OBSERVATION_MODIFIER", 17, 23]]], ["Growth was accompanied by an increase in biomass, decrease in 4-FP, and formation of fluoride (Fig. 3) .", [["4-FP", "CHEMICAL", 62, 66], ["fluoride", "CHEMICAL", 85, 93], ["4-FP", "CHEMICAL", 62, 66], ["fluoride", "CHEMICAL", 85, 93], ["4-FP", "SIMPLE_CHEMICAL", 62, 66], ["fluoride", "SIMPLE_CHEMICAL", 85, 93], ["an increase in biomass", "PROBLEM", 26, 48], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["biomass", "OBSERVATION_MODIFIER", 41, 48], ["decrease", "OBSERVATION_MODIFIER", 50, 58]]], ["After 120 h, there was complete conversion of 1 mM 4-FP, and 1 mM fluoride was formed, indicating that there was no transient accumulation of fluorinated intermediates over the whole growth period.", [["4-FP", "CHEMICAL", 51, 55], ["fluoride", "CHEMICAL", 66, 74], ["4-FP", "CHEMICAL", 51, 55], ["fluoride", "CHEMICAL", 66, 74], ["4-FP", "SIMPLE_CHEMICAL", 51, 55], ["fluoride", "SIMPLE_CHEMICAL", 66, 74], ["transient accumulation of fluorinated intermediates", "PROBLEM", 116, 167], ["no", "UNCERTAINTY", 113, 115], ["transient", "OBSERVATION_MODIFIER", 116, 125], ["accumulation", "OBSERVATION_MODIFIER", 126, 138], ["fluorinated intermediates", "OBSERVATION", 142, 167]]], ["When cells grown on 4-FP were incubated in the presence of the iron chelator 2,2\u2032-dipyridyl, no 4-FP degradation occurred, and no fluoride was released in the medium.", [["cells", "ANATOMY", 5, 10], ["4-FP", "CHEMICAL", 20, 24], ["iron", "CHEMICAL", 63, 67], ["2,2\u2032-dipyridyl", "CHEMICAL", 77, 91], ["4-FP", "CHEMICAL", 96, 100], ["fluoride", "CHEMICAL", 130, 138], ["4-FP", "CHEMICAL", 20, 24], ["iron", "CHEMICAL", 63, 67], ["2,2\u2032-dipyridyl", "CHEMICAL", 77, 91], ["4-FP", "CHEMICAL", 96, 100], ["fluoride", "CHEMICAL", 130, 138], ["cells", "CELL", 5, 10], ["4-FP", "SIMPLE_CHEMICAL", 20, 24], ["iron chelator 2,2\u2032-dipyridyl", "SIMPLE_CHEMICAL", 63, 91], ["4-FP", "SIMPLE_CHEMICAL", 96, 100], ["fluoride", "SIMPLE_CHEMICAL", 130, 138], ["the iron chelator", "TREATMENT", 59, 76], ["dipyridyl", "TREATMENT", 82, 91], ["fluoride", "TREATMENT", 130, 138]]], ["This indicates that initial or further enzymes involved in 4-FP metabolism require ferrous ions for activity.ResultsTo isolate intermediates of the degradation of 4-FP, samples from a batch culture containing 4 mM 4-FP were taken at appropriate intervals and analyzed by GC, HPLC, and LC-MS.", [["samples", "ANATOMY", 169, 176], ["4-FP", "CHEMICAL", 59, 63], ["ferrous", "CHEMICAL", 83, 90], ["4-FP", "CHEMICAL", 163, 167], ["4-FP", "CHEMICAL", 214, 218], ["4-FP", "CHEMICAL", 59, 63], ["ferrous", "CHEMICAL", 83, 90], ["4-FP", "CHEMICAL", 163, 167], ["4-FP", "CHEMICAL", 214, 218], ["4-FP", "SIMPLE_CHEMICAL", 59, 63], ["ferrous ions", "SIMPLE_CHEMICAL", 83, 95], ["4-FP", "SIMPLE_CHEMICAL", 163, 167], ["4-FP", "SIMPLE_CHEMICAL", 214, 218], ["further enzymes", "TEST", 31, 46], ["ferrous ions", "TREATMENT", 83, 95], ["a batch culture", "TEST", 182, 197], ["GC", "TEST", 271, 273], ["HPLC", "TEST", 275, 279], ["LC", "ANATOMY", 285, 287]]], ["Metabolites that were detected were numbered in order of time of appearance in the culture.", [["the culture", "TEST", 79, 90]]], ["GC analysis indicated that at least four metabolites were formed and degraded over time (Table 1) .", [["GC analysis", "TEST", 0, 11]]], ["Metabolite I, the earliest product that was observed, had the same retention time as an authentic hydroquinone standard and metabolite II had the same retention time as a standard of hydroxyquinol.", [["hydroquinone", "CHEMICAL", 98, 110], ["metabolite II", "CHEMICAL", 124, 137], ["hydroxyquinol", "CHEMICAL", 183, 196], ["hydroquinone", "CHEMICAL", 98, 110], ["hydroxyquinol", "CHEMICAL", 183, 196], ["Metabolite I", "GENE_OR_GENE_PRODUCT", 0, 12], ["hydroquinone", "SIMPLE_CHEMICAL", 98, 110], ["hydroxyquinol", "SIMPLE_CHEMICAL", 183, 196], ["an authentic hydroquinone standard", "TREATMENT", 85, 119], ["hydroxyquinol", "TREATMENT", 183, 196]]], ["GC-MS analysis showed that the mass spectrum of metabolite I was indeed similar to that of the hydroquinone standard, with a molecular ion peak at 110 and at 55 m/z.", [["hydroquinone", "CHEMICAL", 95, 107], ["hydroquinone", "CHEMICAL", 95, 107], ["hydroquinone", "SIMPLE_CHEMICAL", 95, 107], ["GC", "TEST", 0, 2], ["MS analysis", "TEST", 3, 14], ["the mass spectrum of metabolite I", "PROBLEM", 27, 60], ["a molecular ion peak", "TEST", 123, 143], ["mass", "OBSERVATION", 31, 35]]], ["Metabolite II gave a molecular ion peak at 126 and 63 m/z, which is typical for hydroxyquinol, and the spectrum coincided with that of a standard.", [["Metabolite II", "CHEMICAL", 0, 13], ["hydroxyquinol", "CHEMICAL", 80, 93], ["hydroxyquinol", "CHEMICAL", 80, 93], ["hydroxyquinol", "SIMPLE_CHEMICAL", 80, 93], ["Metabolite II", "TEST", 0, 13], ["a molecular ion peak", "TEST", 19, 39], ["hydroxyquinol", "TREATMENT", 80, 93]]], ["Metabolites V and VI were detected by GC but did not ionize in GC-MS under the conditions tested and were not identified.", [["VI", "GENE_OR_GENE_PRODUCT", 18, 20], ["Metabolites V", "TEST", 0, 13], ["GC", "TEST", 63, 65]]], ["When the supernatant of IF1 cells growing on 4 mM 4-FP were subjected to HPLC analysis, four peaks were detected (Table 1) .", [["supernatant", "ANATOMY", 9, 20], ["IF1 cells", "ANATOMY", 24, 33], ["4-FP", "CHEMICAL", 50, 54], ["4-FP", "CHEMICAL", 50, 54], ["IF1 cells", "CELL", 24, 33], ["4-FP", "SIMPLE_CHEMICAL", 50, 54], ["IF1 cells", "CELL_LINE", 24, 33], ["IF1 cells", "PROBLEM", 24, 33], ["HPLC analysis", "TEST", 73, 86]]], ["Metabolite I had the same retention time as the hydroquinone standard, and metabolite II coeluted with an authentic standard of hydroxyquinol.", [["hydroquinone", "CHEMICAL", 48, 60], ["metabolite II", "CHEMICAL", 75, 88], ["hydroxyquinol", "CHEMICAL", 128, 141], ["hydroquinone", "CHEMICAL", 48, 60], ["hydroxyquinol", "CHEMICAL", 128, 141], ["hydroquinone", "SIMPLE_CHEMICAL", 48, 60], ["hydroxyquinol", "SIMPLE_CHEMICAL", 128, 141], ["the hydroquinone standard", "TREATMENT", 44, 69], ["hydroxyquinol", "TREATMENT", 128, 141]]], ["Hydroquinone was detected in culture supernatants by HPLC between 7.5 and 51 h (Fig. 4) .", [["supernatants", "ANATOMY", 37, 49], ["Hydroquinone", "CHEMICAL", 0, 12], ["Hydroquinone", "CHEMICAL", 0, 12], ["Hydroquinone", "SIMPLE_CHEMICAL", 0, 12], ["Hydroquinone", "TREATMENT", 0, 12], ["culture supernatants", "TEST", 29, 49], ["HPLC", "TEST", 53, 57]]], ["LC-MS analysis of the extracted samples of the supernatant revealed the presence of a compound (VII) of which the negative ion spectrum shows a molecular ion peak at 159 m/z and a peak at 80 m/z, which are expected for the negative ionization of 3-oxoadipate.ResultsThe above results suggest that 4-FP is initially converted to hydroquinone.", [["samples", "ANATOMY", 32, 39], ["supernatant", "ANATOMY", 47, 58], ["3-oxoadipate", "CHEMICAL", 246, 258], ["4-FP", "CHEMICAL", 297, 301], ["hydroquinone", "CHEMICAL", 328, 340], ["3-oxoadipate", "CHEMICAL", 246, 258], ["4-FP", "CHEMICAL", 297, 301], ["hydroquinone", "CHEMICAL", 328, 340], ["3-oxoadipate", "SIMPLE_CHEMICAL", 246, 258], ["4-FP", "SIMPLE_CHEMICAL", 297, 301], ["hydroquinone", "SIMPLE_CHEMICAL", 328, 340], ["LC", "TEST", 0, 2], ["MS analysis", "TEST", 3, 14], ["the extracted samples", "TEST", 18, 39], ["hydroquinone", "TREATMENT", 328, 340]]], ["The most likely enzyme involved in such a conversion is a 4-FP monooxygenase.ResultsEnzyme activitiesTo test inducibility of enzymes involved in 4-FP degradation, cells of Arthrobacter sp. strain IF1 were grown on glucose or 4-FP, washed, and tested for oxygen consumption in the presence of different substrates.", [["cells", "ANATOMY", 163, 168], ["4-FP", "CHEMICAL", 58, 62], ["4-FP", "CHEMICAL", 145, 149], ["glucose", "CHEMICAL", 214, 221], ["4-FP", "CHEMICAL", 225, 229], ["oxygen", "CHEMICAL", 254, 260], ["4-FP", "CHEMICAL", 58, 62], ["4-FP", "CHEMICAL", 145, 149], ["glucose", "CHEMICAL", 214, 221], ["4-FP", "CHEMICAL", 225, 229], ["oxygen", "CHEMICAL", 254, 260], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 58, 76], ["4-FP", "SIMPLE_CHEMICAL", 145, 149], ["cells", "CELL", 163, 168], ["Arthrobacter sp", "ORGANISM", 172, 187], ["IF1", "GENE_OR_GENE_PRODUCT", 196, 199], ["glucose", "SIMPLE_CHEMICAL", 214, 221], ["4-FP", "SIMPLE_CHEMICAL", 225, 229], ["oxygen", "SIMPLE_CHEMICAL", 254, 260], ["4-FP monooxygenase", "PROTEIN", 58, 76], ["enzymes", "PROTEIN", 125, 132], ["IF1", "PROTEIN", 196, 199], ["a 4-FP monooxygenase", "TREATMENT", 56, 76], ["Enzyme activities", "TEST", 84, 101], ["test inducibility", "TEST", 104, 121], ["enzymes", "TEST", 125, 132], ["Arthrobacter sp", "PROBLEM", 172, 187], ["strain IF1", "PROBLEM", 189, 199], ["glucose", "TEST", 214, 221], ["oxygen consumption", "TREATMENT", 254, 272], ["most likely", "UNCERTAINTY", 4, 15]]], ["Washed suspensions of cells grown on 4-FP rapidly oxidized 4-FP, hydroquinone, and 1,2,4-benzenetriol (hydroxyquinol) without a lag.", [["cells", "ANATOMY", 22, 27], ["4-FP", "CHEMICAL", 37, 41], ["4-FP", "CHEMICAL", 59, 63], ["hydroquinone", "CHEMICAL", 65, 77], ["1,2,4-benzenetriol", "CHEMICAL", 83, 101], ["hydroxyquinol", "CHEMICAL", 103, 116], ["4-FP", "CHEMICAL", 37, 41], ["4-FP", "CHEMICAL", 59, 63], ["hydroquinone", "CHEMICAL", 65, 77], ["1,2,4-benzenetriol", "CHEMICAL", 83, 101], ["hydroxyquinol", "CHEMICAL", 103, 116], ["cells", "CELL", 22, 27], ["4-FP", "SIMPLE_CHEMICAL", 37, 41], ["4-FP", "SIMPLE_CHEMICAL", 59, 63], ["hydroquinone", "SIMPLE_CHEMICAL", 65, 77], ["1,2,4-benzenetriol", "SIMPLE_CHEMICAL", 83, 101], ["hydroxyquinol", "SIMPLE_CHEMICAL", 103, 116], ["hydroquinone", "TREATMENT", 65, 77], ["benzenetriol", "TREATMENT", 89, 101], ["hydroxyquinol", "TREATMENT", 103, 116], ["cells grown", "OBSERVATION", 22, 33]]], ["Catechol and 4-fluorocatechol did not stimulate (Table 2 ).", [["Catechol", "CHEMICAL", 0, 8], ["4-fluorocatechol", "CHEMICAL", 13, 29], ["Catechol", "CHEMICAL", 0, 8], ["4-fluorocatechol", "CHEMICAL", 13, 29], ["Catechol", "SIMPLE_CHEMICAL", 0, 8], ["4-fluorocatechol", "SIMPLE_CHEMICAL", 13, 29], ["Catechol", "TEST", 0, 8], ["fluorocatechol", "TREATMENT", 15, 29]]], ["This result indicates that 4fluorocatechol and catechol are not likely intermediates and that hydroquinone and hydroxyquinol are.", [["4fluorocatechol", "CHEMICAL", 27, 42], ["catechol", "CHEMICAL", 47, 55], ["hydroquinone", "CHEMICAL", 94, 106], ["hydroxyquinol", "CHEMICAL", 111, 124], ["4fluorocatechol", "CHEMICAL", 27, 42], ["catechol", "CHEMICAL", 47, 55], ["hydroquinone", "CHEMICAL", 94, 106], ["hydroxyquinol", "CHEMICAL", 111, 124], ["4fluorocatechol", "SIMPLE_CHEMICAL", 27, 42], ["catechol", "SIMPLE_CHEMICAL", 47, 55], ["hydroquinone", "SIMPLE_CHEMICAL", 94, 106], ["hydroxyquinol", "SIMPLE_CHEMICAL", 111, 124], ["4fluorocatechol and catechol", "TREATMENT", 27, 55], ["hydroquinone", "TREATMENT", 94, 106], ["hydroxyquinol", "TREATMENT", 111, 124], ["not likely", "UNCERTAINTY", 60, 70]]], ["Glucose-grown cells did not oxidize any of the aromatic substrates tested with the exception of hydroxyquinol.", [["cells", "ANATOMY", 14, 19], ["Glucose", "CHEMICAL", 0, 7], ["hydroxyquinol", "CHEMICAL", 96, 109], ["Glucose", "CHEMICAL", 0, 7], ["hydroxyquinol", "CHEMICAL", 96, 109], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["cells", "CELL", 14, 19], ["hydroxyquinol", "SIMPLE_CHEMICAL", 96, 109], ["Glucose-grown cells", "CELL_LINE", 0, 19], ["Glucose", "TEST", 0, 7], ["the aromatic substrates", "TEST", 43, 66], ["hydroxyquinol", "TREATMENT", 96, 109], ["grown cells", "OBSERVATION", 8, 19]]], ["This observation implies that hydroxyquinol may be converted by a constitutive oxygenase, whereas most other enzymes seem inducible.", [["hydroxyquinol", "CHEMICAL", 30, 43], ["hydroxyquinol", "CHEMICAL", 30, 43], ["hydroxyquinol", "SIMPLE_CHEMICAL", 30, 43], ["oxygenase", "GENE_OR_GENE_PRODUCT", 79, 88], ["constitutive oxygenase", "PROTEIN", 66, 88], ["enzymes", "PROTEIN", 109, 116], ["hydroxyquinol", "TREATMENT", 30, 43], ["a constitutive oxygenase", "TREATMENT", 64, 88]]], ["Cells grown with hydroxyquinol showed complete conversion of benzenetriol in the presence or absence of 2,2\u2032dipyridyl, indicating that the putative hydroxyquinol oxygenase does not require ferrous ions to be active and that oxidation beyond this compound is not inhibited by the chelator.", [["Cells", "ANATOMY", 0, 5], ["hydroxyquinol", "CHEMICAL", 17, 30], ["benzenetriol", "CHEMICAL", 61, 73], ["2,2\u2032dipyridyl", "CHEMICAL", 104, 117], ["hydroxyquinol", "CHEMICAL", 148, 161], ["ferrous", "CHEMICAL", 189, 196], ["hydroxyquinol", "CHEMICAL", 17, 30], ["benzenetriol", "CHEMICAL", 61, 73], ["2,2\u2032dipyridyl", "CHEMICAL", 104, 117], ["hydroxyquinol", "CHEMICAL", 148, 161], ["ferrous", "CHEMICAL", 189, 196], ["Cells", "CELL", 0, 5], ["hydroxyquinol", "SIMPLE_CHEMICAL", 17, 30], ["benzenetriol", "SIMPLE_CHEMICAL", 61, 73], ["2,2\u2032dipyridyl", "SIMPLE_CHEMICAL", 104, 117], ["hydroxyquinol oxygenase", "GENE_OR_GENE_PRODUCT", 148, 171], ["ferrous ions", "SIMPLE_CHEMICAL", 189, 201], ["chelator", "SIMPLE_CHEMICAL", 279, 287], ["hydroxyquinol oxygenase", "PROTEIN", 148, 171], ["Cells", "TEST", 0, 5], ["hydroxyquinol", "TREATMENT", 17, 30], ["benzenetriol", "TREATMENT", 61, 73], ["2,2\u2032dipyridyl", "TREATMENT", 104, 117], ["the putative hydroxyquinol oxygenase", "TREATMENT", 135, 171], ["ferrous ions", "TREATMENT", 189, 201]]], ["The formation of hydroquinone, which can be readily oxidized by 4-FP-grown cells, is in agreement with the involvement in 4-FP degradation of a 4-FP monooxygenase that is induced by 4-FP.ResultsTo study in more detail the degradation pathway of 4-FP by strain IF1, cell-free extracts of IF1 grown on 4-FP were investigated for the presence of several enzyme activities (Table 3) .", [["cells", "ANATOMY", 75, 80], ["cell", "ANATOMY", 265, 269], ["extracts", "ANATOMY", 275, 283], ["hydroquinone", "CHEMICAL", 17, 29], ["4-FP", "CHEMICAL", 64, 68], ["4-FP", "CHEMICAL", 144, 148], ["4-FP", "CHEMICAL", 245, 249], ["4-FP", "CHEMICAL", 300, 304], ["hydroquinone", "CHEMICAL", 17, 29], ["4-FP", "CHEMICAL", 64, 68], ["4-FP", "CHEMICAL", 122, 126], ["4-FP", "CHEMICAL", 144, 148], ["4-FP", "CHEMICAL", 245, 249], ["4-FP", "CHEMICAL", 300, 304], ["hydroquinone", "SIMPLE_CHEMICAL", 17, 29], ["4-FP", "SIMPLE_CHEMICAL", 64, 68], ["cells", "CELL", 75, 80], ["4-FP", "SIMPLE_CHEMICAL", 122, 126], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 144, 162], ["4-FP", "SIMPLE_CHEMICAL", 245, 249], ["IF1", "GENE_OR_GENE_PRODUCT", 260, 263], ["cell", "CELL", 265, 269], ["extracts", "ORGANISM_SUBSTANCE", 275, 283], ["IF1", "GENE_OR_GENE_PRODUCT", 287, 290], ["4-FP", "SIMPLE_CHEMICAL", 300, 304], ["4-FP-grown cells", "CELL_LINE", 64, 80], ["IF1", "PROTEIN", 260, 263], ["IF1", "PROTEIN", 287, 290], ["hydroquinone", "TREATMENT", 17, 29], ["a 4-FP monooxygenase", "TREATMENT", 142, 162], ["IF1", "PROBLEM", 287, 290]]], ["When catechol 1,2-and 2,3-dioxygenases were tested for, no activity was found.", [["catechol 1,2-and 2,3-dioxygenases", "CHEMICAL", 5, 38], ["catechol", "CHEMICAL", 5, 13], ["catechol 1,2-and 2,3-dioxygenases", "SIMPLE_CHEMICAL", 5, 38], ["catechol 1,2-and 2,3-dioxygenases", "PROTEIN", 5, 38], ["catechol", "TEST", 5, 13]]], ["Furthermore, no activity was detectable for 4-fluorocatechol dioxygenase.", [["4-fluorocatechol", "CHEMICAL", 44, 60], ["4-fluorocatechol", "CHEMICAL", 44, 60], ["4-fluorocatechol dioxygenase", "SIMPLE_CHEMICAL", 44, 72], ["fluorocatechol dioxygenase", "PROTEIN", 46, 72], ["no", "UNCERTAINTY", 13, 15]]], ["Consequently, the pathway does not proceed through catechol or a substituted catechol.", [["catechol", "CHEMICAL", 51, 59], ["catechol", "CHEMICAL", 77, 85], ["catechol", "CHEMICAL", 51, 59], ["catechol", "CHEMICAL", 77, 85], ["catechol", "SIMPLE_CHEMICAL", 51, 59], ["catechol", "SIMPLE_CHEMICAL", 77, 85], ["a substituted catechol", "TREATMENT", 63, 85]]], ["When cell extracts were assayed for 4-FP monooxygenase, activity could be found in the presence of NADH but not in the presence of NADPH as the reducing cosubstrate.", [["cell extracts", "ANATOMY", 5, 18], ["4-FP", "CHEMICAL", 36, 40], ["NADH", "CHEMICAL", 99, 103], ["NADPH", "CHEMICAL", 131, 136], ["4-FP", "CHEMICAL", 36, 40], ["NADH", "CHEMICAL", 99, 103], ["NADPH", "CHEMICAL", 131, 136], ["cell extracts", "ORGANISM_SUBSTANCE", 5, 18], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 36, 54], ["NADH", "SIMPLE_CHEMICAL", 99, 103], ["NADPH", "SIMPLE_CHEMICAL", 131, 136], ["NADH", "PROBLEM", 99, 103], ["the reducing cosubstrate", "TREATMENT", 140, 164]]], ["This observation indicates that the cells contain an NADH-dependent 4-FP monooxygenase activity.", [["cells", "ANATOMY", 36, 41], ["NADH", "CHEMICAL", 53, 57], ["4-FP", "CHEMICAL", 68, 72], ["NADH", "CHEMICAL", 53, 57], ["4-FP", "CHEMICAL", 68, 72], ["cells", "CELL", 36, 41], ["NADH", "SIMPLE_CHEMICAL", 53, 57], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 68, 86], ["This observation", "TEST", 0, 16], ["the cells", "PROBLEM", 32, 41], ["an NADH", "TEST", 50, 57]]], ["HPLC assays of incubations of cell extracts with 4-FP showed that substrate conversion was complete.", [["cell extracts", "ANATOMY", 30, 43], ["4-FP", "CHEMICAL", 49, 53], ["4-FP", "CHEMICAL", 49, 53], ["cell extracts", "ORGANISM_SUBSTANCE", 30, 43], ["4-FP", "SIMPLE_CHEMICAL", 49, 53], ["HPLC assays", "TEST", 0, 11], ["cell extracts", "TEST", 30, 43], ["substrate conversion", "TREATMENT", 66, 86]]], ["The formation of the putative 4-FP monooxygenase was induced by 4-FP because no activity was found in extracts of cells grown in the presence of glucose.ResultsWhen hydroquinone was used as an assay substrate, its typical spectrophotometric peak at 288 nm was not replaced by a peak absorbing at 290 to 320 nm, which would have pointed to formation of hydroxymuconic semialdehyde.", [["extracts", "ANATOMY", 102, 110], ["cells", "ANATOMY", 114, 119], ["4-FP", "CHEMICAL", 30, 34], ["4-FP", "CHEMICAL", 64, 68], ["glucose", "CHEMICAL", 145, 152], ["hydroquinone", "CHEMICAL", 165, 177], ["hydroxymuconic semialdehyde", "CHEMICAL", 352, 379], ["4-FP", "CHEMICAL", 30, 34], ["4-FP", "CHEMICAL", 64, 68], ["glucose", "CHEMICAL", 145, 152], ["hydroquinone", "CHEMICAL", 165, 177], ["hydroxymuconic semialdehyde", "CHEMICAL", 352, 379], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 30, 48], ["4-FP", "SIMPLE_CHEMICAL", 64, 68], ["extracts", "ORGANISM_SUBSTANCE", 102, 110], ["cells", "CELL", 114, 119], ["glucose", "SIMPLE_CHEMICAL", 145, 152], ["hydroquinone", "SIMPLE_CHEMICAL", 165, 177], ["hydroxymuconic semialdehyde", "SIMPLE_CHEMICAL", 352, 379], ["putative 4-FP monooxygenase", "PROTEIN", 21, 48], ["extracts of cells", "PROBLEM", 102, 119], ["glucose", "TEST", 145, 152], ["hydroquinone", "TREATMENT", 165, 177], ["an assay substrate", "TEST", 190, 208], ["its typical spectrophotometric peak", "TEST", 210, 245], ["hydroxymuconic semialdehyde", "PROBLEM", 352, 379], ["320 nm", "OBSERVATION_MODIFIER", 303, 309], ["hydroxymuconic semialdehyde", "OBSERVATION", 352, 379]]], ["Thus, no hydroquinone dioxygenase was induced, or its product was rapidly further converted.", [["hydroquinone", "CHEMICAL", 9, 21], ["hydroquinone", "CHEMICAL", 9, 21], ["hydroquinone", "SIMPLE_CHEMICAL", 9, 21], ["hydroquinone dioxygenase", "PROTEIN", 9, 33], ["hydroquinone dioxygenase", "TREATMENT", 9, 33], ["no", "UNCERTAINTY", 6, 8], ["hydroquinone dioxygenase", "OBSERVATION", 9, 33]]], ["The latter was ruled out by the observation that added hydroxymuconic semialdehyde was not converted by cell extracts of strain IF1, indicating that no hydroxymuconic semialdehyde dehydrogenase was induced during growth in the presence of 4-FP.", [["cell extracts", "ANATOMY", 104, 117], ["hydroxymuconic semialdehyde", "CHEMICAL", 55, 82], ["semialdehyde", "CHEMICAL", 167, 179], ["4-FP.", "CHEMICAL", 239, 244], ["hydroxymuconic semialdehyde", "CHEMICAL", 55, 82], ["hydroxymuconic semialdehyde", "CHEMICAL", 152, 179], ["4-FP.", "CHEMICAL", 239, 244], ["hydroxymuconic semialdehyde", "SIMPLE_CHEMICAL", 55, 82], ["cell extracts", "ORGANISM_SUBSTANCE", 104, 117], ["IF1", "GENE_OR_GENE_PRODUCT", 128, 131], ["hydroxymuconic semialdehyde dehydrogenase", "GENE_OR_GENE_PRODUCT", 152, 193], ["IF1", "PROTEIN", 128, 131], ["hydroxymuconic semialdehyde dehydrogenase", "PROTEIN", 152, 193], ["hydroxymuconic semialdehyde", "PROBLEM", 55, 82], ["strain IF1", "PROBLEM", 121, 131], ["hydroxymuconic semialdehyde dehydrogenase", "PROBLEM", 152, 193], ["semialdehyde dehydrogenase", "OBSERVATION", 167, 193]]], ["These results make it unlikely that hydroxymuconic semialdehyde is an intermediate in the 4-FP pathway by strain IF1.ResultsWhen cell extracts were assayed for hydroxyquinol degradation, complete conversion of the substrate was observed with HPLC.", [["cell extracts", "ANATOMY", 129, 142], ["semialdehyde", "CHEMICAL", 51, 63], ["hydroxyquinol", "CHEMICAL", 160, 173], ["hydroxymuconic semialdehyde", "CHEMICAL", 36, 63], ["4-FP", "CHEMICAL", 90, 94], ["hydroxyquinol", "CHEMICAL", 160, 173], ["hydroxymuconic semialdehyde", "SIMPLE_CHEMICAL", 36, 63], ["IF1", "GENE_OR_GENE_PRODUCT", 113, 116], ["cell extracts", "ORGANISM_SUBSTANCE", 129, 142], ["hydroxyquinol", "SIMPLE_CHEMICAL", 160, 173], ["IF1", "PROTEIN", 113, 116], ["hydroxymuconic semialdehyde", "PROBLEM", 36, 63], ["cell extracts", "TEST", 129, 142], ["hydroxyquinol degradation", "TREATMENT", 160, 185], ["HPLC", "TEST", 242, 246], ["intermediate", "OBSERVATION_MODIFIER", 70, 82]]], ["When the reaction was monitored spectrophotometrically, the peak at 287 nm, typical of hydroxyquinol, was substituted by a peak at 245 nm, typical of maleylacetate.", [["hydroxyquinol", "CHEMICAL", 87, 100], ["maleylacetate", "CHEMICAL", 150, 163], ["hydroxyquinol", "CHEMICAL", 87, 100], ["maleylacetate", "CHEMICAL", 150, 163], ["hydroxyquinol", "SIMPLE_CHEMICAL", 87, 100], ["maleylacetate", "SIMPLE_CHEMICAL", 150, 163], ["hydroxyquinol", "TREATMENT", 87, 100], ["maleylacetate", "TREATMENT", 150, 163]]], ["This indicates the involvement of a hydroxyquinol oxygenase that converts hydroxyquinol into maleylacetate, which is further converted into 3-oxoadipate.DiscussionThis study reports the isolation and characterization of Arthrobacter strain IF1, an organism capable of growth with 4-FP as a sole source of carbon and energy.", [["hydroxyquinol", "CHEMICAL", 36, 49], ["hydroxyquinol", "CHEMICAL", 74, 87], ["maleylacetate", "CHEMICAL", 93, 106], ["3-oxoadipate", "CHEMICAL", 140, 152], ["4-FP", "CHEMICAL", 280, 284], ["hydroxyquinol", "CHEMICAL", 36, 49], ["hydroxyquinol", "CHEMICAL", 74, 87], ["maleylacetate", "CHEMICAL", 93, 106], ["3-oxoadipate", "CHEMICAL", 140, 152], ["4-FP", "CHEMICAL", 280, 284], ["carbon", "CHEMICAL", 305, 311], ["hydroxyquinol oxygenase", "GENE_OR_GENE_PRODUCT", 36, 59], ["hydroxyquinol", "SIMPLE_CHEMICAL", 74, 87], ["maleylacetate", "SIMPLE_CHEMICAL", 93, 106], ["3-oxoadipate", "SIMPLE_CHEMICAL", 140, 152], ["Arthrobacter strain", "ORGANISM", 220, 239], ["IF1", "GENE_OR_GENE_PRODUCT", 240, 243], ["4-FP", "SIMPLE_CHEMICAL", 280, 284], ["carbon", "SIMPLE_CHEMICAL", 305, 311], ["hydroxyquinol oxygenase", "PROTEIN", 36, 59], ["Arthrobacter strain IF1", "SPECIES", 220, 243], ["a hydroxyquinol oxygenase", "TREATMENT", 34, 59], ["hydroxyquinol into maleylacetate", "TREATMENT", 74, 106], ["This study", "TEST", 163, 173], ["the isolation", "TEST", 182, 195], ["Arthrobacter strain IF1", "PROBLEM", 220, 243], ["an organism", "PROBLEM", 245, 256]]], ["The biodegradation of 4-FP by strain IF1 was analyzed by GC, GC-MS, HPLC, LC-MS, oxygen uptake experiments, and measurements of enzymatic activities.", [["4-FP", "CHEMICAL", 22, 26], ["oxygen", "CHEMICAL", 81, 87], ["4-FP", "CHEMICAL", 22, 26], ["oxygen", "CHEMICAL", 81, 87], ["4-FP", "SIMPLE_CHEMICAL", 22, 26], ["IF1", "GENE_OR_GENE_PRODUCT", 37, 40], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["The biodegradation", "TEST", 0, 18], ["GC", "TEST", 57, 59], ["GC", "TEST", 61, 63], ["MS", "TEST", 64, 66], ["HPLC", "TEST", 68, 72], ["LC", "TEST", 74, 76], ["MS", "PROBLEM", 77, 79], ["oxygen uptake experiments", "TEST", 81, 106], ["LC", "ANATOMY", 74, 76]]], ["A metabolic pathway is proposed on the basis of the results of this study (steps 1 and 2, ortho-cleavage) and by analogy with other systems 5) .", [["this study", "TEST", 63, 73], ["metabolic pathway", "OBSERVATION", 2, 19]]], ["We suggest that the degradation of 4-FP in strain IF1 starts with the conversion by a monooxygenase to benzoquinone, which is immediately reduced to hydroquinone.", [["4-FP", "CHEMICAL", 35, 39], ["benzoquinone", "CHEMICAL", 103, 115], ["hydroquinone", "CHEMICAL", 149, 161], ["4-FP", "CHEMICAL", 35, 39], ["benzoquinone", "CHEMICAL", 103, 115], ["hydroquinone", "CHEMICAL", 149, 161], ["4-FP", "SIMPLE_CHEMICAL", 35, 39], ["IF1", "GENE_OR_GENE_PRODUCT", 50, 53], ["benzoquinone", "SIMPLE_CHEMICAL", 103, 115], ["hydroquinone", "SIMPLE_CHEMICAL", 149, 161], ["IF1", "PROTEIN", 50, 53], ["monooxygenase", "PROTEIN", 86, 99], ["a monooxygenase to benzoquinone", "TREATMENT", 84, 115], ["hydroquinone", "TREATMENT", 149, 161]]], ["Hydroquinone then undergoes a further hydroxylation to form hydroxyquinol.", [["Hydroquinone", "CHEMICAL", 0, 12], ["hydroxyquinol", "CHEMICAL", 60, 73], ["Hydroquinone", "CHEMICAL", 0, 12], ["hydroxyquinol", "CHEMICAL", 60, 73], ["Hydroquinone", "SIMPLE_CHEMICAL", 0, 12], ["hydroxyquinol", "SIMPLE_CHEMICAL", 60, 73], ["Hydroquinone", "TREATMENT", 0, 12], ["a further hydroxylation", "TREATMENT", 28, 51], ["hydroxyquinol", "TREATMENT", 60, 73]]], ["This benzenetriol is the ring fission substrate, which is transformed by ortho-cleavage and yields maleylacetate, which is further converted to 3oxoadipate.DiscussionUp to now, two main metabolic routes for the aerobic degradation of halogenated phenols have been described in the literature.", [["benzenetriol", "CHEMICAL", 5, 17], ["maleylacetate", "CHEMICAL", 99, 112], ["3oxoadipate", "CHEMICAL", 144, 155], ["halogenated phenols", "CHEMICAL", 234, 253], ["benzenetriol", "CHEMICAL", 5, 17], ["maleylacetate", "CHEMICAL", 99, 112], ["3oxoadipate", "CHEMICAL", 144, 155], ["halogenated phenols", "CHEMICAL", 234, 253], ["benzenetriol", "SIMPLE_CHEMICAL", 5, 17], ["maleylacetate", "SIMPLE_CHEMICAL", 99, 112], ["3oxoadipate", "SIMPLE_CHEMICAL", 144, 155], ["halogenated phenols", "SIMPLE_CHEMICAL", 234, 253], ["the ring fission substrate", "TREATMENT", 21, 47], ["maleylacetate", "TREATMENT", 99, 112], ["3oxoadipate", "TREATMENT", 144, 155], ["the aerobic degradation", "PROBLEM", 207, 230], ["halogenated phenols", "TREATMENT", 234, 253], ["ring fission substrate", "OBSERVATION", 25, 47], ["halogenated phenols", "OBSERVATION", 234, 253]]], ["In bacteria that degrade mono-and dichlorophenols, a degradation pathway is usually observed in which the substituted phenol is hydroxylated to the corresponding catechol, which is followed by orthocleavage of the aromatic ring (Haggblom 1992; Hollender et al. 1997; Wieser et al. 1994 ).", [["mono-and dichlorophenols", "CHEMICAL", 25, 49], ["phenol", "CHEMICAL", 118, 124], ["catechol", "CHEMICAL", 162, 170], ["mono-and dichlorophenols", "CHEMICAL", 25, 49], ["phenol", "CHEMICAL", 118, 124], ["catechol", "CHEMICAL", 162, 170], ["mono", "SIMPLE_CHEMICAL", 25, 29], ["dichlorophenols", "SIMPLE_CHEMICAL", 34, 49], ["phenol", "SIMPLE_CHEMICAL", 118, 124], ["catechol", "SIMPLE_CHEMICAL", 162, 170], ["bacteria", "PROBLEM", 3, 11], ["mono", "TEST", 25, 29], ["dichlorophenols", "TREATMENT", 34, 49], ["a degradation pathway", "PROBLEM", 51, 72], ["aromatic ring", "OBSERVATION", 214, 227]]], ["On the other hand, biodegradation pathways in which the substituted phenol is converted via hydroquinone to maleylacetate have been found, mainly in organisms that grow on polyhalophenols or 4-nitrophenol (Kiyohara et al. 1992; Xun et al. 1992; Kadiyala and Spain 1998; Nordin et al. 2005; Perry and Zylstra 2007) .", [["phenol", "CHEMICAL", 68, 74], ["hydroquinone", "CHEMICAL", 92, 104], ["maleylacetate", "CHEMICAL", 108, 121], ["polyhalophenols", "CHEMICAL", 172, 187], ["4-nitrophenol", "CHEMICAL", 191, 204], ["phenol", "CHEMICAL", 68, 74], ["hydroquinone", "CHEMICAL", 92, 104], ["maleylacetate", "CHEMICAL", 108, 121], ["polyhalophenols", "CHEMICAL", 172, 187], ["4-nitrophenol", "CHEMICAL", 191, 204], ["phenol", "SIMPLE_CHEMICAL", 68, 74], ["hydroquinone", "SIMPLE_CHEMICAL", 92, 104], ["maleylacetate", "SIMPLE_CHEMICAL", 108, 121], ["polyhalophenols", "SIMPLE_CHEMICAL", 172, 187], ["4-nitrophenol", "SIMPLE_CHEMICAL", 191, 204], ["the substituted phenol", "TREATMENT", 52, 74], ["hydroquinone", "TREATMENT", 92, 104], ["maleylacetate", "TREATMENT", 108, 121], ["polyhalophenols", "TREATMENT", 172, 187]]], ["Most studies have focused on the organisms and pathways that involve degradation via catechols.DiscussionA clear indication for the first step in the 4-FP catabolic pathway of strain IF1 was obtained by mass spectroscopic analysis of culture supernatants, which indicated the formation of hydroquinone as an early nonfluorinated intermediate.", [["supernatants", "ANATOMY", 242, 254], ["catechols", "CHEMICAL", 85, 94], ["hydroquinone", "CHEMICAL", 289, 301], ["catechols", "CHEMICAL", 85, 94], ["4-FP", "CHEMICAL", 150, 154], ["hydroquinone", "CHEMICAL", 289, 301], ["catechols", "SIMPLE_CHEMICAL", 85, 94], ["4-FP", "SIMPLE_CHEMICAL", 150, 154], ["IF1", "GENE_OR_GENE_PRODUCT", 183, 186], ["hydroquinone", "SIMPLE_CHEMICAL", 289, 301], ["IF1", "PROTEIN", 183, 186], ["Most studies", "TEST", 0, 12], ["degradation via catechols", "PROBLEM", 69, 94], ["strain IF1", "PROBLEM", 176, 186], ["mass spectroscopic analysis", "TEST", 203, 230], ["culture supernatants", "TEST", 234, 254], ["hydroquinone", "TREATMENT", 289, 301]]], ["This result, in combination with the enzyme assays and oxygen uptake experiments, suggests the involvement of an inducible 4-FP monooxygenase that is NADH dependent, although the first expected product of this reaction, i.e., benzoquinone, was not detected.", [["oxygen", "CHEMICAL", 55, 61], ["NADH", "CHEMICAL", 150, 154], ["benzoquinone", "CHEMICAL", 226, 238], ["oxygen", "CHEMICAL", 55, 61], ["4-FP", "CHEMICAL", 123, 127], ["NADH", "CHEMICAL", 150, 154], ["benzoquinone", "CHEMICAL", 226, 238], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 123, 141], ["NADH", "SIMPLE_CHEMICAL", 150, 154], ["benzoquinone", "SIMPLE_CHEMICAL", 226, 238], ["4-FP monooxygenase", "PROTEIN", 123, 141], ["the enzyme assays", "TEST", 33, 50], ["oxygen uptake experiments", "TEST", 55, 80], ["an inducible 4-FP monooxygenase", "PROBLEM", 110, 141], ["NADH dependent", "PROBLEM", 150, 164], ["this reaction", "PROBLEM", 205, 218], ["benzoquinone", "TREATMENT", 226, 238], ["oxygen uptake", "OBSERVATION", 55, 68], ["NADH dependent", "OBSERVATION_MODIFIER", 150, 164]]], ["Monooxygenation of an aromatic substrate carrying an electronwithdrawing halogen group or a nitro-substituent can result in simultaneous hydroxylation and dehalogenation or nitrite removal.", [["nitro-substituent", "CHEMICAL", 92, 109], ["nitrite", "CHEMICAL", 173, 180], ["halogen", "CHEMICAL", 73, 80], ["nitro", "CHEMICAL", 92, 97], ["nitrite", "CHEMICAL", 173, 180], ["nitro-substituent", "SIMPLE_CHEMICAL", 92, 109], ["nitrite", "SIMPLE_CHEMICAL", 173, 180], ["an aromatic substrate", "PROBLEM", 19, 40], ["an electronwithdrawing halogen group", "TREATMENT", 50, 86], ["a nitro-substituent", "TREATMENT", 90, 109], ["simultaneous hydroxylation", "TREATMENT", 124, 150], ["dehalogenation", "TREATMENT", 155, 169], ["nitrite removal", "TREATMENT", 173, 188], ["aromatic substrate", "OBSERVATION", 22, 40]]], ["This has, for example, been described for the conversion of tetrafluoro-p-hydroxybenzoate by parahydroxybenzoate hydroxylase (Husain et al. 1980 ) and the oxidation of 2,4-6-trifluorophenol by a monooxygenase from Ralstonia eutropha JMP134 (Xun and Webster 2004) .", [["tetrafluoro-p-hydroxybenzoate", "CHEMICAL", 60, 89], ["parahydroxybenzoate", "CHEMICAL", 93, 112], ["2,4-6-trifluorophenol", "CHEMICAL", 168, 189], ["tetrafluoro-p-hydroxybenzoate", "CHEMICAL", 60, 89], ["parahydroxybenzoate", "CHEMICAL", 93, 112], ["2,4-6-trifluorophenol", "CHEMICAL", 168, 189], ["tetrafluoro-p-hydroxybenzoate", "SIMPLE_CHEMICAL", 60, 89], ["parahydroxybenzoate hydroxylase", "SIMPLE_CHEMICAL", 93, 124], ["2,4-6-trifluorophenol", "SIMPLE_CHEMICAL", 168, 189], ["Ralstonia eutropha JMP134", "SIMPLE_CHEMICAL", 214, 239], ["monooxygenase", "PROTEIN", 195, 208], ["Ralstonia eutropha", "SPECIES", 214, 232], ["Ralstonia eutropha", "SPECIES", 214, 232], ["tetrafluoro", "TREATMENT", 60, 71], ["p-hydroxybenzoate", "TREATMENT", 72, 89], ["parahydroxybenzoate hydroxylase", "TREATMENT", 93, 124], ["the oxidation", "TREATMENT", 151, 164], ["trifluorophenol", "TREATMENT", 174, 189]]], ["The quinone that is produced is chemically reduced by NADH to a hydroxyquinol, leading to a net stoichiometry of two NADH oxidized per halide or nitrite that is released (Fig. 5) .", [["quinone", "CHEMICAL", 4, 11], ["NADH", "CHEMICAL", 54, 58], ["hydroxyquinol", "CHEMICAL", 64, 77], ["NADH", "CHEMICAL", 117, 121], ["nitrite", "CHEMICAL", 145, 152], ["quinone", "CHEMICAL", 4, 11], ["NADH", "CHEMICAL", 54, 58], ["hydroxyquinol", "CHEMICAL", 64, 77], ["NADH", "CHEMICAL", 117, 121], ["halide", "CHEMICAL", 135, 141], ["nitrite", "CHEMICAL", 145, 152], ["quinone", "SIMPLE_CHEMICAL", 4, 11], ["NADH", "SIMPLE_CHEMICAL", 54, 58], ["hydroxyquinol", "SIMPLE_CHEMICAL", 64, 77], ["NADH", "SIMPLE_CHEMICAL", 117, 121], ["halide", "SIMPLE_CHEMICAL", 135, 141], ["nitrite", "SIMPLE_CHEMICAL", 145, 152], ["The quinone", "TREATMENT", 0, 11], ["a hydroxyquinol", "TREATMENT", 62, 77], ["a net stoichiometry of two NADH oxidized", "TREATMENT", 90, 130], ["nitrite", "TREATMENT", 145, 152]]], ["As in our case, no transient accumulation of a benzoquinone is usually observed, indicating that benzoquinone reduction is rapid.", [["benzoquinone", "CHEMICAL", 47, 59], ["benzoquinone", "CHEMICAL", 97, 109], ["benzoquinone", "CHEMICAL", 47, 59], ["benzoquinone", "CHEMICAL", 97, 109], ["benzoquinone", "SIMPLE_CHEMICAL", 47, 59], ["benzoquinone", "SIMPLE_CHEMICAL", 97, 109], ["transient accumulation of a benzoquinone", "PROBLEM", 19, 59], ["benzoquinone reduction", "TREATMENT", 97, 119], ["no", "UNCERTAINTY", 16, 18], ["transient", "OBSERVATION_MODIFIER", 19, 28], ["accumulation", "OBSERVATION_MODIFIER", 29, 41], ["benzoquinone reduction", "OBSERVATION", 97, 119], ["rapid", "OBSERVATION_MODIFIER", 123, 128]]], ["Other examples of halophenol degradation with formation of hydroquinone derivatives are the degradation of trichlorophenol to 2,6-dichlorohydroquinone by a strain of Pseudomonas pickettii (Kiyohara et al. 1992) , the degradation of pentachlorophenol by a Sphingobium sp. through hydroxylation by a flavoprotein monooxygenase (Xun and Orser 1991) , and the degradation of 4-chlorophenol by an Arthrobacter sp.", [["halophenol", "CHEMICAL", 18, 28], ["hydroquinone", "CHEMICAL", 59, 71], ["trichlorophenol", "CHEMICAL", 107, 122], ["2,6-dichlorohydroquinone", "CHEMICAL", 126, 150], ["pentachlorophenol", "CHEMICAL", 232, 249], ["4-chlorophenol", "CHEMICAL", 371, 385], ["halophenol", "CHEMICAL", 18, 28], ["hydroquinone", "CHEMICAL", 59, 71], ["trichlorophenol", "CHEMICAL", 107, 122], ["2,6-dichlorohydroquinone", "CHEMICAL", 126, 150], ["pentachlorophenol", "CHEMICAL", 232, 249], ["4-chlorophenol", "CHEMICAL", 371, 385], ["halophenol", "SIMPLE_CHEMICAL", 18, 28], ["hydroquinone derivatives", "SIMPLE_CHEMICAL", 59, 83], ["trichlorophenol", "SIMPLE_CHEMICAL", 107, 122], ["2,6-dichlorohydroquinone", "SIMPLE_CHEMICAL", 126, 150], ["Pseudomonas pickettii", "ORGANISM", 166, 187], ["pentachlorophenol", "SIMPLE_CHEMICAL", 232, 249], ["Sphingobium sp", "ORGANISM", 255, 269], ["flavoprotein monooxygenase", "GENE_OR_GENE_PRODUCT", 298, 324], ["4-chlorophenol", "SIMPLE_CHEMICAL", 371, 385], ["Arthrobacter sp", "ORGANISM", 392, 407], ["flavoprotein monooxygenase", "PROTEIN", 298, 324], ["Pseudomonas pickettii", "SPECIES", 166, 187], ["Pseudomonas pickettii", "SPECIES", 166, 187], ["halophenol degradation", "TREATMENT", 18, 40], ["hydroquinone derivatives", "TREATMENT", 59, 83], ["trichlorophenol", "TREATMENT", 107, 122], ["dichlorohydroquinone", "TREATMENT", 130, 150], ["Pseudomonas pickettii", "PROBLEM", 166, 187], ["pentachlorophenol", "TREATMENT", 232, 249], ["hydroxylation", "TREATMENT", 279, 292], ["a flavoprotein monooxygenase", "TREATMENT", 296, 324], ["chlorophenol", "TREATMENT", 373, 385], ["an Arthrobacter sp", "TREATMENT", 389, 407], ["hydroquinone derivatives", "OBSERVATION", 59, 83]]], ["(Bae et al. 1996) .DiscussionOur results further indicate that hydroquinone is not the ring fission substrate because no enzymatic activities for hydroquinone dioxygenase or hydroxymuconic semialdehyde dehydrogenase were found.", [["hydroquinone", "CHEMICAL", 63, 75], ["hydroquinone", "CHEMICAL", 146, 158], ["semialdehyde", "CHEMICAL", 189, 201], ["hydroquinone", "CHEMICAL", 63, 75], ["hydroquinone", "CHEMICAL", 146, 158], ["hydroxymuconic semialdehyde", "CHEMICAL", 174, 201], ["hydroquinone", "SIMPLE_CHEMICAL", 63, 75], ["hydroquinone dioxygenase", "SIMPLE_CHEMICAL", 146, 170], ["hydroxymuconic semialdehyde dehydrogenase", "GENE_OR_GENE_PRODUCT", 174, 215], ["hydroquinone dioxygenase", "PROTEIN", 146, 170], ["hydroxymuconic semialdehyde dehydrogenase", "PROTEIN", 174, 215], ["hydroquinone", "TREATMENT", 63, 75], ["enzymatic activities", "PROBLEM", 121, 141], ["hydroquinone dioxygenase", "PROBLEM", 146, 170], ["hydroxymuconic semialdehyde dehydrogenase", "PROBLEM", 174, 215]]], ["Instead, upon conversion of hydroquinone by strain IF1, we observed the formation of a transient metabolite that was identified as hydroxyquinol, indicating that a second hydroxylation takes place before ring fission.", [["hydroquinone", "CHEMICAL", 28, 40], ["hydroxyquinol", "CHEMICAL", 131, 144], ["hydroquinone", "CHEMICAL", 28, 40], ["hydroxyquinol", "CHEMICAL", 131, 144], ["hydroquinone", "SIMPLE_CHEMICAL", 28, 40], ["IF1", "GENE_OR_GENE_PRODUCT", 51, 54], ["hydroxyquinol", "SIMPLE_CHEMICAL", 131, 144], ["IF1", "PROTEIN", 51, 54], ["hydroquinone", "TREATMENT", 28, 40], ["a transient metabolite", "PROBLEM", 85, 107], ["hydroxyquinol", "TREATMENT", 131, 144], ["a second hydroxylation", "TREATMENT", 162, 184]]], ["The production of hydroxyquinol could be due to the action of a separate hydroquinone monooxygenase, or it could be caused by a second hydroxylation step by the 4-FP monooxygenase.", [["hydroxyquinol", "CHEMICAL", 18, 31], ["hydroquinone", "CHEMICAL", 73, 85], ["4-FP", "CHEMICAL", 161, 165], ["hydroxyquinol", "CHEMICAL", 18, 31], ["hydroquinone", "CHEMICAL", 73, 85], ["4-FP", "CHEMICAL", 161, 165], ["hydroxyquinol", "SIMPLE_CHEMICAL", 18, 31], ["hydroquinone monooxygenase", "GENE_OR_GENE_PRODUCT", 73, 99], ["4-FP monooxygenase", "GENE_OR_GENE_PRODUCT", 161, 179], ["hydroquinone monooxygenase", "PROTEIN", 73, 99], ["4-FP monooxygenase", "PROTEIN", 161, 179], ["hydroxyquinol", "TREATMENT", 18, 31], ["a separate hydroquinone monooxygenase", "TREATMENT", 62, 99], ["a second hydroxylation step", "TREATMENT", 126, 153], ["the 4-FP monooxygenase", "TREATMENT", 157, 179]]], ["Conversion of hydroquinone to hydroxyquinol before ring fission was also suggested for strains Arthrobacter that degrade 4-nitrophenol (Perry and Zylstra 2007) and 4-chlorophenol (Nordin et al. 2005) .", [["hydroquinone", "CHEMICAL", 14, 26], ["hydroxyquinol", "CHEMICAL", 30, 43], ["4-nitrophenol", "CHEMICAL", 121, 134], ["4-chlorophenol", "CHEMICAL", 164, 178], ["hydroquinone", "CHEMICAL", 14, 26], ["hydroxyquinol", "CHEMICAL", 30, 43], ["4-nitrophenol", "CHEMICAL", 121, 134], ["Zylstra 2007", "CHEMICAL", 146, 158], ["4-chlorophenol", "CHEMICAL", 164, 178], ["hydroquinone", "SIMPLE_CHEMICAL", 14, 26], ["hydroxyquinol", "SIMPLE_CHEMICAL", 30, 43], ["4-nitrophenol", "SIMPLE_CHEMICAL", 121, 134], ["Perry", "SIMPLE_CHEMICAL", 136, 141], ["Zylstra", "SIMPLE_CHEMICAL", 146, 153], ["4-chlorophenol", "SIMPLE_CHEMICAL", 164, 178], ["hydroquinone", "TREATMENT", 14, 26], ["hydroxyquinol", "TREATMENT", 30, 43], ["ring fission", "TREATMENT", 51, 63], ["strains Arthrobacter", "PROBLEM", 87, 107], ["chlorophenol", "TREATMENT", 166, 178]]], ["Ring fission of hydroxyquinol would produce maleylacetate, which we did not detect as an intermediate in 4-FP degradation, but a transient metabolite was found with mass properties identical to those of 3oxoadipate, which is expected to be the next intermediate in hydroxyquinol degradation.DiscussionMost cometabolic transformations of fluorophenols described in the literature involve the initial action of a phenol hydroxylase that results in the formation of fluorocatechols, which are subsequently transformed into fluoromuconates through a catechol 1,2-dioxygenase.", [["hydroxyquinol", "CHEMICAL", 16, 29], ["maleylacetate", "CHEMICAL", 44, 57], ["4-FP", "CHEMICAL", 105, 109], ["3oxoadipate", "CHEMICAL", 203, 214], ["hydroxyquinol", "CHEMICAL", 265, 278], ["fluorophenols", "CHEMICAL", 337, 350], ["phenol", "CHEMICAL", 411, 417], ["fluorocatechols", "CHEMICAL", 463, 478], ["fluoromuconates", "CHEMICAL", 520, 535], ["catechol", "CHEMICAL", 546, 554], ["hydroxyquinol", "CHEMICAL", 16, 29], ["maleylacetate", "CHEMICAL", 44, 57], ["4-FP", "CHEMICAL", 105, 109], ["3oxoadipate", "CHEMICAL", 203, 214], ["hydroxyquinol", "CHEMICAL", 265, 278], ["fluorophenols", "CHEMICAL", 337, 350], ["phenol", "CHEMICAL", 411, 417], ["fluorocatechols", "CHEMICAL", 463, 478], ["fluoromuconates", "CHEMICAL", 520, 535], ["catechol", "CHEMICAL", 546, 554], ["hydroxyquinol", "SIMPLE_CHEMICAL", 16, 29], ["maleylacetate", "SIMPLE_CHEMICAL", 44, 57], ["4-FP", "SIMPLE_CHEMICAL", 105, 109], ["3oxoadipate", "SIMPLE_CHEMICAL", 203, 214], ["hydroxyquinol", "SIMPLE_CHEMICAL", 265, 278], ["fluorophenols", "SIMPLE_CHEMICAL", 337, 350], ["phenol hydroxylase", "GENE_OR_GENE_PRODUCT", 411, 429], ["fluorocatechols", "SIMPLE_CHEMICAL", 463, 478], ["fluoromuconates", "SIMPLE_CHEMICAL", 520, 535], ["catechol 1,2-dioxygenase", "SIMPLE_CHEMICAL", 546, 570], ["phenol hydroxylase", "PROTEIN", 411, 429], ["catechol 1,2-dioxygenase", "PROTEIN", 546, 570], ["hydroxyquinol", "TREATMENT", 16, 29], ["a transient metabolite", "PROBLEM", 127, 149], ["mass properties", "PROBLEM", 165, 180], ["fluorophenols", "TREATMENT", 337, 350], ["a phenol hydroxylase", "TREATMENT", 409, 429], ["the formation of fluorocatechols", "PROBLEM", 446, 478], ["a catechol", "TREATMENT", 544, 554], ["intermediate", "OBSERVATION_MODIFIER", 89, 101], ["mass", "OBSERVATION", 165, 169]]], ["The conversion usually proceeds with lactonization and elimination of fluoride (Boersma et al. 2001; Bondar et al. 1999; Finkelstein et al. 2000; Boersma et al. 1998; Bondar et al. 1998 ).", [["fluoride", "CHEMICAL", 70, 78], ["fluoride", "CHEMICAL", 70, 78], ["fluoride", "SIMPLE_CHEMICAL", 70, 78], ["lactonization", "TREATMENT", 37, 50], ["fluoride", "TREATMENT", 70, 78]]], ["Our results suggest that Arthrobacter strain IF1, which grows on 4-FP, possesses a new pathway for the degradation of 4-FP that involves immediate defluorination by a monooxygenase.", [["4-FP", "CHEMICAL", 65, 69], ["4-FP", "CHEMICAL", 118, 122], ["4-FP", "CHEMICAL", 65, 69], ["4-FP", "CHEMICAL", 118, 122], ["Arthrobacter strain", "ORGANISM", 25, 44], ["IF1", "GENE_OR_GENE_PRODUCT", 45, 48], ["4-FP", "SIMPLE_CHEMICAL", 65, 69], ["4-FP", "SIMPLE_CHEMICAL", 118, 122], ["IF1", "PROTEIN", 45, 48], ["monooxygenase", "PROTEIN", 167, 180], ["Arthrobacter strain IF1", "PROBLEM", 25, 48], ["a monooxygenase", "TREATMENT", 165, 180], ["Arthrobacter strain", "OBSERVATION", 25, 44]]], ["Strain IF1 avoids the accumulation of possible toxic metabolites such as 3-or 4-fluorocatechol by this initial dehalogenation.", [["3-or 4-fluorocatechol", "CHEMICAL", 73, 94], ["3-or 4-fluorocatechol", "CHEMICAL", 73, 94], ["IF1", "GENE_OR_GENE_PRODUCT", 7, 10], ["3-or 4-fluorocatechol", "SIMPLE_CHEMICAL", 73, 94], ["IF1", "PROTEIN", 7, 10], ["Strain IF1", "PROBLEM", 0, 10], ["toxic metabolites", "PROBLEM", 47, 64], ["this initial dehalogenation", "TREATMENT", 98, 125], ["possible", "UNCERTAINTY", 38, 46], ["toxic", "OBSERVATION_MODIFIER", 47, 52]]]], "807cc20de41c4d6fb5c6fcf5296e58135ba94a6b": [["binding energy score between RBD and ACE2, we highlighted the putative jump in the affinity from a progenitor form of SARS-CoV-2 to the current virus responsible for COVID-19 outbreak.", [["progenitor", "ANATOMY", 99, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["SARS-CoV-2", "ORGANISM", 118, 128], ["RBD", "PROTEIN", 29, 32], ["ACE2", "PROTEIN", 37, 41], ["SARS-CoV", "SPECIES", 118, 126], ["binding energy score", "TEST", 0, 20], ["ACE2", "TEST", 37, 41], ["SARS", "PROBLEM", 118, 122], ["CoV", "TEST", 123, 126], ["COVID", "TEST", 166, 171]]], ["Our result was consistent with previously reported phylogenetic analysis and corroborates the opinion that the interface segment of the spike protein RBD might be acquired by SARS-CoV-2 via a complex evolutionary process rather than a progressive accumulation of mutations.", [["RBD", "GENE_OR_GENE_PRODUCT", 150, 153], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 175, 185], ["spike protein", "PROTEIN", 136, 149], ["RBD", "PROTEIN", 150, 153], ["SARS-CoV", "SPECIES", 175, 183], ["phylogenetic analysis", "TEST", 51, 72], ["the spike protein RBD", "PROBLEM", 132, 153], ["SARS", "PROBLEM", 175, 179], ["CoV", "TEST", 180, 183], ["a complex evolutionary process", "PROBLEM", 190, 220], ["a progressive accumulation of mutations", "PROBLEM", 233, 272], ["consistent with", "UNCERTAINTY", 15, 30], ["progressive", "OBSERVATION_MODIFIER", 235, 246], ["accumulation of mutations", "OBSERVATION", 247, 272]]], ["We also highlighted the relevance of Q493 and P499 amino acid residues of SARS-CoV-2 RBD for binding to human ACE2 and maintaining the stability of the interface.", [["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 51, 61], ["Q493", "GENE_OR_GENE_PRODUCT", 37, 41], ["P499", "SIMPLE_CHEMICAL", 46, 50], ["amino acid", "AMINO_ACID", 51, 61], ["human", "ORGANISM", 104, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["Q493", "PROTEIN", 37, 41], ["SARS-CoV-2 RBD", "PROTEIN", 74, 88], ["human ACE2", "PROTEIN", 104, 114], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["amino acid residues", "TEST", 51, 70], ["SARS", "PROBLEM", 74, 78], ["CoV", "TEST", 79, 82], ["RBD", "PROBLEM", 85, 88], ["human ACE2", "TEST", 104, 114], ["stability", "OBSERVATION_MODIFIER", 135, 144]]], ["Moreover, we show from the structural analysis that it is unlikely for the interface residues to be the result of genetic engineering.", [["the structural analysis", "TEST", 23, 46], ["the interface residues", "PROBLEM", 71, 93], ["unlikely for", "UNCERTAINTY", 58, 70]]], ["Finally, we studied the impact of eight different variants located at the interaction surface of ACE2, on the complex formation with SARS-CoV-2 RBD.", [["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["ACE2", "PROTEIN", 97, 101], ["SARS-CoV-2 RBD", "PROTEIN", 133, 147], ["SARS-CoV", "SPECIES", 133, 141], ["SARS", "PROBLEM", 133, 137], ["surface", "OBSERVATION_MODIFIER", 86, 93]]], ["We found that none of them is likely to disrupt the interaction with the viral RBD of SARS-CoV-2.", [["SARS", "DISEASE", 86, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["viral RBD", "PROTEIN", 73, 82], ["SARS-CoV", "SPECIES", 86, 94], ["the viral RBD of SARS", "PROBLEM", 69, 90], ["CoV", "TEST", 91, 94], ["viral RBD", "OBSERVATION", 73, 82]]]], "PMC7487083": [["Study sponsors had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.Ethical ApprovalApproval was not required.Conflicts of interestAll authors report no potential conflicts.Uncited references", [["the study", "TEST", 30, 39], ["interpretation of data", "TEST", 80, 102], ["Ethical ApprovalApproval", "TREATMENT", 199, 223], ["no potential", "UNCERTAINTY", 281, 293], ["conflicts", "OBSERVATION", 294, 303]]]], "PMC7522694": [["FundingNo funding sources.Competing interestsNone declared.Ethical approvalNot required.", [["Ethical approval", "TREATMENT", 59, 75], ["No", "UNCERTAINTY", 7, 9], ["funding sources", "OBSERVATION", 10, 25]]]], "PMC7267360": [["Therefore, it was taught using superficial or simple memorization approaches, for the unique purpose of passing the exam (Dawson, Bruce, Heys, & Stewart, 2009).", [["the exam", "TEST", 112, 120]]]], "9c979ed4fc62f7aeb5f532f226cc42fc7ac55a35": [["The coronavirus disease-COVID-pandemic has heightened the awareness of aerosol generation by human expiratory events and their potential role in viral respiratory disease transmission Concerns over high severe acute respiratory syndrome-coronavirus-SARS-CoV-viral burden of mucosal surfaces has raised questions about the aerosol-generating potential and dangers of many otorhinolaryngologic procedures However the risks of aerosol generation and associated viral transmission by droplet or airborne routes for many otorhinolaryngology procedures are largely unknown Indoor aerosol and droplet viral respiratory transmission risk is influenced by factors aerosol or droplet properties indoor airflow virus-specific factors and host-specific factors Herein we elaborate on known aerosol vs droplet properties indoor airflow and aerosol-generating events to provide context for risks of aerosol infectious transmission We also provide simple but typically effective measures for mitigating the spread and inhalation of viral aerosols in indoor settings Understanding principles of infectious transmission aerosol and droplet generation as well as concepts of indoor airflow will assist in the integration of new data on SARS-CoV-transmission and activities that can generate aerosol to best inform on the need for escala-Many otorhinolaryngology procedures involve instrumentation of respiratory mucosal surfaces and proximity to a patient's airway for a period ranging from minutes to hours, and there has been concern that many of these procedures may be aerosol-generating procedures (AGPs) that increase the risk of contracting COVID-19 due to inhalation of airborne droplets or aerosols.", [["respiratory", "ANATOMY", 151, 162], ["mucosal", "ANATOMY", 274, 281], ["respiratory mucosal", "ANATOMY", 1382, 1401], ["airway", "ANATOMY", 1440, 1446], ["coronavirus disease-COVID-pandemic", "DISEASE", 4, 38], ["viral respiratory disease", "DISEASE", 145, 170], ["acute respiratory syndrome", "DISEASE", 210, 236], ["SARS", "DISEASE", 249, 253], ["SARS", "DISEASE", 1218, 1222], ["COVID-19", "CHEMICAL", 1630, 1638], ["COVID-19", "CHEMICAL", 1630, 1638], ["coronavirus", "ORGANISM", 4, 15], ["human", "ORGANISM", 93, 98], ["SARS-CoV", "ORGANISM", 249, 257], ["mucosal surfaces", "PATHOLOGICAL_FORMATION", 274, 290], ["CoV", "ORGANISM", 1223, 1226], ["patient", "ORGANISM", 1430, 1437], ["airway", "MULTI-TISSUE_STRUCTURE", 1440, 1446], ["coronavirus", "SPECIES", 4, 15], ["human", "SPECIES", 93, 98], ["-coronavirus-SARS-CoV-viral", "SPECIES", 236, 263], ["patient", "SPECIES", 1430, 1437], ["human", "SPECIES", 93, 98], ["SARS-CoV", "SPECIES", 1218, 1226], ["The coronavirus disease", "PROBLEM", 0, 23], ["pandemic", "PROBLEM", 30, 38], ["aerosol generation", "TREATMENT", 71, 89], ["human expiratory events", "PROBLEM", 93, 116], ["viral respiratory disease transmission", "PROBLEM", 145, 183], ["high severe acute respiratory syndrome", "PROBLEM", 198, 236], ["coronavirus", "PROBLEM", 237, 248], ["SARS", "PROBLEM", 249, 253], ["CoV", "PROBLEM", 254, 257], ["viral burden of mucosal surfaces", "PROBLEM", 258, 290], ["the aerosol", "TREATMENT", 318, 329], ["many otorhinolaryngologic procedures", "TREATMENT", 366, 402], ["aerosol generation", "TREATMENT", 424, 442], ["many otorhinolaryngology procedures", "TREATMENT", 511, 546], ["Indoor aerosol", "TREATMENT", 567, 581], ["droplet viral respiratory transmission risk", "TREATMENT", 586, 629], ["airflow virus", "PROBLEM", 692, 705], ["known aerosol vs droplet properties", "TREATMENT", 772, 807], ["aerosol", "TREATMENT", 827, 834], ["aerosol infectious transmission", "TREATMENT", 885, 916], ["viral aerosols", "TREATMENT", 1017, 1031], ["infectious transmission aerosol", "TREATMENT", 1079, 1110], ["droplet generation", "TREATMENT", 1115, 1133], ["escala", "TREATMENT", 1312, 1318], ["Many otorhinolaryngology procedures", "TREATMENT", 1319, 1354], ["instrumentation", "TREATMENT", 1363, 1378], ["respiratory mucosal surfaces", "PROBLEM", 1382, 1410], ["these procedures", "TREATMENT", 1531, 1547], ["procedures (AGPs", "TREATMENT", 1574, 1590], ["contracting COVID", "PROBLEM", 1618, 1635], ["airborne droplets", "TREATMENT", 1660, 1677], ["coronavirus disease", "OBSERVATION", 4, 23], ["respiratory disease", "OBSERVATION", 151, 170], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["respiratory syndrome", "OBSERVATION", 216, 236], ["respiratory mucosal", "ANATOMY", 1382, 1401], ["airway", "ANATOMY", 1440, 1446], ["airborne droplets", "OBSERVATION", 1660, 1677]]], ["[5] [6] [7] [8] [9] The lack of studies within the otorhinolaryngology field assessing the aerosol-generating potential of procedures involving mucosal surfaces pre-COVID-19 made it challenging to understand in an evidence-based fashion the potential risks of SARS-CoV-2 transmission associated with instrumentation of the upper airway; that is, whether these procedures may be infectious AGPs.", [["mucosal", "ANATOMY", 144, 151], ["upper airway", "ANATOMY", 323, 335], ["SARS", "DISEASE", 260, 264], ["[5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 19], ["mucosal", "PATHOLOGICAL_FORMATION", 144, 151], ["SARS-CoV-2", "ORGANISM", 260, 270], ["upper airway", "ORGANISM_SUBDIVISION", 323, 335], ["AGPs", "GENE_OR_GENE_PRODUCT", 389, 393], ["the otorhinolaryngology field", "TEST", 47, 76], ["the aerosol", "TREATMENT", 87, 98], ["mucosal surfaces pre-COVID", "TREATMENT", 144, 170], ["SARS", "PROBLEM", 260, 264], ["instrumentation of the upper airway", "PROBLEM", 300, 335], ["infectious AGPs", "PROBLEM", 378, 393], ["upper", "ANATOMY_MODIFIER", 323, 328], ["airway", "ANATOMY", 329, 335], ["may be", "UNCERTAINTY", 371, 377], ["infectious", "OBSERVATION", 378, 388]]], ["At the early stages of the pandemic, based on the risks of exposure to high viral load mucosal surfaces, 10, 11 as well as on the lack of any immunity to SARS-CoV-2 and of any vaccines or effective treatments, an array of practice changes to protect health-care workers and patients were recommended and instituted for otorhinolaryngology procedures involving upper airway mucosal surfaces.", [["mucosal", "ANATOMY", 87, 94], ["upper airway mucosal", "ANATOMY", 360, 380], ["SARS", "DISEASE", 154, 158], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 87, 103], ["SARS-CoV-2", "ORGANISM", 154, 164], ["patients", "ORGANISM", 274, 282], ["upper airway mucosal", "MULTI-TISSUE_STRUCTURE", 360, 380], ["patients", "SPECIES", 274, 282], ["SARS-CoV", "SPECIES", 154, 162], ["high viral load mucosal surfaces", "PROBLEM", 71, 103], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["any vaccines", "TREATMENT", 172, 184], ["effective treatments", "TREATMENT", 188, 208], ["practice changes", "TREATMENT", 222, 238], ["otorhinolaryngology procedures", "TREATMENT", 319, 349], ["upper airway mucosal surfaces", "PROBLEM", 360, 389], ["early stages", "OBSERVATION_MODIFIER", 7, 19], ["upper", "ANATOMY_MODIFIER", 360, 365], ["airway", "ANATOMY", 366, 372], ["mucosal surfaces", "OBSERVATION", 373, 389]]], ["9, [12] [13] [14] [15] [16] [17] Respiratory disease transmission can occur through contact (touching a contaminated surface followed by self-inoculation of the eyes, nose, or mouth), droplet FIGURE 1.", [["surface", "ANATOMY", 117, 124], ["eyes", "ANATOMY", 161, 165], ["nose", "ANATOMY", 167, 171], ["mouth", "ANATOMY", 176, 181], ["9, [12] [13] [14] [15] [16] [17", "CHEMICAL", 0, 31], ["[12] [13] [14] [15] [16] [17] Respiratory", "SIMPLE_CHEMICAL", 3, 44], ["eyes", "ORGAN", 161, 165], ["nose", "ORGANISM_SUBDIVISION", 167, 171], ["mouth", "ORGANISM_SUBDIVISION", 176, 181], ["Respiratory disease transmission", "PROBLEM", 33, 65], ["a contaminated surface", "TREATMENT", 102, 124], ["eyes", "ANATOMY", 161, 165], ["nose", "ANATOMY", 167, 171], ["mouth", "ANATOMY", 176, 181]]], ["Three possible mechanisms of respiratory pathogen transmission.", [["respiratory pathogen transmission", "DISEASE", 29, 62], ["respiratory pathogen transmission", "PROBLEM", 29, 62], ["possible mechanisms of", "UNCERTAINTY", 6, 28], ["respiratory pathogen", "OBSERVATION", 29, 49]]], ["Transmission can occur through self-inoculation after contact with droplets that settle on surfaces, direct deposition/inspiration of infectious droplets in the mouth or nose and deposition on the eyes, as well as through airborne transmission with inhalation of aerosols.", [["mouth", "ANATOMY", 161, 166], ["nose", "ANATOMY", 170, 174], ["eyes", "ANATOMY", 197, 201], ["mouth", "ORGANISM_SUBDIVISION", 161, 166], ["nose", "ORGANISM_SUBDIVISION", 170, 174], ["eyes", "ORGAN", 197, 201], ["droplets", "TREATMENT", 67, 75], ["direct deposition/inspiration", "TREATMENT", 101, 130], ["infectious droplets", "PROBLEM", 134, 153], ["inhalation of aerosols", "TREATMENT", 249, 271], ["infectious droplets", "OBSERVATION", 134, 153], ["mouth", "ANATOMY", 161, 166], ["nose", "ANATOMY", 170, 174], ["eyes", "ANATOMY", 197, 201]]], ["Short range (<2 to 3 meters) aerosol transmission can be difficult to separate from droplet transmission and long-range transmission for viral respiratory pathogens, including influenza and coronaviruses, remains controversial.", [["viral respiratory pathogens", "DISEASE", 137, 164], ["influenza and coronaviruses", "DISEASE", 176, 203], ["droplet transmission", "TEST", 84, 104], ["long-range transmission", "TREATMENT", 109, 132], ["viral respiratory pathogens", "PROBLEM", 137, 164], ["influenza", "PROBLEM", 176, 185], ["coronaviruses", "PROBLEM", 190, 203], ["respiratory pathogens", "OBSERVATION", 143, 164]]]], "f7a11e5baa5e088b65978fc74acb291553b0f57c": [["the gastrointestinal tract, bronchial muscle, and blood vessels and block histamine-induced increases in capillary permeability (Gilman et al., 1985) .", [["gastrointestinal tract", "ANATOMY", 4, 26], ["bronchial muscle", "ANATOMY", 28, 44], ["blood vessels", "ANATOMY", 50, 63], ["capillary", "ANATOMY", 105, 114], ["histamine", "CHEMICAL", 74, 83], ["histamine", "CHEMICAL", 74, 83], ["gastrointestinal tract", "PATHOLOGICAL_FORMATION", 4, 26], ["bronchial muscle", "TISSUE", 28, 44], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 50, 63], ["histamine", "SIMPLE_CHEMICAL", 74, 83], ["capillary", "TISSUE", 105, 114], ["block histamine", "TREATMENT", 68, 83], ["capillary permeability", "PROBLEM", 105, 127], ["gastrointestinal tract", "ANATOMY", 4, 26], ["bronchial muscle", "ANATOMY", 28, 44], ["blood vessels", "ANATOMY", 50, 63], ["increases", "OBSERVATION_MODIFIER", 92, 101], ["capillary permeability", "OBSERVATION", 105, 127]]], ["They are used in allergic disorders to relieve symptoms of histamine release.", [["allergic disorders", "DISEASE", 17, 35], ["histamine", "CHEMICAL", 59, 68], ["histamine", "CHEMICAL", 59, 68], ["histamine", "SIMPLE_CHEMICAL", 59, 68], ["allergic disorders", "PROBLEM", 17, 35], ["symptoms", "PROBLEM", 47, 55], ["histamine release", "TREATMENT", 59, 76]]], ["The hydrochloride form of triprolidine is used in drugs, and annual usage in the United States is estimated to be over 2 million tablets.", [["hydrochloride", "CHEMICAL", 4, 17], ["triprolidine", "CHEMICAL", 26, 38], ["hydrochloride", "CHEMICAL", 4, 17], ["triprolidine", "CHEMICAL", 26, 38], ["hydrochloride", "SIMPLE_CHEMICAL", 4, 17], ["triprolidine", "SIMPLE_CHEMICAL", 26, 38], ["The hydrochloride", "TREATMENT", 0, 17], ["triprolidine", "TREATMENT", 26, 38], ["drugs", "TREATMENT", 50, 55]]], ["Usual oral doses, given 3 or 4 times daily, are 2.5 mg for adults, 1.25 mg for children 6 to 12 years old, and 0.3 to 0.9 mg for younger children.", [["oral", "ANATOMY", 6, 10], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["children", "ORGANISM", 79, 87], ["children", "ORGANISM", 137, 145], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 137, 145], ["Usual oral doses", "TREATMENT", 0, 16]]]], "PMC7260574": [["IntroductionIn 2019, a novel strain of coronavirus was found in humans1.", [["coronavirus", "ORGANISM", 39, 50], ["coronavirus", "SPECIES", 39, 50], ["coronavirus", "PROBLEM", 39, 50]]], ["On February 11, 2020, WHO announced a new name for the epidemic disease: Corona Virus Disease (COVID-19).", [["Corona Virus Disease", "DISEASE", 73, 93], ["Corona Virus", "ORGANISM", 73, 85], ["the epidemic disease", "PROBLEM", 51, 71], ["Corona Virus Disease", "PROBLEM", 73, 93], ["COVID", "TEST", 95, 100], ["Corona Virus", "ANATOMY", 73, 85]]], ["Meanwhile, the International Committee on Taxonomy of Viruses named the novel coronavirus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).", [["coronavirus", "DISEASE", 78, 89], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 100, 138], ["coronavirus", "ORGANISM", 78, 89], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 93, 152], ["Viruses", "TREATMENT", 54, 61], ["the novel coronavirus", "PROBLEM", 68, 89], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 93, 138], ["SARS", "TEST", 142, 146], ["CoV", "TEST", 147, 150], ["Severe", "OBSERVATION_MODIFIER", 93, 99], ["Acute", "OBSERVATION_MODIFIER", 100, 105], ["Respiratory Syndrome", "OBSERVATION", 106, 126]]], ["As of May 16th, 2020, the epidemic of COVID-19 has caused more than 4,400,000 laboratory-confirmed cases and more than 300,000 reported deaths2.IntroductionCOVID-19 is the third known zoonotic coronavirus disease3 after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).", [["COVID-19", "CHEMICAL", 38, 46], ["zoonotic coronavirus disease3", "DISEASE", 184, 213], ["Acute Respiratory Syndrome", "DISEASE", 227, 253], ["SARS", "DISEASE", 255, 259], ["Middle East Respiratory Syndrome", "DISEASE", 265, 297], ["MERS", "DISEASE", 299, 303], ["coronavirus", "ORGANISM", 193, 204], ["coronavirus", "SPECIES", 193, 204], ["COVID", "TEST", 38, 43], ["IntroductionCOVID", "TEST", 144, 161], ["the third known zoonotic coronavirus disease3", "PROBLEM", 168, 213], ["Severe Acute Respiratory Syndrome", "PROBLEM", 220, 253], ["SARS)", "PROBLEM", 255, 260], ["Middle East Respiratory Syndrome", "PROBLEM", 265, 297], ["zoonotic coronavirus disease3", "OBSERVATION", 184, 213], ["Severe", "OBSERVATION_MODIFIER", 220, 226], ["Acute", "OBSERVATION_MODIFIER", 227, 232], ["Respiratory Syndrome", "OBSERVATION", 233, 253], ["Middle", "ANATOMY_MODIFIER", 265, 271], ["Respiratory Syndrome", "OBSERVATION", 277, 297]]], ["SARS is a zoonosis caused by SARS-CoV, which has infected 8096 humans, including 774 deaths (mortality rate 9.6%), in at least 29 countries4.", [["SARS", "DISEASE", 0, 4], ["zoonosis", "DISEASE", 10, 18], ["SARS-CoV", "DISEASE", 29, 37], ["deaths", "DISEASE", 85, 91], ["SARS-CoV", "ORGANISM", 29, 37], ["humans", "ORGANISM", 63, 69], ["humans", "SPECIES", 63, 69], ["SARS-CoV", "SPECIES", 29, 37], ["humans", "SPECIES", 63, 69], ["SARS", "PROBLEM", 0, 4], ["a zoonosis", "PROBLEM", 8, 18], ["SARS", "PROBLEM", 29, 33], ["mortality rate", "TEST", 93, 107], ["zoonosis", "OBSERVATION", 10, 18]]], ["Another highly pathogenic coronavirus, MERS-CoV, has been reported in 27 countries with reported viral infection and 858 associated deaths (mortality rate 34.4%).5 Research indicates that SARS-CoV was transmitted from civet cats to humans and MERS-CoV was transmitted from dromedary camels to humans.", [["viral infection", "DISEASE", 97, 112], ["deaths", "DISEASE", 132, 138], ["SARS", "DISEASE", 188, 192], ["coronavirus", "ORGANISM", 26, 37], ["MERS-CoV", "ORGANISM", 39, 47], ["SARS-CoV", "ORGANISM", 188, 196], ["cats", "ORGANISM", 224, 228], ["humans", "ORGANISM", 232, 238], ["MERS-CoV", "ORGANISM", 243, 251], ["camels", "ORGANISM_SUBDIVISION", 283, 289], ["humans", "ORGANISM", 293, 299], ["coronavirus", "SPECIES", 26, 37], ["cats", "SPECIES", 224, 228], ["humans", "SPECIES", 232, 238], ["humans", "SPECIES", 293, 299], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 188, 196], ["humans", "SPECIES", 232, 238], ["MERS-CoV", "SPECIES", 243, 251], ["humans", "SPECIES", 293, 299], ["Another highly pathogenic coronavirus", "PROBLEM", 0, 37], ["viral infection", "PROBLEM", 97, 112], ["mortality rate", "TEST", 140, 154], ["SARS", "PROBLEM", 188, 192], ["CoV", "PROBLEM", 193, 196], ["CoV", "PROBLEM", 248, 251], ["pathogenic", "OBSERVATION_MODIFIER", 15, 25], ["coronavirus", "OBSERVATION", 26, 37], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112]]], ["However, the intermediate host of SARS-CoV-2 has not been identified6, 7, 8.IntroductionSARS-CoV-2, together with SARS-CoV and MERS-CoV, has posed significant threats to international health due to theirs high pathogenicity and infectivity.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 76, 98], ["SARS-CoV", "ORGANISM", 114, 122], ["MERS-CoV", "ORGANISM", 127, 135], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 114, 122], ["MERS-CoV", "SPECIES", 127, 135], ["IntroductionSARS", "TEST", 76, 92], ["high pathogenicity and infectivity", "PROBLEM", 205, 239], ["intermediate", "OBSERVATION_MODIFIER", 13, 25], ["host", "OBSERVATION_MODIFIER", 26, 30], ["infectivity", "OBSERVATION", 228, 239]]], ["Vaccination is an important strategy to provide protection from infectious diseases.", [["infectious diseases", "DISEASE", 64, 83], ["Vaccination", "TREATMENT", 0, 11], ["infectious diseases", "PROBLEM", 64, 83], ["infectious", "OBSERVATION", 64, 74]]], ["However, to date, no vaccine has been approved to prevent coronavirus infection, indicating the need for further development of novel and effective vaccines against coronavirus infection.IntroductionIn this review, we will illustrate vaccine design targets, review current advances and potential strategies for vaccine development based on the spike (S) protein of SARS-CoV and MERS-CoV, and focus on how to improve the efficacy of vaccines through adjuvant formulations.", [["coronavirus infection", "DISEASE", 58, 79], ["coronavirus infection", "DISEASE", 165, 186], ["coronavirus", "ORGANISM", 58, 69], ["coronavirus", "ORGANISM", 165, 176], ["SARS-CoV", "ORGANISM", 365, 373], ["MERS-CoV", "ORGANISM", 378, 386], ["spike (S) protein", "PROTEIN", 344, 361], ["coronavirus", "SPECIES", 165, 176], ["coronavirus", "SPECIES", 58, 69], ["SARS-CoV", "SPECIES", 365, 373], ["MERS-CoV", "SPECIES", 378, 386], ["vaccine", "TREATMENT", 21, 28], ["coronavirus infection", "PROBLEM", 58, 79], ["novel and effective vaccines", "TREATMENT", 128, 156], ["coronavirus infection", "PROBLEM", 165, 186], ["potential strategies", "TREATMENT", 286, 306], ["vaccine development", "TREATMENT", 311, 330], ["the spike", "TEST", 340, 349], ["SARS", "TEST", 365, 369], ["vaccines", "TREATMENT", 432, 440], ["adjuvant formulations", "TREATMENT", 449, 470], ["infection", "OBSERVATION", 70, 79]]], ["Overall, these strategies may provide useful guidance for vaccine development of SARS-CoV-2.Spike protein: a key target for coronaviruses vaccineCoronaviruses are widespread in nature.", [["SARS", "DISEASE", 81, 85], ["SARS-CoV-2", "ORGANISM", 81, 91], ["Spike", "GENE_OR_GENE_PRODUCT", 92, 97], ["coronaviruses", "ORGANISM", 124, 137], ["Spike protein", "PROTEIN", 92, 105], ["SARS-CoV", "SPECIES", 81, 89], ["vaccine", "TREATMENT", 58, 65], ["SARS", "PROBLEM", 81, 85], ["Spike protein", "PROBLEM", 92, 105], ["coronaviruses vaccineCoronaviruses", "PROBLEM", 124, 158], ["widespread", "OBSERVATION_MODIFIER", 163, 173]]], ["It can cause respiratory and intestinal infections in animals and humans.", [["respiratory", "ANATOMY", 13, 24], ["intestinal", "ANATOMY", 29, 39], ["respiratory and intestinal infections", "DISEASE", 13, 50], ["intestinal", "ORGAN", 29, 39], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["respiratory and intestinal infections in animals", "PROBLEM", 13, 61], ["intestinal", "ANATOMY", 29, 39], ["infections", "OBSERVATION", 40, 50]]], ["According to the phylogenetic relationships, coronavirus can be divided into four genera: Alpha, Beta, Gamma and Delta.", [["coronavirus", "ORGANISM", 45, 56], ["Delta", "GENE_OR_GENE_PRODUCT", 113, 118], ["Alpha, Beta, Gamma and Delta", "PROTEIN", 90, 118], ["coronavirus", "PROBLEM", 45, 56], ["Alpha, Beta", "TREATMENT", 90, 101], ["Delta", "TREATMENT", 113, 118]]], ["Alpha and beta genera can infect mammals, while gamma and delta genera are mostly avian coronaviruses9.", [["Alpha", "GENE_OR_GENE_PRODUCT", 0, 5], ["beta", "GENE_OR_GENE_PRODUCT", 10, 14], ["gamma", "GENE_OR_GENE_PRODUCT", 48, 53], ["delta genera", "ORGANISM", 58, 70], ["avian", "ORGANISM", 82, 87], ["coronaviruses9", "CANCER", 88, 102], ["Alpha and beta genera", "PROTEIN", 0, 21], ["gamma", "PROTEIN", 48, 53], ["Alpha and beta genera", "TREATMENT", 0, 21], ["beta genera", "OBSERVATION_MODIFIER", 10, 21]]], ["There are seven known coronavirus that can infect humans: 229E, OC43, NL63, HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2.", [["coronavirus", "ORGANISM", 22, 33], ["humans", "ORGANISM", 50, 56], ["229E", "GENE_OR_GENE_PRODUCT", 58, 62], ["OC43", "GENE_OR_GENE_PRODUCT", 64, 68], ["NL63", "GENE_OR_GENE_PRODUCT", 70, 74], ["HKU1", "GENE_OR_GENE_PRODUCT", 76, 80], ["SARS-CoV", "ORGANISM", 82, 90], ["MERS-CoV", "ORGANISM", 92, 100], ["SARS-CoV-2", "ORGANISM", 105, 115], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["SARS-CoV", "SPECIES", 82, 90], ["MERS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 105, 113], ["seven known coronavirus", "PROBLEM", 10, 33], ["OC43", "TEST", 64, 68], ["NL63", "TEST", 70, 74], ["HKU1", "TEST", 76, 80], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["MERS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["coronavirus", "OBSERVATION", 22, 33]]], ["The first four viruses cause only mild minor respiratory illness.", [["respiratory", "ANATOMY", 45, 56], ["respiratory illness", "DISEASE", 45, 64], ["mild minor respiratory illness", "PROBLEM", 34, 64], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["minor", "OBSERVATION_MODIFIER", 39, 44], ["respiratory illness", "OBSERVATION", 45, 64]]], ["The other three strains\u2014SARS-CoV, MERS-CoV and SARS-CoV-2\u2014are zoonotic and lead to severe respiratory syndrome10, 11, 12.Spike protein: a key target for coronaviruses vaccineCoronaviruses are the largest single positive-strand RNA viruses with a genome of 27\u201232 kb13.", [["SARS", "DISEASE", 24, 28], ["respiratory syndrome10", "DISEASE", 90, 112], ["SARS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "ORGANISM", 34, 42], ["SARS-CoV-2\u2014are", "ORGANISM", 47, 61], ["Spike", "GENE_OR_GENE_PRODUCT", 121, 126], ["coronaviruses", "ORGANISM", 153, 166], ["kb13", "GENE_OR_GENE_PRODUCT", 262, 266], ["Spike protein", "PROTEIN", 121, 134], ["27\u201232 kb13", "DNA", 256, 266], ["SARS-CoV", "SPECIES", 24, 32], ["MERS-CoV", "SPECIES", 34, 42], ["SARS-CoV-2\u2014are", "SPECIES", 47, 61], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["severe respiratory syndrome10", "PROBLEM", 83, 112], ["Spike protein", "PROBLEM", 121, 134], ["coronaviruses vaccineCoronaviruses", "PROBLEM", 153, 187], ["strand RNA viruses", "PROBLEM", 220, 238], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["respiratory", "ANATOMY", 90, 101], ["largest", "OBSERVATION_MODIFIER", 196, 203], ["strand RNA viruses", "OBSERVATION", 220, 238]]], ["The virus genome mainly encodes four structural proteins: spike (S), nucleocapsid (N), membrane (M), envelope (E) proteins.", [["membrane", "ANATOMY", 87, 95], ["spike (S)", "GENE_OR_GENE_PRODUCT", 58, 67], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 69, 85], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 101, 113], ["virus genome", "DNA", 4, 16], ["structural proteins", "PROTEIN", 37, 56], ["spike (S)", "PROTEIN", 58, 67], ["nucleocapsid (N), membrane (M), envelope (E) proteins", "PROTEIN", 69, 122], ["The virus genome", "PROBLEM", 0, 16], ["spike (S), nucleocapsid (N), membrane (M), envelope (E) proteins", "PROBLEM", 58, 122], ["virus genome", "OBSERVATION", 4, 16]]], ["S protein forms the spikes on the surface of coronaviruses and mediates adsorption and fusion of the virus and host cells.", [["surface", "ANATOMY", 34, 41], ["cells", "ANATOMY", 116, 121], ["surface", "CELLULAR_COMPONENT", 34, 41], ["host cells", "CELL", 111, 121], ["S protein", "PROTEIN", 0, 9], ["host cells", "CELL_TYPE", 111, 121], ["S protein", "TEST", 0, 9], ["the spikes", "PROBLEM", 16, 26], ["coronaviruses", "PROBLEM", 45, 58], ["mediates adsorption", "TREATMENT", 63, 82], ["fusion", "TREATMENT", 87, 93], ["the virus", "PROBLEM", 97, 106], ["spikes", "OBSERVATION_MODIFIER", 20, 26], ["host cells", "OBSERVATION", 111, 121]]], ["N protein forms a helical capsid, which locates inside the viral membrane to protect viral RNA.", [["membrane", "ANATOMY", 65, 73], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["N protein", "PROTEIN", 0, 9], ["helical capsid", "PROTEIN", 18, 32], ["viral RNA", "RNA", 85, 94], ["a helical capsid", "PROBLEM", 16, 32], ["the viral membrane", "TREATMENT", 55, 73], ["viral RNA", "PROBLEM", 85, 94], ["helical capsid", "OBSERVATION_MODIFIER", 18, 32], ["viral membrane", "OBSERVATION", 59, 73], ["viral RNA", "OBSERVATION", 85, 94]]], ["M and E proteins are important components of the viral envelope, and together mediate the assembly process of the virus14.", [["E proteins", "GENE_OR_GENE_PRODUCT", 6, 16], ["M and E proteins", "PROTEIN", 0, 16], ["the viral envelope", "PROBLEM", 45, 63], ["the virus", "PROBLEM", 110, 119], ["viral envelope", "OBSERVATION", 49, 63]]], ["Among the four structural proteins, S protein is the leading mediator of virus entry and is the main factor that determines the virulence and host range of the virus.Spike protein: a key target for coronaviruses vaccineSARS-CoV, MERS-CoV, and SARS-CoV-2 have strong human-to-human characteristics, which is attributed to the interaction between S protein and host cell surface receptors.", [["cell surface", "ANATOMY", 364, 376], ["S protein", "GENE_OR_GENE_PRODUCT", 36, 45], ["Spike", "GENE_OR_GENE_PRODUCT", 166, 171], ["coronaviruses vaccineSARS-CoV", "ORGANISM", 198, 227], ["MERS-CoV", "ORGANISM", 229, 237], ["SARS-CoV-2", "ORGANISM", 243, 253], ["human", "ORGANISM", 266, 271], ["human", "ORGANISM", 275, 280], ["S protein", "GENE_OR_GENE_PRODUCT", 345, 354], ["host cell surface receptors", "GENE_OR_GENE_PRODUCT", 359, 386], ["structural proteins", "PROTEIN", 15, 34], ["S protein", "PROTEIN", 36, 45], ["Spike protein", "PROTEIN", 166, 179], ["S protein", "PROTEIN", 345, 354], ["host cell surface receptors", "PROTEIN", 359, 386], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 275, 280], ["coronaviruses vaccineSARS-CoV", "SPECIES", 198, 227], ["MERS-CoV", "SPECIES", 229, 237], ["SARS-CoV", "SPECIES", 243, 251], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 275, 280], ["the virus", "PROBLEM", 156, 165], ["Spike protein", "TEST", 166, 179], ["coronaviruses vaccineSARS", "TEST", 198, 223], ["CoV", "TEST", 224, 227], ["MERS", "TEST", 229, 233], ["CoV", "TEST", 234, 237], ["SARS", "TEST", 243, 247], ["CoV", "TEST", 248, 251], ["host cell surface receptors", "TREATMENT", 359, 386], ["virus", "OBSERVATION", 73, 78], ["virus", "OBSERVATION", 160, 165], ["host cell", "OBSERVATION", 359, 368]]], ["SARS-CoV and SARS-CoV-2 use the angiotensin-converting enzyme 2 (ACE2) as a receptor15,16, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4; also known as CD26) as a receptor17.", [["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 32, 43], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 13, 23], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 32, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 113, 135], ["DPP4", "GENE_OR_GENE_PRODUCT", 137, 141], ["CD26", "GENE_OR_GENE_PRODUCT", 157, 161], ["receptor17", "GENE_OR_GENE_PRODUCT", 168, 178], ["angiotensin-converting enzyme 2", "PROTEIN", 32, 63], ["ACE2", "PROTEIN", 65, 69], ["MERS-CoV", "PROTEIN", 99, 107], ["dipeptidyl peptidase 4", "PROTEIN", 113, 135], ["DPP4", "PROTEIN", 137, 141], ["CD26", "PROTEIN", 157, 161], ["receptor17", "PROTEIN", 168, 178], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 13, 21], ["MERS-CoV", "SPECIES", 99, 107], ["SARS", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["the angiotensin", "TREATMENT", 28, 43], ["converting enzyme", "TEST", 44, 61], ["a receptor", "TEST", 74, 84], ["dipeptidyl peptidase 4 (DPP4", "TREATMENT", 113, 141]]], ["The distribution of receptors in humans and their affinity with S proteins determine the extent of tissue tropism and the intensity of transmission of coronavirus.", [["tissue", "ANATOMY", 99, 105], ["coronavirus", "DISEASE", 151, 162], ["humans", "ORGANISM", 33, 39], ["S proteins", "GENE_OR_GENE_PRODUCT", 64, 74], ["tissue", "TISSUE", 99, 105], ["coronavirus", "ORGANISM", 151, 162], ["S proteins", "PROTEIN", 64, 74], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["receptors in humans", "PROBLEM", 20, 39], ["S proteins", "TEST", 64, 74], ["tissue tropism", "PROBLEM", 99, 113], ["coronavirus", "PROBLEM", 151, 162], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["tissue tropism", "OBSERVATION", 99, 113]]], ["The epidemiology and biological characteristics of SARS-CoV, MERS-CoV and SARS-CoV-2 are summarized in Table 12, 3, 4, 5, 6, 7, 8,12,15, 16, 17.Spike protein: a key target for coronaviruses vaccineS protein is a large type I transmembrane glycoprotein whose trimers constitute the spike structure on the surface of the virus.", [["surface", "ANATOMY", 304, 311], ["SARS", "DISEASE", 51, 55], ["SARS-CoV", "ORGANISM", 51, 59], ["MERS-CoV", "ORGANISM", 61, 69], ["SARS-CoV-2", "ORGANISM", 74, 84], ["Spike", "GENE_OR_GENE_PRODUCT", 144, 149], ["surface", "CELLULAR_COMPONENT", 304, 311], ["Table 12, 3, 4, 5, 6, 7, 8,12,15, 16, 17", "DNA", 103, 143], ["Spike protein", "PROTEIN", 144, 157], ["coronaviruses vaccineS protein", "PROTEIN", 176, 206], ["type I transmembrane glycoprotein", "PROTEIN", 218, 251], ["trimers", "PROTEIN", 258, 265], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 74, 82], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["MERS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82], ["Spike protein", "PROBLEM", 144, 157], ["coronaviruses vaccineS protein", "PROBLEM", 176, 206], ["a large type I transmembrane glycoprotein whose trimers", "TREATMENT", 210, 265], ["the spike structure", "PROBLEM", 277, 296], ["the virus", "PROBLEM", 315, 324], ["large", "OBSERVATION_MODIFIER", 212, 217], ["virus", "OBSERVATION", 319, 324]]], ["The S protein (Fig. 1B) can be divided into two functional subunits: an N-terminal S1 domain contains signal peptide and receptor binding domain (RBD), and a C-terminal S2 domain contains fusion peptide and two heptapeptide repeats (HR1 and HR2) to facilitate viral fusion.", [["N", "CHEMICAL", 72, 73], ["C", "CHEMICAL", 158, 159], ["S protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 15, 22], ["HR2", "GENE_OR_GENE_PRODUCT", 241, 244], ["S protein", "PROTEIN", 4, 13], ["1B", "PROTEIN", 20, 22], ["N-terminal S1 domain", "PROTEIN", 72, 92], ["receptor binding domain", "PROTEIN", 121, 144], ["RBD", "PROTEIN", 146, 149], ["C-terminal S2 domain", "PROTEIN", 158, 178], ["heptapeptide repeats", "PROTEIN", 211, 231], ["HR1", "PROTEIN", 233, 236], ["HR2", "PROTEIN", 241, 244], ["The S protein (Fig", "TREATMENT", 0, 18], ["an N-terminal S1 domain", "TREATMENT", 69, 92], ["signal peptide", "TREATMENT", 102, 116], ["receptor binding domain (RBD)", "PROBLEM", 121, 150], ["a C-terminal S2 domain", "TREATMENT", 156, 178], ["fusion peptide", "TREATMENT", 188, 202], ["two heptapeptide repeats (HR1 and HR2", "TREATMENT", 207, 244], ["viral fusion", "TREATMENT", 260, 272], ["terminal", "ANATOMY_MODIFIER", 160, 168], ["S2", "ANATOMY", 169, 171], ["fusion peptide", "OBSERVATION", 188, 202], ["viral fusion", "OBSERVATION", 260, 272]]], ["RBD mediates the binding of virus and cell receptor, which then triggers a conformational change of the S protein, exposing HR1 and HR2 to form a 6-helix bundle fusion core structure, further leading to membrane fusion and viral RNA release18, 19, 20, 21.", [["cell", "ANATOMY", 38, 42], ["membrane", "ANATOMY", 203, 211], ["RBD", "DISEASE", 0, 3], ["RBD", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 38, 42], ["HR1", "GENE_OR_GENE_PRODUCT", 124, 127], ["HR2", "GENE_OR_GENE_PRODUCT", 132, 135], ["membrane", "CELLULAR_COMPONENT", 203, 211], ["RBD", "PROTEIN", 0, 3], ["virus and cell receptor", "PROTEIN", 28, 51], ["S protein", "PROTEIN", 104, 113], ["HR1", "PROTEIN", 124, 127], ["HR2", "PROTEIN", 132, 135], ["6-helix bundle fusion core structure", "PROTEIN", 146, 182], ["viral RNA", "RNA", 223, 232], ["the binding of virus and cell receptor", "PROBLEM", 13, 51], ["the S protein", "TEST", 100, 113], ["a 6-helix bundle fusion core structure", "TREATMENT", 144, 182], ["membrane fusion", "TREATMENT", 203, 218], ["viral RNA", "TEST", 223, 232], ["virus", "OBSERVATION", 28, 33], ["membrane fusion", "OBSERVATION", 203, 218], ["viral RNA", "OBSERVATION", 223, 232]]], ["Furthermore, S protein carries B-cell epitopes, which induces the body to produce neutralizing antibody and provides immune protection22.", [["B-cell", "ANATOMY", 31, 37], ["body", "ANATOMY", 66, 70], ["B-cell", "CELL", 31, 37], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["S protein", "PROTEIN", 13, 22], ["B-cell epitopes", "PROTEIN", 31, 46], ["neutralizing antibody", "PROTEIN", 82, 103], ["B-cell epitopes", "PROBLEM", 31, 46], ["neutralizing antibody", "PROBLEM", 82, 103], ["immune protection22", "TREATMENT", 117, 136], ["cell epitopes", "OBSERVATION", 33, 46], ["neutralizing antibody", "OBSERVATION", 82, 103]]], ["Because the S protein is involved in viral infection and is responsible for inducing host immune response and virus-neutralizing antibodies, it has been considered a key target for vaccine design.Spike protein: a key target for coronaviruses vaccineAntigen-specific targets of S protein include full-length S protein, S1 subunits, RBD and S2 subunits.", [["viral infection", "DISEASE", 37, 52], ["Spike", "GENE_OR_GENE_PRODUCT", 196, 201], ["coronaviruses", "ORGANISM", 228, 241], ["S protein", "GENE_OR_GENE_PRODUCT", 277, 286], ["S protein", "GENE_OR_GENE_PRODUCT", 307, 316], ["S1", "GENE_OR_GENE_PRODUCT", 318, 320], ["RBD", "GENE_OR_GENE_PRODUCT", 331, 334], ["S2", "GENE_OR_GENE_PRODUCT", 339, 341], ["S protein", "PROTEIN", 12, 21], ["neutralizing antibodies", "PROTEIN", 116, 139], ["Spike protein", "PROTEIN", 196, 209], ["S protein", "PROTEIN", 277, 286], ["full-length S protein", "PROTEIN", 295, 316], ["S1 subunits", "PROTEIN", 318, 329], ["RBD", "PROTEIN", 331, 334], ["S2 subunits", "PROTEIN", 339, 350], ["the S protein", "TEST", 8, 21], ["viral infection", "PROBLEM", 37, 52], ["virus", "PROBLEM", 110, 115], ["neutralizing antibodies", "PROBLEM", 116, 139], ["vaccine design", "TREATMENT", 181, 195], ["Spike protein", "PROBLEM", 196, 209], ["coronaviruses vaccine", "TREATMENT", 228, 249], ["Antigen", "TEST", 249, 256], ["S protein", "TEST", 277, 286], ["length S protein", "TEST", 300, 316], ["S1 subunits", "TEST", 318, 329], ["viral infection", "OBSERVATION", 37, 52], ["responsible for", "UNCERTAINTY", 60, 75]]], ["Viral vector vaccines encoding full-length S protein or S1 subunits have been demonstrated to induce high levels of neutralizing antibodies in various animal models23,24.", [["full-length S protein", "GENE_OR_GENE_PRODUCT", 31, 52], ["S1", "GENE_OR_GENE_PRODUCT", 56, 58], ["full-length S protein", "PROTEIN", 31, 52], ["S1 subunits", "PROTEIN", 56, 67], ["neutralizing antibodies", "PROTEIN", 116, 139], ["Viral vector vaccines", "TREATMENT", 0, 21], ["S1 subunits", "TREATMENT", 56, 67], ["neutralizing antibodies", "TEST", 116, 139], ["neutralizing antibodies", "OBSERVATION", 116, 139]]], ["However, some non-neutralizing epitopes on full-length S protein or S1 subunits may compete with neutralizing epitopes, leading to several safety concerns, including inflammatory and immunopathological effects such as pulmonary eosinophilic infiltration and antibody-dependent enhancement (ADE) following subsequent viral challenge of vaccinated animals22,25,26.", [["pulmonary eosinophilic", "ANATOMY", 218, 240], ["S protein", "GENE_OR_GENE_PRODUCT", 55, 64], ["S1", "GENE_OR_GENE_PRODUCT", 68, 70], ["non-neutralizing epitopes", "PROTEIN", 14, 39], ["full-length S protein", "PROTEIN", 43, 64], ["S1 subunits", "PROTEIN", 68, 79], ["neutralizing epitopes", "PROTEIN", 97, 118], ["some non-neutralizing epitopes", "PROBLEM", 9, 39], ["full-length S protein", "TREATMENT", 43, 64], ["S1 subunits", "TREATMENT", 68, 79], ["neutralizing epitopes", "PROBLEM", 97, 118], ["inflammatory and immunopathological effects", "PROBLEM", 166, 209], ["pulmonary eosinophilic infiltration", "PROBLEM", 218, 253], ["antibody-dependent enhancement", "PROBLEM", 258, 288], ["subsequent viral challenge of vaccinated animals", "TREATMENT", 305, 353], ["non-neutralizing", "OBSERVATION_MODIFIER", 14, 30], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178], ["pulmonary", "ANATOMY", 218, 227], ["eosinophilic infiltration", "OBSERVATION", 228, 253], ["dependent", "OBSERVATION_MODIFIER", 267, 276], ["enhancement", "OBSERVATION_MODIFIER", 277, 288]]], ["ADE is a phenomenon in which non-neutralizing antibodies are produced following an infection or a vaccination leads to enhanced infection27.", [["ADE", "DISEASE", 0, 3], ["infection", "DISEASE", 83, 92], ["non-neutralizing antibodies", "PROTEIN", 29, 56], ["infection27", "PROTEIN", 128, 139], ["a phenomenon", "PROBLEM", 7, 19], ["non-neutralizing antibodies", "TEST", 29, 56], ["an infection", "PROBLEM", 80, 92], ["a vaccination", "TREATMENT", 96, 109], ["enhanced infection27", "PROBLEM", 119, 139], ["phenomenon", "OBSERVATION", 9, 19], ["infection", "OBSERVATION", 83, 92]]], ["One approach to mitigate the adverse effects of ADE is to narrow the immune response to target only critical or beneficial epitopes28.", [["epitopes28", "PROTEIN", 123, 133]]], ["Vaccines based on RBD elicited a robust protective immune response and neutralizing antibodies.", [["RBD", "PROTEIN", 18, 21], ["neutralizing antibodies", "PROTEIN", 71, 94], ["Vaccines", "TREATMENT", 0, 8], ["RBD", "PROBLEM", 18, 21], ["neutralizing antibodies", "TEST", 71, 94], ["neutralizing antibodies", "OBSERVATION", 71, 94]]], ["At the same time, RBD does not contain non-neutralizing epitopes that may cause harmful immune responses, which is a hot spot for CoV vaccine development.", [["CoV", "ORGANISM", 130, 133], ["RBD", "PROTEIN", 18, 21], ["non-neutralizing epitopes", "PROTEIN", 39, 64], ["CoV", "SPECIES", 130, 133], ["RBD", "PROBLEM", 18, 21], ["non-neutralizing epitopes", "PROBLEM", 39, 64], ["harmful immune responses", "PROBLEM", 80, 104], ["a hot spot", "PROBLEM", 115, 125], ["CoV vaccine development", "TREATMENT", 130, 153], ["non-neutralizing", "OBSERVATION", 39, 55]]], ["It is worth mentioning that RBD has relatively low immunogenicity and often requires repeated doses and adjuvants29, 30, 31.", [["RBD", "DISEASE", 28, 31], ["RBD", "PROTEIN", 28, 31], ["RBD", "PROBLEM", 28, 31], ["relatively low immunogenicity", "PROBLEM", 36, 65], ["adjuvants29", "TREATMENT", 104, 115], ["RBD", "OBSERVATION", 28, 31], ["low immunogenicity", "OBSERVATION_MODIFIER", 47, 65]]], ["Because the S2 subunit is highly conserved and not prone to mutation, S2 region has become an important target for the development of protective vaccines.", [["S2", "GENE_OR_GENE_PRODUCT", 12, 14], ["S2 subunit", "PROTEIN", 12, 22], ["S2 region", "DNA", 70, 79], ["protective vaccines", "TREATMENT", 134, 153]]], ["However, reports regarding the presence of neutralizing epitopes in S2 and a protective role for antibodies to S2 have been inconsistent.", [["S2", "GENE_OR_GENE_PRODUCT", 68, 70], ["antibodies to S2", "GENE_OR_GENE_PRODUCT", 97, 113], ["neutralizing epitopes", "PROTEIN", 43, 64], ["S2", "PROTEIN", 68, 70], ["antibodies", "PROTEIN", 97, 107], ["S2", "PROTEIN", 111, 113], ["neutralizing epitopes in S2", "PROBLEM", 43, 70], ["antibodies to S2", "PROBLEM", 97, 113], ["neutralizing", "OBSERVATION", 43, 55]]], ["Several studies demonstrated that S2 domain could induce specific cellular immune response and a high level of total IgG but little neutralizing antibodies against coronavirus infection32,33.", [["cellular", "ANATOMY", 66, 74], ["coronavirus infection", "DISEASE", 164, 185], ["S2", "GENE_OR_GENE_PRODUCT", 34, 36], ["cellular", "CELL", 66, 74], ["IgG", "GENE_OR_GENE_PRODUCT", 117, 120], ["coronavirus", "ORGANISM", 164, 175], ["S2 domain", "PROTEIN", 34, 43], ["total IgG", "PROTEIN", 111, 120], ["neutralizing antibodies", "PROTEIN", 132, 155], ["coronavirus", "SPECIES", 164, 175], ["Several studies", "TEST", 0, 15], ["S2 domain", "PROBLEM", 34, 43], ["total IgG", "TEST", 111, 120], ["little neutralizing antibodies", "PROBLEM", 125, 155], ["coronavirus infection", "PROBLEM", 164, 185], ["cellular immune response", "OBSERVATION", 66, 90]]], ["On the contrary, there are also reports that showed that S2 domain contains neutralizing epitopes and could induce neutralizing antibodies34,35.Spike protein: a key target for coronaviruses vaccineN protein serves multiple functions in viral replication, transcription, and assembly of the viral genome complex, which is more conservative than other proteins, such as S and M. Therefore, N protein has been also widely reported as a target antigen.", [["Spike", "GENE_OR_GENE_PRODUCT", 144, 149], ["coronaviruses", "ORGANISM", 176, 189], ["vaccineN", "GENE_OR_GENE_PRODUCT", 190, 198], ["N protein", "GENE_OR_GENE_PRODUCT", 388, 397], ["S2 domain", "PROTEIN", 57, 66], ["neutralizing epitopes", "PROTEIN", 76, 97], ["neutralizing antibodies34,35", "PROTEIN", 115, 143], ["Spike protein", "PROTEIN", 144, 157], ["coronaviruses vaccineN protein", "PROTEIN", 176, 206], ["viral genome complex", "PROTEIN", 290, 310], ["N protein", "PROTEIN", 388, 397], ["S2 domain", "PROBLEM", 57, 66], ["neutralizing epitopes", "PROBLEM", 76, 97], ["neutralizing antibodies", "TEST", 115, 138], ["Spike protein", "PROBLEM", 144, 157], ["coronaviruses vaccineN protein", "TREATMENT", 176, 206], ["viral replication", "TREATMENT", 236, 253], ["the viral genome complex", "PROBLEM", 286, 310], ["neutralizing epitopes", "OBSERVATION", 76, 97], ["neutralizing antibodies", "OBSERVATION", 115, 138], ["viral replication", "OBSERVATION", 236, 253], ["viral genome", "OBSERVATION", 290, 302]]], ["N proteins have been shown to be highly immunogenic and capable of triggering T cell responses36.", [["T cell", "ANATOMY", 78, 84], ["T cell", "CELL", 78, 84], ["N proteins", "PROTEIN", 0, 10]]], ["Remarkably, many studies indicated that the serum containing anti-N protein does not contain neutralizing antibodies against coronavirus infection37,38.", [["serum", "ANATOMY", 44, 49], ["coronavirus infection", "DISEASE", 125, 146], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["coronavirus", "ORGANISM", 125, 136], ["anti-N protein", "PROTEIN", 61, 75], ["neutralizing antibodies", "PROTEIN", 93, 116], ["coronavirus", "SPECIES", 125, 136], ["many studies", "TEST", 12, 24], ["the serum", "TEST", 40, 49], ["anti-N protein", "TEST", 61, 75], ["neutralizing antibodies", "TEST", 93, 116], ["coronavirus infection", "PROBLEM", 125, 146]]], ["In addition, vaccines based on N protein not only failed to protect from homologous or heterologous challenge, but resulted in enhanced immunopathology with eosinophilic infiltrates within the lungs of SARS-CoV-challenged mice39.", [["eosinophilic infiltrates", "ANATOMY", 157, 181], ["lungs", "ANATOMY", 193, 198], ["SARS", "DISEASE", 202, 206], ["eosinophilic infiltrates", "PATHOLOGICAL_FORMATION", 157, 181], ["lungs", "ORGAN", 193, 198], ["SARS-CoV", "ORGANISM", 202, 210], ["mice39", "ORGANISM", 222, 228], ["N protein", "PROTEIN", 31, 40], ["SARS-CoV", "SPECIES", 202, 210], ["vaccines", "TREATMENT", 13, 21], ["N protein", "TREATMENT", 31, 40], ["heterologous challenge", "TREATMENT", 87, 109], ["enhanced immunopathology", "PROBLEM", 127, 151], ["eosinophilic infiltrates", "PROBLEM", 157, 181], ["eosinophilic infiltrates", "OBSERVATION", 157, 181], ["lungs", "ANATOMY", 193, 198]]]], "PMC7471482": [["Wenn die Mutter der Sechsj\u00e4hrigen verbietet, das Pferd zu streicheln, antwortet das Kind altklug: \u201eJa, ich wei\u00df, wegen Corona!\u201c 6.", [["Wenn die Mutter der Sechsj\u00e4hrigen verbietet, das Pferd zu streicheln, antwortet das Kind altklug: \u201eJa, ich wei\u00df", "SPECIES", 0, 111]]], ["Alles scheint normal zu sein, die H\u00e4user und Gesch\u00e4fte sind nicht zerst\u00f6rt.", [["zu sein", "OBSERVATION", 21, 28]]], ["Fu\u00dfballspiele und kulturelle Veranstaltungen sind abgesagt oder finden vor nahezu leeren Zuschauertrib\u00fcnen statt.", [["Fu\u00dfballspiele", "TEST", 0, 13]]], ["Die Selbststabilisierung durch Aktivit\u00e4ten mit Freunden, durch Feste und durch Kulturveranstaltungen ist eingeschr\u00e4nkt.Die Corona-Krise als psychische KriseViele Menschen erleben die gegenw\u00e4rtige Zeit der Corona-Krise aber auch als Bereicherung.", [["Die Selbststabilisierung durch Aktivit\u00e4ten mit Freunden, durch Feste und durch Kulturveranstaltungen ist eingeschr\u00e4nkt", "SPECIES", 0, 118]]], ["Die Krise f\u00fchrt oft zu einer Entschleunigung im Alltag.", [["Die", "PROBLEM", 0, 3]]], ["Sie merken ihre Liebe zu ihren Bezugspersonen und allgemein zu den Menschen und zu der Welt.", [["Sie merken ihre Liebe zu ihren Bezugspersonen und allgemein zu den Menschen und zu der Welt", "SPECIES", 0, 91], ["Sie merken ihre Liebe zu ihren Bezugspersonen", "TREATMENT", 0, 45]]], ["Sie erleben die eigenen Werte tiefer und sp\u00fcren in allem vielleicht sogar einen tieferen Sinn.Die Corona-Krise als psychische KriseDer Lockdown in der Corona-Krise war potenziell eine traumatisierende Situation und kann es wieder werden.", [["Die Corona-Krise als psychische KriseDer Lockdown in der Corona-Krise war potenziell eine traumatisierende Situation und kann es wieder werden", "SPECIES", 94, 236]]], ["Eine traumatisierende Situation (Kr\u00fcger 2020, S. 215 f.) ist definiert als eine Situation, in der man 1. nicht k\u00e4mpfen kann, aus der man 2. aber auch nicht fliehen kann und in der man 3. trotzdem immer weiter einer existenziellen Bedrohung ausgesetzt ist.", [["man", "SPECIES", 98, 101], ["man", "SPECIES", 133, 136], ["man", "SPECIES", 180, 183], ["trotzdem", "TREATMENT", 187, 195]]], ["In der Corona-Krise ist das die Bedrohung durch den Tod, durch Vereinsamung, durch den drohenden Verlust von Bezugspersonen, durch Existenzangst oder durch das Ausgeliefertsein und die Hilflosigkeit als Kranker.", [["durch den drohenden Verlust von Bezugspersonen, durch Existenzangst oder durch das Ausgeliefertsein und die Hilflosigkeit als Kranker", "SPECIES", 77, 210]]], ["Therapeutisch ist es wichtig, gegebenenfalls die traumatisierende Qualit\u00e4t der aktuellen Situation als solche zu w\u00fcrdigen.Fallbeispiel 1: Eine 84-j\u00e4hrige Patientin, Frau B., lebt in einem Altenheim mit 400 anderen BewohnerInnen.", [["Therapeutisch ist es wichtig, gegebenenfalls die traumatisierende Qualit\u00e4t der aktuellen Situation als solche zu w\u00fcrdigen", "SPECIES", 0, 121]]], ["Sie ist dort im Heim-Beirat t\u00e4tig.", [["Sie ist dort im Heim-Beirat t\u00e4tig", "SPECIES", 0, 33]]], ["Sie f\u00fchlt sich zu Beginn des Lockdowns v\u00f6llig \u00fcberfordert.", [["Sie f\u00fchlt sich zu Beginn des Lockdowns v\u00f6llig \u00fcberfordert", "SPECIES", 0, 57]]], ["Einige HeimbewohnerInnen lassen trotz der Kontaktsperre Angeh\u00f6rige durch die Gartenpforte ins Heim.", [["Einige HeimbewohnerInnen lassen trotz", "TREATMENT", 0, 37]]], ["Frau B. klagt: \u201eDie sitzen blass in ihren Zimmern und wissen oft nicht, was geschieht.", [["Frau B. klagt: \u201eDie sitzen blass in ihren Zimmern und wissen oft nicht", "SPECIES", 0, 70]]], ["Wenn sie informiert werden, vergessen sie das wieder.\u201c Der Lockdown ist f\u00fcr die Menschen in dem Heim seelisch eine Katastrophe.Der Therapeut fordert Frau B. in der Videotherapie auf, in ihrem Zimmer einen zweiten Stuhl neben sich zu stellen: \u201eDas ist Ihr Angst-Stuhl.", [["Stuhl neben sich zu stellen: \u201eDas ist Ihr Angst-Stuhl", "SPECIES", 213, 266]]], ["Der andere Stuhl, auf dem Sie sitzen, ist der Bew\u00e4ltigungs-Stuhl.\u201c Er teilt der Patientin mit: \u201eIch selbst habe in der jetzigen Krise ebenfalls Angst.", [["Der andere Stuhl, auf dem Sie sitzen, ist der Bew\u00e4ltigungs-Stuhl.\u201c", "SPECIES", 0, 66], ["Ich", "PROBLEM", 96, 99]]], ["Ich \u00fcberlege, was die bedrohlichen Informationen \u00fcber das Corona-Virus f\u00fcr mich bedeuten.", [["Ich", "PROBLEM", 0, 3]]], ["Ich sp\u00fcre Stress.", [["Ich sp\u00fcre Stress", "PROBLEM", 0, 16]]], ["Wenn ich mich damit zu viel besch\u00e4ftige, habe ich Albtr\u00e4ume und werde innerlich taub.\u201c Der Therapeut stellt auch neben sich selbst einen zweiten Stuhl: \u201eDieser andere Stuhl steht da f\u00fcr meine eigene Bew\u00e4ltigung der Angst.\u201c Er wechselt auf diesen zweiten Stuhl: \u201eIch habe inzwischen verschiedene M\u00f6glichkeiten gefunden, die mir guttun und die mir aus dem Gef\u00fchl des Nebels heraushelfen.", [["Er wechselt auf diesen zweiten Stuhl: \u201eIch habe inzwischen verschiedene M\u00f6glichkeiten gefunden, die mir guttun und die mir aus dem Gef\u00fchl des Nebels heraushelfen", "SPECIES", 223, 384], ["ich", "PROBLEM", 5, 8], ["Ich", "PROBLEM", 262, 265]]], ["Ich versuche zum Beispiel, einer alten Tante in Dresden zu helfen.", [["Dresden zu helfen", "SPECIES", 48, 65], ["Ich", "PROBLEM", 0, 3]]], ["Ich arbeite gern in meinem Garten.", [["Ich", "PROBLEM", 0, 3], ["meinem Garten", "OBSERVATION", 20, 33]]], ["Ich skype mit meinen Enkelinnen.\u201cDer Therapeut stellt im Sinne des psychodramatischen Antwortens (Kr\u00fcger 2020, S. 195 ff.) einen dritten Stuhl neben sich: \u201eIch bin Ihnen gegen\u00fcber aber nicht nur der begegnende Mensch, sondern auch der fachlich kompetente Therapeut.", [["Ich", "PROBLEM", 0, 3]]], ["Daf\u00fcr steht dieser Stuhl.\u201c Er setzt sich auf den dritten Stuhl und fragt: \u201eAls fachlich kompetenter Therapeut m\u00f6chte ich von Ihnen wissen: Welche M\u00f6glichkeiten haben Sie gefunden, um sich selbst zu stabilisieren?", [["Er setzt sich auf den dritten Stuhl und fragt: \u201eAls fachlich kompetenter Therapeut m\u00f6chte ich von Ihnen wissen: Welche M\u00f6glichkeiten haben Sie gefunden, um sich selbst zu stabilisieren", "SPECIES", 27, 211]]], ["Schreiben Sie diese Handlungen bitte auf ein Blatt Papier auf!\u201c Der Therapeut erfasst mit der Patientin zusammen die Selbststabilisierungstechniken, die sie selbst schon benutzt.", [["Schreiben Sie diese Handlungen bitte auf ein Blatt Papier auf!\u201c", "SPECIES", 0, 63]]], ["Sie hilft anderen: \u201eIch winke jeden Tag um 18 Uhr vom Balkon aus einer Bewohnerin zu, die im Haus gegen\u00fcber wohnt.", [["Sie hilft anderen: \u201eIch winke jeden Tag um 18 Uhr vom Balkon aus einer Bewohnerin zu, die im Haus gegen\u00fcber wohnt", "SPECIES", 0, 113], ["Ich", "PROBLEM", 20, 23]]], ["Frau G. macht einmal t\u00e4glich Tele-Gymnastik.", [["Gymnastik", "PROBLEM", 34, 43]]], ["Sie hat den Zugang dazu \u00fcber \u201eTele-Gym\u201c im Fernsehen gefunden.", [["Sie hat den Zugang dazu \u00fcber \u201eTele-Gym\u201c im Fernsehen gefunden", "SPECIES", 0, 61]]], ["Frau B. telefoniert jeden Tag mit ihrer Schwester in den USA.", [["Tag", "GENE_OR_GENE_PRODUCT", 26, 29], ["Frau B. telefoniert jeden", "SPECIES", 0, 25]]], ["Der Therapeut benennt weitere Selbststabilisierungstechniken, die die Patientin schon anwendet oder anwenden k\u00f6nnte: 6. \u201eSie nehmen bei mir Therapiestunden, die Sie unterst\u00fctzen und stabilisieren.\u201c 7. \u201eSie k\u00f6nnen in der Not den zweiten Stuhl f\u00fcr Ihr Bew\u00e4ltigungs-Ich neben sich stellen und den Zettel mit Ihren Selbststabilisierungstechniken darauflegen.", [["Ich", "PROBLEM", 263, 266]]], ["Sie werden merken, dass tut Ihnen gut.\u201cDie 84-j\u00e4hrige Patientin erz\u00e4hlt eine Woche sp\u00e4ter: \u201eIch habe mich im Internet \u00fcber das Grundgesetz informiert unter den Stichw\u00f6rtern \u201aGrundgesetz, k\u00f6rperliche Gesundheit\u2018.", [["dass tut Ihnen gut.\u201cDie 84-j\u00e4hrige Patientin erz\u00e4hlt eine Woche sp\u00e4ter: \u201eIch habe mich im Internet \u00fcber das Grundgesetz informiert unter den Stichw\u00f6rtern \u201aGrundgesetz", "SPECIES", 19, 185]]], ["Ich fand darin einen Paragrafen, der das Recht auf k\u00f6rperliche Unversehrtheit beinhaltet.", [["Ich fand darin einen Paragrafen, der das Recht auf k\u00f6rperliche Unversehrtheit beinhaltet", "SPECIES", 0, 88], ["Ich", "PROBLEM", 0, 3]]], ["Ich habe daraufhin als Beiratsmitglied die Heimleitung aufgefordert: Sie sollen dieses Verfassungsrecht f\u00fcr die HeimbewohnerInnen garantieren und den Zugang von Angeh\u00f6rigen zum Heim durch die Gartenpforten stoppen.", [["Ich habe daraufhin als Beiratsmitglied die Heimleitung aufgefordert", "SPECIES", 0, 67], ["Sie sollen dieses Verfassungsrecht f\u00fcr die HeimbewohnerInnen garantieren und den Zugang von Angeh\u00f6rigen zum Heim durch die Gartenpforten stoppen", "SPECIES", 69, 213], ["Ich", "PROBLEM", 0, 3]]], ["Die Heimleitung hat daraufhin den Code in den Zugangst\u00fcren zu den H\u00e4usern ver\u00e4ndert.", [["Die Heimleitung hat daraufhin den Code in den Zugangst\u00fcren zu den H\u00e4usern ver\u00e4ndert", "SPECIES", 0, 83]]], ["Alle BesucherInnen m\u00fcssen jetzt durch den bewachten Haupteingang kommen und k\u00f6nnen kontrolliert werden.", [["BesucherInnen m\u00fcssen jetzt durch den bewachten Haupteingang kommen und k\u00f6nnen kontrolliert werden", "SPECIES", 5, 102]]], ["Das hat mir gutgetan, dass Sie mir auch etwas \u00fcber Ihre eigenen \u00c4ngste erz\u00e4hlt haben!\u201cKrisenintervention und individuelle SelbststabilisierungstechnikenDer oder die TherapeutIn hat in der Krisenintervention die Funktion eines oder einer Doppelg\u00e4ngerIn.", [["Krisenintervention", "TREATMENT", 86, 104]]], ["Sie oder er hilft den Patienten, pers\u00f6nliche \u00c4ngste in der Corona-Krise und Selbststabilisierungstechniken zu erfassen:Der oder die TherapeutIn stellt neben den oder die PatientIn den Stuhl f\u00fcr seine oder ihre Selbstrepr\u00e4sentanz im Corona-Konflikt und gegen\u00fcber davon einen anderen Stuhl f\u00fcr das Corona-Virus.", [["Patient", "SPECIES", 170, 177], ["Sie oder er hilft den Patienten, pers\u00f6nliche \u00c4ngste in der Corona-Krise und Selbststabilisierungstechniken zu erfassen:Der oder die Therapeut", "SPECIES", 0, 141], ["Selbstrepr\u00e4sentanz", "TEST", 210, 228], ["Corona", "TEST", 232, 238]]], ["Er oder sie deutet auf den Stuhl neben ihm oder ihr: \u201eDas ist Ihr Angst-Ich, Ihr gestresstes Ich.\u201cDer oder die TherapeutIn fordert den oder die PatientIn auf, die \u00c4ngste und Stressfaktoren, die er oder sie zurzeit hat, mit Gegenst\u00e4nden auf dem Angst-Stuhl zu symbolisieren.", [["Er oder sie deutet auf den Stuhl neben ihm oder ihr: \u201eDas ist Ihr Angst-Ich, Ihr gestresstes Ich.\u201cDer oder die TherapeutIn fordert den oder die PatientIn auf, die \u00c4ngste und Stressfaktoren, die er oder sie zurzeit hat, mit Gegenst\u00e4nden auf dem Angst-Stuhl zu symbolisieren", "SPECIES", 0, 272], ["Ich", "PROBLEM", 72, 75], ["Ich", "PROBLEM", 93, 96]]], ["Das k\u00f6nnen zum Beispiel sein: 1. finanzielle Existenzangst, 2. die Angst vor dem Verlust der alten Eltern oder von FreundInnen, 3. die Angst, selbst an Corona zu erkranken oder 4. die Angst, die Kontrolle \u00fcber das eigene Leben zu verlieren.Der oder die TherapeutIn fordert den oder die PatientIn auf, das Ausma\u00df jeder dieser \u00c4ngste auf einer Skala von 0 bis 10 festzulegen.Er oder Sie ersetzt bei einer einzelnen massiven Angst das kleine Symbol durch einen gro\u00dfen Gegenstand, zum Beispiel durch einen Papierkorb.", [["Der oder die TherapeutIn fordert den oder die PatientIn auf, das Ausma\u00df jeder dieser \u00c4ngste auf einer Skala von 0 bis 10 festzulegen", "SPECIES", 240, 372]]], ["Er oder sie w\u00fcrdigt dadurch die Gr\u00f6\u00dfe dieser Angst.Der oder die ProtagonistIn wechselt einmal auf den Angststuhl und l\u00e4sst die schlimmste Angst in sich zu.Er oder sie wechselt wieder zur\u00fcck in sein Alltags-Ich.Der oder die TherapeutIn fragt: \u201eWie gehen Sie damit um, wenn Sie ihre schlimmste Angst f\u00fchlen?", [["Ich", "PROBLEM", 206, 209], ["Ich", "OBSERVATION", 206, 209]]], ["Wie helfen Sie sich, um da herauszukommen?\u201cDer oder die PatientIn schreibt sich die selbst gefundenen Handlungen auf ein Papier auf und legt dieses Papier vor sich auf den Tisch.Der oder die TherapeutIn nennt ihm oder ihr bei Bedarf zus\u00e4tzliche Selbststabilisierungstechniken.Krisenintervention und individuelle SelbststabilisierungstechnikenSelbststabilisierungstechniken sind Handlungen, die helfen, aus der existenziellen Not einer traumatisierenden Situation oder eines Traumafilms herauszukommen.", [["Wie helfen Sie sich, um da herauszukommen?\u201cDer oder die PatientIn schreibt sich die selbst gefundenen Handlungen auf ein Papier auf und legt dieses Papier vor sich auf den Tisch", "SPECIES", 0, 177], ["Krisenintervention", "TREATMENT", 276, 294]]], ["Er oder sie gibt es bei Bedarf auch an PatientInnen weiter:Die Iren benutzten fr\u00fcher in Krisenzeiten den Spruch: \u201eIt could be worse\u201c.", [["Er oder sie gibt es bei Bedarf auch an PatientInnen weiter:Die Iren benutzten fr\u00fcher", "SPECIES", 0, 84]]], ["Wenn wirklich 3 % der Menschen auf der Welt sterben sollten, \u00fcberleben immer noch 97 %.", [["Menschen auf der Welt sterben sollten, \u00fcberleben immer noch 97", "SPECIES", 22, 84]]], ["Denn dann gibt es vermutlich eine Impfung, die vor einer Infektion sch\u00fctzt.Machen Sie schriftlich ein Verzeichnis von den Handlungen im Alltag, die Ihnen guttun.", [["Denn dann gibt es vermutlich eine Impfung, die vor einer Infektion sch\u00fctzt", "SPECIES", 0, 74], ["Machen Sie schriftlich ein Verzeichnis von den Handlungen im Alltag, die Ihnen guttun", "SPECIES", 75, 160]]], ["Bei einem ICE-Ungl\u00fcck gibt es in Deutschland Kriseninterventionsteams.", [["Bei einem ICE-Ungl\u00fcck gibt", "SPECIES", 0, 26]]], ["Das Erz\u00e4hlen aktiviert die Konfliktverarbeitung und hilft, keine Traumafolgest\u00f6rung zu entwickeln.", [["Das Erz\u00e4hlen aktiviert die Konfliktverarbeitung und hilft, keine Traumafolgest\u00f6rung zu entwickeln", "SPECIES", 0, 97]]], ["Wenn Sie sich mit jemand austauschen, kann geteiltes Leid zu halbem Leid werden.Nehmen Sie wieder Beziehung auf zu alten Freundinnen oder Freunden, die Sie sonst nur zu Weihnachten oder zum Geburtstag sprechen.", [["Wenn Sie sich mit jemand austauschen, kann geteiltes Leid zu halbem Leid werden", "SPECIES", 0, 79], ["Nehmen Sie wieder Beziehung auf zu alten Freundinnen oder Freunden, die Sie sonst nur zu Weihnachten oder zum Geburtstag sprechen", "SPECIES", 80, 209]]], ["Ich selbst habe damit in der Corona-Krise neu angefangen.", [["Ich", "PROBLEM", 0, 3]]], ["Ich selbst skype jetzt mit meinen zwei jugendlichen Enkelinnen etwa 14-t\u00e4gig zu dem Thema: \u201eFragen zu Gott und der Welt.\u201cWenn es Ihnen seelisch schlecht geht, machen Sie die folgende Selbststabilisierungs\u00fcbung (Christine Rost 2013, m\u00fcndliche Mitteilung): Strecken Sie hier und jetzt ausgiebig Ihre Glieder und ver\u00e4ndern Sie Ihre Atmung.", [["Ich selbst skype jetzt mit meinen zwei jugendlichen Enkelinnen etwa 14-t\u00e4gig zu dem Thema: \u201eFragen zu Gott und der Welt.\u201cWenn es Ihnen seelisch schlecht geht, machen Sie die folgende Selbststabilisierungs\u00fcbung (Christine Rost 2013, m\u00fcndliche Mitteilung): Strecken Sie hier und jetzt ausgiebig Ihre Glieder und ver\u00e4ndern Sie Ihre Atmung", "SPECIES", 0, 335], ["Ich", "PROBLEM", 0, 3], ["etwa", "TEST", 63, 67]]], ["Das sensomotorische Handeln bei dieser \u00dcbung hilft Ihnen eventuell, in Ihr gesundes Alltags-Ich zur\u00fcckzukehren.Lenken Sie sich ab mit dem Hobby, das sie am liebsten m\u00f6gen.", [["Das sensomotorische Handeln bei dieser \u00dcbung hilft", "SPECIES", 0, 50], ["Lenken Sie sich ab mit dem Hobby, das sie am liebsten m\u00f6gen", "SPECIES", 111, 170], ["Ich", "OBSERVATION", 92, 95]]], ["Ich selbst gehe oft in unseren gro\u00dfen Garten.", [["Ich", "PROBLEM", 0, 3], ["gro\u00dfen Garten", "OBSERVATION", 31, 44]]], ["Ich ziehe Unkraut und f\u00fchle dabei die Erde an den Fingern.", [["Ich", "PROBLEM", 0, 3]]], ["ARD und ZDF haben eine gro\u00dfe Mediathek, aus denen man Filme ausw\u00e4hlen kann.", [["man", "SPECIES", 50, 53]]], ["Gehen sie spazieren, fahren Sie Fahrrad oder joggen Sie.", [["Gehen sie spazieren", "SPECIES", 0, 19]]], ["Bieten Sie ihnen an, f\u00fcr sie bei Bedarf einzukaufen.", [["f\u00fcr sie bei Bedarf einzukaufen", "SPECIES", 21, 51]]], ["Oder telefonieren Sie mit ihnen einmal in der Woche.", [["Oder telefonieren", "SPECIES", 0, 17]]], ["Das Ausleben von Mitgef\u00fchl und das Helfen tut nicht nur dem anderen gut, sondern auch Ihnen selbst.", [["gut", "ANATOMY", 68, 71]]], ["Es f\u00f6rdert in Ihrem Gehirn die Aussch\u00fcttung von Dopamin und verbessert dadurch Ihre eigene Verarbeitung des negativen Stresses.Schreiben Sie alle Ihre eigenen positiven Eigenschaften und F\u00e4higkeiten untereinander auf ein Blatt Papier.", [["Ihre eigenen positiven Eigenschaften und F\u00e4higkeiten untereinander auf ein Blatt Papier", "SPECIES", 146, 233]]], ["Finden Sie in alten Situationen neue L\u00f6sungen.Wenn es Ihnen in dieser Zeit gerade wieder schlecht geht, stellen Sie neben sich einen zweiten Stuhl f\u00fcr Ihr \u201eAngst-Ich\u201c.", [["Ich", "PROBLEM", 162, 165], ["Ich", "OBSERVATION", 162, 165]]], ["Der Stuhl, auf dem Sie gerade sitzen, repr\u00e4sentiert dann Ihr gesundes Alltags-Ich.", [["Ich", "PROBLEM", 78, 81], ["Ich", "OBSERVATION", 78, 81]]], ["Setzen Sie sich auf den Stuhl Ihres Angst-Ichs.", [["Setzen Sie sich auf den Stuhl Ihres Angst-Ichs", "SPECIES", 0, 46]]], ["Legen Sie Ihre Liste der Selbststabilisierungstechniken auf den anderen Stuhl Ihres Alltags-Ichs.", [["Legen Sie Ihre Liste der Selbststabilisierungstechniken auf den anderen Stuhl Ihres Alltags-Ichs", "SPECIES", 0, 96]]], ["Sie werden merken, Ihr Gef\u00fchl von Ohnmacht, Hilflosigkeit und Vergeblichkeit wird geringer.Krisenintervention und individuelle SelbststabilisierungstechnikenEine traumatisierende Situation l\u00e4hmt die eigene innere Konfliktverarbeitung und die \u00e4u\u00dfere Handlungsf\u00e4higkeit.", [["Hilflosigkeit", "TREATMENT", 44, 57], ["Krisenintervention", "TREATMENT", 91, 109]]], ["PatientInnen k\u00f6nnen ihre innere Konfliktverarbeitung bei Bedarf mithilfe der Technik des Bew\u00e4ltigungsm\u00e4rchens (Kr\u00fcger 2020, S. 288 ff.) aus der Blockade befreien.\u00dcbung 1: Ein Bew\u00e4ltigungsm\u00e4rchen besteht aus einer Leidensgeschichte, der m\u00e4rchenhafter Umwandlung und der Erf\u00fcllung der eigentlichen Sehnsucht.", [["PatientInnen k\u00f6nnen ihre innere Konfliktverarbeitung bei Bedarf mithilfe der Technik des Bew\u00e4ltigungsm\u00e4rchens (Kr\u00fcger 2020, S. 288 ff.) aus der Blockade befreien", "SPECIES", 0, 161], ["Konfliktverarbeitung bei Bedarf mithilfe der Technik des", "TREATMENT", 32, 88], ["aus der Blockade befreien", "TREATMENT", 136, 161]]], ["Wie s\u00e4he es aus, wenn das geschieht?\u201c Schreiben Sie handlungsnah auf, wie sich Ihre Sehnsucht erf\u00fcllt.", [["Schreiben", "CHEMICAL", 38, 47], ["Schreiben", "CHEMICAL", 38, 47], ["Schreiben", "SPECIES", 38, 47]]], ["Denken Sie sich als letztes den Zwischenteil des M\u00e4rchens aus, die Phase der m\u00e4rchenhaften Umwandlung.Krisenintervention und individuelle SelbststabilisierungstechnikenDie Technik des Bew\u00e4ltigungsm\u00e4rchens ist komplex.", [["Krisenintervention", "TREATMENT", 102, 120]]], ["Der Patient sp\u00fcrt beim Schreiben seine Selbstwirksamkeit.", [["Patient", "SPECIES", 4, 11]]], ["Das M\u00e4rchen ist zwar ein M\u00e4rchen und also eine Utopie.", [["Das M\u00e4rchen ist zwar ein M\u00e4rchen und also eine Utopie", "SPECIES", 0, 53]]], ["Vielleicht kommen Sie aber doch einmal in Not oder sind sehr gestresst.", [["Vielleicht kommen", "SPECIES", 0, 17]]], ["Stellen Sie dann einen zweiten Stuhl neben sich f\u00fcr Ihr Angst-Ich.", [["Ich", "PROBLEM", 62, 65], ["Ich", "OBSERVATION", 62, 65]]], ["Sie merken wieder, dass Ihnen zu anderen Zeiten die eigenen Kompetenzen voll zur Verf\u00fcgung stehen.Die verschiedenen \u00c4ngste und ihre BehandlungDie Corona-Krise aktualisiert in der Seele der Menschen neben neuen \u00c4ngsten auch alte Konflikte und Abwehrformen.", [["Die verschiedenen \u00c4ngste und ihre BehandlungDie Corona-Krise aktualisiert in der Seele der Menschen neben neuen \u00c4ngsten auch alte Konflikte und Abwehrformen", "SPECIES", 98, 254]]], ["Der oder die TherapeutIn sollte deshalb bei Bedarf den pers\u00f6nlichen Umgang des oder der KlientIn mit sich selbst in der gegenw\u00e4rtigen Corona-Krise ansprechen und erkunden.", [["sollte deshalb bei Bedarf den pers\u00f6nlichen Umgang des oder der Klient", "SPECIES", 25, 94], ["sollte deshalb bei Bedarf", "TREATMENT", 25, 50]]], ["Denn die Art der individuellen \u00c4ngste der PatientInnen bestimmt das weitere therapeutische Vorgehen (Kr\u00fcger 2020, S. 315 ff.).", [["PatientInnen bestimmt das weitere therapeutische Vorgehen (Kr\u00fcger 2020, S. 315 ff.", "SPECIES", 42, 124]]], ["1), 2. um eine Realangst, 3. um eine \u00fcbertriebene Angst, 4. um einen drohenden Identit\u00e4tsverlust oder 5. um eine drohende Retraumatisierung durch die aktuelle Krise.Die verschiedenen \u00c4ngste und ihre BehandlungReal begr\u00fcndete \u00c4ngste kann man nur vermindern, indem man real etwas gegen die Angst tut.", [["man", "SPECIES", 237, 240], ["Die verschiedenen \u00c4ngste und ihre Behandlung", "SPECIES", 165, 209]]], ["Der oder die Betroffene informiert sich \u00fcber das Corona-Virus und die Corona-Krise in den Fernsehnachrichten, im Radio, in der Zeitung und im pers\u00f6nlichen Gespr\u00e4ch.", [["Betroffene", "TREATMENT", 13, 23]]], ["B. das inzwischen preisgekr\u00f6nte \u201eCorona-Update im Radiosender NDR-Info\u201c an oder l\u00e4dt sich dieses aus der Mediathek herunter.", [["B. das inzwischen preisgekr\u00f6nte \u201eCorona-Update im Radiosender NDR-Info\u201c an oder l\u00e4dt sich dieses aus der Mediathek herunter", "SPECIES", 0, 123]]], ["Der Virologe Prof. Drosten beantwortet darin die Fragen einer Wissenschafts-Journalistin.", [["Journalistin", "CHEMICAL", 76, 88], ["Journalistin", "TREATMENT", 76, 88]]], ["Er oder sie l\u00e4dt sich die Corona-App herunter, die ihn bzw. sie m\u00f6glicherweise warnt, dass er oder sie Kontakt mit einem oder einer Infizierten hatte.Die verschiedenen \u00c4ngste und ihre BehandlungWichtige Informationen \u00fcber die Corona-Pandemie sind:Wir und unsere Bezugspersonen sind individuell gef\u00e4hrdet, schwer zu erkranken oder sogar zu sterben, je \u00e4lter man ist, desto mehr.Die Infektionsgefahr ist nach Prof. Drosten (NDR-Info, Corona-Podcast) in geschlossenen R\u00e4umen ohne Durchzug von Luft bei engem Kontakt mit vielen Menschen neunzehn Mal gr\u00f6\u00dfer als drau\u00dfen im Freien.Solange unser Gesundheitssystem gut funktioniert, werden in Deutschland innerhalb der n\u00e4chsten zwei Jahre ungef\u00e4hr 0,3\u20130,5 % der Bev\u00f6lkerung direkt oder indirekt durch das Virus sterben.", [["man", "SPECIES", 357, 360], ["Die verschiedenen \u00c4ngste und ihre BehandlungWichtige Informationen \u00fcber die Corona-Pandemie sind:Wir und unsere Bezugspersonen sind individuell gef\u00e4hrdet, schwer zu erkranken oder sogar zu sterben, je \u00e4lter man ist, desto mehr", "SPECIES", 150, 376]]], ["Bei einem totalen Zusammenbruch des Gesundheitssystems w\u00fcrden aber zus\u00e4tzlich ungef\u00e4hr 3 % oder 1\u20132 Mio.", [["Bei einem totalen Zusammenbruch des Gesundheitssystems w\u00fcrden aber zus\u00e4tzlich ungef\u00e4hr", "SPECIES", 0, 86], ["Bei einem totalen Zusammenbruch des Gesundheitssystems", "TREATMENT", 0, 54], ["zus\u00e4tzlich ungef\u00e4hr", "TREATMENT", 67, 86]]], ["Menschen sterben.", [["Menschen sterben", "SPECIES", 0, 16]]], ["Diese Zahlen schlie\u00dfen die sogenannte \u201e\u00dcbersterblichkeit\u201c mit ein.", [["Diese Zahlen schlie\u00dfen die sogenannte \u201e\u00dcbersterblichkeit\u201c mit ein", "SPECIES", 0, 65]]], ["Das sind die nicht erfassten Corona-Toten und die Menschen, die in der Zeit der Corona-Krise an anderen Krankheiten sterben, weil sie nicht oder zu sp\u00e4t zum Arzt oder ins Krankenhaus gehen.Die Gefahr einer Infektion durch das Covid-19-Virus wird vermutlich in einem Jahr vor\u00fcber sein, weil wir uns dann gegen das Virus impfen lassen k\u00f6nnen.Die verschiedenen \u00c4ngste und ihre Behandlung\u00dcbertriebene \u00c4ngste setzen sich zusammen aus einer Realangst und einer neurotischen Angst.", [["Die Gefahr einer Infektion durch das Covid-19-Virus wird vermutlich in einem Jahr vor\u00fcber sein, weil wir uns dann gegen das Virus impfen lassen k\u00f6nnen", "SPECIES", 189, 339], ["Die verschiedenen \u00c4ngste und ihre Behandlung\u00dcbertriebene \u00c4ngste setzen sich zusammen aus einer Realangst und einer neurotischen Angst", "SPECIES", 340, 473], ["Covid", "TEST", 226, 231], ["Virus wird vermutlich", "TREATMENT", 235, 256]]], ["Der oder die TherapeutIn behandelt in einem solchen Fall auch den neurotischen oder traumatischen Anteil an der \u00fcbertriebenen Angst: Er oder sie l\u00e4sst den oder die PatientIn mit dem psychodramatischen Dialog eine nicht vollendete Trauerarbeit aus der Kindheit nachholen.", [["Patient", "SPECIES", 164, 171]]], ["Im Psychodrama nennen wir einen solchen Identit\u00e4tsanteil eine \u201eRolle im kulturellen Atom\u201c.Die verschiedenen \u00c4ngste und ihre BehandlungWir Menschen entwickeln durch den Widerspruch zwischen der Alltags-Wirklichkeit und der Corona-Wirklichkeit (siehe Kap.", [["Die verschiedenen \u00c4ngste und ihre BehandlungWir Menschen entwickeln durch den Widerspruch zwischen der Alltags-Wirklichkeit und der Corona-Wirklichkeit (siehe Kap", "SPECIES", 90, 252], ["Im Psychodrama nennen wir", "TREATMENT", 0, 25]]], ["1) eine mehr oder weniger starke Ich-Konfusion zwischen Alltags-Ich und Angst Ich.", [["mehr oder weniger starke Ich-Konfusion zwischen Alltags-Ich und Angst Ich", "SPECIES", 8, 81], ["Ich", "PROBLEM", 33, 36], ["Ich", "PROBLEM", 64, 67], ["Ich", "PROBLEM", 78, 81]]], ["Aber auch das Alltags-Ich will gelebt sein, sonst werden wir psychisch krank.", [["Ich", "PROBLEM", 22, 25]]], ["Wir Menschen entwickeln in der Corona-Krise idealerweise die F\u00e4higkeit, zwischen dem Alltags-Ich und dem Angst-Ich frei hin und her zu wechseln.", [["zwischen dem Alltags-Ich und dem Angst-Ich frei hin und her zu wechseln", "SPECIES", 72, 143], ["Ich", "PROBLEM", 93, 96], ["Ich", "PROBLEM", 111, 114]]], ["Wir vollziehen dabei eine Ich-Spaltung im Dienste unseres Ichs (siehe Kap.", [["Wir vollziehen dabei eine Ich-Spaltung im Dienste unseres", "SPECIES", 0, 57], ["Wir", "TEST", 0, 3], ["Ich", "PROBLEM", 26, 29], ["Ichs", "PROBLEM", 58, 62]]], ["In der Corona-Krise verst\u00e4rkt sich dieser starre Selbstschutz gegen negative Gef\u00fchle.Fallbeispiel 2: Frau F. meint in ihrer Einzeltherapie: \u201eIch habe jetzt in der Corona-Krise keine Angst.\u201c Sie ist stark christlich orientiert und glaubt: \u201eDas Leben auf der Erde ist Leiden, das eigentliche Leben kommt erst nach dem Tod.", [["Sie ist stark christlich orientiert und glaubt: \u201eDas Leben auf der Erde ist Leiden, das eigentliche Leben kommt erst nach dem Tod", "SPECIES", 190, 319], ["sich", "PROBLEM", 30, 34], ["Ich", "PROBLEM", 141, 144]]], ["Ich bete viel.\u201c Das Gl\u00e4ubigsein hilft ihr in schwierigen Situationen, nicht in ihren alten Traumafilm aus der Kindheit wegzurutschen.", [["Ich", "PROBLEM", 0, 3]]], ["Es dient ihr als Selbstschutz gegen eigene negative Gef\u00fchle von Verlorensein.", [["Verlorensein", "CHEMICAL", 64, 76], ["von Verlorensein", "OBSERVATION", 60, 76]]], ["Sie erleben die gegenw\u00e4rtige Situation dann so, als ob ihr Kindheitstrauma jetzt in der Gegenwart geschehen w\u00fcrde.Fallbeispiel 3: Frau L. \u00e4u\u00dfert in der Einzeltherapie: \u201eIch denke jetzt in der Corona-Krise manchmal daran, mir das Leben zu nehmen.\u201c Sie bef\u00fcrchtet, dass durch die Corona-Krise und die wirtschaftlichen Folgen die staatliche Ordnung in Deutschland zusammenbrechen wird: \u201eEs kommt dann zu Gewalt.", [["dass durch die Corona-Krise und die wirtschaftlichen Folgen die staatliche Ordnung in Deutschland zusammenbrechen wird: \u201eEs kommt dann zu Gewalt", "SPECIES", 263, 407], ["Ich", "PROBLEM", 169, 172]]], ["Man ist nirgends mehr sicher.", [["Man", "SPECIES", 0, 3]]], ["Frau L. hatte also nie lernen k\u00f6nnen, mit negativen Gef\u00fchlen angemessen umzugehen.Theorie der Krisenintervention in einer potenziell traumatisierenden Corona-KriseDie gegenw\u00e4rtige Corona-Krise ist f\u00fcr unsere PatientInnen und KlientInnen und ebenso f\u00fcr uns TherapeutInnen und BeraterInnen eine Chaossituation.", [["Die gegenw\u00e4rtige Corona-Krise ist f\u00fcr unsere PatientInnen und KlientInnen und ebenso f\u00fcr uns TherapeutInnen und BeraterInnen eine Chaossituation", "SPECIES", 163, 307]]], ["Wir Menschen entwickeln eine mehr oder weniger gro\u00dfe Ich-Konfusion zwischen unserem Alltags-Ich und unserem Angst-Ich.", [["Ich-Konfusion zwischen unserem Alltags-Ich und unserem Angst-Ich", "SPECIES", 53, 117], ["Ich", "PROBLEM", 53, 56], ["Ich", "PROBLEM", 92, 95], ["Ich", "PROBLEM", 114, 117], ["Ich", "OBSERVATION", 114, 117]]], ["In dieser Situation ist es wichtig, die F\u00e4higkeit zur Ich-Spaltung zwischen dem Alltags-Ich und dem Angst-Ich zu entwickeln.", [["F\u00e4higkeit zur Ich-Spaltung zwischen dem Alltags-Ich und dem Angst-Ich zu entwickeln", "SPECIES", 40, 123], ["zur Ich", "PROBLEM", 50, 57], ["Ich", "PROBLEM", 88, 91], ["Ich", "PROBLEM", 106, 109]]], ["Das Ziel der Therapie oder Beratung ist also nicht, dass die PatientInnen keine negativen Gef\u00fchle mehr haben.\u00dcbung 3: Erz\u00e4hlen Sie einmal einer Freundin oder einem Freund f\u00fcnf Minuten lang von Ihren \u00c4ngsten in der Corona-Krise.", [["Freund", "SPECIES", 164, 170], ["Erz\u00e4hlen Sie einmal einer", "TREATMENT", 118, 143]]], ["Fangen Sie dann das Gespr\u00e4ch noch einmal von vorn an und stellen Sie dabei aber einen zweiten Stuhl neben sich auf f\u00fcr Ihr Angst-Ich.", [["Fangen Sie dann das Gespr\u00e4ch noch einmal von vorn an und stellen", "SPECIES", 0, 64], ["Ich", "PROBLEM", 129, 132], ["Ich", "OBSERVATION", 129, 132]]], ["Wenn Sie von der Rolle Ihres Alltags-Ichs in die Rolle Ihres Angst-Ichs wechseln und wieder zur\u00fcck, aktivieren Sie in jedem der beiden Ich-Zust\u00e4nde getrennt von dem anderen die zugeh\u00f6rigen Denk\u2011, F\u00fchl- und Handlungsmuster.", [["Wenn Sie von der Rolle Ihres Alltags-Ichs in die Rolle Ihres Angst-Ichs wechseln und wieder zur\u00fcck, aktivieren Sie in jedem der beiden Ich-Zust\u00e4nde getrennt von dem anderen die zugeh\u00f6rigen Denk\u2011, F\u00fchl- und Handlungsmuster", "SPECIES", 0, 221], ["Ich", "PROBLEM", 135, 138]]], ["Sie lernen dadurch, psychosomatisch zwischen den beiden Ich-Zust\u00e4nden zu unterscheiden.", [["Sie lernen dadurch, psychosomatisch zwischen den beiden Ich-Zust\u00e4nden zu unterscheiden", "SPECIES", 0, 86], ["Ich", "PROBLEM", 56, 59]]], ["Es hebt die metakognitive St\u00f6rung der Ich-Konfusion auf, indem es den unbewussten Wechsel zwischen dem Angst-Ich und dem gesunden Alltags-Ich mithilfe der Zwei-St\u00fchle-Technik im Als-ob-Modus des Spiels nachvollzieht.", [["Es hebt die metakognitive St\u00f6rung der Ich-Konfusion auf, indem es den unbewussten Wechsel zwischen dem Angst-Ich und dem gesunden Alltags-Ich mithilfe der Zwei-St\u00fchle-Technik im Als-ob-Modus des Spiels nachvollzieht", "SPECIES", 0, 215], ["Ich", "PROBLEM", 109, 112], ["Alltags", "TEST", 130, 137], ["Ich", "PROBLEM", 138, 141], ["Zwei-St\u00fchle", "TEST", 155, 166], ["ob", "ANATOMY", 182, 184]]]]}